Disease on EC 3.4.21.5 - thrombin
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Abetalipoproteinemia
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Abnormalities, Multiple
Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity.
Abortion, Habitual
Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study.
Abortion, Spontaneous
Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study.
Abortion, Spontaneous
Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe).
Abortion, Spontaneous
Increased thrombin generation measured in the presence of thrombomodulin in women with early pregnancy loss.
Abortion, Spontaneous
Platelet function in patients with a history of unexplained recurrent miscarriage who subsequently miscarry again.
Abruptio Placentae
Abruption-induced preterm delivery is associated with thrombin-mediated functional progesterone withdrawal in decidual cells.
Abruptio Placentae
Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone.
Abruptio Placentae
Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Abruptio Placentae
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Abruptio Placentae
Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes.
Abscess
Complications of modern diagnostic cerebral angiography in an academic medical center.
Abscess
Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution.
Acidosis
Acidosis induced by carbon dioxide insufflation decreases heparin potency: a risk factor for thrombus formation.
Acidosis
Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis.
Acidosis
Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability.
Acidosis
Coagulopathy induced by acidosis, hypothermia and hypocalcaemia in severe bleeding.
Acidosis
Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro.
Acidosis
Effects of emergency treatment mode of damage-control orthopedics in pelvic fracture complicated with multiple fractures.
Acidosis
Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs.
Acidosis
Preconditioning Effect of Remifentanil Versus Fentanyl in Prevalence of Early Graft Dysfunction in Patients After Liver Transplant: A Randomized Clinical Trial.
Acquired Immunodeficiency Syndrome
A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
Acquired Immunodeficiency Syndrome
Clinical use of topical thrombin as a surgical hemostat.
Acquired Immunodeficiency Syndrome
Lupus anticoagulant associated with specific inhibition of factor VII in a patient with AIDS.
Acquired Immunodeficiency Syndrome
Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes.
Acquired Immunodeficiency Syndrome
The use of new procoagulants in blunt and penetrating trauma.
Acquired Immunodeficiency Syndrome
Thrombin use in surgery: an evidence-based review of its clinical use.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
Activated Protein C Resistance
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Activated Protein C Resistance
Acquired resistance to activated protein C in breast cancer patients.
Activated Protein C Resistance
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Activated Protein C Resistance
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Activated Protein C Resistance
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Activated Protein C Resistance
An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
Activated Protein C Resistance
Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives.
Activated Protein C Resistance
Changes of hemostatic variables during oral contraceptive use.
Activated Protein C Resistance
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Activated Protein C Resistance
Development of a calibrated automated thrombography based thrombin generation test in mouse plasma.
Activated Protein C Resistance
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia.
Activated Protein C Resistance
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Activated Protein C Resistance
Effect of blood loss during caesarean section on coagulation parameters.
Activated Protein C Resistance
Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Activated Protein C Resistance
Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.
Activated Protein C Resistance
Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.
Activated Protein C Resistance
Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay.
Activated Protein C Resistance
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Activated Protein C Resistance
Effects of hormone replacement on hemostasis in spontaneous menopause.
Activated Protein C Resistance
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Activated Protein C Resistance
Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.
Activated Protein C Resistance
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Activated Protein C Resistance
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Activated Protein C Resistance
Exercise-induced activation of coagulation in subjects with activated protein C resistance.
Activated Protein C Resistance
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Activated Protein C Resistance
Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism.
Activated Protein C Resistance
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Activated Protein C Resistance
Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever.
Activated Protein C Resistance
Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis.
Activated Protein C Resistance
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Activated Protein C Resistance
Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.
Activated Protein C Resistance
Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of a?2GPI and aPS/PT antibodies.
Activated Protein C Resistance
Lemierre syndrome variant: Staphylococcus aureus associated with thrombosis of both the right internal jugular vein and the splenic vein after the exploration of a river cave.
Activated Protein C Resistance
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Activated Protein C Resistance
Molecular biology and pathophysiology of APC resistance: current insights and clinical implications.
Activated Protein C Resistance
No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.
Activated Protein C Resistance
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Activated Protein C Resistance
Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice.
Activated Protein C Resistance
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
Activated Protein C Resistance
Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance.
Activated Protein C Resistance
Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
Activated Protein C Resistance
Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC).
Activated Protein C Resistance
Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.
Activated Protein C Resistance
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Activated Protein C Resistance
Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
Activated Protein C Resistance
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Activated Protein C Resistance
The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.
Activated Protein C Resistance
The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
Activated Protein C Resistance
The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature.
Activated Protein C Resistance
The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index.
Activated Protein C Resistance
The effects of transport temperature and time on routine and specialized coagulation assays.
Activated Protein C Resistance
The use of direct oral anticoagulants in inherited thrombophilia.
Activated Protein C Resistance
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Activated Protein C Resistance
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Activated Protein C Resistance
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
Activated Protein C Resistance
Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.
Activated Protein C Resistance
Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
Activated Protein C Resistance
Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
Acute Coronary Syndrome
A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes.
Acute Coronary Syndrome
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Acute Coronary Syndrome
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
Acute Coronary Syndrome
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Acute Coronary Syndrome
Acute myocardial ischemia and infarction: making the right decisions in antithrombotic and reperfusion therapies.
Acute Coronary Syndrome
Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Acute Coronary Syndrome
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
Acute Coronary Syndrome
Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes.
Acute Coronary Syndrome
Antiplatelet and antithrombin therapies in the acute coronary syndromes.
Acute Coronary Syndrome
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
Acute Coronary Syndrome
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Acute Coronary Syndrome
Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery.
Acute Coronary Syndrome
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Acute Coronary Syndrome
Clinician update: direct thrombin inhibitors in acute coronary syndromes.
Acute Coronary Syndrome
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Acute Coronary Syndrome
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Acute Coronary Syndrome
Coagulation activation and long-term outcome in acute coronary syndromes.
Acute Coronary Syndrome
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
Acute Coronary Syndrome
Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator.
Acute Coronary Syndrome
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Acute Coronary Syndrome
Comparison of Safety and Efficacy of Bivalirudin Versus Unfractionated Heparin in High-Risk Patients Undergoing Percutaneous Coronary Intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin Study).
Acute Coronary Syndrome
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Acute Coronary Syndrome
Current Update on Glycoprotein IIb-IIIa and Direct Thrombin Inhibition in Percutaneous Coronary Intervention for Non-ST Elevation Acute Coronary Syndromes: Balancing Bleeding Risk and Antiplatelet Efficacy.
Acute Coronary Syndrome
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion.
Acute Coronary Syndrome
Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET.
Acute Coronary Syndrome
Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.
Acute Coronary Syndrome
Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
Acute Coronary Syndrome
Direct thrombin inhibitor-bivalirudin functionalized plasma polymerized allylamine coating for improved biocompatibility of vascular devices.
Acute Coronary Syndrome
Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
Acute Coronary Syndrome
Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions.
Acute Coronary Syndrome
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Acute Coronary Syndrome
Direct thrombin inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention: special effects in selected patients?
Acute Coronary Syndrome
Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group.
Acute Coronary Syndrome
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention.
Acute Coronary Syndrome
Direct thrombin inhibitors in acute coronary syndromes: present and future.
Acute Coronary Syndrome
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Acute Coronary Syndrome
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Acute Coronary Syndrome
Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation.
Acute Coronary Syndrome
Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy.
Acute Coronary Syndrome
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Acute Coronary Syndrome
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Acute Coronary Syndrome
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
Acute Coronary Syndrome
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial.
Acute Coronary Syndrome
Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion.
Acute Coronary Syndrome
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Acute Coronary Syndrome
Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention.
Acute Coronary Syndrome
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Acute Coronary Syndrome
Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events.
Acute Coronary Syndrome
Failure of thrombin generation markers to triage patients presenting with chest pain.
Acute Coronary Syndrome
Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction.
Acute Coronary Syndrome
Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET.
Acute Coronary Syndrome
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Acute Coronary Syndrome
Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.
Acute Coronary Syndrome
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Acute Coronary Syndrome
Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense.
Acute Coronary Syndrome
Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.
Acute Coronary Syndrome
Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.
Acute Coronary Syndrome
ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.
Acute Coronary Syndrome
In the Bivalirudin Era, are we still Looking for a Potent Antiplatelet Agent?
Acute Coronary Syndrome
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Acute Coronary Syndrome
Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease.
Acute Coronary Syndrome
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Acute Coronary Syndrome
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Acute Coronary Syndrome
Is the use of unfractionated heparin in acute coronary syndrome outmoded?
Acute Coronary Syndrome
Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates.
Acute Coronary Syndrome
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.
Acute Coronary Syndrome
Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?
Acute Coronary Syndrome
Mental stress and physical exercise increase platelet-dependent thrombin generation.
Acute Coronary Syndrome
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
Acute Coronary Syndrome
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
Acute Coronary Syndrome
New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
Acute Coronary Syndrome
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Acute Coronary Syndrome
Novel oral anticoagulants in the management of coronary artery disease.
Acute Coronary Syndrome
Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 inhibition and Thrombin Receptor Antagonists.
Acute Coronary Syndrome
Oral antiplatelet therapy in acute coronary syndromes: recent developments.
Acute Coronary Syndrome
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Acute Coronary Syndrome
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Acute Coronary Syndrome
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.
Acute Coronary Syndrome
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Acute Coronary Syndrome
Plasma tissue factor in coronary artery disease: further step to the understanding of the basic mechanisms of coronary artery thrombosis.
Acute Coronary Syndrome
Platelet Activation Determined by Flow Cytometry Persists Despite Antithrombotic Therapy in Patients with Unstable Angina and Non-Q-Wave Myocardial Infarction.
Acute Coronary Syndrome
Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery.
Acute Coronary Syndrome
Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.
Acute Coronary Syndrome
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response.
Acute Coronary Syndrome
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Acute Coronary Syndrome
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
Acute Coronary Syndrome
Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
Acute Coronary Syndrome
Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.
Acute Coronary Syndrome
Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase.
Acute Coronary Syndrome
Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes.
Acute Coronary Syndrome
Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Acute Coronary Syndrome
Role of oral anticoagulants in patients after an acute coronary syndrome.
Acute Coronary Syndrome
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Acute Coronary Syndrome
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Acute Coronary Syndrome
Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells.
Acute Coronary Syndrome
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.
Acute Coronary Syndrome
Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.
Acute Coronary Syndrome
Systematic Review of Hirudin in Acute Coronary Syndromes and Percutaneous Coronary Intervention.
Acute Coronary Syndrome
TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1.
Acute Coronary Syndrome
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
Acute Coronary Syndrome
The clinical and economic impact of bivalirudin for percutaneous coronary intervention.
Acute Coronary Syndrome
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
Acute Coronary Syndrome
The GUSTO 2b and related studies. Global Use of Strategies to Open Occluded Coronary Arteries.
Acute Coronary Syndrome
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
Acute Coronary Syndrome
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential.
Acute Coronary Syndrome
Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients.
Acute Coronary Syndrome
Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition.
Acute Coronary Syndrome
Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion.
Acute Coronary Syndrome
Thrombin induces cyclooxygenase-2 expression and prostaglandin E(2) release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages.
Acute Coronary Syndrome
Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.
Acute Coronary Syndrome
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
Acute Coronary Syndrome
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Acute Coronary Syndrome
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Acute Coronary Syndrome
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Acute Coronary Syndrome
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
Acute Coronary Syndrome
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Acute Coronary Syndrome
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Acute Coronary Syndrome
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Acute Coronary Syndrome
[New oral anticoagulants: recommendations, precautions and perspectives for use].
Acute Coronary Syndrome
[Persistent activation and/or reactivation in the subacute phase of unstable angina. Reasons for prolonged antithrombotic treatment]
Acute Coronary Syndrome
[Prehospital treatment with bivalirudin in acute myocardial infarction referred for primary angioplasty. About 152 consecutive patients study.]
Acute Kidney Injury
Argatroban for anticoagulation in continuous renal replacement therapy.
Acute Kidney Injury
Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane.
Acute Kidney Injury
Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.
Acute Kidney Injury
Sustained local inhibition of thrombin preserves renal microarchitecture and function after onset of acute kidney injury.
Acute Kidney Injury
Thrombin down-regulates the TGF-beta-mediated synthesis of collagen and fibronectin by human proximal tubule epithelial cells through the EPCR-dependent activation of PAR-1.
Acute Kidney Injury
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Acute Kidney Injury
[New findings on the physiopathology of acute hemolytic transfusion reactions]
Acute Lung Injury
Crosstalk between thrombosis and inflammation in lung reperfusion injury.
Acute Lung Injury
Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs.
Acute Lung Injury
Heparin improves gas exchange during experimental acute lung injury in newborn piglets.
Acute Lung Injury
Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.
Acute Lung Injury
Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury.
Acute Lung Injury
Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells.
Acute Lung Injury
Platelet Activation and Aggregation Promote Lung Inflammation and Influenza Virus Pathogenesis.
Acute Lung Injury
Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A2: role of EP4 receptor.
Acute Lung Injury
Thrombin inhibitors reduce intrapulmonary accumulation of fibrinogen and procoagulant activity of bronchoalveolar lavage fluid during acute lung injury induced by pulmonary overdistention in newborn piglets.
Acute Lung Injury
Tissue factor-dependent coagulation protease signaling in acute lung injury.
Adenocarcinoma
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Adenocarcinoma
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Adenocarcinoma
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Adenocarcinoma
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.
Adenocarcinoma
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide.
Adenocarcinoma
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Adenocarcinoma
Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells.
Adenocarcinoma
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Adenocarcinoma
Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.
Adenocarcinoma
Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.
Adenocarcinoma of Lung
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Adenocarcinoma of Lung
TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.
Adenomyosis
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Adrenocortical Hyperfunction
Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism.
Afibrinogenemia
A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice.
Afibrinogenemia
Chronic subdural hematoma in a patient with congenital afibrinogenemia successfully treated with fibrinogen replacement.
Afibrinogenemia
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Afibrinogenemia
Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution.
Afibrinogenemia
Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
Afibrinogenemia
Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion.
Afibrinogenemia
Stimulation of fibrinogen synthesis by thrombin in rabbits with ancrod-induced afibrinogenemia.
Afibrinogenemia
Techniques for evaluating the cause of bleeding in the ICU. Diagnostic clues and keys to interpreting hemostatic tests.
Afibrinogenemia
Thromboelastography and thrombin generation assay in inherited afibrinogenemia.
Afibrinogenemia
[Analysis of gene mutation spectrum and pharmacokinetics of fibrinogen infusion in 146 cases of congenital fibrinogen disorders].
Afibrinogenemia
[Congenital afibrinogenemia. II. Studies on thrombin formation and inactivation (silent coagulation)]
Afibrinogenemia
[Inherited Afibrinogenemia Caused by Compound Heterozygous Mutations in the Beta beta-Chain of Fibrinogen.]
Afibrinogenemia
[The importance of the enzyme preparation ancistron-N in the diagnosis of disseminated intravascular coagulation]
Albuminuria
Low but sustained coagulation activation ameliorates glucose induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy.
Albuminuria
Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes.
Albuminuria
Procoagulant activity in patients with combined type 2 diabetes and coronary artery disease: No effects of long-term exercise training.
Albuminuria
Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients.
Albuminuria
Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease.
Altitude Sickness
Hypobaric Hypoxia Causes Elevated Thrombin Generation Mediated by FVIII that is Balanced by Decreased Platelet Activation.
Alveolar Bone Loss
Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol.
Alzheimer Disease
Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease.
Alzheimer Disease
Control of hippocampal pKr-2 expression reduces neurotoxic symptoms in 5XFAD mice.
Alzheimer Disease
Cyclin D1, cdk4, and Bim are involved in thrombin-induced apoptosis in cultured cortical neurons.
Alzheimer Disease
Femtomolar Detection of Thrombin in Serum and Cerebrospinal Fluid via Direct Electrocatalysis of Oxygen Reduction by the Covalent G4-Hemin-Aptamer Complex.
Alzheimer Disease
First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease.
Alzheimer Disease
HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.
Alzheimer Disease
Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect.
Alzheimer Disease
Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease.
Alzheimer Disease
Non-age related differences in thrombin responses by platelets from male patients with advanced Alzheimer's disease.
Alzheimer Disease
Protease nexin-1, a potent thrombin inhibitor, is reduced around cerebral blood vessels in Alzheimer's disease.
Alzheimer Disease
Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases.
Alzheimer Disease
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Alzheimer Disease
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Alzheimer Disease
Short-term treatment with dabigatran alters protein expression patterns in a late-stage tau-based Alzheimer's disease mouse model.
Alzheimer Disease
The Alzheimer's disease peptide ?-amyloid promotes thrombin generation through activation of coagulation factor XII: comment.
Alzheimer Disease
The Alzheimer's disease peptide ?-amyloid promotes thrombin generation through activation of coagulation factor XII: reply.
Alzheimer Disease
The Alzheimer's disease peptide A? promotes thrombin generation through activation of coagulation factor XII.
Alzheimer Disease
Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis.
Alzheimer Disease
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain.
Alzheimer Disease
Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities.
Alzheimer Disease
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Alzheimer Disease
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase.
Alzheimer Disease
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase.
Alzheimer Disease
[Changes in the blood clotting system of patients with atherosclerotic and senile dementias]
Amnesia
Recovery from trauma induced amnesia correlates with normalization of thrombin activity in the mouse hippocampus.
Amyloidosis
A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia.
Amyloidosis
Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality.
Amyloidosis
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Amyotrophic Lateral Sclerosis
Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders.
Anaphylaxis
Anaphylactic reaction to bovine thrombin in ultrasound-guided treatment of femoral pseudoaneurysm.
Anaphylaxis
Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention.
Anaphylaxis
Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population.
Anaphylaxis
[Anaphylactic shock following topical use of thrombin for irrigation of urinary bladder]
Anaphylaxis
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
Anemia
A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm.
Anemia
Acute kidney injury in high-risk cardiac surgery patients: roles of inflammation and coagulation.
Anemia
Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man.
Anemia
Decreased thrombin activity by a Congolese herbal medicine used in sickle cell anemia.
Anemia
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Anemia
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Anemia
Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
Anemia
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Anemia
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Anemia, Aplastic
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Anemia, Sickle Cell
Decreased thrombin activity by a Congolese herbal medicine used in sickle cell anemia.
Anemia, Sickle Cell
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Anemia, Sickle Cell
Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis.
Anemia, Sickle Cell
Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation.
Anemia, Sickle Cell
Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation.
Anemia, Sickle Cell
Excess of heme induces tissue factor-dependent activation of coagulation in mice.
Anemia, Sickle Cell
Hypercoagulability in sickle cell disease: new approaches to an old problem.
Anemia, Sickle Cell
Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception.
Anemia, Sickle Cell
Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.
Anemia, Sickle Cell
Plasma levels of some blood coagulation parameters in Nigerian homozygous sickle cell patients (HbSS) in steady state.
Anemia, Sickle Cell
Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.
Anemia, Sickle Cell
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Anemia, Sickle Cell
The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells.
Anemia, Sickle Cell
The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease.
Anemia, Sickle Cell
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
Anemia, Sickle Cell
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Anemia, Sickle Cell
Thrombin Generation in Children with Sickle Cell Disease: Relationship with Age, Hemolysis, Transcranial Doppler Velocity and Hydroxyurea Treatment.
Anemia, Sickle Cell
Thrombin generation in vivo and ex vivo in sickle cell disease patients.
Anemia, Sickle Cell
Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children.
Anemia, Sickle Cell
Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.
Aneurysm
A case of gastroduodenal artery aneurysm in a HIV-positive patient treated by combined percutaneous thrombin injection and endovascular coil embolization.
Aneurysm
A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm.
Aneurysm
A ruptured aneurysm after stent graft puncture during computed tomography-guided thrombin injection.
Aneurysm
Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate?
Aneurysm
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Aneurysm
Branch ligatures and blood aspiration for post-traumatic superficial temporal artery pseudoaneurysm: surgical technique.
Aneurysm
Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair.
Aneurysm
Colonic necrosis subsequent to catheter-directed thrombin embolization of the inferior mesenteric artery via the superior mesenteric artery: a complication in the management of a type II endoleak.
Aneurysm
Combined Endovascular Exclusion with Percutaneous Sac Aspiration and Thrombin Injection in the Management of Popliteal Artery Aneurysm.
Aneurysm
Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion.
Aneurysm
CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair.
Aneurysm
Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection.
Aneurysm
Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm.
Aneurysm
Embolization of a Giant Hepatic Venous Aneurysm by Complementary Use of Coils, Vascular Plug, and Thrombin.
Aneurysm
Embolization of an Internal Iliac Artery Aneurysm after Image-Guided Direct Puncture.
Aneurysm
Endoscopic ultrasound-guided thrombin injection in a large splenic artery aneurysm: first report in a patient with tropical chronic pancreatitis.
Aneurysm
Endovascular Solution to Endoleak Phenomenon After Open Repair of Abdominal Aortic Aneurysm.
Aneurysm
Endovascular therapy of arteriovenous malformation in a male patient with severe post-coital pelvic pain.
Aneurysm
EVAR: critical applied aortic morphology relevant to type-II endoleaks following device enhancement in patients with abdominal aortic aneurysms.
Aneurysm
Feasibility and Safety of Vascular Closure Devices in an Antegrade Approach to Either the Common Femoral Artery or the Superficial Femoral Artery.
Aneurysm
Iliac artery pseudoaneurysm presenting as a paravertebral collection: a potentially fatal mimic.
Aneurysm
Innominate artery aneurysm with hemoptysis and airway compression in a patient with bovine aortic arch.
Aneurysm
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Aneurysm
Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report.
Aneurysm
Interventional therapy for stenosis and aneurysm in renal graft artery: report of 9 cases.
Aneurysm
Intraprocedural and postprocedural perigraft arterial sac embolization (PASE) for endoleak treatment.
Aneurysm
Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass?
Aneurysm
Ischemic colitis following translumbar thrombin injection for treatment of endoleak.
Aneurysm
Laser-assisted transprosthesial coil embolization combined with thrombin injection for treatment of an endoleak type II after endovascular aneurysm repair.
Aneurysm
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Aneurysm
Microsurgical and Endovascular Management of Congenital Iliac Aneurysms in the Neonatal Period: Two Cases and a Literature Review.
Aneurysm
Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution.
Aneurysm
Percutaneous Cyanoacrylate Glue Injection into the Renal Pseudoaneurysm to Control Intractable Hematuria After Percutaneous Nephrolithotomy.
Aneurysm
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Aneurysm
Percutaneous injection therapy for a peripheral pulmonary artery pseudoaneurysm after failed transcatheter coil embolization.
Aneurysm
Percutaneous occlusion of posttraumatic aortic arch pseudoaneurysm by catheter-based delivery of thrombin.
Aneurysm
Percutaneous puncture and embolisation for pancreatitis-related pseudoaneurysm: the feasibility of thrombin injection even in collection of fluid surrounding the pseudoaneurysm.
Aneurysm
Percutaneous thrombin embolization of a pancreatico-duodenal artery pseudoaneurysm after failing of the endovascular treatment.
Aneurysm
Percutaneous thrombin injection to complete SMA pseudoaneurysm exclusion after failing of endograft placement.
Aneurysm
Percutaneous treatment of a ruptured superior mesenteric artery aneurysm in a child.
Aneurysm
Posttraumatic Lingual Artery Pseudoaneurysm Treated with Ultrasound-Guided Percutaneous Thrombin Injection.
Aneurysm
Prophylactic Aneurysm Embolization during EVAR Is Safe, Improves Sac Regression and Decreases the Incidence of Type II Endoleak.
Aneurysm
Radial Artery Pseudoaneurysms Treated by Ultrasound-Guided Differential Compression: An Effective and Simple Method.
Aneurysm
Reperfusion of splanchnic artery aneurysm following transcatheter embolization: treatment with percutaneous thrombin injection.
Aneurysm
Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice.
Aneurysm
Ruptured left gastric artery aneurysm successfully treated by thrombin injection: case report and literature review.
Aneurysm
Saccular Aneurysm of Superior Vena Cava Treated with Percutaneous, Transcatheter Thrombin Injection.
Aneurysm
Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms.
Aneurysm
Sonographically guided thrombin injection for the treatment of femoral artery pseudoaneurysm.
Aneurysm
Spontaneous pseudo-aneurysm of the deep femoral artery treated by a covered stent.
Aneurysm
Strategies of endoleak management following endoluminal treatment of abdominal aortic aneurysms in 95 patients: how, when and why.
Aneurysm
Strategies to Reduce the Rate of Type II Endoleaks: Routine Intraoperative Embolization of the Inferior Mesenteric Artery and Thrombin Injection Into the Aneurysm Sac.
Aneurysm
Temporary aneurysm neck balloon occlusion during percutaneous thrombin embolization of a superficial femoral artery pseudoaneurysm.
Aneurysm
The dermatan sulfate-dependent anticoagulant pathway is mostly preserved in aneurysm and in severe atherosclerotic lesions while the heparan sulfate pathway is disrupted.
Aneurysm
The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm.
Aneurysm
Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm.
Aneurysm
Thrombin injection for treatment of brachial artery pseudoaneurysm at the site of a hemodialysis fistula: report of two patients.
Aneurysm
Thrombin obliteration of subclavian artery aneurysm with intravascular balloon protection.
Aneurysm
Transcatheter thrombosis of a leaking saccular aneurysm of the main renal artery with preservation of renal blood flow.
Aneurysm
Transcaval embolization as an alternative technique for the treatment of type II endoleak after endovascular aortic aneurysm repair.
Aneurysm
Transluminal coil embolization of an inferior gluteal artery aneurysm by ultrasound-guided direct puncture of the target vessel.
Aneurysm
Transluminal thrombin injection and exclusion of a paramesenteric abdominal aortic aneurysm.
Aneurysm
Traumatic Inferior Gluteal Artery Aneurysm Managed with Emergency Transcatheter Thrombin Injection.
Aneurysm
Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin.
Aneurysm
Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection.
Aneurysm
Treatment of type II endoleak with a transcatheter transcaval approach: results at 1-year follow-up.
Aneurysm
Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac.
Aneurysm
Treatment protocol of traumatic pseudoaneurysm of the superficial temporal artery.
Aneurysm
Ultrasound guided percutaneous thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Aneurysm
Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience.
Aneurysm
Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience.
Aneurysm
Upper gastrointestinal bleeding due to hepatic artery aneurysm: Case report and literature review.
Aneurysm
Use of FloSeal in the endovascular treatment of voluminous aneurysm of a lower gluteus artery.
Aneurysm
[Iatrogenic aneurysm of the hepatic artery. Treatment by percutaneous injection of thrombin and selective arterial embolization]
Aneurysm
[Minimally invasive percutaneous contrast-ultrasound guided thrombin occlusion of iatrogenic pseudoaneurysm]
Aneurysm
[The treatment of iatrogenic spurious aneurysm of the femoral artery by direct thrombin injection]
Aneurysm, Dissecting
Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product.
Aneurysm, False
A Bail Out Solution for an Urgent Situation: Endovascular Exclusion and Embolization of an Infected Femoral Pseudoaneurysm.
Aneurysm, False
A cost effective endovascular approach for management of post-catheterization profunda femoris artery pseudoaneurysm using thrombin.
Aneurysm, False
A hybrid approach for vascular control and repair of an expanding iatrogenic femoral artery pseudoaneurysm.
Aneurysm, False
A novel approach to the management of carotid blowout syndrome: the use of thrombin in a case of failed covered stenting.
Aneurysm, False
A novel approach to treating a post-sternotomy internal mammary artery pseudoaneurysm.
Aneurysm, False
A novel interventional method for treating femoral pseudoaneurysms: results from a monocentric experience.
Aneurysm, False
A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm.
Aneurysm, False
A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection.
Aneurysm, False
A Possible Allergic Reaction Case to Thrombin Injected into Pseudoaneurysm After Radiofrequency Ablation.
Aneurysm, False
A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication.
Aneurysm, False
A prospective study on ultrasound-guided compression therapy or thrombin injection for treatment of iatrogenic false aneurysms in patients receiving full-dose anti-platelet therapy.
Aneurysm, False
A prospective study on ultrasound-guided percutaneous thrombin injection for treatment of iatrogenic post-catheterisation femoral pseudoaneurysms.
Aneurysm, False
A Pseudoaneurysm of the Deep Palmar Arch After Penetrating Trauma to the Hand: Successful Exclusion by Ultrasound Guided Percutaneous Thrombin Injection.
Aneurysm, False
A Rare Case of Axillary Artery Pseudoaneurysm Due to Shoulder Dislocation Treated With Percutaneous Thrombin Injection.
Aneurysm, False
A Rare Case of Iatrogenic Pseudoaneurysm of the Left Brachiocephalic Vein After Central Venous Catheterization Treated With Thrombin Injection.
Aneurysm, False
Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
Aneurysm, False
Acute arterial occlusion after ultrasound-guided thrombin injection of a common femoral artery pseudoaneurysm with a wide, short neck.
Aneurysm, False
Anaphylactic reaction to bovine thrombin in ultrasound-guided treatment of femoral pseudoaneurysm.
Aneurysm, False
Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention.
Aneurysm, False
Anastomotic Pseudoaneurysm Formation After Bypass Grafting to Porcelainized Peroneal Artery: Successful Treatment by Percutaneous Thrombin Injection.
Aneurysm, False
Angiography-guided percutaneous thrombin injection for haemostasis of active bleeding complicated by femoral access: a case report.
Aneurysm, False
Arterial complications associated with cardiac catheterization in pediatric patients with a previous history of kawasaki disease.
Aneurysm, False
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Aneurysm, False
Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula.
Aneurysm, False
Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique.
Aneurysm, False
Brachial pseudoaneurysm of the neonate with partial response to thrombin injections and late spontaneous thrombosis and regression during expectant management.
Aneurysm, False
Cannulated screw for proximal tibial fracture complicated by iatrogenic popliteal pseudoaneurysm: definitive treatment by ultrasound-guided thrombin injection.
Aneurysm, False
Cardiologist operated ultrasound guided thrombin injection as a safe and efficacious first line treatment for iatrogenic femoral artery pseudoaneurysms.
Aneurysm, False
Catheter-directed endovascular application of thrombin: Report of 3 cases and review of the literature.
Aneurysm, False
Choosing a treatment method for post-catheterization pseudoaneurysms guided by the late to early velocity index.
Aneurysm, False
Coil embolization of inferior epigastric artery pseudoaneurysm after percutaneous thrombin injection failure: a case report.
Aneurysm, False
Combined endovascular intervention and percutaneous thrombin injection in the treatment of iatrogenic pseudoaneurysm. Case report.
Aneurysm, False
Combined percutaneous thrombin injection and endovascular treatment of gastroduodenal artery pseudoaneurysm (PAGD): case report.
Aneurysm, False
Combined thrombin-collagen injection for the management of an iatrogenic pseudoanuerysm in the popliteal region.
Aneurysm, False
Combining Percutaneous Ultrasound-Guided Hematoma Aspiration and Compression Repair to Treat Femoral Artery Pseudoaneurysm after Cardiac Catheterization.
Aneurysm, False
Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection.
Aneurysm, False
Comparison of the Efficacy and Safety of Two Dosing Protocols for Ultrasound Guided Thrombin Injection in Patients with Iatrogenic Femoral Pseudoaneurysms.
Aneurysm, False
Comparison of ultrasound-guided thrombin injection of iatrogenic pseudoaneurysms based on neck dimension.
Aneurysm, False
Complete percutaneous decannulation from femoral venoarterial extracorporeal membrane oxygenation.
Aneurysm, False
Complex subclavian artery pseudoaneurysm causing failure of endovascular stent repair with salvage by percutaneous thrombin injection.
Aneurysm, False
Complications of modern diagnostic cerebral angiography in an academic medical center.
Aneurysm, False
Complications of percutaneous thrombin injection in patients with postcatheterization femoral pseudoaneurysm.
Aneurysm, False
Compression repair versus low-dose thrombin injection for the treatment of iatrogenic femoral pseudoaneurysm: a retrospective case-control study.
Aneurysm, False
Contrast-enhanced ultrasound-guided thrombin injection in the management of iatrogenic pseudoaneurysm (PSA): A case report and review of literatures.
Aneurysm, False
Correction of procedural arterial pseudoaneurysms: established and novel procedures.
Aneurysm, False
CT-guided percutaneous thrombin injection for treatment of an inferior pancreaticoduodenal artery pseudoaneurysm.
Aneurysm, False
CT-Guided Thrombin Injection to Control Rapid Expansion of Ascending Aortic False Aneurysm 15 Months After Bentall-Bono Operation.
Aneurysm, False
Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection.
Aneurysm, False
Day-Case Treatment of Peripheral Arterial Disease: Results from a Multi-Center European Study.
Aneurysm, False
Deep Pelvic Postprostatectomy Pseudoaneurysm Treated by Transrectal Ultrasound-Guided Thrombin Injection.
Aneurysm, False
Delayed femoral vein thrombosis after ultrasound-guided thrombin injection of a postcatheterization pseudoaneurysm.
Aneurysm, False
Development of nonobstructive intraarterial thrombi after injection of thrombin into pseudoaneurysms.
Aneurysm, False
Dissecting pseudoaneurysm of the proper hepatic artery repaired by primary anastomosis: a case report.
Aneurysm, False
Distal radial pseudoaneurysm after chronic total occlusion percutaneous coronary intervention resolved by percutaneous thrombin injection.
Aneurysm, False
Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Aneurysm, False
Duplex-directed thrombin injection as a method to treat femoral artery pseudoaneurysms.
Aneurysm, False
Duplex-guided thrombin injection for iatrogenic femoral artery pseudoaneurysm is effective even in anticoagulated patients.
Aneurysm, False
Duplex-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Aneurysm, False
Effective treatment of iatrogenic femoral pseudoaneurysms by combined endovascular balloon inflation and percutaneous thrombin injection.
Aneurysm, False
Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injections using two approaches: bolus versus slow injection. A prospective randomised trial.
Aneurysm, False
Efficacy of a novel procedure sheath and closure device during diagnostic catheterization: the multicenter randomized clinical trial of the FISH device.
Aneurysm, False
Embolotherapy of a high-flow false aneurysm by using an occlusion balloon, thrombin, steel coils, and a detachable balloon.
Aneurysm, False
Endoscopic and percutaneous ultrasound-guided thrombin and glue injection in a pseudoaneurysm of the right hepatic artery.
Aneurysm, False
Endoscopic ultrasound guided thrombin injection of angiographically occult pancreatitis associated visceral artery pseudoaneurysms: Case series.
Aneurysm, False
Endoscopic ultrasound-guided coil embolization and thrombin injection of a bleeding gastroduodenal artery pseudoaneurysm.
Aneurysm, False
Endoscopic ultrasound-guided thrombin injection for management of visceral artery pseudoaneurysm: A novel approach.
Aneurysm, False
Endoscopic ultrasound-guided thrombin injection for the treatment of pancreatic pseudoaneurysm.
Aneurysm, False
Endoscopic ultrasound-guided thrombin injection, a management approach for visceral artery pseudoaneurysms.
Aneurysm, False
Endovascular coil embolization for large femoral false aneurysms: two case reports.
Aneurysm, False
Endovascular management of an infected superficial femoral artery pseudoaneurysm.
Aneurysm, False
Endovascular management of femoral access-site and access-related vascular complications following percutaneous coronary interventions (PCI).
Aneurysm, False
Endovascular repair of a large post-traumatic calf pseudoaneurysm and arteriovenous fistula.
Aneurysm, False
Endovascular retrograde recanalization in Asian critical limb ischaemia patients.
Aneurysm, False
Endovascular Treatment of a Giant Aorto-Ostial Renal Artery Pseudoaneurysm.
Aneurysm, False
Endovascular treatment of refractory iatrogenic femoral artery pseudoaneurysm using Amplatzer vascular plugs following unsuccessful retrograde Angio-Seal deployment.
Aneurysm, False
Erratum to: Deep Pelvic Postprostatectomy Pseudoaneurysm Treated by Transrectal Ultrasound-Guided Thrombin Injection.
Aneurysm, False
EUS-guided thrombin injection of cystic artery pseudoaneurysm leading to Mirizzi's syndrome and hemobilia.
Aneurysm, False
Evaluation of Morphological and Clinical Factors Related to Failure of Percutaneous Treatment with Thrombin Injection of Femoral Pseudoaneurysms from Cardiac Catheterization.
Aneurysm, False
Expanded indications for ultrasound-guided thrombin injection of pseudoaneurysms.
Aneurysm, False
Expect the unexpected: acute and subacute coronary stent thrombosis following percutaneous thrombin injection for treatment of femoral pseudoaneurysm.
Aneurysm, False
External carotid artery pseudoaneurysm following microvascular free flap reconstruction. The role of endovascular thrombin injection in embolization: a case report and review.
Aneurysm, False
Extravasating uterine pseudoaneurysm: A rare cause of postpartum haemorrhage.
Aneurysm, False
Factors associated with pseudoaneurysm development and necessity for reintervention: a single centre study.
Aneurysm, False
Fascial suture technique versus open femoral access for thoracic endovascular aortic repair.
Aneurysm, False
Fatal Complication after Thrombin Injection for Post-Catheterization Femoral Pseudoaneurysm.
Aneurysm, False
Feasibility and Safety of Vascular Closure Devices in an Antegrade Approach to Either the Common Femoral Artery or the Superficial Femoral Artery.
Aneurysm, False
Femoral Arterial Haemostasis Using an Anchored Collagen Plug after Percutaneous EVAR with an Ultra-Low Profile Device: Prospective Audit of an Evolving "Post-Close" Technique.
Aneurysm, False
Femoral artery thrombosis after percutaneous thrombin injection of an external iliac artery pseudoaneurysm.
Aneurysm, False
Femoral artery thrombosis following percutaneous treatment with thrombin injection of a femoral artery pseudoaneurysm: a case report.
Aneurysm, False
Femoral pseudoaneurysms: management with percutaneous thrombin injections--success rates and effects on systemic coagulation.
Aneurysm, False
Flow reduction aided thrombin injection for complex femoral pseudoaneurysms: Case series and review of the literature.
Aneurysm, False
Hepatic artery pseudoaneurysm after liver transplantation: treatment with percutaneous thrombin injection.
Aneurysm, False
How to perform ultrasound-assisted thrombin injection for closure of iatrogenic femoral pseudoaneurysm.
Aneurysm, False
Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection.
Aneurysm, False
Human thrombin injection for the percutaneous treatment of iatrogenic pseudoaneurysms.
Aneurysm, False
Iatrogenic Femoral Pseudoaneurysm and Secondary Ipsilateral Deep Vein Thrombosis: An Indication for Early Surgical Exploration.
Aneurysm, False
Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes.
Aneurysm, False
Iatrogenic femoral pseudoaneurysms: thrombin injection after failed US-guided compression.
Aneurysm, False
Iatrogenic pseudoaneurysms: comparison of treatment modalities, including duplex-guided thrombin injection.
Aneurysm, False
Iatrogenic subclavian artery pseudoaneurysm causing airway compromise: treatment with percutaneous thrombin injection.
Aneurysm, False
Iatrogenic thyroid pseudoaneurysm following thyroid nodule radiofrequency ablation.
Aneurysm, False
Iatrogenic venous pseudoaneurysm: case report and review of the literature.
Aneurysm, False
Imaging-guided percutaneous thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms.
Aneurysm, False
Impact of thrombin injection in femoral artery pseudoaneurysms with AV-fistula.
Aneurysm, False
Incidence of infectious complications after an ultrasound-guided intervention.
Aneurysm, False
Inferior epigastric artery pseudoaneurysm: ultrasound diagnosis and treatment with percutaneous thrombin.
Aneurysm, False
Intercostal artery pseudoaneurysm after ultrasound-guided liver biopsy: a case report and review of the literature.
Aneurysm, False
Intercostal artery pseudoaneurysm: a rare complication of transaortic transcatheter aortic valve implantation.
Aneurysm, False
Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report.
Aneurysm, False
Interventional treatment of arterial injury during blind central venous catheterisation in the upper thorax: experience from two centres.
Aneurysm, False
Interventional treatment of bleeding complications due to percutaneous cannulation for peripheral extracorporeal membrane oxygenation.
Aneurysm, False
Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab.
Aneurysm, False
Ipsilateral femoral vein compression: a contraindication to thrombin injection of femoral pseudoaneurysms.
Aneurysm, False
Large femoral aneurysm as a late complication after vessel closure device application.
Aneurysm, False
Large iatrogenic pseudoaneurysm of the posterior tibial artery treated with sonographically guided thrombin injection.
Aneurysm, False
Late to early velocity index as a predictor of iatrogenic femoral artery pseudoaneurysm recurrence in patients treated with ultrasound-guided thrombin injection.
Aneurysm, False
Letter to 'Novel approach to uterine artery pseudoaneurysm embolization for delayed post-partum hemorrhage': Thrombin really necessary?
Aneurysm, False
Low-dose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms.
Aneurysm, False
Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm.
Aneurysm, False
Lumbar artery pseudoaneurysm following renal biopsy: treatment with ultrasound-guided thrombin injection.
Aneurysm, False
Management of an Iatrogenic Pseudoaneurysm of the Superior Gluteal Artery by Percutaneous Ultrasound-Guided Thrombin Injection: A Case Report.
Aneurysm, False
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Aneurysm, False
Managing coronary artery vein bypass graft stump pseudoaneurysm: a novel approach.
Aneurysm, False
Medial plantar artery pseudoaneurysm following percutaneous pinning for lisfranc fracture-dislocation.
Aneurysm, False
Midterm Results of the Treatment of Penetrating Abdominal Aortic or Iliac Artery Ulcer with the BeGraft Balloon-Expandable Covered Stent-A Single-Center Experience.
Aneurysm, False
Minimally invasive application of thrombin in the treatment of pseudoaneurysms following open aortic surgery.
Aneurysm, False
Minimally invasive intervention of radial artery pseudoaneurysm using percutaneous thrombin injection.
Aneurysm, False
Minimally Invasive Repair of a Left Ventricular Pseudoaneurysm After Surgical Patch Reconstruction of an Infarct-Related Free Posterior Wall Rupture: CT-Guided Intervention.
Aneurysm, False
Minimally invasive therapy of pseudoaneurysms of the trunk: application of thrombin.
Aneurysm, False
Non-invasive repair of an iatrogenic tibial artery branch pseudoaneurysm after intramedullary nailing.
Aneurysm, False
Nonsurgical Repair of a Pseudoaneurysm in a Cynomolgus Macaque (Macaca fascicularis).
Aneurysm, False
Novel approach to uterine artery pseudoaneurysm embolization for delayed post-partum hemorrhage: Thrombin really necessary? Reply.
Aneurysm, False
Occlusion of a giant splenic artery pseudoaneurysm with percutaneous thrombin-collagen injection.
Aneurysm, False
Occlusion of iatrogenic pseudoaneurysms with percutaneous ultrasound guided thrombin injection.
Aneurysm, False
Occlusion of postcatheterisation femoral pseudoaneurysms with percutaneous thrombin injection under ultrasound guidance.
Aneurysm, False
Occlusion of pseudoaneurysms using human or bovine thrombin using contrast-enhanced ultrasound guidance.
Aneurysm, False
Outcomes of Ultrasound-Guided Thrombin Injection of Nongroin Arterial Pseudoaneurysms.
Aneurysm, False
Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection.
Aneurysm, False
Paravertebral pseudoaneurysm thrombosed after percutaneous thrombin injection.
Aneurysm, False
Pathological fracture of the clavicle causing subclavian pseudoaneurysm formation.
Aneurysm, False
Pelvic arterial pseudoaneurysm-a rare complication of Cesarean section: diagnosis and novel treatment.
Aneurysm, False
Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution.
Aneurysm, False
Percutaneous Decannulation Instead of Surgical Removal for Weaning After Venoarterial Extracorporeal Membrane Oxygenation-A Crossed Perclose ProGlide Closure Device Technique Using a Hemostasis Valve Y Connector.
Aneurysm, False
Percutaneous duplex-guided thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms.
Aneurysm, False
Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization.
Aneurysm, False
Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short- and midterm ultrasound follow-up.
Aneurysm, False
Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: an alternative to sonographically guided compression.
Aneurysm, False
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Aneurysm, False
Percutaneous occlusion of posttraumatic aortic arch pseudoaneurysm by catheter-based delivery of thrombin.
Aneurysm, False
Percutaneous puncture and embolisation for pancreatitis-related pseudoaneurysm: the feasibility of thrombin injection even in collection of fluid surrounding the pseudoaneurysm.
Aneurysm, False
Percutaneous repair of abdominal aortic pseudoaneurysm by catheter-based delivery of thrombin.
Aneurysm, False
Percutaneous repair of radial artery pseudoaneurysm in a hemodialysis patient using sonographically guided thrombin injection.
Aneurysm, False
Percutaneous suture technique with ProGlide to manage vascular access pseudoaneurysm after percutaneous coronary intervention procedure: A case report.
Aneurysm, False
Percutaneous thrombin embolisation of an iatrogenic pseudoaneurysm of the subclavian artery with neuroprotection in a critically ill patient.
Aneurysm, False
Percutaneous thrombin embolization of a pancreatico-duodenal artery pseudoaneurysm after failing of the endovascular treatment.
Aneurysm, False
Percutaneous thrombin embolization of a post-traumatic superficial temporal artery pseudoaneurysm.
Aneurysm, False
Percutaneous thrombin embolization of a ruptured peripancreatic pseudoaneurysm.
Aneurysm, False
Percutaneous Thrombin Injection Based on Computational Fluid Dynamics of Femoral Artery Pseudoaneurysms.
Aneurysm, False
Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm of the gastroduodenal artery.
Aneurysm, False
Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm.
Aneurysm, False
Percutaneous Thrombin Injection for Treatment of a Hepatic Arterial Pseudoaneurysm after the Placement of a Transjugular Intrahepatic Portosystemic Shunt.
Aneurysm, False
Percutaneous thrombin injection for treatment of an intrarenal pseudoaneurysm.
Aneurysm, False
Percutaneous thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms: a case for caution.
Aneurysm, False
Percutaneous thrombin injection in an infant to treat hepatic artery pseudoaneurysm after failed embolization.
Aneurysm, False
Percutaneous thrombin injection of a femoral artery pseudoaneurysm with simultaneous venous balloon occlusion of a communicating arteriovenous fistula.
Aneurysm, False
Percutaneous thrombin injection of a pulmonary artery pseudoaneurysm refractory to coil embolization.
Aneurysm, False
Percutaneous Thrombin Injection of Common Carotid Artery Pseudoaneurysm without Cerebral Protection.
Aneurysm, False
Percutaneous thrombin injection to complete SMA pseudoaneurysm exclusion after failing of endograft placement.
Aneurysm, False
Percutaneous thrombin injection to treat a post-traumatic hepatic pseudoaneurysm.
Aneurysm, False
Percutaneous thrombin injection treatment of a femoral artery pseudoaneurysm with simultaneous arterial balloon occlusion: Case report and review of the literature.
Aneurysm, False
Percutaneous thrombin injection treatment of a gluteal pseudoaneurysm following radiofrequency ablation of a hip osteoid osteoma in a 6-year-old boy.
Aneurysm, False
Percutaneous thrombin injection treatment of a profunda femoris pseudoaneurysm after femoral neck fracture.
Aneurysm, False
Percutaneous thrombin injection under sonographic guidance for exclusion of non-catheterizable post-pancreatitis pseudoaneurysm of the superior mesenteric artery: a minimally invasive and expeditious treatment option.
Aneurysm, False
Percutaneous thrombin injection with a distal embolic protection device for treatment of a common carotid artery pseudoaneurysm.
Aneurysm, False
Percutaneous transthoracic embolisation for massive haemoptysis secondary to peripheral pulmonary artery pseudoaneurysms.
Aneurysm, False
Percutaneous treatment of a splenic artery pseudoaneurysm by thrombin injection.
Aneurysm, False
Percutaneous Treatment of Iatrogenic Pseudoaneurysms by Cyanoacrylate-Based Wall-Gluing.
Aneurysm, False
Percutaneous ultrasonographically guided thrombin injection of iatrogenic pseudoaneurysms in unusual sites.
Aneurysm, False
Percutaneous ultrasound guided thrombin injection for axillary artery pseudoaneurysm following stenting of the arterial duct in two infants: Case report with review of literature.
Aneurysm, False
Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms.
Aneurysm, False
Percutaneous ultrasound-guided thrombin injection as first-line treatment of pancreatic pseudoaneurysm.
Aneurysm, False
Percutaneous ultrasound-guided thrombin injection for coagulation of post-traumatic pseudoaneurysms.
Aneurysm, False
Percutaneous ultrasound-guided thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms.
Aneurysm, False
Percutaneous ultrasound-guided thrombin injection for the treatment of pseudoaneurysms.
Aneurysm, False
Percutaneous ultrasound-guided thrombin injection is effective even in infants with external iliac artery pseudoaneurysms.
Aneurysm, False
Percutaneous ultrasound-guided thrombin injection of a post-traumatic pancreatic pseudoaneurysm in a pediatric patient.
Aneurysm, False
Personal experiences in direct ultrasound-guided injection of thrombin into the lumen of pseudoaneurysm as a method of treatment in case of iatrogenic femoral artery damage.
Aneurysm, False
Post-catheterization pseudoaneurysm in a one-year-old child treated by ultrasound-guided human thrombin injection.
Aneurysm, False
Post-sternotomy intercostal artery pseudoaneurysm. Sonographic diagnosis and thrombosis by ultrasound-guided percutaneous thrombin injection.
Aneurysm, False
Post-traumatic hepatic artery pseudoaneurysm treated with endovascular embolization and thrombin injection.
Aneurysm, False
Post-traumatic pseudoaneurysm of the medial plantar artery with arteriovenous fistula treated by coil embolization of the main feeding artery and percutaneous thrombin injection.
Aneurysm, False
Postcatheterization femoral artery pseudoaneurysms: therapeutic options. A case-controlled study.
Aneurysm, False
Postcatheterization pseudoaneurysm: results of US-guided percutaneous thrombin injection in 240 patients.
Aneurysm, False
Postcatheterization pseudoaneurysms: new developments in the diagnosis and treatment with ultrasound.
Aneurysm, False
Postpyelolithotomy renal artery pseudoaneurysm management with percutaneous thrombin injection: a case report.
Aneurysm, False
Posttraumatic Lingual Artery Pseudoaneurysm Treated with Ultrasound-Guided Percutaneous Thrombin Injection.
Aneurysm, False
Posttraumatic pseudoaneurysm of the hepatic artery: treatment with ultrasound-guided percutaneous transhepatic thrombin injection.
Aneurysm, False
Predictors of Groin Access Pseudoaneurysm Complication: A 10-Year Institutional Experience.
Aneurysm, False
Procedural outcomes with use of the flash ostial system in aorto-coronary ostial lesions.
Aneurysm, False
Prolonged generalized urticarial reaction after percutaneous thrombin injection for treatment of a femoral artery pseudoaneurysm.
Aneurysm, False
Prospective randomized study comparing ultrasound-guided thrombin injection to compression in the treatment of femoral pseudoaneurysms.
Aneurysm, False
Protected carotid stenting: safety and efficacy of the MedNova NeuroShield filter.
Aneurysm, False
Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection.
Aneurysm, False
Pseudoaneurysm after vacuum-assisted breast biopsy treated with percutaneous thrombin injection.
Aneurysm, False
Pseudoaneurysm following vertebral biopsy and treatment with percutaneous thrombin injection.
Aneurysm, False
Pseudoaneurysm in a patient with haemophilia A: thrombin injection plugs the hole.
Aneurysm, False
Pseudoaneurysm in association with a knee endoprothesis operation in an inhibitor-positive haemophilia A patient - treatment with local thrombin.
Aneurysm, False
Pseudoaneurysm in the iliac fossa after renal transplantation--treatment with ultrasound-guided thrombin injection.
Aneurysm, False
Pseudoaneurysm of the breast related to 18-gauge core biopsy: successful repair using sonographically guided thrombin injection.
Aneurysm, False
Pseudoaneurysm of the inferior epigastric artery: a rare complication of laparoscopic ventral hernia repair.
Aneurysm, False
Pseudoaneurysm of the superior lateral genicular artery following anterior cruciate ligament repair.
Aneurysm, False
Pseudoaneurysms of the extremity without fracture: treatment with percutaneous ultrasound-guided thrombin injection.
Aneurysm, False
Radial artery pseudoaneurysm: a maneuver to decrease the risk of thrombin therapy.
Aneurysm, False
Radial Artery Pseudoaneurysms Treated by Ultrasound-Guided Differential Compression: An Effective and Simple Method.
Aneurysm, False
Re: Internal mammary artery pseudoaneurysm complicating central venous line placement: treatment with percutaneous thrombin injection.
Aneurysm, False
Recurrence of dialysis shunt pseudoaneurysm following percutaneous thrombin embolization.
Aneurysm, False
Recurrence of Thrombin-Injected Pseudoaneurysms Under Ultrasound Guidance: A 10-Year Retrospective Analysis.
Aneurysm, False
Regarding "A prospective study of ultrasound-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication".
Aneurysm, False
Regarding "Bovine thrombin injection for the treatment of iatrogenic arterial pseudoaneurysms: is it too good to be true?".
Aneurysm, False
Renal artery pseudoaneurysm following renal transplantation and treatment by percutaneous thrombin injection.
Aneurysm, False
Response to article on endoscopic ultrasound-guided thrombin injection, a management approach for visceral artery pseudoaneurysms.
Aneurysm, False
Response to letter on endoscopic ultrasound-guided thrombin injection a management approach for visceral artery pseudoaneurysm: case series.
Aneurysm, False
Results of a new human recombinant thrombin for the treatment of arterial pseudoaneurysm.
Aneurysm, False
Safety and Effectiveness of Percutaneous Low-Dose Thrombin Injection for Femoral Puncture Site Pseudoaneurysms in Neurointervention: Single-Center Experience.
Aneurysm, False
Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort.
Aneurysm, False
Safety and efficacy of the StarClose vascular closure system using 7-F and 8-F sheath sizes: a consecutive single-center analysis.
Aneurysm, False
Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms.
Aneurysm, False
Salvage of autogenous dialysis access with balloon-assisted thrombin injection.
Aneurysm, False
Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms.
Aneurysm, False
Secondary Femoral Access Hemostasis During Transcatheter Aortic Valve Replacement: Impact of Vascular Closure Devices.
Aneurysm, False
Severe allergic reaction: A rare complication of ultrasound-guided injection of thrombin in a femoral pseudoaneurysm.
Aneurysm, False
Short-term results with transcatheter aortic valve replacement for treatment of left ventricular assist device patients with symptomatic aortic insufficiency.
Aneurysm, False
Sonographically guided percutaneous thrombin injection for treatment of a vein graft pseudoaneurysm.
Aneurysm, False
Sonographically guided percutaneous thrombin injection versus sonographically guided compression for femoral artery pseudoaneurysms.
Aneurysm, False
Sonographically guided thrombin injection for the treatment of femoral artery pseudoaneurysm.
Aneurysm, False
Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution.
Aneurysm, False
Splenic artery pseudoaneurysm treated with thrombin injection guided by endoscopic ultrasound.
Aneurysm, False
Spontaneous external jugular vein pseudoaneurysm treated by thrombin injection: Case report and literature review.
Aneurysm, False
Stent graft exclusion of pseudo-aneurysm arising from PTFE hemodialysis graft after recurrence following ultrasound guided thrombin injection.
Aneurysm, False
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Aneurysm, False
Successful balloon assisted percutaneous thrombin injection of right subclavian artery pseudoaneurysm.
Aneurysm, False
Successful direct thrombin injection of a femoral artery pseudoaneurysm in an anticoagulated patient with a mechanical mitral valve.
Aneurysm, False
Successful endovascular treatment of a hemodialysis graft pseudoaneurysm by covered stent and direct percutaneous thrombin injection.
Aneurysm, False
Successful percutaneous thrombin injection of a brachial artery pseudoaneurysm in a neonate.
Aneurysm, False
Successful Percutaneous Transcatheter Closure of a Common Femoral Artery Pseudoaneurysm With Use of MicroVascular Plug Despite Continued Catheter-Directed Thrombolysis.
Aneurysm, False
Successful Post-Pancreatitis Pseudoaneurysm Coagulation by Percutaneous Computed Tomography (CT)-Guided Thrombin Injection.
Aneurysm, False
Successful sonographically guided thrombin injection in an infant with a femoral artery pseudoaneurysm.
Aneurysm, False
Successful Treatment of a Common Femoral Arterial Pseudoaneurysm with US-Guided Thrombin Injection: A Case Report.
Aneurysm, False
Successful treatment of a femoral artery pseudoaneurysm mimicking a deep venous thrombosis following cardiac catheterization.
Aneurysm, False
Successful treatment of a femoral pseudoaneurysm by ultrasonographically-guided application of a suture-mediated closure device.
Aneurysm, False
Successful treatment of a mycotic pseudoaneurysm of the brachial artery with percutaneous ultrasound-guided thrombin injection and antibiotics.
Aneurysm, False
Successful treatment of a two centimeter breast pseudoaneurysm with thrombin injection.
Aneurysm, False
Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection.
Aneurysm, False
Successful Treatment of Iatrogenic Subclavian Artery Pseudoaneurysm by Ultrasound-Guided Thrombin Injection.
Aneurysm, False
Successful treatment of uterine artery pseudoaneurysm with laparoscopic temporary clamping of bilateral uterine arteries, followed by hysteroscopic surgery.
Aneurysm, False
Superior mesenteric artery pseudoaneurysm following pancreaticoduodenectomy: management by endovascular stent-graft placement and transluminal thrombin injection.
Aneurysm, False
Surgical Treatment of an Extrarenal Pseudoaneurysm After Kidney Transplantation.
Aneurysm, False
Temporary aneurysm neck balloon occlusion during percutaneous thrombin embolization of a superficial femoral artery pseudoaneurysm.
Aneurysm, False
The recurrence of iatrogenic femoral artery pseudoaneurysm after occlusion by ultrasound guided percutaneous thrombin injection.
Aneurysm, False
The Use of ExoSeal Vascular Closure Device for Direct Antegrade Superficial Femoral Artery Puncture Site Hemostasis.
Aneurysm, False
Therapeutic thrombin injection of pseudoaneurysms: a multicenter experience.
Aneurysm, False
Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm.
Aneurysm, False
Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child.
Aneurysm, False
Thrombin injection for failed stent graft repair of perforated atherosclerotic aortic ulcer.
Aneurysm, False
Thrombin injection for treatment of brachial artery pseudoaneurysm at the site of a hemodialysis fistula: report of two patients.
Aneurysm, False
Thrombin injection for treatment of false aneurysms after failed compression therapy in patients on full-dose antiplatelet and heparin therapy.
Aneurysm, False
Thrombin injection of a pancreaticoduodenal artery pseudoaneurysm after failed attempts at transcatheter embolization.
Aneurysm, False
Thrombin Injection to Treat an Iatrogenic Internal Mammary Artery Pseudoaneurysm.
Aneurysm, False
Thrombin injection to treat pseudoaneurysm of internal mammary artery bypass graft: a case report.
Aneurysm, False
Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis.
Aneurysm, False
Thrombosis of a proximal aortic false aneurysm following AAA repair by endovascular thrombin injection.
Aneurysm, False
Transarterial Thrombin Injection Secured with an Embolic Protection Device as a Treatment for a Superior Mesenteric Artery Pseudoaneurysm.
Aneurysm, False
Transcatheter occlusion of a profunda femoral artery pseudoaneurysm using thrombin.
Aneurysm, False
Translumbar thrombin embolization of an aortic pseudoaneurysm complicating lumbar disk surgery.
Aneurysm, False
Transluminal occlusion of a pseudoaneurysm arising from a thoracic aortic graft patch using catheter delivery of thrombin.
Aneurysm, False
Transvaginal ultrasound-guided direct thrombin injection for the treatment of intramyometrial pseudoaneurysm in a young female with uterine hemorrhage after failed uterine artery embolization.
Aneurysm, False
Traumatic Aorto-Cisterna Chlyi Fistula with Treatment of Aortic Pseudoaneurysm with CT-Guided Thrombin Injection.
Aneurysm, False
Traumatic axillary artery pseudoaneurysm treated with intravascular balloon occlusion and percutaneous thrombin injection.
Aneurysm, False
Traumatic Inferior Gluteal Artery Aneurysm Managed with Emergency Transcatheter Thrombin Injection.
Aneurysm, False
Traumatic Pseudoaneurysm of Anterior Tibial Artery Treated by Thrombin Injection.
Aneurysm, False
Traumatic pseudoaneurysm of the anterior tibial artery treated with ultrasound-guided thrombin injection in a pediatric patient.
Aneurysm, False
Traumatic pseudoaneurysm of the ulnar artery treated with ultrasound guided thrombin injection.
Aneurysm, False
Treatment of a radial artery pseudoaneurysm with ultrasound-guided percutaneous thrombin injection in a patient with Behçet's syndrome.
Aneurysm, False
Treatment of a splenic artery pseudoaneurysm by endoscopic ultrasound-guided thrombin injection.
Aneurysm, False
Treatment of an extracapsular post-renal biopsy pseudoaneurysm with ultrasound-guided thrombin injection.
Aneurysm, False
Treatment of an iatrogenic femoral artery pseudoaneurysm with concomitant arteriovenous fistula with percutaneous implantation of an amplatzer vascular plug.
Aneurysm, False
Treatment of an iatrogenic femoral artery pseudoaneurysm with percutaneous duplex-guided injection of thrombin.
Aneurysm, False
Treatment of arterial pseudoaneurysms with percutaneous ultrasound-guided thrombin injection.
Aneurysm, False
Treatment of Common Femoral Artery Pseudoaneurysm: A Novel Approach Utilizing a VASCADE Percutaneous Closure Device.
Aneurysm, False
Treatment of femoral artery pseudoaneurysm with percutaneous thrombin injection.
Aneurysm, False
Treatment of femoral artery pseudoaneurysms using percutaneous thrombin injection under ultrasound guidance alone-proceed with caution.
Aneurysm, False
Treatment of femoral artery pseudoaneurysms using ultrasound-guided thrombin injection.
Aneurysm, False
Treatment of femoral artery pseudoaneurysms with percutaneous thrombin injection.
Aneurysm, False
Treatment of femoral pseudoaneurysms. Percutaneous US-guided thrombin injection versus US-guided compression.
Aneurysm, False
Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair.
Aneurysm, False
Treatment of iatrogenic femoral artery false aneurysms with ultrasound-guided thrombin injection.
Aneurysm, False
Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection.
Aneurysm, False
Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin.
Aneurysm, False
Treatment of iatrogenic femoral pseudoaneurysm by ultrasound-guided compression therapy and thrombin injection.
Aneurysm, False
Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients.
Aneurysm, False
Treatment of iatrogenic pseudoaneurysm of brachial artery with percutaneous ultrasonographically guided thrombin injection (PUGTI): a case report and a literature review.
Aneurysm, False
Treatment of Iatrogenic Pseudoaneurysms Using Ultrasound-Guided Thrombin Injection over a 5-Year Period.
Aneurysm, False
Treatment of pancreatic pseudoaneurysm with percutaneous transabdominal thrombin injection.
Aneurysm, False
Treatment of post-catheterization femoral artery pseudo-aneurysm with para-aneurysmal saline injection.
Aneurysm, False
Treatment of postcatheterisation false aneurysms: ultrasound-guided compression vs ultrasound-guided thrombin injection.
Aneurysm, False
Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection.
Aneurysm, False
Treatment of radial and ulnar artery pseudoaneurysms using percutaneous thrombin injection.
Aneurysm, False
Treatment of spontaneous lumbar artery pseudoaneurysm by computed tomography--guided thrombin injection.
Aneurysm, False
Treatment of subclavian artery pseudoaneurysm with use of US-guided percutaneous thrombin injection.
Aneurysm, False
Treatment options for traumatic pseudoaneurysms of the paravisceral abdominal aorta.
Aneurysm, False
Treatment protocol of traumatic pseudoaneurysm of the superficial temporal artery.
Aneurysm, False
Treatment strategies for bleeding from gastroduodenal artery pseudoaneurysms complicating the course of chronic pancreatitis-A case series of 10 patients.
Aneurysm, False
Ulnar pseudoaneurysm after transulnar coronary angiogram treated with percutaneous ultrasound-guided thrombin injection.
Aneurysm, False
Ultrasonic-guided percutaneous injection of pancreatic pseudoaneurysm with thrombin.
Aneurysm, False
Ultrasonography-guided percutaneous thrombin injection of postcatheterization pseudoaneurysms.
Aneurysm, False
Ultrasound Guided Compression Versus Ultrasound Guided Thrombin Injection for the Treatment of Post-Catheterization Femoral Pseudoaneurysms: Systematic Review and Meta-Analysis of Comparative Studies.
Aneurysm, False
Ultrasound Guided Local Endovascular Coiling of an Iatrogenic Superficial Temporal Artery Pseudoaneurysm.
Aneurysm, False
Ultrasound Guided Percutaneous Injection of Thrombin: Effective Technique for Treatment of Iatrogenic Femoral Pseudoaneurysms.
Aneurysm, False
Ultrasound guided percutaneous thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Aneurysm, False
Ultrasound guided percutaneous thrombin injection for the treatment of post-catheterisation femoral pseudoaneurysm.
Aneurysm, False
Ultrasound guided percutaneous thrombin injection in a radial artery pseudoaneurysm following percutaneous coronary intervention.
Aneurysm, False
Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention.
Aneurysm, False
Ultrasound guided thrombin injection of pseudoaneurysm of the radial artery after percutaneous coronary intervention.
Aneurysm, False
Ultrasound guided thrombin injection to treat a pseudoaneurysm secondary to chronic pancreatitis.
Aneurysm, False
Ultrasound-guided percutaneous thrombin for the management of superior mesenteric artery pseudoaneurysm.
Aneurysm, False
Ultrasound-guided percutaneous thrombin injection for femoral artery pseudoaneurysms.
Aneurysm, False
Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm.
Aneurysm, False
Ultrasound-guided percutaneous thrombin injection for treatment of extrarenal pseudoaneurysm after renal transplantation.
Aneurysm, False
Ultrasound-guided percutaneous thrombin injection for treatment of femoral pseudoaneurysms: technical note.
Aneurysm, False
Ultrasound-guided percutaneous thrombin injection of iatrogenic upper extremity pseudoaneurysms.
Aneurysm, False
Ultrasound-guided thrombin injection for pseudoaneurysms: a case series at a local hospital.
Aneurysm, False
Ultrasound-guided thrombin injection for the treatment of an iatrogenic hepatic artery pseudoaneurysm: a case report.
Aneurysm, False
Ultrasound-Guided Thrombin Injection for the Treatment of Femoral Pseudoaneurysm in Pediatric Patients.
Aneurysm, False
Ultrasound-guided thrombin injection for the treatment of iatrogenic pseudoaneurysm of the femoral artery.
Aneurysm, False
Ultrasound-guided thrombin injection for the treatment of postcatheterization pseudoaneurysms.
Aneurysm, False
Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience.
Aneurysm, False
Ultrasound-guided thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms compared with open surgery: first experiences from a single institution.
Aneurysm, False
Ultrasound-guided thrombin injection for treatment of superficial traumatic pseudoaneurysms and associated expanding hematomas: experience in five patients.
Aneurysm, False
Ultrasound-guided thrombin injection in the management of pseudoaneurysm after percutaneous arterial access.
Aneurysm, False
Ultrasound-guided thrombin injection in the treatment of iatrogenic arterial pseudoaneurysms: Single-center experience.
Aneurysm, False
Ultrasound-guided thrombin injection is a safe and durable treatment for femoral pseudoaneurysms.
Aneurysm, False
Ultrasound-Guided Thrombin Injection Is a Safe and Effective Treatment for Femoral Artery Pseudoaneurysm in the Morbidly Obese.
Aneurysm, False
Ultrasound-guided thrombin injection is the treatment of choice for femoral pseudoaneurysms.
Aneurysm, False
Ultrasound-guided thrombin injection of iatrogenic femoral pseudoaneurysms: a prospective analysis.
Aneurysm, False
Ultrasound-guided thrombin injection of iatrogenic groin pseudoaneurysm: Doppler features and technical tips.
Aneurysm, False
Ultrasound-guided thrombin injection of iatrogenic pseudoaneurysm at a community hospital.
Aneurysm, False
Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience.
Aneurysm, False
Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience.
Aneurysm, False
Ultrasound-guided thrombin injection: an alternative treatment for femoral artery pseudoaneurysm with better efficiency and safety.
Aneurysm, False
Ultrasound-guided thrombin injections for arterial pseudoaneurysms: a 14-year study conducted at King Khalid University Hospital Vascular Lab.
Aneurysm, False
Ultrasound-guided transvaginal thrombin injection of uterine arteries pseudoaneurysms.
Aneurysm, False
US-guided percutaneous thrombin injection: a new method of repair of superficial temporal artery pseudoaneurysm.
Aneurysm, False
Use of an endovascular stent graft and percutaneous thrombin injection to treat an iatrogenic hepatic artery pseudoaneurysm.
Aneurysm, False
Use of the 8-f angio-seal vascular closure device in large-caliber arteriotomies.
Aneurysm, False
Usefulness of ultrasonography in diagnosis, percutaneous management and follow up of post-traumatic scalp pseudoaneurysms.
Aneurysm, False
Utility of percutaneous thrombin injection for treating visceral pseudoaneurysms.
Aneurysm, False
Varied percutaneous and endovascular management of large iatrogenic Profunda Femoris artery pseudoaneurysm.
Aneurysm, False
Vascular and interventional case of the day. Pancreatic head pseudoaneurysm treated with percutaneous thrombin injection.
Aneurysm, False
[Acute femoral artery thrombosis after thrombin injection of a pseudoaneurysm]
Aneurysm, False
[Application of the percutaneuos thrombin injection in treatment of iatrogenic femoral pseudoaneurysms]
Aneurysm, False
[Comment to article Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.]
Aneurysm, False
[Feasibility, efficacy and safety of transbrachial access for interventional therapy on paravalvular leak post surgical valve replacement].
Aneurysm, False
[Femoral artery pseudoaneurysms: treatment with ultrasound guided thrombin injection in 28 patients]
Aneurysm, False
[Femoral pseudoaneurysms - ultrasound-guided thrombin injection as a method of treatment]
Aneurysm, False
[Minimally invasive percutaneous contrast-ultrasound guided thrombin occlusion of iatrogenic pseudoaneurysm]
Aneurysm, False
[Percutaneous thrombin injection for closure of femoral pseudoaneurysms: preliminary experience]
Aneurysm, False
[Puncture treatment of pseudoaneurysms of femoral arteries with the use of human thrombin].
Aneurysm, False
[The treatment of iatrogenic spurious aneurysm of the femoral artery by direct thrombin injection]
Aneurysm, False
[Treatment of iatrogenic femoral pseudoaneurysms by ultrasound-guided percutaneous thrombin injection: effectiveness and complications]
Aneurysm, False
[Treatment of iatrogenic femoral pseudoaneurysms with thrombin injection--results in 54 patients]
Aneurysm, False
[Treatment of post-catheterization pseudoaneurysms by ultrasound-guided thrombin injection: A single-center experience and practical guideline].
Aneurysm, False
[Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.]
Aneurysm, False
[Ultrasound guided percutaneous thrombin injection for treatment of a pseudoaneurysm after inguinal or brachial catheterization; good results in 14 patients]
Aneurysm, False
[Ultrasound-guided intraluminal thrombin injection for false aneurysm: report of one case]
Aneurysm, False
[Ultrasound-guided percutaneous thrombin injection therapy for the treatment of iatrogenic brachial pseudoaneurysms].
Aneurysm, False
[Ultrasound-guided thrombin injection for the treatment of femoral artery pseudoaneurysms--report of three cases]
Aneurysm, False
[US-guided percutaneous management of femoral artery pseudoaneurysms by thrombin injection: personal experience and review of the literature]
Aneurysm, False
[Usefulness of sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms]
Aneurysm, Infected
Mycotic Aneurysm of the Hepatic Artery: A Case Report and its Management.
Aneurysm, Infected
Percutaneous thrombin embolization of a hepatic artery mycotic aneurysm.
Aneurysm, Ruptured
A ruptured aneurysm after stent graft puncture during computed tomography-guided thrombin injection.
Angina Pectoris
Functional and antigenic antithrombin III in angina pectoris and acute myocardial infarction patients.
Angina Pectoris
Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis.
Angina Pectoris
[The effect of plasmasorption on the content of natural antibodies to thrombin and alpha 2-macroglobulin in stenocardia patients]
Angina Pectoris
[The prognostic significance of changes in the level of natural antibodies to thrombin in stenocardia patients]
Angina Pectoris
[Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease]
Angina, Stable
Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
Angina, Stable
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
Angina, Stable
Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients.
Angina, Stable
Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction.
Angina, Stable
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Angina, Stable
Markers of hemostatic activation in affected coronary arteries during angioplasty.
Angina, Stable
Platelet release reaction and prostaglandin pathway activation in angina patients during exercise: effect of indobufen.
Angina, Stable
Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet' Response to Clopidogrel in Patients with Stable Angina.
Angina, Stable
The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention.
Angina, Stable
Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation.
Angina, Stable
[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease]
Angina, Unstable
A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.
Angina, Unstable
Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris.
Angina, Unstable
Activation of blood coagulation by plaque rupture: mechanisms and prevention.
Angina, Unstable
Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
Angina, Unstable
Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization.
Angina, Unstable
Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Angina, Unstable
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Angina, Unstable
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy).
Angina, Unstable
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy).
Angina, Unstable
Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Angina, Unstable
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Angina, Unstable
Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina.
Angina, Unstable
Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris.
Angina, Unstable
Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction.
Angina, Unstable
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.
Angina, Unstable
Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Angina, Unstable
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
Angina, Unstable
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Angina, Unstable
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Angina, Unstable
Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study.
Angina, Unstable
Fibrinopeptide A excretion in urine: a marker of the cumulative thrombin activity in stable versus unstable angina patients.
Angina, Unstable
G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
Angina, Unstable
Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Angina, Unstable
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Angina, Unstable
In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
Angina, Unstable
Increased number of thromboxane A2-prostaglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation.
Angina, Unstable
Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: the role of thrombosis, fibrinolysis and atherosclerotic burden.
Angina, Unstable
Lack of Correlation Between Activation of Hemostatic Mechanism and Inflammation in Unstable Angina Pectoris.
Angina, Unstable
Platelet-dependent thrombin generation in patients with unstable angina pectoris.
Angina, Unstable
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Angina, Unstable
Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
Angina, Unstable
Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina.
Angina, Unstable
Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
Angina, Unstable
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
Angina, Unstable
Synthetic direct thrombin inhibitors in unstable angina - more questions than answers.
Angina, Unstable
Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina.
Angina, Unstable
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.
Angina, Unstable
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Angina, Unstable
Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest.
Angina, Unstable
Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
Angina, Unstable
Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal?
Angina, Unstable
Thrombomodulin--endothelial thrombin receptor in blood of patients with unstable angina pectoris.
Angina, Unstable
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Angina, Unstable
Transient intermittent lymphocyte activation is responsible for the instability of angina.
Angina, Unstable
Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty.
Angina, Unstable
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Angina, Unstable
[Clinical presentation of unstable angina may influence the formation of thrombin during spontaneous episodes of ischemia]
Angina, Unstable
[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins]
Angioedema
Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency.
Angioedema
Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency.
Angioedema
Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant.
Angioedemas, Hereditary
Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.
Angioedemas, Hereditary
Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency.
Angioedemas, Hereditary
Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant.
Angiomyolipoma
Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection.
Anthrax
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Antiphospholipid Syndrome
A catastrophic antiphospholipid syndrome complicated with heparin-induced thrombocytopaenia, successfully managed with double filtration plasmapheresis, steroids and a direct thrombin inhibitor.
Antiphospholipid Syndrome
A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.
Antiphospholipid Syndrome
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Antiphospholipid Syndrome
Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome.
Antiphospholipid Syndrome
Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.
Antiphospholipid Syndrome
Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms.
Antiphospholipid Syndrome
Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events.
Antiphospholipid Syndrome
Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency.
Antiphospholipid Syndrome
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Antiphospholipid Syndrome
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Antiphospholipid Syndrome
Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin.
Antiphospholipid Syndrome
Identification of thrombin antibodies in patients with antiphospholipid syndrome.
Antiphospholipid Syndrome
Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome.
Antiphospholipid Syndrome
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Antiphospholipid Syndrome
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
Antiphospholipid Syndrome
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Antiphospholipid Syndrome
Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.
Antiphospholipid Syndrome
Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome.
Antiphospholipid Syndrome
Thrombin Generation in a patient with Triple Positive Antiphospholipid Syndrome Treated with Three Different Anticoagulants.
Antiphospholipid Syndrome
Thrombin inhibition profiles in healthy individuals and thrombophilic patients.
Antiphospholipid Syndrome
Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay.
Antithrombin III Deficiency
A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor.
Antithrombin III Deficiency
Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
Antithrombin III Deficiency
An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Antithrombin III Deficiency
Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.
Antithrombin III Deficiency
Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
Antithrombin III Deficiency
Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.
Antithrombin III Deficiency
Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes.
Antithrombin III Deficiency
The transient increase of plasma thrombin-antithrombin III (TAT) complex levels in patients with congenital antithrombin III deficiency during antithrombin III administration is due to extraction of thrombin from fibrin.
Antithrombin III Deficiency
Thrombin generation and formation of thrombin-antithrombin III complexes in congenital antithrombin III deficiency.
Aortic Aneurysm
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Aortic Aneurysm
Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice.
Aortic Aneurysm, Abdominal
A case of hybrid repair of ruptured abdominal aortic aneurysm with use of thrombin for acute treatment of type II endoleak.
Aortic Aneurysm, Abdominal
Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate?
Aortic Aneurysm, Abdominal
Changes in circulating markers of coagulation and fibrinolysis after EVAR.
Aortic Aneurysm, Abdominal
Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair.
Aortic Aneurysm, Abdominal
Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair.
Aortic Aneurysm, Abdominal
Effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis.
Aortic Aneurysm, Abdominal
Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping.
Aortic Aneurysm, Abdominal
Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair.
Aortic Aneurysm, Abdominal
Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass?
Aortic Aneurysm, Abdominal
Ischaemia and reperfusion during open abdominal aortic aneurysm surgery induce extensive thrombin generation and activity.
Aortic Aneurysm, Abdominal
Markers of proteolysis, fibrinolysis, and coagulation in relation to size and growth rate of abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Percutaneous direct thrombin injection with hydrodissection to manage type II endoleak after endovascular abdominal aortic aneurysm repair.
Aortic Aneurysm, Abdominal
Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery.
Aortic Aneurysm, Abdominal
Successful treatment of a type-II endoleak with percutaneous CT-guided thrombin injection in a patient after endovascular abdominal aortic aneurysm repair.
Aortic Aneurysm, Abdominal
The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Transluminal thrombin injection and exclusion of a paramesenteric abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac.
Aortic Aneurysm, Abdominal
Vascular surgical society of great britain and ireland: inhibition of systemic fibrinolysis is associated with myocardial injury in patients operated on for ruptured abdominal aortic aneurysm
Aortic Aneurysm, Abdominal
[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.]
Aortic Aneurysm, Thoracic
Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice.
Aortic Coarctation
Endovascular management of a rare complication of an aortic coarctation.
Aortic Coarctation
Platelet-derived microparticles promote endothelial cell proliferation in hypertension via miR-142-3p.
Aortic Valve Stenosis
Activated factor XI and tissue factor in aortic stenosis: links with thrombin generation.
Aortic Valve Stenosis
Ambivalent effect of aortic stenosis on von Willebrand factor and thrombin generation. Is transvalvular gradient the guilty party?
Aortic Valve Stenosis
Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration.
Aortic Valve Stenosis
Exercise stress testing enhances blood coagulation and impairs fibrinolysis in asymptomatic aortic valve stenosis.
Aortic Valve Stenosis
Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties.
Aortic Valve Stenosis
Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease.
Aortic Valve Stenosis
Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis.
Aortic Valve Stenosis
Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis.
Aortic Valve Stenosis
Oral Anticoagulation Therapy and Progression of Calcific Aortic Valve Stenosis: Factor Xa versus Factor IIa Inhibition?
Aortic Valve Stenosis
Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin.
Appendicitis
[The role of thyroid and thymic hormones in regulation of fibrinolytic and pro-coagulant activity of leukocytes in patients with acute destructive appendicitis]
Arenaviridae Infections
Haemostatic derangements associated with arenavirus infection in the guinea-pig: radioimmunoassay of fibrinopeptide A to assess thrombin action in infected animals.
Arrhythmias, Cardiac
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Arrhythmias, Cardiac
Platelet reactivity and mean platelet volume as risk markers of thrombogenesis in atrial fibrillation.
Arrhythmias, Cardiac
Thrombin facilitation of voltage-gated sodium channel activation in human cardiomyocytes: implications for ischemic sodium loading.
Arterial Occlusive Diseases
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Arterial Occlusive Diseases
Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
Arterial Occlusive Diseases
Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban.
Arterial Occlusive Diseases
Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin.
Arterial Occlusive Diseases
Thrombin and platelet inhibition with low-dose calcium-heparin in comparison with ASA in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class.
Arterial Occlusive Diseases
Thrombin-antithrombin complex and the prothrombin fragment in arterial and venous blood of patients with peripheral arterial disease.
Arteriosclerosis
Fibrin formation and degradation in patients with arteriosclerotic disease.
Arteriosclerosis
Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds.
Arteriosclerosis
[Effect of alimentary lipemia on thrombin generation in the plasma of healthy persons and in arteriosclerosis]
Arteriosclerosis
[Pathogenesis of arteriosclerosis. Thrombin, factor XIII and fibronectin as regulators of fibroblast proliferation, endothelial cells and smooth muscle cells]
Arteriosclerosis
[The thrombin generation test and heparin overloading in normal subjects and patients with arteriosclerosis]
Arteriovenous Fistula
Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
Arteriovenous Fistula
Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula.
Arteriovenous Fistula
Endovascular repair of a large post-traumatic calf pseudoaneurysm and arteriovenous fistula.
Arteriovenous Fistula
Interventional treatment of arterial injury during blind central venous catheterisation in the upper thorax: experience from two centres.
Arteriovenous Fistula
Percutaneous thrombin injection of a femoral artery pseudoaneurysm with simultaneous venous balloon occlusion of a communicating arteriovenous fistula.
Arteriovenous Fistula
Post-traumatic pseudoaneurysm of the medial plantar artery with arteriovenous fistula treated by coil embolization of the main feeding artery and percutaneous thrombin injection.
Arteriovenous Fistula
Ultrasound-guided thrombin injection in the management of pseudoaneurysm after percutaneous arterial access.
Arteriovenous Malformations
Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Arteriovenous Malformations
Nonsurgical treatment of scalp arteriovenous malformation using a combination of ultrasound-guided thrombin injection and transarterial coil embolization.
Arthritis
Autoantibody-mediated arthritis in the absence of C3 and activating Fc? receptors: C5 is activated by the coagulation cascade.
Arthritis
Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis.
Arthritis
Prothrombin gene expression in articular cartilage with a putative role in cartilage degeneration secondary to joint immobility.
Arthritis
Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.
Arthritis
Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody.
Arthritis
Thrombin promotes matrix metalloproteinase-13 expression through the PKC? c-Src/EGFR/PI3K/Akt/AP-1 signaling pathway in human chondrocytes.
Arthritis, Experimental
Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Arthritis, Rheumatoid
A hirudin-sensitive, growth-related proteinase from human fibroblasts.
Arthritis, Rheumatoid
Alterations of the thrombin generation profile in rheumatoid arthritis.
Arthritis, Rheumatoid
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Arthritis, Rheumatoid
Assessment of hemostatic disturbances in women with established rheumatoid arthritis.
Arthritis, Rheumatoid
Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro.
Arthritis, Rheumatoid
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
Arthritis, Rheumatoid
Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Osteopontin is dispensable for protection against high load systemic fungal infection.
Arthritis, Rheumatoid
Relationship between cathepsin B and thrombin in rheumatoid arthritis.
Arthritis, Rheumatoid
The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.
Arthritis, Rheumatoid
Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition.
Arthritis, Rheumatoid
Thrombin in inflammation and healing: relevance to rheumatoid arthritis.
Arthritis, Rheumatoid
Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor.
Arthritis, Rheumatoid
Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis.
Arthritis, Rheumatoid
Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue.
Arthritis, Rheumatoid
Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Thrombin stimulates cell proliferation in human fibroblast-like synoviocytes in nuclear factor-kappaB activation and protein kinase C mediated pathway.
Arthritis, Rheumatoid
Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts.
Arthritis, Rheumatoid
Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis.
Arthritis, Rheumatoid
Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Arthritis, Rheumatoid
Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1.
Arthritis, Rheumatoid
Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin.
Arthus Reaction
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Asthma
A functional polymorphism (-603A --> G) in the tissue factor gene promoter is associated with adult-onset asthma.
Asthma
Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation.
Asthma
alpha-Thrombin increases cytosolic calcium and induces human airway smooth muscle cell proliferation.
Asthma
alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors.
Asthma
Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes-associated protein.
Asthma
Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma.
Asthma
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Asthma
Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice.
Asthma
Impaired fibrinolysis and lower levels of plasma ?2-macroglobulin are associated with an increased risk of severe asthma exacerbations.
Asthma
Increased thrombin activity after allergen challenge: a potential link to airway remodeling?
Asthma
Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells.
Asthma
Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF?, in Peripheral Blood.
Asthma
Role of the extracellular signal-regulated kinase 1/2 signaling pathway in the process of thrombin-promoting airway remodeling in ovalbumin-allergic rats.
Asthma
The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.
Asthma
Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways.
Asthma
[Potential mechanisms of airway remodeling initiated by activated thrombin in asthma]
Astrocytoma
A requirement for Ras protein function in thrombin-stimulated mitogenesis in astrocytoma cells.
Astrocytoma
A rho exchange factor mediates thrombin and Galpha(12)-induced cytoskeletal responses.
Astrocytoma
Ca2+ mobilization mediated by transient receptor potential canonical 3 is associated with thrombin-induced morphological changes in 1321N1 human astrocytoma cells.
Astrocytoma
Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes.
Astrocytoma
Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells.
Astrocytoma
G12 requirement for thrombin-stimulated gene expression and DNA synthesis in 1321N1 astrocytoma cells.
Astrocytoma
Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma.
Astrocytoma
Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation.
Astrocytoma
Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis.
Astrocytoma
Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2.
Astrocytoma
Subnanomolar concentrations of thrombin enhance the volume-sensitive efflux of taurine from human 1321N1 astrocytoma cells.
Astrocytoma
The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain.
Astrocytoma
The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells.
Astrocytoma
Thrombin and trypsin act at the same site to stimulate phosphoinositide hydrolysis and calcium mobilization.
Astrocytoma
Thrombin produces phosphorylation of cytosolic phospholipase A2 by a mitogen-activated protein kinase kinase-independent mechanism in the human astrocytoma cell line 1321N1.
Astrocytoma
Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61.
Astrocytoma
Thrombin receptors modulate insulin-stimulated phosphatidylinositol 3,4,5-trisphosphate accumulation in 1321N1 astrocytoma cells.
Atherosclerosis
A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice.
Atherosclerosis
A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production.
Atherosclerosis
A peptide analogue of thrombin receptor-activating peptide inhibits thrombin and thrombin-receptor-activating peptide-induced vascular smooth muscle cell proliferation.
Atherosclerosis
Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms.
Atherosclerosis
Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation.
Atherosclerosis
Acute and persistent platelet and coagulant activities in atherothrombosis.
Atherosclerosis
Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB.
Atherosclerosis
Anti-hypertensive effect of the Dongchunghacho, Isaria sinclairii, in the spontaneously hypertensive rats.
Atherosclerosis
Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys.
Atherosclerosis
Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells.
Atherosclerosis
Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN.
Atherosclerosis
Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation.
Atherosclerosis
Association of aortic valve sclerosis with thrombin generation in hypertensive patients.
Atherosclerosis
Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E.
Atherosclerosis
Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates.
Atherosclerosis
Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice.
Atherosclerosis
Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin.
Atherosclerosis
Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate.
Atherosclerosis
Baicalin Protects against Thrombin-Induced Cell Injury in Human Umbilical Vein Endothelial Cells.
Atherosclerosis
Bi-cell surface plasmon resonance detection of aptamer mediated thrombin capture in serum.
Atherosclerosis
Blood coagulation and the risk of atherothrombosis: a complex relationship.
Atherosclerosis
cAMP response element-binding protein mediates thrombin-induced proliferation of vascular smooth muscle cells.
Atherosclerosis
Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study.
Atherosclerosis
Comparative beneficial effects on platelet functions and atherosclerosis of dietary linoleic and gamma-linolenic acids in the rabbit.
Atherosclerosis
Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin.
Atherosclerosis
Crystal structures of protease nexin-1 in complex with heparin and thrombin suggest a 2-step recognition mechanism.
Atherosclerosis
Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.
Atherosclerosis
Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation.
Atherosclerosis
Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Atherosclerosis
Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
Atherosclerosis
Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits.
Atherosclerosis
Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE-/--LDLR-/- Double-Knockout Mice.
Atherosclerosis
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
Atherosclerosis
EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells.
Atherosclerosis
Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.
Atherosclerosis
Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.
Atherosclerosis
Formation of factor Va by atherosclerotic rabbit aorta mediates factor Xa-catalyzed prothrombin activation.
Atherosclerosis
Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.
Atherosclerosis
Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells.
Atherosclerosis
Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
Atherosclerosis
Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.
Atherosclerosis
Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Atherosclerosis
High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention.
Atherosclerosis
Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.
Atherosclerosis
Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system.
Atherosclerosis
Impaired platelet prostacyclin receptor activity: a monozygotic twin study discordant for spinal cord injury.
Atherosclerosis
In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity.
Atherosclerosis
Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes.
Atherosclerosis
Induction of synthesis of a large heparan sulfate proteoglycan, perlecan, by thrombin in cultured human coronary smooth muscle cells.
Atherosclerosis
Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Atherosclerosis
Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis.
Atherosclerosis
Intima-Media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction.
Atherosclerosis
Loss of Biglycan Enhances Thrombin Generation in ApoE-Deficient Mice Implications for Inflammation and Atherosclerosis.
Atherosclerosis
Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.
Atherosclerosis
Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy.
Atherosclerosis
Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis.
Atherosclerosis
Mitochondrial protein CMPK2 regulates IFN alpha-enhanced foam cell formation, potentially contributing to premature atherosclerosis in SLE.
Atherosclerosis
Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
Atherosclerosis
N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients.
Atherosclerosis
Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis.
Atherosclerosis
New nonlipid effects of statins and their clinical relevance in cardiovascular disease.
Atherosclerosis
Non-conventional hemostatic risk factors for coronary heart disease in individuals with spinal cord injury.
Atherosclerosis
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Atherosclerosis
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.
Atherosclerosis
Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial.
Atherosclerosis
Pharmacologic agents in stroke prevention, acute stroke therapy, and interventional procedures.
Atherosclerosis
Phloretin suppresses thrombin-mediated leukocyte-platelet-endothelial interactions.
Atherosclerosis
Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis.
Atherosclerosis
Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.
Atherosclerosis
Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors.
Atherosclerosis
Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis.
Atherosclerosis
Platelet-Derived Exosomal MicroRNA-25-3p Inhibits Coronary Vascular Endothelial Cell Inflammation Through Adam10 via the NF-?B Signaling Pathway in ApoE-/- Mice.
Atherosclerosis
Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis.
Atherosclerosis
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Atherosclerosis
Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats.
Atherosclerosis
Protective role of serpina3c as a novel thrombin inhibitor against atherosclerosis in mice.
Atherosclerosis
Protein Kinase C? Via Activating Transcription Factor 2-Mediated CD36 Expression and Foam Cell Formation of Ly6Chi Cells Contributes to Atherosclerosis.
Atherosclerosis
Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease.
Atherosclerosis
Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase.
Atherosclerosis
Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells.
Atherosclerosis
Regenerated Endothelium and Its Senescent Response to Aggregating Platelets.
Atherosclerosis
Relationship between thrombin generation and carotid intima-media thickness.
Atherosclerosis
Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis.
Atherosclerosis
Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty.
Atherosclerosis
Short-term venous stasis induces fibrinolytic activation but not thrombin formation.
Atherosclerosis
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Atherosclerosis
Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.
Atherosclerosis
Suppressing thrombin generation is compatible with the development of atherosclerosis in mice.
Atherosclerosis
The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice : Dabigatran etexilate and atherosclerosis.
Atherosclerosis
The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.
Atherosclerosis
The effect of thrombin on low-density lipoprotein permeability and uptake by an arterial endothelial smooth muscle cell bilayer.
Atherosclerosis
The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in Apolipoprotein E-deficient mice.
Atherosclerosis
The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein.
Atherosclerosis
The isoelectric point of thrombin and its behaviour compared to prothrombin at some solid surfaces.
Atherosclerosis
Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors.
Atherosclerosis
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Atherosclerosis
Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
Atherosclerosis
Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Atherosclerosis
Thrombin activates NF-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle cells: role of thrombin in atherosclerosis and restenosis.
Atherosclerosis
Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process.
Atherosclerosis
Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis.
Atherosclerosis
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis.
Atherosclerosis
Thrombin as a regulator of inflammation and reparative processes in tissues.
Atherosclerosis
Thrombin contraction of vascular smooth muscle: implications for vasospasm.
Atherosclerosis
Thrombin generation markers and coronary heart disease risk factors in a Polish population sample.
Atherosclerosis
Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Src-dependent pathway in vascular smooth muscle cells.
Atherosclerosis
Thrombin induces interleukin-6 expression through the cAMP response element in vascular smooth muscle cells.
Atherosclerosis
Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-?B signaling pathway activation in vascular endothelial cells.
Atherosclerosis
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
Atherosclerosis
Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells.
Atherosclerosis
Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways.
Atherosclerosis
Thrombin stimulates mitogenesis in pig cerebrovascular smooth muscle cells involving activation of pro-matrix metalloproteinase-2.
Atherosclerosis
Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism.
Atherosclerosis
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Atherosclerosis
Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia.
Atherosclerosis
Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro.
Atherosclerosis
Thrombin-induced glucose transport via Src-p38 MAPK pathway in vascular smooth muscle cells.
Atherosclerosis
Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation.
Atherosclerosis
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Atherosclerosis
Tissue factor-driven thrombin generation and inflammation in atherosclerosis.
Atherosclerosis
Transcriptional regulation of platelet-derived growth factor-B chain by thrombin in endothelial cells: involvement of Egr-1 and CREB-binding protein.
Atherosclerosis
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Atherosclerosis
Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor.
Atherosclerosis
[Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?]
Atherosclerosis
[Genetic conditioned changes in activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) and recurrent miscarriages]
Atherosclerosis
[Regulation of the endothelial function by thrombomodulin and/or thrombin receptor]
Atrial Fibrillation
?T -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Atrial Fibrillation
A Case of Liver Failure Due to Dabigatran Treated with Venovenous He-modiafiltration and Idarucizumab.
Atrial Fibrillation
A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor.
Atrial Fibrillation
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Atrial Fibrillation
A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Atrial Fibrillation
A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses.
Atrial Fibrillation
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
Atrial Fibrillation
A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
Atrial Fibrillation
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.
Atrial Fibrillation
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
Atrial Fibrillation
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Atrial Fibrillation
Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin.
Atrial Fibrillation
Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation.
Atrial Fibrillation
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Atrial Fibrillation
Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.
Atrial Fibrillation
Acute myocardial infarction after switching from warfarin to dabigatran.
Atrial Fibrillation
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Atrial Fibrillation
Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation.
Atrial Fibrillation
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
Atrial Fibrillation
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
Atrial Fibrillation
An overview of anticoagulants, antiplatelet agents, and the combination in patients with mechanical heart valves.
Atrial Fibrillation
Analysis of the influence of dabigatran on coagulation factors and inhibitors.
Atrial Fibrillation
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Atrial Fibrillation
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
Atrial Fibrillation
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Atrial Fibrillation
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Atrial Fibrillation
Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Atrial Fibrillation
Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
Atrial Fibrillation
Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden.
Atrial Fibrillation
Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease.
Atrial Fibrillation
Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
Atrial Fibrillation
Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran.
Atrial Fibrillation
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Atrial Fibrillation
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Atrial Fibrillation
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Atrial Fibrillation
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
Atrial Fibrillation
Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran.
Atrial Fibrillation
Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy.
Atrial Fibrillation
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Atrial Fibrillation
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Atrial Fibrillation
Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series.
Atrial Fibrillation
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Atrial Fibrillation
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Atrial Fibrillation
Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran.
Atrial Fibrillation
Coagulation derangement and risk factors for valve thrombosis following transcatheter aortic valve implantation.
Atrial Fibrillation
Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
Atrial Fibrillation
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease.
Atrial Fibrillation
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Atrial Fibrillation
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Atrial Fibrillation
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Atrial Fibrillation
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Atrial Fibrillation
Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
Atrial Fibrillation
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Atrial Fibrillation
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
Atrial Fibrillation
Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation.
Atrial Fibrillation
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.
Atrial Fibrillation
Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
Atrial Fibrillation
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Atrial Fibrillation
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.
Atrial Fibrillation
Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.
Atrial Fibrillation
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Atrial Fibrillation
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation.
Atrial Fibrillation
Cutting through the statistical fog: understanding and evaluating non-inferiority trials.
Atrial Fibrillation
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Atrial Fibrillation
Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study.
Atrial Fibrillation
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Atrial Fibrillation
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
Atrial Fibrillation
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment.
Atrial Fibrillation
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: reply.
Atrial Fibrillation
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Atrial Fibrillation
Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation.
Atrial Fibrillation
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Atrial Fibrillation
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Atrial Fibrillation
Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
Atrial Fibrillation
Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Atrial Fibrillation
Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
Atrial Fibrillation
Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.
Atrial Fibrillation
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.
Atrial Fibrillation
Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
Atrial Fibrillation
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.
Atrial Fibrillation
Dabigatran overdose secondary to acute kidney injury and amiodarone use.
Atrial Fibrillation
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
Atrial Fibrillation
Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.
Atrial Fibrillation
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study.
Atrial Fibrillation
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study).
Atrial Fibrillation
Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?
Atrial Fibrillation
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience.
Atrial Fibrillation
Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
Atrial Fibrillation
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Atrial Fibrillation
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Atrial Fibrillation
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
Atrial Fibrillation
Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Atrial Fibrillation
Dental management considerations for a patient taking dabigatran etexilate: a case report.
Atrial Fibrillation
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Atrial Fibrillation
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Atrial Fibrillation
Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population.
Atrial Fibrillation
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Atrial Fibrillation
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Atrial Fibrillation
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Atrial Fibrillation
Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Atrial Fibrillation
Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation.
Atrial Fibrillation
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Atrial Fibrillation
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Atrial Fibrillation
Direct thrombin inhibitors versus warfarin in nonvalvular atrial fibrillation.
Atrial Fibrillation
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.
Atrial Fibrillation
Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
Atrial Fibrillation
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Atrial Fibrillation
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Atrial Fibrillation
Effect of hypertension on anticoagulated patients with atrial fibrillation.
Atrial Fibrillation
Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation.
Atrial Fibrillation
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Atrial Fibrillation
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Atrial Fibrillation
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
Atrial Fibrillation
Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Atrial Fibrillation
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Atrial Fibrillation
Effects of aspirin on status of thrombin generation in atrial fibrillation.
Atrial Fibrillation
Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.
Atrial Fibrillation
Emerging role of direct thrombin inhibitors in nonvalvular atrial fibrillation: potential and peril.
Atrial Fibrillation
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.
Atrial Fibrillation
Ex Vivo Thrombin Generation in Patients With Venous Thromboembolic Disease or Atrial Fibrillation on Long-Term Oral Anticoagulation.
Atrial Fibrillation
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Atrial Fibrillation
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Atrial Fibrillation
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Atrial Fibrillation
Generation of an anti-dabigatran monoclonal antibody and its employment in a highly sensitive and specific enzyme-linked immunosorbent assay for serum dabigatran.
Atrial Fibrillation
Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice.
Atrial Fibrillation
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Atrial Fibrillation
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Atrial Fibrillation
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Atrial Fibrillation
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Atrial Fibrillation
Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation.
Atrial Fibrillation
Hypercoagulability existing in the local left atrium of patient with mitral stenosis.
Atrial Fibrillation
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Atrial Fibrillation
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Atrial Fibrillation
Impaired renal function and bleeding in elderly treated with dabigatran.
Atrial Fibrillation
Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Atrial Fibrillation
In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke.
Atrial Fibrillation
Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment.
Atrial Fibrillation
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Atrial Fibrillation
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Atrial Fibrillation
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Atrial Fibrillation
Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran.
Atrial Fibrillation
Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.
Atrial Fibrillation
Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran.
Atrial Fibrillation
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Atrial Fibrillation
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Atrial Fibrillation
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect.
Atrial Fibrillation
Left atrial appendage thrombus on full-dose dabigatran treatment: a case report.
Atrial Fibrillation
Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation.
Atrial Fibrillation
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Atrial Fibrillation
Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?
Atrial Fibrillation
Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report.
Atrial Fibrillation
Management of dabigatran-induced bleeding with continuous venovenous hemodialysis.
Atrial Fibrillation
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Atrial Fibrillation
Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study.
Atrial Fibrillation
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Atrial Fibrillation
Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
Atrial Fibrillation
Monitoring the roles of prothrombin activation fragment 1 and 2 (F1?+?2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
Atrial Fibrillation
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Atrial Fibrillation
New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery.
Atrial Fibrillation
Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm.
Atrial Fibrillation
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Atrial Fibrillation
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Atrial Fibrillation
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
Atrial Fibrillation
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Atrial Fibrillation
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Atrial Fibrillation
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Atrial Fibrillation
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Atrial Fibrillation
Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran.
Atrial Fibrillation
Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment.
Atrial Fibrillation
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Atrial Fibrillation
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Atrial Fibrillation
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
Atrial Fibrillation
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal.
Atrial Fibrillation
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: reply to a rebuttal.
Atrial Fibrillation
Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
Atrial Fibrillation
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Atrial Fibrillation
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Atrial Fibrillation
Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke.
Atrial Fibrillation
Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels.
Atrial Fibrillation
Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.
Atrial Fibrillation
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Atrial Fibrillation
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Atrial Fibrillation
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
Atrial Fibrillation
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration.
Atrial Fibrillation
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Atrial Fibrillation
Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.
Atrial Fibrillation
Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.
Atrial Fibrillation
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Atrial Fibrillation
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Atrial Fibrillation
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Atrial Fibrillation
S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Atrial Fibrillation
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Atrial Fibrillation
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Atrial Fibrillation
SPORTIF III and SPORTIF V: Stroke Prevention Using the Direct Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation.
Atrial Fibrillation
Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack.
Atrial Fibrillation
Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
Atrial Fibrillation
Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Atrial Fibrillation
Stroke prevention using an oral thrombin inhibitor in atrial fibrillation.
Atrial Fibrillation
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. Pooled Analysis from the SPORTIF III and V Studies.
Atrial Fibrillation
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Atrial Fibrillation
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Atrial Fibrillation
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
Atrial Fibrillation
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Atrial Fibrillation
The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation.
Atrial Fibrillation
The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation.
Atrial Fibrillation
The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs.
Atrial Fibrillation
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
Atrial Fibrillation
The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation.
Atrial Fibrillation
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
Atrial Fibrillation
The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios.
Atrial Fibrillation
The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran.
Atrial Fibrillation
Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban.
Atrial Fibrillation
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke.
Atrial Fibrillation
Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Atrial Fibrillation
Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects.
Atrial Fibrillation
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Atrial Fibrillation
Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
Atrial Fibrillation
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
Atrial Fibrillation
Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Atrial Fibrillation
Trials and tribulations of non-inferiority: the ximelagatran experience.
Atrial Fibrillation
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Atrial Fibrillation
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Atrial Fibrillation
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function.
Atrial Fibrillation
Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
Atrial Fibrillation
Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit.
Atrial Fibrillation
Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
Atrial Fibrillation
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
Atrial Fibrillation
Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation.
Atrial Fibrillation
Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
Atrial Fibrillation
Will this be the end of the anticoagulation clinic for patients with atrial fibrillation?
Atrial Fibrillation
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Atrial Fibrillation
Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Atrial Fibrillation
Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
Atrial Fibrillation
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
Atrial Fibrillation
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
Atrial Fibrillation
[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]
Atrial Fibrillation
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
Atrial Fibrillation
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
Atrial Fibrillation
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Atrial Fibrillation
[Dabigatran therapy--perioperative management and interpretation of coagulation tests].
Atrial Fibrillation
[Dabigatran: a new therapeutic alternative in the prevention of stroke].
Atrial Fibrillation
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
Atrial Fibrillation
[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Atrial Fibrillation
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Atrial Fibrillation
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013.]
Atrial Fibrillation
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
Atrial Fibrillation
[Modern Approaches to Prevention of Thromboembolic Complications in Patients With Nonvalvular Atrial Fibrillation With a Direct Thrombin Inhibitor Dabigatran].
Atrial Fibrillation
[New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring].
Atrial Fibrillation
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
Atrial Fibrillation
[New oral anticoagulants: recommendations, precautions and perspectives for use].
Atrial Fibrillation
[Non-valvular atrial fibrillation: direct thrombin inhibitors versus VKA].
Atrial Fibrillation
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Atrial Fibrillation
[Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay].
Atrial Fibrillation
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Atrial Fibrillation
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Atrial Fibrillation
[The effects of continuous renal replacement therapy (CRRT) and intermittent haemodialysis (IHD) in the treatment of dabigatran overdose. Case report].
Atrial Fibrillation
[Waiting for the new oral anticoagulants: questions and answers about dabigatran].
Atrial Fibrillation
[Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status]
Autoimmune Diseases
Effects of calorie restriction and ?-3 dietary fat on aging in short-and long-lived rodents.
Autoimmune Diseases
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
Autoimmune Diseases
Osteopontin: another piece in the systemic lupus erythematosus immunopathology puzzle.
Autoimmune Diseases
Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study.
Autoimmune Diseases
The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease.
Autoimmune Diseases
Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseases.
Autoimmune Diseases
[Acquired factor V deficiency: A rare bleeding disorder with variable clinical presentations.]
Azotemia
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Bacteremia
An outbreak of pseudobacteremia caused by Enterobacter cloacae from a phlebotomist's vial of thrombin.
Bacteremia
Complete antithrombin replacement for anticoagulation for cardiopulmonary bypass to repair severe infective mitral valve endocarditis.
Bacteremia
Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study.
Bacterial Infections
Disseminated intravascular coagulation and bacterial infections in the elderly.
Bacterial Infections
Fibrinogenolytic and anticoagulant activities in the tissue covering the stingers of marine stingrays Dasyatis sephen and Aetobatis narinari.
Bacterial Infections
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Bacterial Infections
[A case of thrombocytopenia due to heparin therapy for a progressing ischemic stroke]
Bernard-Soulier Syndrome
Binding of thrombin to functionally defective platelets: a hypothesis on the nature of the thrombin receptor.
Bernard-Soulier Syndrome
Cloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation.
Bernard-Soulier Syndrome
Contrasting effects of thrombin and the thrombin receptor peptide, SFLLRN, on aggregation and release of 14C-serotonin by human platelets pretreated with chymotrypsin or serratia marcescens protease.
Bernard-Soulier Syndrome
Defective thrombin-induced calcium changes and aggregation of Bernard-Soulier platelets are not associated with deficient moderate-affinity receptors.
Bernard-Soulier Syndrome
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
Bernard-Soulier Syndrome
Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome.
Bernard-Soulier Syndrome
Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin.
Bernard-Soulier Syndrome
Molecular abnormalities in Glanzmann's thrombasthenia, Bernard-Soulier syndrome, and platelet-type von Willebrand's disease.
Bernard-Soulier Syndrome
Molecular characterization of two mutations in platelet glycoprotein (GP) Ib alpha in two Finnish Bernard-Soulier syndrome families.
Bernard-Soulier Syndrome
Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of Bothrops jararaca.
Bernard-Soulier Syndrome
[Genetic markers and thrombin reaction in a family of Bernard-Soulier syndrome]
beta-Thalassemia
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
beta-Thalassemia
Protein C levels in beta-thalassemia major patients in the east Nile delta of Egypt.
Bicuspid Aortic Valve Disease
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Bile Duct Diseases
[Plasma antithrombin and thrombin inhibitor in liver parenchymal and bile duct disease.]
Biliary Tract Diseases
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Biliary Tract Neoplasms
Experimental and clinical studies on liver regeneration following transcatheter portal embolization.
Blister
Effect of spontaneous pathology and thrombin on leukocyte adhesion to rat aortic endothelium.
Blister
Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases.
Blister
Rapid preparation of small-volume autologous fibrinogen concentrate and its same day use in bleb leaks after glaucoma filtration surgery.
Blister
The use of autologous fibrinogen concentrate in treating ocular hypotony after glaucoma filtration surgery.
Blood Coagulation Disorders
Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Blood Coagulation Disorders
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
Blood Coagulation Disorders
[On the diagnosis of blood coagulation disorders in obstetrics by means of the thrombin time determination]
Blood Platelet Disorders
Failure to mobilize intracellular calcium in response to thrombin in a patient with familial thrombocytopathy characterized by macrothrombocytopenia and abnormal platelet membrane complexes.
Blood Platelet Disorders
Thrombin generation in patients with cirrhosis: the role of platelets.
Bone Diseases, Metabolic
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.
Bone Resorption
Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro.
Bone Resorption
Cyclosporine A inhibits bone resorption in cultured neonatal mouse calvaria.
Bone Resorption
Divergent effects of protein kinase C (PKC) inhibitors staurosporine and bisindolylmaleimide I (GF109203X) on bone resorption.
Bone Resorption
Effect of auranofin on resorption, prostaglandin synthesis and ultrastructure of bone cells in cultured mouse calvaria.
Bone Resorption
Experimental considerations on the measurement of prostaglandins during long-time incubations of neonatal mouse calvaria.
Bone Resorption
Expression of the thrombin receptor in developing bone and associated tissues.
Bone Resorption
Prostaglandin-related bone resorption in cultured neonatal mouse calvaria: evaluation of biopotency of nonsteroidal anti-inflammatory drugs.
Bone Resorption
RANKL induces components of the extrinsic coagulation pathway in osteoclasts.
Bone Resorption
Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria.
Bone Resorption
Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants.
Bone Resorption
Role of bacterial proteinases in matrix destruction and modulation of host responses.
Bone Resorption
Suramin is a potent inhibitor of calcemic hormone- and growth factor-induced bone resorption in vitro.
Bone Resorption
Thrombin effects on osteoblastic cells. II. Structure-function relationships.
Bone Resorption
Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism.
Bone Resorption
Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells.
Bradycardia
Pulmonary Arterial Hypertension and Endothelial Dysfunction Is Linked to NADPH Oxidase-Derived Superoxide Formation in Venous Thrombosis and Pulmonary Embolism in Mice.
Brain Concussion
Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
Brain Diseases
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Brain Diseases
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Brain Edema
A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats.
Brain Edema
A novel aspect of thrombin in the tissue reaction following central nervous system injury.
Brain Edema
A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model.
Brain Edema
Activation of p44/42 mitogen activated protein kinases in thrombin-induced brain tolerance.
Brain Edema
Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning.
Brain Edema
Brain pericytes are the most thrombin-sensitive matrix metalloproteinase-9-releasing cell type constituting the blood-brain barrier in vitro.
Brain Edema
Complement inhibition attenuates brain edema and neurological deficits induced by thrombin.
Brain Edema
Cytopathological alterations and therapeutic approaches in Binswanger's disease.
Brain Edema
Effects of brain hypothermia on brain edema formation after intracerebral hemorrhage in rats.
Brain Edema
Effects of focal mild hypothermia on thrombin-induced brain edema formation and the expression of protease activated receptor-1, matrix metalloproteinase-9 and aquaporin 4 in rats.
Brain Edema
Expression of matrix metalloproteinse-9 in thrombin-induced brain edema formation in rats.
Brain Edema
Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation.
Brain Edema
Induction of colligin may attenuate brain edema following intracerebral hemorrhage.
Brain Edema
Intracerebral hemorrhage induces edema and oxidative stress and alters N-methyl-D-aspartate receptor subunits expression.
Brain Edema
Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model.
Brain Edema
Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages.
Brain Edema
Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin.
Brain Edema
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Brain Edema
Short period of early reperfusion aggravates blood-brain barrier dysfunction during permanent focal ischemia in rats.
Brain Edema
Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment.
Brain Edema
Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models.
Brain Edema
Testing the effect of PAR1 inhibitors on Plasmodium falciparum-induced loss of endothelial cell barrier function.
Brain Edema
The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage.
Brain Edema
The role of the coagulation cascade in brain edema formation after intracerebral hemorrhage.
Brain Edema
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Brain Edema
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Brain Edema
Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1.
Brain Edema
Thrombin hemostatic matrix leading to acute cerebral edema and sterile fluid collection formation post-tumor resection: two cases.
Brain Edema
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Brain Edema
Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats.
Brain Edema
Thrombin inhibits aquaporin 4 expression through protein kinase C-dependent pathway in cultured astrocytes.
Brain Edema
Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron.
Brain Edema
Thrombin preconditioning reduces iron-induced brain swelling and brain atrophy.
Brain Edema
Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells.
Brain Edema
Thrombin preconditioning, heat shock proteins and thrombin-induced brain edema.
Brain Edema
Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway.
Brain Edema
Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1.
Brain Edema
Time course of upregulation of inflammatory mediators in the hemorrhagic brain in rats: correlation with brain edema.
Brain Edema
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Brain Edema
[Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin]
Brain Infarction
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
Brain Infarction
Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy.
Brain Injuries
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Brain Injuries
Acute subdural hematoma: new model delineation and effects of coagulation inhibitors.
Brain Injuries
Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-?B Signaling.
Brain Injuries
Chronic thrombin exposure results in an increase in apolipoprotein-E levels.
Brain Injuries
Complement inhibition attenuates brain edema and neurological deficits induced by thrombin.
Brain Injuries
Concomitant intracerebral infusion of tissue plasminogen activator and thrombin leads to brain injury.
Brain Injuries
Disturbances of the coagulatory system in patients with severe cerebral trauma. I.
Brain Injuries
Effect of minimally invasive surgery for cerebral hematoma evacuation in different stages on motor evoked potential and thrombin in dog model of intracranial hemorrhage.
Brain Injuries
Effects of alpha-thrombin on superoxide dismutase levels in human cerebral microvascular endothelial cells.
Brain Injuries
Heme oxygenase-1 contributes to pathology associated with thrombin-induced striatal and cortical injury in organotypic slice culture.
Brain Injuries
In models of intracerebral hemorrhage, rivaroxaban is superior to warfarin to limit blood brain barrier disruption and hematoma expansion.
Brain Injuries
Increase in brain thrombin activity after experimental intracerebral hemorrhage.
Brain Injuries
Inhibition of prostaglandin E2 receptor EP3 mitigates thrombin-induced brain injury.
Brain Injuries
Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow.
Brain Injuries
Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury.
Brain Injuries
Long-time course of protease-activated receptor-1 expression after intracerebral hemorrhage in rats.
Brain Injuries
PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats.
Brain Injuries
Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation.
Brain Injuries
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Brain Injuries
Prothrombin overexpressed in post-natal neurones requires blood factors for activation in the mouse brain.
Brain Injuries
Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases.
Brain Injuries
Regulation of neurons and astrocytes by thrombin and protease nexin-1. Relationship to brain injury.
Brain Injuries
Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors.
Brain Injuries
Relative Importance of Proteinase-Activated Receptor-1 Versus Matrix Metalloproteinases in Intracerebral Hemorrhage-Mediated Neurotoxicity in Mice.
Brain Injuries
Role of red blood cell lysis and iron in hydrocephalus after intraventricular hemorrhage.
Brain Injuries
ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia.
Brain Injuries
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Brain Injuries
Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat.
Brain Injuries
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
Brain Injuries
The action of thrombin in intracerebral hemorrhage induced brain damage is mediated via PKC?/PKC? signaling.
Brain Injuries
The deleterious or beneficial effects of different agents in intracerebral hemorrhage: think big, think small, or is hematoma size important?
Brain Injuries
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
Brain Injuries
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Brain Injuries
Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention.
Brain Injuries
Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats.
Brain Injuries
Thrombin inhibitor ameliorates secondary damage in rat brain injury: suppression of inflammatory cells and vimentin-positive astrocytes.
Brain Injuries
Thrombin is a potent mitogen for rat astroblasts but not for oligodendroblasts and neuroblasts in primary culture.
Brain Injuries
Transient receptor potential canonical 3 (TRPC3) mediates thrombin-induced astrocyte activation and upregulates its own expression in cortical astrocytes.
Brain Injuries
Transient receptor potential canonical 3 inhibitor Pyr3 improves outcomes and attenuates astrogliosis after intracerebral hemorrhage in mice.
Brain Injuries
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Brain Injuries
[Secondary blood coagulation disturbances after severe head injuries (author's transl)]
Brain Injuries
[Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin]
Brain Injuries, Traumatic
Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-?B Signaling.
Brain Injuries, Traumatic
Depression following traumatic brain injury in mice is associated with down-regulation of hippocampal astrocyte glutamate transporters by thrombin.
Brain Injuries, Traumatic
Early posttraumatic changes in coagulation and fibrinolysis systems in isolated severe traumatic brain injury patients and its influence on immediate outcome.
Brain Injuries, Traumatic
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Brain Injuries, Traumatic
Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury.
Brain Injuries, Traumatic
Thrombin Hemostatic Matrix Reduces Heterotopic Ossification in Acetabular Fractures fixed via the Kocher-Langenbeck Approach.
Brain Injuries, Traumatic
Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes.
Brain Injuries, Traumatic
Thrombin preferentially induces autophagy in glia cells in the rat central nervous system.
Brain Ischemia
A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.
Brain Ischemia
Activation of p44/42 mitogen activated protein kinases in thrombin-induced brain tolerance.
Brain Ischemia
Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity.
Brain Ischemia
Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons.
Brain Ischemia
Dabigatran abrogates brain endothelial cell permeability in response to thrombin.
Brain Ischemia
Effects and mechanisms of triacetylshikimic acid on platelet adhesion to neutrophils induced by thrombin and reperfusion after focal cerebral ischemia in rats.
Brain Ischemia
Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
Brain Ischemia
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
Brain Ischemia
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
Brain Ischemia
Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors.
Brain Ischemia
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
Brain Ischemia
Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition.
Brain Ischemia
New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
Brain Ischemia
Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).
Brain Ischemia
Preconditioning with thrombin can be protective or worsen damage after endothelin-1-induced focal ischemia in rats.
Brain Ischemia
Role of protease-activated receptor-1 in brain injury after experimental global cerebral ischemia.
Brain Ischemia
The prevalence of protein C, protein S, and antithrombin III deficiency in non-APS/SLE Chinese adults with noncardiac cerebral ischemia.
Brain Ischemia
The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations.
Brain Ischemia
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Brain Ischemia
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Brain Ischemia
Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes.
Brain Ischemia
Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway.
Brain Ischemia
Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1.
Brain Ischemia
Transient focal ischemia in rat brain differentially regulates mRNA expression of protease-activated receptors 1 to 4.
Brain Neoplasms
Efficacy of a topical gelatin-thrombin hemostatic matrix, FLOSEAL®, in intracranial tumor resection.
Brain Neoplasms
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors.
Brain Neoplasms
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Brain Neoplasms
The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells.
Brain Neoplasms
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Breast Diseases
The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients.
Breast Neoplasms
Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction.
Breast Neoplasms
Breast Cancer Chemotherapy Induces the Release of Cell Free DNA, a Novel Procoagulant Stimulus.
Breast Neoplasms
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Breast Neoplasms
Comparison of breast carcinoma prognostic/predictive biomarkers on cell blocks obtained by various methods: Cellient, formalin and thrombin.
Breast Neoplasms
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
Breast Neoplasms
Determination of HER2/neu Status: A Pilot Study Comparing HER2/neu Dual In Situ Hybridization DNA Probe Cocktail Assay Performed on Cell Blocks to Immunohistochemisty and Fluorescence In Situ Hybridization Performed on Histologic Specimens.
Breast Neoplasms
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Breast Neoplasms
Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer.
Breast Neoplasms
Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients.
Breast Neoplasms
Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells.
Breast Neoplasms
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.
Breast Neoplasms
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
Breast Neoplasms
Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion.
Breast Neoplasms
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
Breast Neoplasms
Phytosomal-curcumin antagonizes cell growth and migration, induced by thrombin through AMP-Kinase in breast cancer.
Breast Neoplasms
Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer.
Breast Neoplasms
PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation.
Breast Neoplasms
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Breast Neoplasms
Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.
Breast Neoplasms
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.
Breast Neoplasms
Protease-Triggered, Integrin-Targeted Cellular Uptake of Recombinant Protein Micelles.
Breast Neoplasms
Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells.
Breast Neoplasms
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Breast Neoplasms
Role of tissue factor expression in thrombin generation by canine tumor cells.
Breast Neoplasms
Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin.
Breast Neoplasms
TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.
Breast Neoplasms
The Effect of Anthracycline-Based (Epirubicin) Adjuvant Chemotherapy on Plasma TAFI and PAI-1 Levels in Operable Breast Cancer.
Breast Neoplasms
The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients.
Breast Neoplasms
The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.
Breast Neoplasms
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
Breast Neoplasms
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Breast Neoplasms
Thrombin receptor overexpression in malignant and physiological invasion processes.
Breast Neoplasms
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.
Breast Neoplasms
Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin.
Breast Neoplasms
Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence.
Breast Neoplasms
[Interest of a thrombin and fibrinogen combipatch in preventing breast cancer seroma after lymph node dissection].
Bronchial Hyperreactivity
Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells.
Bronchiolitis Obliterans
alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors.
Budd-Chiari Syndrome
Budd-Chiari syndrome in a young female with factor V Leiden mutation: successful treatment with lepirudin, a direct thrombin inhibitor.
Budd-Chiari Syndrome
Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment.
Burkitt Lymphoma
Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production.
Carcinogenesis
A new type of thrombin inhibitor, noncytotoxic phospholipase A(2), from the Naja haje cobra venom.
Carcinogenesis
Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer.
Carcinogenesis
Expression of protease-activated receptors and tissue factor in human liver.
Carcinogenesis
Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1.
Carcinogenesis
Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages.
Carcinogenesis
Platelets contribute to the initiation of colitis-associated cancer by promoting immunosuppression.
Carcinogenesis
The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development.
Carcinogenesis
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Carcinogenesis
Transcriptomic profiles of tumor-associated neutrophils reveal prominent roles in enhancing angiogenesis in liver tumorigenesis in zebrafish.
Carcinoma
Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Carcinoma
Alcoholism and carcinoma change the intracellular pH and activate platelet Na+/H+-exchange in men.
Carcinoma
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Carcinoma
Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome.
Carcinoma
Circulating vascular endothelial growth factor correlates with systemic thrombin generation in patients with pancreatic carcinoma.
Carcinoma
Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection.
Carcinoma
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Carcinoma
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Carcinoma
Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model.
Carcinoma
Effect of thrombin receptor expression on microvessel endothelial cells, and survival by coagulation state in oesophageal squamous cell carcinoma.
Carcinoma
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Carcinoma
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Carcinoma
Elevated plasma D-dimer as a predictor of postoperative complications after radical cystectomy.
Carcinoma
Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues.
Carcinoma
Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells.
Carcinoma
Identification of G protein-coupled receptors potently stimulating migration of human transitional-cell carcinoma cells.
Carcinoma
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Carcinoma
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Carcinoma
Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
Carcinoma
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors.
Carcinoma
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Carcinoma
PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells.
Carcinoma
PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism.
Carcinoma
Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines.
Carcinoma
Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung.
Carcinoma
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.
Carcinoma
Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.
Carcinoma
Sphingolipid receptor signaling and function in human bladder carcinoma cells: inhibition of LPA- but enhancement of thrombin-stimulated cell motility.
Carcinoma
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
Carcinoma
Stimulation of protease activated receptors on RT4 cells mediates arachidonic acid release via Ca2+ independent phospholipase A2.
Carcinoma
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
Carcinoma
Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products.
Carcinoma
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Carcinoma
Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data.
Carcinoma
Transient increase in thrombin generation during radiotherapy of uterine carcinoma: A preliminary study using thrombin-antithrombin III complex measurements.
Carcinoma
Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines.
Carcinoma
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
Carcinoma, Bronchogenic
Treatment of malignant tracheobronchial stenosis by Dacron mesh-covered Z-stents.
Carcinoma, Embryonal
Cyclic AMP-mediated augmentation of thrombomodulin gene expression: cell type-dependent usage of control regions.
Carcinoma, Hepatocellular
alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis.
Carcinoma, Hepatocellular
Demonstration of the presence of protease-cutting site in the spacer of hepatitis B viral Pol protein.
Carcinoma, Hepatocellular
Experimental and clinical studies on liver regeneration following transcatheter portal embolization.
Carcinoma, Hepatocellular
Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin.
Carcinoma, Hepatocellular
Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation.
Carcinoma, Hepatocellular
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Carcinoma, Hepatocellular
Inhibitor against coagulation factor V after liver transplantation.
Carcinoma, Hepatocellular
Interaction of thrombin and factor Xa with bovine vascular endothelial cells, smooth muscle cells and rat hepatoma cells.
Carcinoma, Hepatocellular
Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues.
Carcinoma, Hepatocellular
Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma.
Carcinoma, Hepatocellular
Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
Carcinoma, Hepatocellular
[High expression of thrombin receptor PAR1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma in early stage].
Carcinoma, Intraductal, Noninfiltrating
Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion.
Carcinoma, Intraductal, Noninfiltrating
PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion.
Carcinoma, Non-Small-Cell Lung
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
Carcinoma, Ovarian Epithelial
The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition.
Carcinoma, Renal Cell
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Carcinoma, Renal Cell
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Carcinoma, Renal Cell
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors.
Carcinoma, Renal Cell
PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells.
Carcinoma, Renal Cell
PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration.
Carcinoma, Renal Cell
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
Carcinoma, Renal Cell
The serine proteinase thrombin promotes migration of human renal carcinoma cells by a PKA-dependent mechanism.
Carcinoma, Renal Cell
Tumour infarction after pre-operative embolisation of renal carcinoma.
Carcinoma, Renal Cell
[Occlusion of the renal artery by intra-arterial injection of thrombin in a case of inoperable renal tumour (author's transl)]
Carcinoma, Renal Cell
[The embolization of inoperable hypernephromas with autogenous fibrin and thrombin]
Carcinoma, Small Cell
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Carcinoma, Small Cell
Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.
Carcinoma, Squamous Cell
Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
Carcinoma, Squamous Cell
Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
Carcinoma, Squamous Cell
Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung.
Carcinoma, Squamous Cell
The enigma PAI-2. Gene expression, evolutionary and functional aspects.
Carcinoma, Squamous Cell
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Carcinosarcoma
Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines.
Carcinosarcoma
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Carcinosarcoma
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Cardiac Tamponade
Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture.
Cardiomegaly
c-Src/Pyk2/EGFR/PI3K/Akt/CREB-activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction.
Cardiomyopathies
Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease.
Cardiomyopathies
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Cardiomyopathies
Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient.
Cardiomyopathies
[Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease]
Cardiomyopathy, Dilated
Activation of coagulation system in dilated cardiomyopathy: comparison of patients with and without left ventricular thrombus.
Cardiomyopathy, Dilated
Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy.
Cardiomyopathy, Hypertrophic
Acute myocardial infarction with diminutive right coronary artery and obstructive hypertrophic cardiomyopathy without significant coronary stenoses.
Cardiomyopathy, Hypertrophic
Fibrin Clot Properties and Thrombin Generation in Hypertrophic Cardiomyopathy.
Cardiomyopathy, Hypertrophic
Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation.
Cardiovascular Diseases
A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling.
Cardiovascular Diseases
A review of global coagulation assays - Is there a role in thrombosis risk prediction?
Cardiovascular Diseases
Aluminum Metasurface with Hybrid Multipolar Plasmons for 1000-Fold Broadband Visible Fluorescence Enhancement and Multiplexed Biosensing.
Cardiovascular Diseases
Anti inflammatory effect of natural honey on bovine thrombin-induced oxidative burst in phagocytes.
Cardiovascular Diseases
Antiplatelet aggregation effects of phenanthrenes from Calanthe arisanensis.
Cardiovascular Diseases
Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity.
Cardiovascular Diseases
Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study.
Cardiovascular Diseases
Blood-based omic profiling supports female susceptibility to tobacco smoke-induced cardiovascular diseases.
Cardiovascular Diseases
Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets-Results from the Gutenberg Health Study.
Cardiovascular Diseases
Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study.
Cardiovascular Diseases
Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease.
Cardiovascular Diseases
Daily variations of functional parameters and density distribution in human blood platelets.
Cardiovascular Diseases
Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status.
Cardiovascular Diseases
Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases.
Cardiovascular Diseases
Does Lipid Profile Affect Thrombin Generation During Ramadan Fasting in Patients With Cardiovascular Risks?
Cardiovascular Diseases
Fibrinogen plasma levels as a marker of thrombin activation in diabetes.
Cardiovascular Diseases
Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection.
Cardiovascular Diseases
High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study.
Cardiovascular Diseases
Highly sensitive host-guest mode homogenous electrochemical thrombin signal amplification aptasensor based on tetraferrocene label.
Cardiovascular Diseases
Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies.
Cardiovascular Diseases
Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting.
Cardiovascular Diseases
In silico Prediction of Inhibitory Constant of Thrombin Inhibitors Using Machine Learning.
Cardiovascular Diseases
Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.
Cardiovascular Diseases
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.
Cardiovascular Diseases
Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
Cardiovascular Diseases
PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes.
Cardiovascular Diseases
Platelet regulation of thrombin generation in cardiovascular disease.
Cardiovascular Diseases
Popular naturally occurring antioxidants as potential anticoagulant drugs.
Cardiovascular Diseases
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Cardiovascular Diseases
Proximity Binding and Metal Ion-Dependent DNAzyme Cyclic Amplification-Integrated Aptasensor for Label-Free and Sensitive Electrochemical Detection of Thrombin.
Cardiovascular Diseases
Real-time measurement of thrombin generation using continuous droplet microfluidics.
Cardiovascular Diseases
Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol.
Cardiovascular Diseases
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Cardiovascular Diseases
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
Cardiovascular Diseases
Screening of direct thrombin inhibitors from Radix Salviae Miltiorrhizae by a peak fractionation approach.
Cardiovascular Diseases
Structure of a novel thrombin inhibitor with an uncharged D-amino acid as P1 residue.
Cardiovascular Diseases
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
Cardiovascular Diseases
The discovery and characterization of a novel nucleotide-based thrombin inhibitor.
Cardiovascular Diseases
The Effect of Omega-3 Polyunsaturated Fatty Acids on Fibrin and Thrombin Generation in Healthy Subjects and Subjects with Cardiovascular Disease.
Cardiovascular Diseases
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Cardiovascular Diseases
Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseases.
Cardiovascular Diseases
Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study.
Cardiovascular Diseases
Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase.
Cardiovascular Diseases
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Cardiovascular Diseases
Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective.
Cardiovascular Diseases
Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician.
Cardiovascular Diseases
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
Cardiovascular Diseases
[Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia]
Carotid Artery Injuries
Factor V Leiden improves in vivo hemostasis in murine hemophilia models.
Carotid Artery Injuries
Glybenclamide: an antidiabetic with in vivo antithrombotic activity.
Carotid Artery Injuries
Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child.
Carotid Artery Thrombosis
Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Carotid Artery Thrombosis
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
Carotid Artery Thrombosis
Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice.
Carotid Artery Thrombosis
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis.
Carotid Artery Thrombosis
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
Carotid Stenosis
Coagulation activation and ultrasound characteristics in patients with carotid artery disease.
Carotid Stenosis
Increased thrombin generation potential in symptomatic versus asymptomatic moderate or severe carotid stenosis and relationship with cerebral microemboli.
Carotid Stenosis
Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection.
Carotid Stenosis
Thrombocyte activation increases with the degree of carotid artery stenosis.
Cataract
Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: role of recombinant hirudin variant III.
Celiac Disease
Onset of Thrombin Generation Occurs More Rapidly in Pediatric Patients With Celiac Disease.
Central Nervous System Diseases
The involvement of thrombin in the pathogenesis of glioblastoma.
Central Nervous System Diseases
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Central Nervous System Infections
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Central Nervous System Neoplasms
Role of Thrombin in Central Nervous System Injury and Disease.
Cerebral Amyloid Angiopathy
Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.
Cerebral Hemorrhage
3CB2, a marker of radial glia, expression after experimental intracerebral hemorrhage: role of thrombin.
Cerebral Hemorrhage
A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats.
Cerebral Hemorrhage
Analysis of thrombin-antithrombin complex contents in plasma and hematoma fluid of hypertensive intracerebral hemorrhage patients after clot removal.
Cerebral Hemorrhage
Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.
Cerebral Hemorrhage
Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning.
Cerebral Hemorrhage
Blood-brain barrier breakdown and repair by Src after thrombin-induced injury.
Cerebral Hemorrhage
Brain injury after intracerebral hemorrhage: the role of thrombin and iron.
Cerebral Hemorrhage
Coated-platelet levels are elevated in patients with transient ischemic attack.
Cerebral Hemorrhage
Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice.
Cerebral Hemorrhage
Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Cerebral Hemorrhage
Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons.
Cerebral Hemorrhage
Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.
Cerebral Hemorrhage
Dabigatran abrogates brain endothelial cell permeability in response to thrombin.
Cerebral Hemorrhage
Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.
Cerebral Hemorrhage
Effect of delayed argatroban treatment on intracerebral hemorrhage-induced edema in the rat.
Cerebral Hemorrhage
Effect of Iron Chelators on Methemoglobin and Thrombin Preconditioning.
Cerebral Hemorrhage
Effect of thrombin on blood brain barrier permeability and its mechanism.
Cerebral Hemorrhage
Effect of thrombin preconditioning on migration of subventricular zone-derived cells after intracerebral hemorrhage in rats.
Cerebral Hemorrhage
Effects of Aerobic Capacity on Thrombin-Induced Hydrocephalus and White Matter Injury.
Cerebral Hemorrhage
Effects of thrombin on the secondary cerebral injury of perihematomal tissues of rats after intracerebral hemorrhage.
Cerebral Hemorrhage
Excitatory and Mitogenic Signaling in Cell Death, Blood-brain Barrier Breakdown, and BBB Repair after Intracerebral Hemorrhage.
Cerebral Hemorrhage
Experimental study on the PAR-1 expression around hemotoma following intracerebral hemorrhage in rats.
Cerebral Hemorrhage
Expression of matrix metalloproteinse-9 in thrombin-induced brain edema formation in rats.
Cerebral Hemorrhage
Expression of thrombin and its associated protein in cerebellum of human and rat after intracerebral hemorrhage.
Cerebral Hemorrhage
Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation.
Cerebral Hemorrhage
Heme oxygenase-1 contributes to pathology associated with thrombin-induced striatal and cortical injury in organotypic slice culture.
Cerebral Hemorrhage
Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
Cerebral Hemorrhage
High CSF thrombin concentration and activity is associated with an unfavorable outcome in patients with intracerebral hemorrhage.
Cerebral Hemorrhage
HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats.
Cerebral Hemorrhage
Impaired adult hippocampal neurogenesis and cognitive ability in a mouse model of intrastriatal hemorrhage.
Cerebral Hemorrhage
Increase in brain thrombin activity after experimental intracerebral hemorrhage.
Cerebral Hemorrhage
Interactions between rat cortico-striatal slice cultures and neutrophil-like HL60 cells under thrombin challenge: Toward elucidation of pathological events in intracerebral hemorrhage.
Cerebral Hemorrhage
Intracerebral hemorrhage induces edema and oxidative stress and alters N-methyl-D-aspartate receptor subunits expression.
Cerebral Hemorrhage
Intracerebral hemorrhage injury mechanisms: glutamate neurotoxicity, thrombin, and Src.
Cerebral Hemorrhage
Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury.
Cerebral Hemorrhage
Letter by Moll regarding article, "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran".
Cerebral Hemorrhage
Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage.
Cerebral Hemorrhage
Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.
Cerebral Hemorrhage
Long-term treatment with nicotine suppresses neurotoxicity of, and microglial activation by, thrombin in cortico-striatal slice cultures.
Cerebral Hemorrhage
Long-time course of protease-activated receptor-1 expression after intracerebral hemorrhage in rats.
Cerebral Hemorrhage
Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model.
Cerebral Hemorrhage
Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin.
Cerebral Hemorrhage
Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation.
Cerebral Hemorrhage
PDGFR-? inhibition preserves blood-brain barrier after intracerebral hemorrhage.
Cerebral Hemorrhage
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Cerebral Hemorrhage
Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats.
Cerebral Hemorrhage
Potentiation of NMDA receptor function by the serine protease thrombin.
Cerebral Hemorrhage
Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo.
Cerebral Hemorrhage
Relative Importance of Proteinase-Activated Receptor-1 Versus Matrix Metalloproteinases in Intracerebral Hemorrhage-Mediated Neurotoxicity in Mice.
Cerebral Hemorrhage
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Cerebral Hemorrhage
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Cerebral Hemorrhage
Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat.
Cerebral Hemorrhage
Sesamin suppresses activation of microglia and p44/42 MAPK pathway, which confers neuroprotection in rat intracerebral hemorrhage.
Cerebral Hemorrhage
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
Cerebral Hemorrhage
SRC kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage.
Cerebral Hemorrhage
Systemic administration of argatroban inhibits protease-activated receptor-1 expression in perihematomal tissue in rats with intracerebral hemorrhage.
Cerebral Hemorrhage
Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment.
Cerebral Hemorrhage
The action of thrombin in intracerebral hemorrhage induced brain damage is mediated via PKC?/PKC? signaling.
Cerebral Hemorrhage
The Cerebral Thrombin System Is Activated after Intracerebral Hemorrhage and Contributes to Secondary Lesion Growth and Poor Neurological Outcome in C57Bl/6 Mice.
Cerebral Hemorrhage
The deleterious or beneficial effects of different agents in intracerebral hemorrhage: think big, think small, or is hematoma size important?
Cerebral Hemorrhage
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
Cerebral Hemorrhage
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Cerebral Hemorrhage
Thrombin preconditioning reduces iron-induced brain swelling and brain atrophy.
Cerebral Hemorrhage
Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells.
Cerebral Hemorrhage
Thrombin promotes pericyte coverage by Tie2 activation in a rat model of intracerebral hemorrhage.
Cerebral Hemorrhage
Thrombin promotes the expression of thrombospondin-1 and -2 in a rat model of intracerebral hemorrhage.
Cerebral Hemorrhage
Thrombin stimulation of guanosine 3',5'-monophosphate formation in murine neuroblastoma cells (clone N1E-115).
Cerebral Hemorrhage
Thrombin-induced apoptosis in neurons through activation of c-Jun-N-terminal kinase.
Cerebral Hemorrhage
Thrombin-induced autophagy: a potential role in intracerebral hemorrhage.
Cerebral Hemorrhage
Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1.
Cerebral Hemorrhage
Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures.
Cerebral Hemorrhage
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Cerebral Hemorrhage
[Dynamic and long-lasting expression of thrombin receptor-1 after intracerebral hemorrhage in rats].
Cerebral Hemorrhage
[Expression of intercellular adhesion molecule-1 and neutrophil infiltration induced by injection of thrombin in rats]
Cerebral Infarction
A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction.
Cerebral Infarction
Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy.
Cerebral Infarction
Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Cerebral Infarction
Hematologic abnormalities occur in both cortical and lacunar infarction.
Cerebral Infarction
Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction.
Cerebral Infarction
Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats.
Cerebral Infarction
The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats.
Cerebral Infarction
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Cerebral Infarction
Treatment of intractable arterial hemorrhage during stereotactic brain biopsy with thrombin. Report of three patients.
Cerebrospinal Fluid Leak
Effective Repair of Dural Tear Using Bioabsorbable Sheet with Fibrin Glue.
Cerebrospinal Fluid Leak
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Cerebrovascular Disorders
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Cerebrovascular Disorders
Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
Cerebrovascular Disorders
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Cerebrovascular Disorders
PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis.
Cerebrovascular Disorders
Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke.
Chagas Disease
Absence of myocardial calcium-independent phospholipase A2? results in impaired PGE2 production and decreased survival in mice with acute Trypanosoma cruzi infection.
Chagas Disease
Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor.
Chickenpox
Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation.
Cholangiocarcinoma
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Cholangiocarcinoma
The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor.
Cholangitis
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
Choledocholithiasis
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
Cholera
Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.
Cholera
Determination of the conformations of bound peptides using NMR-transferred nOe techniques.
Cholera
Effect of cholera toxin on histamine release from bone marrow-derived mouse mast cells.
Cholera
Electrogenerated trisbipyridyl Ru(II)-/nitrilotriacetic-polypyrene copolymer for the easy fabrication of label-free photoelectrochemical immunosensor and aptasensor: application to the determination of thrombin and anti-cholera toxin antibody.
Cholera
Frontal affinity chromatography-mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor.
Cholera
Mechanisms of cholera toxin prevention of thrombin- and PMA-induced endothelial cell barrier dysfunction.
Cholera
Possible involvement of a GTP-binding protein, the substrate of islet-activating protein, in receptor-mediated signaling responsible for cell proliferation.
Cholera
Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL.
Cholera
Thrombin exerts a dual effect on stimulated adenylate cyclase in hamster fibroblasts, an inhibition via a GTP-binding protein and a potentiation via activation of protein kinase C.
Cholera
Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP.
Cholestasis
The Coagulation System Contributes to {alpha}V{beta}6 Integrin Expression and Liver Fibrosis Induced by Cholestasis.
Cholesteatoma
A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug.
Chondrosarcoma
Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway.
Choroidal Effusions
Recurrent hemorrhagic choroidal detachment associated with disseminated intravascular coagulation.
Chronic Limb-Threatening Ischemia
A direct thrombin inhibitor, lepirudin, for thrombophilic patients with inoperable critical limb ischemia.
Chronic Limb-Threatening Ischemia
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Chronic Limb-Threatening Ischemia
Altered coagulation profile in peripheral artery disease patients.
Chronic Urticaria
Activation of the Blood Coagulation System in Patients with Chronic Spontaneous Urticaria.
Chronic Urticaria
Activation of the Intrinsic Coagulation Pathway in Patients With Chronic Urticaria.
Chronic Urticaria
Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria.
Chronic Urticaria
Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test.
Chronic Urticaria
Increased thrombin generation potential in patients with chronic spontaneous urticaria.
Chronic Urticaria
Mast cells are critical for the limitation of thrombin-induced skin inflammation.
Chronic Urticaria
Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum.
Chronic Urticaria
Severe chronic urticaria is associated with elevated plasma levels of D-dimer.
Classical Swine Fever
Isothermal Self-Primer EXPonential Amplification Reaction (SPEXPAR) for Highly Sensitive Detection of Single-Stranded Nucleic Acids and Proteins.
coagulation factor ixa deficiency
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
coagulation factor ixa deficiency
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
coagulation factor viia deficiency
Characterization of thrombin generation potential of leukemic and solid tumor cells by the calibrated automated thrombography.
coagulation factor viia deficiency
Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation.
coagulation factor viia deficiency
Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice.
coagulation factor viia deficiency
Congenital combined defects of factor VII: a critical review.
coagulation factor viia deficiency
Generation of genetically-altered mice producing very low levels of coagulation factorVII.
coagulation factor viia deficiency
Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders.
coagulation factor viia deficiency
Recombinant activated factor VII in clinical practice: a 2014 update.
coagulation factor viia deficiency
Recombinant activated factor VII: 30 years of research and innovation.
coagulation factor viia deficiency
Recombinant activated factor VII: mechanisms of action and current indications.
coagulation factor viia deficiency
The Story of Serum Prothrombin Conversion Accelerator, Proconvertin, Stable Factor, Cothromboplastin, Prothrombin Accelerator or Autoprothrombin I, and Their Subsequent Merging into Factor VII.
coagulation factor viia deficiency
Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency.
coagulation factor xa deficiency
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
coagulation factor xa deficiency
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
coagulation factor xa deficiency
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
coagulation factor xa deficiency
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
coagulation factor xa deficiency
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
coagulation factor xia deficiency
Anesthetic management using peripheral nerve block in patients with factor XI deficiency: a case report.
coagulation factor xia deficiency
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
coagulation factor xia deficiency
The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency.
coagulation factor xia deficiency
Thrombin generation in patients with factor XI deficiency and clinical bleeding risk.
coagulation factor xiia deficiency
Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins.
Coinfection
A cost effective endovascular approach for management of post-catheterization profunda femoris artery pseudoaneurysm using thrombin.
Coinfection
Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways.
Colitis
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
Colitis
The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.
Colitis
Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study.
Colitis
Thrombin mediates the extraintestinal thrombosis associated with experimental colitis.
Colitis, Ischemic
Ischemic colitis following translumbar thrombin injection for treatment of endoleak.
Colitis, Ulcerative
Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.
Colitis, Ulcerative
Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.
Colitis, Ulcerative
Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.
Colitis, Ulcerative
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.
Colitis-Associated Neoplasms
Thrombin drives tumorigenesis in colitis-associated colon cancer.
Colonic Neoplasms
Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.
Colonic Neoplasms
Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase.
Colonic Neoplasms
Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.
Colonic Neoplasms
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Colonic Neoplasms
Microfluidic reveals generation of platelet-strings on tumor-activated endothelium.
Colonic Neoplasms
The role of coagulation and platelets in colon cancer-associated thrombosis.
Colonic Neoplasms
Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin.
Colonic Neoplasms
Thrombin-dependent modulation of ?1-integrin-mediated signaling up-regulates prolidase and HIF-1? through p-FAK in colorectal cancer cells.
Colonic Neoplasms
Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.
Colonic Neoplasms
[Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors]
Colorectal Neoplasms
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
Colorectal Neoplasms
PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer.
Colorectal Neoplasms
Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells.
Coma
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Communicable Diseases
A new fibrin sealant from Crotalus durissus terrificus venom: applications in medicine.
Communicable Diseases
Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants.
Communicable Diseases
The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC.
Communicable Diseases
Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: a systematic review.
Confusion
A reunification of the US ("NIH") and International Unit into a single standard for Thrombin.
Confusion
From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia.
Congenital Abnormalities
Hemophilia A in cardiac operations: a model of reduced thrombin generation.
Congenital Abnormalities
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
Congenital Abnormalities
[Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia]
Congenital Disorders of Glycosylation
Congenital disorders of glycosylation as an unusual cause of antithrombin deficiency and elevated thrombin generation.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Congenital disorders of glycosylation as an unusual cause of antithrombin deficiency and elevated thrombin generation.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies.
Conjunctivitis
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
Contracture
Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current.
Contracture
Effects of microtubules and microfilaments on [Ca(2+)](i) and contractility in a reconstituted fibroblast fiber.
Contracture
Effects of monocrotaline pyrrole and thrombin on pulmonary endothelial cell junction and matrix adhesion proteins.
Coronary Artery Disease
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
Coronary Artery Disease
Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis.
Coronary Artery Disease
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Coronary Artery Disease
Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
Coronary Artery Disease
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction.
Coronary Artery Disease
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Coronary Artery Disease
Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease.
Coronary Artery Disease
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Coronary Artery Disease
Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation.
Coronary Artery Disease
Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.
Coronary Artery Disease
Argatroban Therapy in Patients with Coronary Artery Disease and Heparin-Induced Thrombocytopenia.
Coronary Artery Disease
Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
Coronary Artery Disease
Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation.
Coronary Artery Disease
Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions.
Coronary Artery Disease
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Coronary Artery Disease
Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries.
Coronary Artery Disease
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment.
Coronary Artery Disease
Coagulation activity and clinical outcome in unstable coronary artery disease.
Coronary Artery Disease
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
Coronary Artery Disease
Correlations between platelet-derived microvesicles and thrombin generation in patients with coronary artery disease.
Coronary Artery Disease
Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis.
Coronary Artery Disease
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
Coronary Artery Disease
Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.
Coronary Artery Disease
Expression of Junctional Adhesion Molecule-C on the Surface of Platelets Supports Adhesion, but not Differentiation, of Human CD34 Cells in Vitro.
Coronary Artery Disease
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Coronary Artery Disease
Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation.
Coronary Artery Disease
Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease.
Coronary Artery Disease
Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Coronary Artery Disease
Identification of new single-nucleotide polymorphisms in the thrombin receptor gene and their effects on coronary artery diseases in Koreans.
Coronary Artery Disease
IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease.
Coronary Artery Disease
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Coronary Artery Disease
Increased plasma thrombin potential is associated with stable coronary artery disease: An angiographically-controlled study.
Coronary Artery Disease
Increased platelet reactivity and platelet-leukocyte aggregation after elective coronary bypass surgery.
Coronary Artery Disease
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Coronary Artery Disease
Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease.
Coronary Artery Disease
Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: the role of thrombosis, fibrinolysis and atherosclerotic burden.
Coronary Artery Disease
Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.
Coronary Artery Disease
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
Coronary Artery Disease
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease.
Coronary Artery Disease
Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis.
Coronary Artery Disease
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Coronary Artery Disease
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
Coronary Artery Disease
No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.
Coronary Artery Disease
Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease.
Coronary Artery Disease
Plasma Markers of Procoagulant Activity Among Individuals with Coronary Artery Disease.
Coronary Artery Disease
Platelet aggregation, coronary artery disease progression and future coronary events.
Coronary Artery Disease
Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.
Coronary Artery Disease
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Coronary Artery Disease
Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis.
Coronary Artery Disease
Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not.
Coronary Artery Disease
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Coronary Artery Disease
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Coronary Artery Disease
Relevance of hemostasis on restenosis in clinically stable patients undergoing elective PTCA.
Coronary Artery Disease
Remote ischemic preconditioning inhibits platelet ?IIb ?3 activation in coronary artery disease patients receiving dual antiplatelet therapy: A randomized trial.
Coronary Artery Disease
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Coronary Artery Disease
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
Coronary Artery Disease
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
Coronary Artery Disease
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
Coronary Artery Disease
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.
Coronary Artery Disease
The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis.
Coronary Artery Disease
Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun.
Coronary Artery Disease
Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Coronary Artery Disease
Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition.
Coronary Artery Disease
Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention.
Coronary Artery Disease
Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease.
Coronary Artery Disease
Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
Coronary Artery Disease
Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease.
Coronary Artery Disease
Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.
Coronary Artery Disease
Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery.
Coronary Artery Disease
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Coronary Artery Disease
Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study Group.
Coronary Artery Disease
[Chronic ischemic cardiopathy: antiplatelet agents and anticoagulants, new protocols for prevention and treatment]
Coronary Artery Disease
[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease]
Coronary Artery Disease
[The role of thrombin activatable fibrinolysis inhibitors (TAFI) in coronary artery disease]
Coronary Artery Disease
[The thrombin generation is associated with the PIA1/A2 beta3, integrin polymorphism in aspirin-treated patients with coronary artery disease: a role of statins]
Coronary Artery Disease
[Thrombin-antithrombin III complexes as a measure of effective heparin treatment?]
Coronary Disease
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
Coronary Disease
Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
Coronary Disease
Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin.
Coronary Disease
Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Coronary Disease
Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury.
Coronary Disease
Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.
Coronary Disease
Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study.
Coronary Disease
Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
Coronary Disease
Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease.
Coronary Disease
RNA-seq Reveals Novel Transcriptome of Genes and Their Isoforms in Human Pulmonary Microvascular Endothelial Cells Treated with Thrombin.
Coronary Disease
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.
Coronary Disease
Short heparin thrombin clotting time, increased fibrinogen and platelet aggregates count in coronary disease: a probable hypercoagulable state.
Coronary Disease
The effect of exercise on thrombin and plasmin generation in middle-aged men.
Coronary Disease
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.
Coronary Disease
Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty.
Coronary Disease
Thrombin generation markers and coronary heart disease risk factors in a Polish population sample.
Coronary Disease
Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels.
Coronary Disease
[Clinical significance of endothelial dysfunction: studies of human coronary circulation in vivo]
Coronary Disease
[Evaluation of the hemostatic potential at coronary artery bypass surgery during long-term aspirin therapy].
Coronary Disease
[Intervening effect of naoxintong on anti-platelet treatment with aspirin]
Coronary Disease
[Relationship between anti-coagulation system changes of coronary heart disease patients and different syndrome-type in TCM]
Coronary Disease
[Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease]
Coronary Occlusion
Heparin resistance in acute coronary occlusion measured by the plasma heparin thrombin time.
Coronary Occlusion
Heparin resistance, measured by the plasma heparin thrombin time, in patients on long-term anticoagulatn therapy with phenylindanedione following coronary occlusion.
Coronary Occlusion
Increased plasma concentration of fibrin monomer in acute myocardial infarction with early reperfusion.
Coronary Occlusion
Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty.
Coronary Occlusion
Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction.
Coronary Occlusion
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Coronary Stenosis
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Coronary Stenosis
Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Coronary Stenosis
Platelet-dependent thrombin generation in patients with unstable angina pectoris.
Coronary Stenosis
Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction.
Coronary Stenosis
Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty.
Coronary Stenosis
Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
Coronary Stenosis
Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
Coronary Stenosis
Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators.
Coronary Stenosis
[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease]
Coronary Thrombosis
A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.
Coronary Thrombosis
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Coronary Thrombosis
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Coronary Thrombosis
Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Coronary Thrombosis
Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Coronary Thrombosis
Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Coronary Thrombosis
Increased lysophosphatidylcholine content induced by thrombin receptor stimulation in adult rabbit cardiac ventricular myocytes.
Coronary Thrombosis
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Coronary Thrombosis
Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury.
Coronary Thrombosis
Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death.
Coronary Thrombosis
Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism.
Coronary Thrombosis
Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
Coronary Thrombosis
Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis.
Coronary Thrombosis
Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Coronary Thrombosis
Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Coronary Thrombosis
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Coronary Vasospasm
Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus.
COVID-19
Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
COVID-19
Complex and prolonged hypercoagulability in coronavirus disease 2019 intensive care unit patients: A thromboelastographic study.
COVID-19
Correction to the article "Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection", Published on Acta Med Port 2021 Jan;34(1):35-46.
COVID-19
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
COVID-19
Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome.
COVID-19
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
COVID-19
D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis.
COVID-19
Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection.
COVID-19
Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19.
COVID-19
Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays.
COVID-19
Extracorporeal Membrane Oxygenation Induces Early Alterations in Coagulation and Fibrinolysis Profiles in COVID-19 Patients with Acute Respiratory Distress Syndrome.
COVID-19
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.
COVID-19
In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation.
COVID-19
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19.
COVID-19
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory.
COVID-19
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
COVID-19
Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19.
COVID-19
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
COVID-19
Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients.
COVID-19
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.
COVID-19
Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater.
COVID-19
Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant.
COVID-19
Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.
COVID-19
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability.
COVID-19
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
COVID-19
Thrombin generation in patients with COVID-19 with and without thromboprophylaxis.
COVID-19
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
COVID-19
Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019.
Craniocerebral Trauma
Coagulofibrinolytic changes after isolated head injury are not different from those in trauma patients without head injury.
Craniocerebral Trauma
Effects of alpha-thrombin on superoxide dismutase levels in human cerebral microvascular endothelial cells.
Craniocerebral Trauma
The incidence and significance of hemostatic abnormalities in patients with head injuries.
Craniocerebral Trauma
Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury.
Craniocerebral Trauma
Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults.
Creutzfeldt-Jakob Syndrome
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Crohn Disease
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
Crohn Disease
Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease.
Crohn Disease
Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.
Crush Syndrome
[Coagulation and fibrinolytic activity of lymph in various pathological conditions (review of own and literature data)].
Cushing Syndrome
Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease.
Cushing Syndrome
Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome.
Cushing Syndrome
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?
Cystadenocarcinoma
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Cystitis
Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis.
Cystitis
Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases.
Cystitis
[New hemostatic therapy of bleeding of bladder by technique of drip-irrigation using a thrombin solution]
Cystitis, Interstitial
Prostacyclin production in tryptase and thrombin stimulated human bladder endothelial cells: effect of pretreatment with phospholipase A2 and cyclooxygenase inhibitors.
Cysts
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Cytochrome-c Oxidase Deficiency
Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency.
Death, Sudden, Cardiac
Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction.
Decompression Sickness
Effects of aspirin and dipyridamole on platelet function, hematology, and blood chemistry of saturation divers.
Decompression Sickness
Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding.
Dehydration
Hypobaric Hypoxia Causes Elevated Thrombin Generation Mediated by FVIII that is Balanced by Decreased Platelet Activation.
Dehydration
NFAT5-sensitive Orai1 expression and store-operated Ca(2+) entry in megakaryocytes.
Dehydration
[Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest]
Dementia
Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study.
Dementia
Content of autoantibodies to bradykinin and beta-amyloid(1-42) as a criterion for biochemical differences between Alzheimer's dementias.
Dementia
Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation.
Dementia
Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells.
Dementia
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Dementia, Vascular
Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes.
Dementia, Vascular
Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
Dementia, Vascular
Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect.
Demyelinating Diseases
Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
Demyelinating Diseases
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Demyelinating Diseases
Thrombin regulates the ability of Schwann cells to support neuritogenesis and to maintain the integrity of the nodes of Ranvier.
Dengue
A propeptide-independent protease from Tannerella sp.6_1_58FAA_CT1 displays trypsin-like specificity.
Dengue
Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection.
Dengue
Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities.
Dengue
Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis.
Dengue
Multivariate time-series analysis of biomarkers from a dengue cohort offers new approaches for diagnosis and prognosis.
Dengue
Novel interactions of domain III from the envelope glycoprotein of dengue 2 virus with human plasma proteins.
Dengue
Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case--control study comparing dengue fever patients with and without bleeding manifestations.
Dengue
Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease.
Dermatitis
PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses.
Dermatitis Herpetiformis
Levels of F(1+2) prothrombin fragments and thrombin - antithrombin III (TAT) complexes in patients with dermatitis herpetiformis.
Diabetes Mellitus
Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
Diabetes Mellitus
Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy.
Diabetes Mellitus
Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Diabetes Mellitus
Dissociation of thrombin generation and platelet secretion in diabetes mellitus.
Diabetes Mellitus
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Diabetes Mellitus
Endothelial HNF4? potentiates angiogenic dysfunction via enhancement of vascular endothelial growth factor resistance in T2DM.
Diabetes Mellitus
Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans.
Diabetes Mellitus
Generation of thrombin activity in relation to factor VIII:C concentrations and vascular complications in type 1 (insulin-dependent) diabetes mellitus.
Diabetes Mellitus
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.
Diabetes Mellitus
Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
Diabetes Mellitus
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Diabetes Mellitus
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Diabetes Mellitus
Intracellular and extracellular pH dynamics in the human placenta from diabetes mellitus.
Diabetes Mellitus
Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study.
Diabetes Mellitus
Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis.
Diabetes Mellitus
Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes.
Diabetes Mellitus
Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.
Diabetes Mellitus
Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes.
Diabetes Mellitus
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial.
Diabetes Mellitus
Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus.
Diabetes Mellitus
The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.
Diabetes Mellitus
The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial.
Diabetes Mellitus
Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control.
Diabetes Mellitus
Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus.
Diabetes Mellitus
Thrombin Receptor-Activating Protein (TRAP)-Activated Akt Is Involved in the Release of Phosphorylated-HSP27 (HSPB1) from Platelets in DM Patients.
Diabetes Mellitus
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Diabetes Mellitus
[Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy]
Diabetes Mellitus
[Evaluation of platelet intracellular calcium ion concentrations with flow cytometry]
Diabetes Mellitus
[Mobilization of intracellular Ca2+ by ADP and thrombin in platelets of patients with diabetes mellitus with vascular complications]
Diabetes Mellitus, Type 1
Acute changes in blood glucose concentration do not promote thrombin generation or fibrin breakdown in type 1 diabetes.
Diabetes Mellitus, Type 1
Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM.
Diabetes Mellitus, Type 1
Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM.
Diabetes Mellitus, Type 1
Do determinants of platelet function co-segregate with genetic markers of type 1 diabetes mellitus?
Diabetes Mellitus, Type 1
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
Diabetes Mellitus, Type 1
Increased intracellular calcium and altered phorbol dibutyrate binding to intact platelets in young subjects with insulin-dependent and non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Increased tissue factor activity promotes thrombin generation at type 1 diabetes onset in children.
Diabetes Mellitus, Type 1
Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study.
Diabetes Mellitus, Type 1
Primary platelet activation in recent-onset type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Reduced guanine nucleotide-stimulated polyphosphoinositide specific phospholipase C in platelet hyperaggregation in IDDM.
Diabetes Mellitus, Type 1
Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes.
Diabetes Mellitus, Type 1
Thrombin generation and factor VIII:C levels in patients with type 1 diabetes complicated by nephropathy.
Diabetes Mellitus, Type 1
[Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy]
Diabetes Mellitus, Type 2
Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men.
Diabetes Mellitus, Type 2
Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
Diabetes Mellitus, Type 2
Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides.
Diabetes Mellitus, Type 2
Carbonylation of platelet proteins occurs as consequence of oxidative stress and thrombin activation, and is stimulated by ageing and type 2 diabetes.
Diabetes Mellitus, Type 2
Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy.
Diabetes Mellitus, Type 2
Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose.
Diabetes Mellitus, Type 2
Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM.
Diabetes Mellitus, Type 2
Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes.
Diabetes Mellitus, Type 2
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.
Diabetes Mellitus, Type 2
Increased intracellular calcium and altered phorbol dibutyrate binding to intact platelets in young subjects with insulin-dependent and non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.
Diabetes Mellitus, Type 2
Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study.
Diabetes Mellitus, Type 2
Platelet free cytosolic calcium concentration during ageing of type 2 diabetic patients.
Diabetes Mellitus, Type 2
Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes.
Diabetes Mellitus, Type 2
Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Diabetes Mellitus, Type 2
Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.
Diabetes Mellitus, Type 2
Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes.
Diabetes Mellitus, Type 2
Secreted modular calcium-binding protein 1 binds and activates thrombin to account for platelet hyperreactivity in diabetes.
Diabetes Mellitus, Type 2
Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease.
Diabetes Mellitus, Type 2
The relationship between insulin sensitivity and serum antithrombin 3 activity in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease.
Diabetes Mellitus, Type 2
Thrombin Receptor-Activating Protein (TRAP)-Activated Akt Is Involved in the Release of Phosphorylated-HSP27 (HSPB1) from Platelets in DM Patients.
Diabetes Mellitus, Type 2
Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes.
Diabetes, Gestational
Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in Patients with GDM.
Diabetic Angiopathies
Increased intraglomerular thrombin formation in diabetic microangiopathy.
Diabetic Angiopathies
Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells.
Diabetic Angiopathies
Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics.
Diabetic Foot
Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study.
Diabetic Nephropathies
Podocyte Integrin-?3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy.
Diabetic Nephropathies
Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease.
Diabetic Nephropathies
Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis.
Diabetic Nephropathies
Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes.
Diabetic Nephropathies
[Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC]
Diabetic Nephropathies
[Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy]
Diabetic Retinopathy
High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment.
Diabetic Retinopathy
Plasma soluble fibrin monomer complexes in the development of diabetic retinopathy.
Diabetic Retinopathy
Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes.
Diabetic Retinopathy
The use of intravitreal thrombin to control hemorrhage during vitrectomy.
Diabetic Retinopathy
Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.
Diabetic Retinopathy
Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy.
Disseminated Intravascular Coagulation
A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
Disseminated Intravascular Coagulation
A prothrombin activator (Lopap) modulating inflammation, coagulation and cell survival mechanisms.
Disseminated Intravascular Coagulation
Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria.
Disseminated Intravascular Coagulation
Active but inoperable thrombin is accumulated in a plasma protein layer surrounding Streptococcus pyogenes.
Disseminated Intravascular Coagulation
Acute generalized, widespread bleeding. Diagnosis and management.
Disseminated Intravascular Coagulation
Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Disseminated Intravascular Coagulation
Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy.
Disseminated Intravascular Coagulation
An unusual case of an ulcerative colitis flare resulting in disseminated intravascular coagulopathy and a bladder hematoma: a case report.
Disseminated Intravascular Coagulation
Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Antithrombin III assay using thrombin in disseminated intravascular coagulation (DIC), other thromboembolic disorders and hepatic diseases.
Disseminated Intravascular Coagulation
Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells.
Disseminated Intravascular Coagulation
Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation.
Disseminated Intravascular Coagulation
Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation.
Disseminated Intravascular Coagulation
Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay.
Disseminated Intravascular Coagulation
Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release.
Disseminated Intravascular Coagulation
Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Coagulation disorders in severely and critically injured patients.
Disseminated Intravascular Coagulation
Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.
Disseminated Intravascular Coagulation
Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thormbin.
Disseminated Intravascular Coagulation
Crocetin administration ameliorates endotoxin-induced disseminated intravascular coagulation in rabbits.
Disseminated Intravascular Coagulation
Crosstalk between coagulation and inflammation in mastitis and metritis in dairy cows.
Disseminated Intravascular Coagulation
Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation.
Disseminated Intravascular Coagulation
Decreased thrombomodulin mRNA expression on peripheral monocytes in disseminated intravascular coagulation patients relates to poor outcomes: The ex vivo effects of lipopolysaccharide and thrombin on monocyte thrombomodulin and CD14 mRNA.
Disseminated Intravascular Coagulation
Diagnostic and Prognostic Value of Plasma Factor V Activity and Parameters in Thrombin Generation for Disseminated Intravascular Coagulation in Patients with Hematological Malignancies.
Disseminated Intravascular Coagulation
Dielectric Blood Coagulometry for the Early Detection of Sepsis-Induced Disseminated Intravascular Coagulation: A Prospective Observational Study.
Disseminated Intravascular Coagulation
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation and bacterial infections in the elderly.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation and its immune mechanisms.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation associated with aortic dissecting aneurysm.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation following Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation in post-dysenteric haemolytic uraemic syndrome.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation. Approach to treatment.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation: clinical and laboratory aspects.
Disseminated Intravascular Coagulation
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Disseminated Intravascular Coagulation
Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT).
Disseminated Intravascular Coagulation
Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits.
Disseminated Intravascular Coagulation
Effect of beta-adrenergic blockade by propranolol upon intravascular coagulation in the rat kidney.
Disseminated Intravascular Coagulation
Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats.
Disseminated Intravascular Coagulation
Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model.
Disseminated Intravascular Coagulation
Effect of platelet on protein degradation in rat skeletal muscle.
Disseminated Intravascular Coagulation
Effects of alpha and beta receptor stimulating and blocking agents on experimental disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban.
Disseminated Intravascular Coagulation
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Disseminated Intravascular Coagulation
Effects of prolonged poisoning by Russell's viper venom on blood coagulation, platelets and fibrinolysis.
Disseminated Intravascular Coagulation
Elevated plasma levels of hepatocyte growth factor in rats experimentally envenomated with Bothrops jararaca venom: Role of snake venom metalloproteases.
Disseminated Intravascular Coagulation
Enhanced thrombin generation in patients receiving intensive care.
Disseminated Intravascular Coagulation
Ex vivo thrombin generation patterns in septic patients with and without disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Fibrinogen proteolysis by thrombin, plasmin and platelet release in relation to disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Fibrinogen survival and fibrinopeptide A in acute leukemia.
Disseminated Intravascular Coagulation
Fibrinolysis in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Fibronectin, platelet factor 4 and beta-thromboglobulin in endemic hepatosplenic schistosomiasis: relation to acute hematemesis.
Disseminated Intravascular Coagulation
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Disseminated Intravascular Coagulation
Hematological parameters and visceral lesions relationships in rabbit viral hemorrhagic disease.
Disseminated Intravascular Coagulation
Hemodynamics of disseminated intravascular coagulation. Effects of intra-aortic thrombin infusions on renal and mesenteric blood flow in the dog.
Disseminated Intravascular Coagulation
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Disseminated Intravascular Coagulation
Heparin Dose and Point-of-Care Measurements of Hemostasis in Cardiac Surgery-Results of a Randomized Controlled Trial.
Disseminated Intravascular Coagulation
Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon.
Disseminated Intravascular Coagulation
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.
Disseminated Intravascular Coagulation
High-dose antithrombin III treatment of severely injured patients: results of a prospective study.
Disseminated Intravascular Coagulation
Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.
Disseminated Intravascular Coagulation
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Disseminated Intravascular Coagulation
Inhibition of thrombin in plasma by heparin or arginine.
Disseminated Intravascular Coagulation
Lack of fibrin formation in exercise-induced activation of coagulation.
Disseminated Intravascular Coagulation
Lepirudin blunts endotoxin-induced coagulation activation.
Disseminated Intravascular Coagulation
Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.
Disseminated Intravascular Coagulation
Lipopolysaccharide-Induced Hemolysis Is Abolished by Inhibition of Thrombin Generation but Not Inhibition of Platelet Aggregation.
Disseminated Intravascular Coagulation
Localization of tissue plasminogen activator on experimental thrombi in rats.
Disseminated Intravascular Coagulation
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Microvascular alterations in thrombin-induced experimental disseminated intravascular coagulation in the dog.
Disseminated Intravascular Coagulation
Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: In vitro effect of thrombin on monocyte CD163 shedding.
Disseminated Intravascular Coagulation
New approaches for the detection of early activation products in thrombotic states.
Disseminated Intravascular Coagulation
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Disseminated Intravascular Coagulation
Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock.
Disseminated Intravascular Coagulation
Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome.
Disseminated Intravascular Coagulation
Pathways of coagulation/fibrinolysis activation in malignancy.
Disseminated Intravascular Coagulation
Phospholipase D1 regulation of TNF-alpha protects against responses to LPS.
Disseminated Intravascular Coagulation
Plasma thrombin assay using a chromogenic substrate in disseminated intravascular coagulation due to snake bite envenomation.
Disseminated Intravascular Coagulation
Plasmatic parameters of coagulation activation in thrombotic microangiopathy.
Disseminated Intravascular Coagulation
Poor prognosis of hypocoagulability assessed by thrombin generation assay in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Protein Z efficiently depletes thrombin generation in disseminated intravascular coagulation with poor prognosis.
Disseminated Intravascular Coagulation
Prothrombin, thrombin and prothrombin fragments in plasma of normal individuals and of patients with laboratory evidence of disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma.
Disseminated Intravascular Coagulation
Rat liver macrophages will not phagocytose fibrin during disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Disseminated Intravascular Coagulation
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Disseminated Intravascular Coagulation
Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Disseminated Intravascular Coagulation
Studies in experimental animals on disseminated intravascular coagulation (DIC).
Disseminated Intravascular Coagulation
Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function.
Disseminated Intravascular Coagulation
The appearance of schistocytes in the peripheral blood in correlation to the degree of disseminated intravascular coagulation. An experimental study in rats.
Disseminated Intravascular Coagulation
The Dynamics of Angiogenic Factors and Their Soluble Receptors in Relation to Organ Dysfunction in Disseminated Intravascular Coagulation Associated with Sepsis.
Disseminated Intravascular Coagulation
The incidence and significance of hemostatic abnormalities in patients with head injuries.
Disseminated Intravascular Coagulation
The influence of durgs on disseminated intravascular coagulation (DIC). II. Effects of naturally occurring and synthetic thrombin inhibitors.
Disseminated Intravascular Coagulation
The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
Disseminated Intravascular Coagulation
The pathogenesis and management of disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
The role of Kupffer's cells in disseminated intravascular coagulation. A morphologic study in thrombin-infused rabbits.
Disseminated Intravascular Coagulation
Thrombin does not alter vascular hyporeactivity in models of endotoxin-induced septic shock in rats.
Disseminated Intravascular Coagulation
Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Disseminated Intravascular Coagulation
Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Disseminated Intravascular Coagulation
Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin.
Disseminated Intravascular Coagulation
Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders.
Disseminated Intravascular Coagulation
Thrombin-induced disseminated intravascular coagulation in the dog. I: Demonstration of microthrombi in lung.
Disseminated Intravascular Coagulation
Thrombin-induced disseminated intravascular coagulation in the dog. II. Cardiorespiratory changes during spontaneous and controlled ventilation.
Disseminated Intravascular Coagulation
Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients.
Disseminated Intravascular Coagulation
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Disseminated Intravascular Coagulation
Treatment of Disseminated Intravascular Coagulation.
Disseminated Intravascular Coagulation
Vascular and dendritic cell coagulation signaling in sepsis progression.
Disseminated Intravascular Coagulation
[Activation of the blood kallikrein-kinin system in disseminated intravascular coagulation in rats. The significance of the pulmonary component and an attempt at correction with aspirin]
Disseminated Intravascular Coagulation
[Disseminated intravascular coagulation in the early stage after severe burn: the role of excessive thrombin generation]
Disseminated Intravascular Coagulation
[Effect of 4-amidinophenylpyruvic acid on the generalized Sanarelli-Shwartzman phenomenon]
Disseminated Intravascular Coagulation
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
Disseminated Intravascular Coagulation
[Effect of MD-805, a synthetic thrombin inhibitor, on disseminated intravascular coagulation developing in hematological disorders]
Disseminated Intravascular Coagulation
[Evaluation of thrombin in urine as a real-time indicator of clotting activation in glomerulonephritis]
Disseminated Intravascular Coagulation
[Experimental studies on disseminated intravascular coagulation (author's transl)]
Disseminated Intravascular Coagulation
[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.]
Disseminated Intravascular Coagulation
[Mathematical assessment of the blood prothrombinase-thrombin activity by the autocoagulation test]
Disseminated Intravascular Coagulation
[Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma]
Disseminated Intravascular Coagulation
[Relationship between thrombinemia and free radical processes in the blood]
Disseminated Intravascular Coagulation
[State of homeostasis under administration of bear fat in rats with exogenous and endogenous thrombinemia].
Disseminated Intravascular Coagulation
[The influence of a synthetic thrombin inhibitor on the disseminated intravascular coagulation in the rabbit (author's transl)]
Disseminated Intravascular Coagulation
[Thrombocytopenia and disseminated intravascular coagulation in low-dose heparin prophylaxis]
Disseminated Intravascular Coagulation
[Use of partial thromboplastin time and thrombin time in the diagnosis of disseminated intravascular coagulation]
Down Syndrome
Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium.
Down Syndrome
Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis.
Drug Resistant Epilepsy
Thrombin decreases expression of the glutamate transporter GLAST and inhibits glutamate uptake in primary cortical astrocytes via the Rho kinase pathway.
Drug-Related Side Effects and Adverse Reactions
Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation.
Drug-Related Side Effects and Adverse Reactions
Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.
Duodenal Ulcer
Endoscopic local injection of ethanolamine oleate and thrombin as an effective treatment for bleeding duodenal ulcer: a controlled trial.
Duodenal Ulcer
[Evaluation of using fibrin tissue adhesive (Beriplast) and preparations of thrombin and adrenalin in injection hemostasis methods for gastric and duodenal ulcer hemorrhage. Randomized, prospective clinical trial]
Dyslipidemias
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Dyslipidemias
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Dyspnea
Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease.
Ecchymosis
Comparison of curative effect between different anticoagulation regimens in continuous renal replacement therapy after cardiac valve replacement.
Ecchymosis
Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation.
Eclampsia
Platelets from eclampsia patients have reduced membrane microviscosity and lower activities of the signalling enzymes.
Edema, Cardiac
Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease.
Eisenmenger Complex
Dual endothelin-1 receptor antagonism attenuates platelet-mediated derangements of blood coagulation in Eisenmenger syndrome.
Embolic Stroke
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Embolic Stroke
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Embolic Stroke
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Embolic Stroke
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Embolic Stroke
Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source?- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
Embolic Stroke
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
Embolic Stroke
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Embolic Stroke
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Embolic Stroke
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke.
Embolic Stroke
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.
Embolic Stroke
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function.
Embolic Stroke
[Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay].
Embolism
A Comparison of Methods for Estimating Glomerular Filtration Rate for a Population in Hawai'i with Non-Valvular Atrial Fibrillation.
Embolism
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Embolism
Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.
Embolism
An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.
Embolism
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Embolism
Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique.
Embolism
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.
Embolism
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Embolism
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Embolism
Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation.
Embolism
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Embolism
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Embolism
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Embolism
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Embolism
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Embolism
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Embolism
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Embolism
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Embolism
Granulocytes mediate the increase in pulmonary vascular permeability after thrombin embolism.
Embolism
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Embolism
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Embolism
Indices of fibrinogen proteolysis and platelet activation during the resolution of pulmonary embolism.
Embolism
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Embolism
Intraoperative embolus formation during cardiopulmonary bypass affects the release of S100B.
Embolism
Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report.
Embolism
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Embolism
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
Embolism
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Embolism
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Embolism
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.
Embolism
Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels.
Embolism
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration.
Embolism
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Embolism
Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms.
Embolism
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Embolism
The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation.
Embolism
The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine.
Embolism
The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation.
Embolism
The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios.
Embolism
Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.
Embolism
Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus.
Embolism
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Embolism
Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Embolism
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Embolism
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
Embolism
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
Embolism
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Embolism
[Waiting for the new oral anticoagulants: questions and answers about dabigatran].
Encephalitis
Differential effects on glial activation by a direct versus an indirect thrombin inhibitor.
Encephalitis
Thrombin Inhibition Reduces the Expression of Brain Inflammation Markers upon Systemic LPS Treatment.
Encephalitis
Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis.
Encephalomyelitis
Increased thrombin inhibition in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.
Encephalomyelitis
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Early detection of thrombin activity in neuroinflammatory disease.
Encephalomyelitis, Autoimmune, Experimental
Increased thrombin inhibition in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.
Encephalomyelitis, Autoimmune, Experimental
Thrombin generation and activity in multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Endocarditis
The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events.
Endoleak
A case of hybrid repair of ruptured abdominal aortic aneurysm with use of thrombin for acute treatment of type II endoleak.
Endoleak
Colonic necrosis subsequent to catheter-directed thrombin embolization of the inferior mesenteric artery via the superior mesenteric artery: a complication in the management of a type II endoleak.
Endoleak
Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion.
Endoleak
CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair.
Endoleak
Direct thrombin injection into aneurysmal sac in a patient with a type II endoleak.
Endoleak
EVAR: critical applied aortic morphology relevant to type-II endoleaks following device enhancement in patients with abdominal aortic aneurysms.
Endoleak
Inexplicable late type Ia endoleak associated with the low-profile Ovation endograft in a patient with favorable neck anatomy: treatment with transcaval coil embolization.
Endoleak
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Endoleak
Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair.
Endoleak
Ischemic colitis following translumbar thrombin injection for treatment of endoleak.
Endoleak
Laser-assisted transprosthesial coil embolization combined with thrombin injection for treatment of an endoleak type II after endovascular aneurysm repair.
Endoleak
Percutaneous direct thrombin injection with hydrodissection to manage type II endoleak after endovascular abdominal aortic aneurysm repair.
Endoleak
Strategies to Reduce the Rate of Type II Endoleaks: Routine Intraoperative Embolization of the Inferior Mesenteric Artery and Thrombin Injection Into the Aneurysm Sac.
Endoleak
Successful treatment of a type-II endoleak with percutaneous CT-guided thrombin injection in a patient after endovascular abdominal aortic aneurysm repair.
Endoleak
The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm.
Endoleak
Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac.
Endoleak
[Endovascular treatment of abdominal aortic aneurysms: 6 years of experience at a single centre.]
Endoleak
[Transarterial occlusion of type 1 endoleak of the aortic arch by coil embolization and thrombin injection after endovascular therapy of retrograde Stanford A dissection]
Endometrial Neoplasms
Application of thrombin gel matrix for the prevention of lymphocele in patients with endometrial cancer: A prospective randomized trial.
Endometrial Neoplasms
Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.
Endometrial Neoplasms
Transient increase in thrombin generation during radiotherapy of uterine carcinoma: A preliminary study using thrombin-antithrombin III complex measurements.
Endometriosis
Assessment of Coagulation Parameters in Women Affected by Endometriosis: Validation Study and Systematic Review of the Literature.
Endometriosis
Chemical pleurodesis with autologous blood and freeze-dried concentrated human thrombin improved spontaneous pneumothorax and thoracic endometriosis: The first case involving a pregnant woman.
Endometriosis
Endometrial epithelial-mesenchymal transition (EMT) by menstruation-related inflammatory factors during hypoxia.
Endometriosis
Fibrin clot properties among women with endometriosis and the impact of ovarian stimulation.
Endometriosis
Novel therapeutic strategies for endometriosis: a pathophysiological perspective.
Endometriosis
Possible involvement of thrombin/protease-activated receptor 1 system in the pathogenesis of endometriosis.
Endometriosis
The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding.
Endophthalmitis
Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery.
Endotoxemia
A novel fibrinogenase from Agkistrodon acutus venom protects against LPS-induced endotoxemia via regulating NF-?B pathway.
Endotoxemia
An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia.
Endotoxemia
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.
Endotoxemia
Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia.
Endotoxemia
Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model.
Endotoxemia
Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs.
Endotoxemia
Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia.
Endotoxemia
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Endotoxemia
Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats.
Endotoxemia
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
Endotoxemia
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.
Endotoxemia
Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees.
Endotoxemia
Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans.
Endotoxemia
Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets.
Endotoxemia
The influence of hypoxia on platelet function and plasmatic coagulation during systemic inflammation in humans in vivo.
Enterocolitis, Necrotizing
Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis.
Eosinophilia
Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Epilepsy
An electrochemical aptasensor based on TiO2/MWCNT and a novel synthesized Schiff base nanocomposite for the ultrasensitive detection of thrombin.
Epilepsy
Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic.
Epilepsy
Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus.
Epilepsy
Lack of association between the prothrombin rs1799963 polymorphism and juvenile myoclonic epilepsy.
Epilepsy
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Epilepsy, Temporal Lobe
Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus.
Epiretinal Membrane
High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment.
Epiretinal Membrane
The use of intravitreal thrombin to control hemorrhage during vitrectomy.
Epistaxis
A novel mutation in the FGB: c.1105C>T turns the codon for amino acid B? Q339 into a stop codon causing hypofibrinogenemia.
Epistaxis
Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Epistaxis
Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation.
Epistaxis
[Injury of internal carotid with uncontrollable epistaxis, cured by intra-arterial thrombin injection; with an experimental contribution.]
Epistaxis
[The determination of activated partial thromboplastin time, coagulate time and thrombin time in patients with epistaxis of indeterminate cause]
Erythromelalgia
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.
Esophageal and Gastric Varices
Absence of disseminated intravascular coagulation with endoscopic sclerosis of esophageal varices.
Esophageal and Gastric Varices
Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system.
Esophageal and Gastric Varices
Endoscopic use of human thrombin in bleeding gastric varices.
Esophageal and Gastric Varices
Injection sclerotherapy of esophageal varices using ethanolamine oleate.
Esophageal and Gastric Varices
Outcomes of endoscopic human thrombin injection in the management of gastric varices.
Esophageal and Gastric Varices
Pathophysiology of shock and DIC complicating endoscopic embolization with thrombin for esophageal varices.
Esophageal and Gastric Varices
Preservation of thrombin generation in cirrhosis despite abnormal results of international normalized ratio: implications for invasive procedures.
Esophageal and Gastric Varices
Recent advances in the endoscopic management of variceal bleeding.
Esophageal and Gastric Varices
Role and safety of human thrombin injection for the treatment of bleeding gastric varices.
Esophageal and Gastric Varices
Safety and Efficacy of Thrombin for Bleeding Gastric Varices: A Systematic Review and Meta-Analysis.
Esophageal and Gastric Varices
Sclerotherapy of esophageal varices by consecutive injection of anhydrous ethanol: 1% polydocanol and thrombin.
Esophageal and Gastric Varices
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Esophageal and Gastric Varices
The use of thrombin injections in the management of bleeding gastric varices: a single-center experience.
Esophageal and Gastric Varices
Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience.
Esophageal and Gastric Varices
Thrombin is effective in arresting bleeding from gastric variceal hemorrhage.
Esophageal and Gastric Varices
Thrombin--an effective treatment for gastric variceal haemorrhage.
Esophageal and Gastric Varices
[Clinical study on coagulation, fibrinolysis, and complement systems after endoscopic injection sclerotherapy of esophageal varices with human thrombin]
Esophageal and Gastric Varices
[Clinical usefulness of the measurement of plasma D-dimer levels]
Esophageal and Gastric Varices
[Pathology and treatment of shock and DIC which complicate endoscopic embolization of esophageal varices with thrombin]
Esophageal and Gastric Varices
[Pathology of shock accompanying endoscopic embolization of esophageal varices using thrombin]
Esophageal Perforation
Treatment of Esophageal Perforation with Primary Closure and Reinforcement Using TachoSil.
Esophageal Squamous Cell Carcinoma
Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection.
Esophageal Squamous Cell Carcinoma
Effect of thrombin receptor expression on microvessel endothelial cells, and survival by coagulation state in oesophageal squamous cell carcinoma.
Essential Hypertension
Basal and stimulated cytosolic platelet calcium in essential hypertension.
Essential Hypertension
Effect of antihypertensive treatment on intracellular calcium concentration and intracellular pH in essential hypertension.
Essential Hypertension
Increased indexes of thrombin activation in advanced stages of hypertension.
Essential Hypertension
Inhibition of platelet aggregability by losartan in essential hypertension.
Essential Hypertension
Platelets in human essential hypertension: in vitro hyperreactivity to thrombin.
Essential Hypertension
Prothrombin activation fragment 1 + 2 and thrombin-antithrombin-III complexes in plasma of patients with essential arterial hypertension.
Essential Hypertension
[Phospholipase C hypersensitivity in hypertensive rats results from innate and acquired factors]
Eye Diseases
PKC isoenzymes differentially modulate the effect of thrombin on MAPK-dependent RPE proliferation.
Eye Diseases
Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation.
Eye Diseases
Thrombin stimulates stress fiber assembly in RPE cells by PKC/CPI-17-mediated MLCP inactivation.
Eye Diseases
Thrombin-activated PAR1 membrane expression is regulated by Rab11a-RCP complex dissociation.
Eye Hemorrhage
[Results of the surgical treatment of eye injuries complicated by hemophthalmos, using thrombin]
Eye Hemorrhage
[Use of thrombin in the prevention and arrest of intraocular hemorrhage during vitrectomy in traumatic hemophthalmos]
Eye Injuries
[Results of the surgical treatment of eye injuries complicated by hemophthalmos, using thrombin]
Factor V Deficiency
Acquired factor V deficiency associated with exposure to bovine thrombin in a burn patient.
Factor V Deficiency
Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma.
Factor V Deficiency
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.
Factor V Deficiency
Thrombin generation assay is a useful pre-operative tool to predict non-bleeding risk in a patient with mild factor V deficiency.
Factor VII Deficiency
Recombinant activated factor VII in clinical practice: a 2014 update.
Factor VII Deficiency
Recombinant activated factor VII: mechanisms of action and current indications.
Factor X Deficiency
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
Factor X Deficiency
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Factor X Deficiency
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
Factor X Deficiency
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
Factor X Deficiency
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Factor XI Deficiency
Anesthetic management using peripheral nerve block in patients with factor XI deficiency: a case report.
Factor XI Deficiency
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
Factor XI Deficiency
The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency.
Factor XI Deficiency
Thrombin generation in patients with factor XI deficiency and clinical bleeding risk.
Factor XII Deficiency
Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins.
Factor XIII Deficiency
Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Factor XIII Deficiency
Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Familial Primary Pulmonary Hypertension
Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Plasma coagulation profiles in patients with severe primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension.
Fatty Liver
Comparison of the coagulation profile of fatty liver haemorrhagic syndrome-susceptible laying hens and normal laying hens.
Fatty Liver
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Fatty Liver
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Fatty Liver
Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.
Fetal Death
Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.
Fetal Death
The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications.
Fetal Growth Retardation
Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins.
Fetal Growth Retardation
Placental syndecan expression is altered in human idiopathic fetal growth restriction.
Fetal Growth Retardation
The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications.
Fetal Growth Retardation
Thrombin activation of endometrial endothelial cells: a possible role in intrauterine growth restriction.
Fetal Growth Retardation
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Fibroma
Fibrin foam and thrombin as used in the surgical removal of a large fibromyxoma of the mandible.
Fibrosarcoma
Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.
Fibrosarcoma
Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro.
Fibrosarcoma
Regulation of prostaglandin synthesis mediated by thrombin and B2 bradykinin receptors in a fibrosarcoma cell line.
Fibrosarcoma
Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin.
Fibrosarcoma
The interaction between fibrinogen and 3H-arginine labelled proteins derived from fibrosarcoma in the presence of thrombin.
Fibrosarcoma
The interaction between fibrinogen and 3H-L-arginine cationic peptides derived from fibrosarcoma in the presence of thrombin.
Fibrosarcoma
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Folic Acid Deficiency
Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats.
Foot Ulcer
Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study.
Fournier Gangrene
Low thrombin tissue sealant ARTISS (Baxter), in complex primary closure after Fournier's gangrene.
Gastritis
Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis.
Gastrointestinal Hemorrhage
Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage.
Gastrointestinal Hemorrhage
Gelfoam and thrombin in treatment of massive upper gastrointestinal hemorrhage.
Gastrointestinal Hemorrhage
Thrombin in the control of upper gastrointestinal hemorrhage; report of three cases.
Gastrointestinal Hemorrhage
Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran.
Gastroparesis
Thrombin action on astrocytes in the hindbrain of the rat disrupts glycemic and respiratory control.
Genetic Diseases, Inborn
Glycoprotein IIb-IIIa and the translocation of Rap2B to the platelet cytoskeleton.
Genetic Diseases, Inborn
Two successful cases of DIEP flaps for breast reconstruction in patients with Factor V Leiden.
Glioblastoma
A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma.
Glioblastoma
A novel PAR-1-type thrombin receptor signaling pathway: cyclic AMP-independent activation of PKA in SNB-19 glioblastoma cells.
Glioblastoma
Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.
Glioblastoma
Functional thrombin receptor PAR1 in primary cultures of human glioblastoma cells.
Glioblastoma
Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma.
Glioblastoma
Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Glioblastoma
Meizothrombin, an intermediate of prothrombin activation, stimulates human glioblastoma cells by interaction with PAR-1-type thrombin receptors.
Glioblastoma
Myocardin-Related Transcription Factor A and Yes-Associated Protein Exert Dual Control in G Protein-Coupled Receptor- and RhoA-Mediated Transcriptional Regulation and Cell Proliferation.
Glioblastoma
Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling.
Glioblastoma
PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells.
Glioblastoma
The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth.
Glioblastoma
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Glioblastoma
Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid beta-protein precursor.
Glioblastoma
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.
Glioblastoma
Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells.
Glioma
A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model.
Glioma
Activity of protein kinase C is necessary for sustained thrombin-induced [Ca2+]i oscillations in rat glioma cells.
Glioma
Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation.
Glioma
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Glioma
Investigation of PAR-1-type thrombin receptors in rat glioma C6 cells with a novel monoclonal anti-PAR-1 antibody (Mab COR7-6H9).
Glioma
Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model.
Glioma
Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling.
Glioma
Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models.
Glioma
The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor.
Glioma
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Glioma
Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes in vitro.
Glioma
Thrombin and PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells.
Glioma
Thrombin reverts the beta-adrenergic agonist-induced morphological response in rat glioma C6 cells.
Glioma
Thrombin-induced cell proliferation and platelet-derived growth factor-AB release from A172 human glioblastoma cells.
Glioma
Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells.
Glioma
Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.
Glioma
Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression.
Glioma
[Ca2+]i oscillations in single rat glioma cells induced by thrombin through activation of cell surface receptors.
Glomerulonephritis
Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay.
Glomerulonephritis
Constitutive expression and modulation of the functional thrombin receptor in the human kidney.
Glomerulonephritis
Cultured rat glomerular epithelial cells show gene expression and production of transforming growth factor-beta: expression is enhanced by thrombin.
Glomerulonephritis
Endothelin-1 in children with acute poststreptococcal glomerulonephritis and hypertension.
Glomerulonephritis
Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Glomerulonephritis
Thrombin increases proliferation and decreases fibrinolytic activity of kidney glomerular epithelial cells.
Glomerulonephritis
Thrombin regulates components of the fibrinolytic system in human mesangial cells.
Glomerulonephritis
Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis.
Glomerulonephritis
Urinary thrombin: a novel marker of glomerular inflammation for the diagnosis of crescentic glomerulonephritis (prospective observational study).
Glomerulonephritis
[Affinity sorbents with tripeptide morpholine ligands for isolation of proteases]
Glomerulonephritis
[Evaluation of thrombin in urine as a real-time indicator of clotting activation in glomerulonephritis]
Glomerulonephritis
[Extracapillary glomerulonephritis with fibrin deposits. Role of thrombin]
Glomerulonephritis
[Role of thrombin and its receptor in the pathogenesis of severe forms of human glomerulonephritis with fibrin deposits]
Glucose Intolerance
[The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity in patients with ischemic heart disease and a disordered carbohydrate tolerance]
Goiter
[The use of the new biological adhesive preparation fibrin polymer in thyroid surgery]
Granuloma
Collagen, fibrinogen and thrombin biological addesive is effective in treating experimental liver injuries.
Granuloma
Fibrin deposition and clearance in chronic granulomatous inflammation: correlation with T-cell function and proteinase inhibitor activity in tissue.
Granuloma
PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses.
Granuloma
The collagen, fibrinogen and thrombin biological adhesive is effective in treating experimental liver injuries.
Granulomatosis with Polyangiitis
Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Gray Platelet Syndrome
Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives.
Gray Platelet Syndrome
Grey platelet syndrome: studies on platelet alpha-granules, lysosomes and defective response to thrombin.
Gray Platelet Syndrome
Immunocytochemical localization of fibrinogen during thrombin-induced aggregation of washed human platelets.
Guillain-Barre Syndrome
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Hantavirus Infections
Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection.
Head Injuries, Closed
Coagulopathy in acute head injury--a study of its role as a prognostic indicator.
Hearing Loss, Sensorineural
Thrombin generation in patients with idiopathic sudden sensorineural hearing loss.
Hearing Loss, Sudden
[The correlation analysis of coagulation detection and blood routine parameters of sudden hearing loss].
Heart Arrest
Day-Case Treatment of Peripheral Arterial Disease: Results from a Multi-Center European Study.
Heart Defects, Congenital
Calibrated automated thrombogram values in infants with cardiac surgery before and after cardiopulmonary bypass.
Heart Defects, Congenital
Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease.
Heart Defects, Congenital
Pediatric patients with congenital heart disease: thrombin generation measured by calibrated automated thrombography.
Heart Defects, Congenital
Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
Heart Defects, Congenital
Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Heart Defects, Congenital
Thrombin generation determined by calibrated automated thrombography (CAT) in pediatric patients with congenital heart disease.
Heart Defects, Congenital
Thrombin generation in paediatric patients with congenital heart disease. Determination by calibrated automated thrombography.
Heart Defects, Congenital
Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations.
Heart Diseases
Coagulation parameters may predict clinical outcomes in patients with septic acute kidney injury.
Heart Diseases
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Heart Diseases
Design, Synthesis and Characterization of Cyclic NU172 Analogues: A Biophysical and Biological Insight.
Heart Diseases
Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels.
Heart Diseases
The relevance of platelet and fibrin thromboembolism of the coronary microcirculation, with special reference to sudden cardiac death.
Heart Diseases
Thrombin generation and activation of the thrombomodulin protein C system in open heart surgery depend on the underlying cardiac disease.
Heart Diseases
Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy.
Heart Failure
A Prothrombotic State in Patients With a History of Left Ventricular Thrombus.
Heart Failure
Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy.
Heart Failure
Anemic comorbidity reduces capacity of endogenous thrombin generation and is associated with consumptive coagulopathy in patients with heart failure.
Heart Failure
Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice.
Heart Failure
Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding.
Heart Failure
Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure.
Heart Failure
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Heart Failure
High-intensity interval training recuperates capacity of endogenous thrombin generation in heart failure patients with reduced ejection fraction.
Heart Failure
Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy.
Heart Failure
Platelet function, thrombin and fibrinolytic activity in patients with heart failure.
Heart Failure
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Heart Failure
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Heart Failure
Successful COMPASS, disappointing COMMANDER HF, what have we learned from these two trials?
Heart Failure
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Heart Failure
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Heart Failure
[Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.]
Heart Rupture
Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study.
Heart Rupture
Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture.
HELLP Syndrome
Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth.
HELLP Syndrome
[Change and significance of coagulation function and von Willebrand factor antigen level in HELLP syndrome].
Hemangioma
Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells.
Hemangioma
Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin.
Hemangioma
[Expression and significance of the proteins in TSP-1 and NF-?B signal pathways of infantile capillary hemangioma].
Hemangioma, Cavernous
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Hemangiosarcoma
Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines.
Hemangiosarcoma
Use of dressing with human fibrin and thrombin during resection of a right atrial angiosarcoma.
Hemarthrosis
Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
Hematologic Diseases
An ultrasensitive chemiluminescence aptasensor for thrombin detection based on iron porphyrin catalyzing luminescence desorbed from chitosan modified magnetic oxide graphene composite.
Hematologic Diseases
Dissecting the contribution of thrombin exosite I in the recognition of thrombin binding aptamer.
Hematologic Neoplasms
Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies.
Hematologic Neoplasms
Diagnostic and Prognostic Value of Plasma Factor V Activity and Parameters in Thrombin Generation for Disseminated Intravascular Coagulation in Patients with Hematological Malignancies.
Hematologic Neoplasms
Elevated extracellular trap formation and contact system activation in acute leukemia.
Hematologic Neoplasms
Thrombin Generation among Sudanese Patients with Hematological Malignancies.
Hematologic Neoplasms
Use of intrapulmonary administration of thrombin in hematological malignancy patients with alveolar haemorrhage: A case series.
Hematologic Neoplasms
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
Hematoma, Subdural
Thrombin contributes to the injury development and neurological deficit after acute subdural hemorrhage in rats only in collaboration with additional blood-derived factors.
Hematoma, Subdural, Acute
Acute subdural hematoma: new model delineation and effects of coagulation inhibitors.
Hematoma, Subdural, Chronic
Irrigation with thrombin solution reduces recurrence of chronic subdural hematoma in high risk patients. - Preliminary report -
Hematuria
Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response.
Hematuria
Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases.
Hematuria
Percutaneous Cyanoacrylate Glue Injection into the Renal Pseudoaneurysm to Control Intractable Hematuria After Percutaneous Nephrolithotomy.
Hematuria
Postpyelolithotomy renal artery pseudoaneurysm management with percutaneous thrombin injection: a case report.
Hematuria
[Effect of thrombin on hematuria after operation for benign prostatic hyperplasia]
Hemochromatosis
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Hemoglobinuria
Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria
Highly purified thrombin, esterase thrombin, and the paroxysmal nocturnal hemoglobinuria hemolytic system.
Hemoglobinuria
Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria. Mechanism of the enhancement of hemolysis by bovine thrombin.
Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria: the role of properdin in the diagnostic thrombin test.
Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria; a specific test for the disease based on the ability of thrombin to activate the hemolytic factor.
Hemoglobinuria
The mechanism of action of preparations of thrombin on hemolysis of red cells from patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria
Thrombin generation and clot retraction studies in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Highly purified thrombin, esterase thrombin, and the paroxysmal nocturnal hemoglobinuria hemolytic system.
Hemoglobinuria, Paroxysmal
Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Hemoglobinuria, Paroxysmal
Paroxysmal nocturnal hemoglobinuria. Mechanism of the enhancement of hemolysis by bovine thrombin.
Hemoglobinuria, Paroxysmal
Paroxysmal nocturnal hemoglobinuria: the role of properdin in the diagnostic thrombin test.
Hemoglobinuria, Paroxysmal
Paroxysmal nocturnal hemoglobinuria; a specific test for the disease based on the ability of thrombin to activate the hemolytic factor.
Hemoglobinuria, Paroxysmal
The mechanism of action of preparations of thrombin on hemolysis of red cells from patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Thrombin generation and clot retraction studies in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
[Role of thrombin in the mechanism of hemolysis and nocturnal paroxysmal hemoglobinuria.]
Hemolytic-Uremic Syndrome
Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
[Markers of thrombin generation in kidney failure of children with epidemic hemolytic uremic syndrome]
Hemoperitoneum
Ultrasound-guided percutaneous periarterial thrombin injection for paracentesis-related hemoperitoneum.
Hemophilia A
A bispecific antibody demonstrates limited measurability in routine coagulation assays.
Hemophilia A
A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
Hemophilia A
A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.
Hemophilia A
A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.
Hemophilia A
A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.
Hemophilia A
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
Hemophilia A
A new parameter in the thrombin generation assay, mean velocity to peak thrombin, reflects factor VIII activity in patients with haemophilia A.
Hemophilia A
A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
Hemophilia A
A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
Hemophilia A
A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
Hemophilia A
A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia.
Hemophilia A
A thrombin generation test; the application in haemophilia and thrombocytopenia.
Hemophilia A
A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
Hemophilia A
Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA.
Hemophilia A
Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect.
Hemophilia A
Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.
Hemophilia A
Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.
Hemophilia A
Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness.
Hemophilia A
An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.
Hemophilia A
An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa.
Hemophilia A
An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency.
Hemophilia A
An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
Hemophilia A
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
Hemophilia A
Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Hemophilia A
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Hemophilia A
Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma.
Hemophilia A
Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation.
Hemophilia A
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation.
Hemophilia A
Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A.
Hemophilia A
Can the diagnostic reliability of the thrombin generation test as a global haemostasis assay be improved? The impact of calcium chloride concentration.
Hemophilia A
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experience.
Hemophilia A
Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.
Hemophilia A
Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay.
Hemophilia A
Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
Hemophilia A
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Hemophilia A
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
Hemophilia A
Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study.
Hemophilia A
Commentary on "Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms".
Hemophilia A
Comparing Thrombin Generation in Patients with Hemophilia A and Patients on Vitamin K Antagonists.
Hemophilia A
Comparison of two laboratory assays in monitoring the efficacy of different prophylaxis regimens for severe haemophilia.
Hemophilia A
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.
Hemophilia A
Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
Hemophilia A
Correlation of thromboelastographic patterns with clinical presentation and rationale for use of antifibrinolytics in severe haemophilia patients.
Hemophilia A
Correlation to FVIII:C in Two Thrombin Generation Tests: TGA-CAT and INNOVANCE ETP.
Hemophilia A
CRM+ haemophilia A due to a missense mutation (372----Cys) at the internal heavy chain thrombin cleavage site.
Hemophilia A
Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis.
Hemophilia A
Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).
Hemophilia A
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.
Hemophilia A
Detection by denaturing gradient gel electrophoresis of an Arg1689Cys mutation in a Chinese patient with mild hemophilia A.
Hemophilia A
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
Hemophilia A
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Hemophilia A
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
Hemophilia A
Effect of factor VIII deficiency on generation of thrombin: a biomechanical approach.
Hemophilia A
Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Hemophilia A
Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Hemophilia A
Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.
Hemophilia A
Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Hemophilia A
Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
Hemophilia A
Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
Hemophilia A
Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
Hemophilia A
Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
Hemophilia A
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
Hemophilia A
Expression and release of platelet protein disulphide isomerase in patients with haemophilia A.
Hemophilia A
Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
Hemophilia A
Factor VIII and thrombin generation assays: relevance to pharmacokinetic studies in haemophilia A.
Hemophilia A
Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.
Hemophilia A
Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
Hemophilia A
Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
Hemophilia A
Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients With Hemophilia Having Inhibitors.
Hemophilia A
Flow and delta-P dictate where thrombin, fibrin, and von Willebrand Factor will be found.
Hemophilia A
From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation.
Hemophilia A
FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Hemophilia A
Global coagulation assays in hemophilia A: A comparison to conventional assays.
Hemophilia A
Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX.
Hemophilia A
Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.
Hemophilia A
Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
Hemophilia A
Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: are these results really discordant?
Hemophilia A
Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
Hemophilia A
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Hemophilia A
Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
Hemophilia A
Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand.
Hemophilia A
In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Hemophilia A
Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A.
Hemophilia A
Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
Hemophilia A
Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Hemophilia A
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
Hemophilia A
Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics.
Hemophilia A
Joint health scores in a haemophilia A cohort from Pakistan with minimal or no access to factor VIII concentrate: correlation with thrombin generation and underlying mutation.
Hemophilia A
Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients.
Hemophilia A
Limited factor VIIa surface localization requirement of the factor VIIa-induced overall thrombin generation in platelet-rich hemophilia A plasma.
Hemophilia A
LPS-induced expression and release of monocyte tissue factor in patients with haemophilia.
Hemophilia A
Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.
Hemophilia A
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
Hemophilia A
Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
Hemophilia A
Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
Hemophilia A
Mechanism of action, development and clinical experience of recombinant FVIIa.
Hemophilia A
Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution.
Hemophilia A
MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia.
Hemophilia A
Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.
Hemophilia A
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
Hemophilia A
Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine.
Hemophilia A
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
Hemophilia A
Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation.
Hemophilia A
Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.
Hemophilia A
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.
Hemophilia A
Plasma and cellular contributions to fibrin network formation, structure and stability.
Hemophilia A
Platelet activation and aggregation: the importance of thrombin activity. A laboratory model.
Hemophilia A
Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.
Hemophilia A
Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
Hemophilia A
Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Hemophilia A
Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.
Hemophilia A
Problems in the detection of carriers of hemophilia A: the influence of stress and thrombin.
Hemophilia A
Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management.
Hemophilia A
Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.
Hemophilia A
Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.
Hemophilia A
Pseudoaneurysm in a patient with haemophilia A: thrombin injection plugs the hole.
Hemophilia A
Pseudoaneurysm in association with a knee endoprothesis operation in an inhibitor-positive haemophilia A patient - treatment with local thrombin.
Hemophilia A
Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A.
Hemophilia A
Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.
Hemophilia A
Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.
Hemophilia A
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.
Hemophilia A
Recombinant activated factor VII: mechanisms of action and current indications.
Hemophilia A
Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report.
Hemophilia A
Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
Hemophilia A
Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.
Hemophilia A
Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitor.
Hemophilia A
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results.
Hemophilia A
Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Hemophilia A
Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A.
Hemophilia A
Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation.
Hemophilia A
Targeting Protease Nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
Hemophilia A
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hemophilia A
The Art and Science of Building a Computational Model to Understand Hemostasis.
Hemophilia A
The coagulation defect in hemophilia with particular reference to the conversion of prothrombin to thrombin and the evolution of the prothrombin conversion accelerator.
Hemophilia A
The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Hemophilia A
The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
Hemophilia A
The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
Hemophilia A
The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
Hemophilia A
The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
Hemophilia A
The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
Hemophilia A
The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
Hemophilia A
The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A.
Hemophilia A
The thrombin generation test in the diagnosis of classical hemophilia and Christmas disease.
Hemophilia A
Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
Hemophilia A
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
Hemophilia A
Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction.
Hemophilia A
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Hemophilia A
Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Hemophilia A
Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.
Hemophilia A
Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
Hemophilia A
Thrombin generation assay and other universal tests for monitoring haemophilia therapy.
Hemophilia A
Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors.
Hemophilia A
Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.
Hemophilia A
Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
Hemophilia A
Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.
Hemophilia A
Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations.
Hemophilia A
Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia.
Hemophilia A
Thrombin generation in a patient with an acquired high-titre factor V inhibitor.
Hemophilia A
Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.
Hemophilia A
Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
Hemophilia A
Thrombin generation in patients with acquired haemophilia and clinical bleeding risk.
Hemophilia A
Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.
Hemophilia A
Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma.
Hemophilia A
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
Hemophilia A
Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective.
Hemophilia A
Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A.
Hemophilia A
Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
Hemophilia A
Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A.
Hemophilia A
Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody.
Hemophilia A
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
Hemophilia A
von Willebrand's disease and hemophilia are associated with diminished thromboxane A2 (TXA2) formation in clotting whole blood.
Hemophilia A
Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?
Hemophilia A
[Clinical analysis and laboratory findings in a patient with acquired hemophilia a.]
Hemophilia A
[Hemophilia B in a mixed breed male dog: treatment of a hemorrhagic crisis with fresh frozen plasma]
Hemophilia B
A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
Hemophilia B
Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
Hemophilia B
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
Hemophilia B
Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B.
Hemophilia B
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Hemophilia B
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
Hemophilia B
Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
Hemophilia B
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Hemophilia B
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Hemophilia B
Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
Hemophilia B
Haemophilia B caused by mutation of a potential thrombin cleavage site in factor IX.
Hemophilia B
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Hemophilia B
Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia.
Hemophilia B
Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Hemophilia B
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Hemophilia B
Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.
Hemophilia B
Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B.
Hemophilia B
The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
Hemophilia B
The thrombin generation test in the diagnosis of classical hemophilia and Christmas disease.
Hemophilia B
Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma.
Hemophilia B
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Hemophilia B
Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
Hemoptysis
Novel Bronchoscopic Management of Airway Bleeding With Absorbable Gelatin and Thrombin Slurry.
Hemoptysis
Treatment of hemoptysis patients by thrombin and fibrinogen-thrombin infusion therapy using a fiberoptic bronchoscope.
Hemoptysis
Treatment of massive hemoptysis with intraarterial thrombin injection of a bronchial artery.
Hemoptysis
[Thrombin instillation therapy through the fiberoptic bronchoscope in cases of hemoptysis (author's transl)]
Hemorrhagic Disorders
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Hemorrhagic Disorders
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.
Hemorrhagic Disorders
Multiple myeloma with polyneuropathy and coagulopathy. A case report of the polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin change (POEMS) syndrome.
Hemorrhagic Disorders
Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Hemorrhagic Disorders
[DISTURBANCES IN THE CHAIN-REACTION OF THROMBIN FORMATION AS A CAUSE OF HEMORRHAGIC DIATHESIS.]
Hemorrhagic Disorders
[DISTURBANCES IN THE CHAIN-REACTION OF THROMBIN FORMATION CAUSING HEMORRHAGIC DIATHESIS.]
Hemorrhagic Fever with Renal Syndrome
Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis.
Hemorrhagic Stroke
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
Hemorrhagic Stroke
Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis.
Hemorrhagic Stroke
Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).
Hemorrhagic Stroke
Prevention of cardioembolic stroke in patients with atrial fibrillation.
Hemorrhagic Stroke
Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
Hemorrhagic Stroke
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
Hemorrhagic Stroke
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
Hemostatic Disorders
Monitoring unfractionated heparin therapy in dogs by measuring thrombin generation.
Hemostatic Disorders
Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs.
Hemostatic Disorders
Supramolecular Aptamers on Graphene Oxide for Efficient Inhibition of Thrombin Activity.
Hepatic Encephalopathy
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.
Hepatic Insufficiency
The relationship of liver insufficiency to fibrinolytic hemorrhage as demonstrated by the serial thrombin time.
Hepatitis
A novel surgical glue composed of gelatin and N-hydroxysuccinimide activated poly(L-glutamic acid): Part 1. Synthesis of activated poly(L-glutamic acid) and its gelation with gelatin.
Hepatitis
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Hepatitis
Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity.
Hepatitis
Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases.
Hepatitis
[Hfgl2/fibroleukin expression in liver and peripheral blood mononuclear cells (PBMC) and its correlation with disease severity]
Hepatitis A
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Hepatitis A
Platelet and fibrinogen survival with 75Se selenomethionine in acute infectious hepatitis.
Hepatitis B
A cohort study of hepatectomy-related complications and prediction model for postoperative liver failure after major liver resection in 1,441 patients without obstructive jaundice.
Hepatitis B
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer.
Hepatitis B
Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease.
Hepatitis B
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Hepatitis C
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Hepatitis C
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Hepatitis C
Modular Combination of Proteolysis-Responsive Transcription and Spherical Nucleic Acids for Smartphone-Based Colorimetric Detection of Protease Biomarkers.
Hepatitis C
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Hepatitis C, Chronic
Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis.
Hepatitis E
Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein Processing.
Hepatorenal Syndrome
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.
Hermanski-Pudlak Syndrome
Enhanced increases in cytosolic Ca2+ in ADP-stimulated platelets from patients with delta-storage pool deficiency--a possible indicator of interactions between granule-bound ADP and the membrane ADP receptor.
Hermanski-Pudlak Syndrome
Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome.
Herpes Simplex
A fast method for obtaining highly pure recombinant herpes simplex virus type 1 thymidine kinase.
Herpes Simplex
Effects of viral activation of the vessel wall on inflammation and thrombosis.
Herpes Simplex
Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium.
Herpes Simplex
Mammalian cell transient expression of tissue factor for the production of antigen.
Herpes Simplex
Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.
Herpes Simplex
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Herpes Zoster
A specific thrombin inhibitor, argatroban, alleviates herpes zoster-associated pain.
Herpes Zoster
Angiopoietin-1 Regulates Brain Endothelial Permeability through PTPN-2 Mediated Tyrosine Dephosphorylation of Occludin.
HIV Infections
Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases.
HIV Infections
Thrombin activates envelope glycoproteins of HIV type 1 and enhances fusion.
Homozygous Familial Hypercholesterolemia
Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling.
Hydrocephalus
Activation of epiplexus macrophages in hydrocephalus caused by subarachnoid hemorrhage and thrombin.
Hydrocephalus
Effects of Aerobic Capacity on Thrombin-Induced Hydrocephalus and White Matter Injury.
Hydrocephalus
Impact of sex differences on thrombin-induced hydrocephalus and white matter injury: the role of neutrophils.
Hydrocephalus
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Hydrocephalus
Role of red blood cell lysis and iron in hydrocephalus after intraventricular hemorrhage.
Hydrocephalus
Thrombin and TGF-beta promote human leptomeningeal cell proliferation in vitro.
Hydrocephalus
Thrombin disrupts vascular endothelial-cadherin and leads to hydrocephalus via protease-activated receptors-1 pathway.
Hydrocephalus
Thrombin-induced TGF-?1 pathway: a cause of communicating hydrocephalus post subarachnoid hemorrhage.
Hydrocephalus, Normal Pressure
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Hyperalgesia
Intrathecal protease-activated receptor stimulation produces thermal hyperalgesia through spinal cyclooxygenase activity.
Hyperalgesia
Protease-activated receptor-1 and platelet-derived growth factor in spinal cord neurons are implicated in neuropathic pain after nerve injury.
Hyperalgesia
Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli.
Hyperalgesia
Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants.
Hyperalgesia
Role of Thrombin in Soluble Thrombomodulin-Induced Suppression of Peripheral HMGB1-Mediated Allodynia in Mice.
Hyperalgesia
Salmon-derived thrombin inhibits development of chronic pain through an endothelial barrier protective mechanism dependent on APC.
Hyperalgesia
The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats.
Hyperalgesia
The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury.
Hyperalgesia
The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury.
Hyperalgesia
Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin.
Hypercholesterolemia
Acute Myocardial Infarction and the Role of Aspirin, Heparin, and Warfarin.
Hypercholesterolemia
Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates.
Hypercholesterolemia
CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia.
Hypercholesterolemia
Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
Hypercholesterolemia
Effects of chronic administration of ethanol on platelets from rabbits with diet-induced hypercholesterolemia. Unchanged characteristics and responses to ADP but reduction of enhanced thrombin-induced, TxA2-independent platelet responses.
Hypercholesterolemia
Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivastatin.
Hypercholesterolemia
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
Hypercholesterolemia
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
Hypercholesterolemia
Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis.
Hypercholesterolemia
Long-term cholesterol feeding alters the reactivity of primate coronary microvessels to platelet products.
Hypercholesterolemia
Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.
Hypercholesterolemia
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.
Hypercholesterolemia
Pathophysiology and initial management of the acute coronary syndromes.
Hypercholesterolemia
Platelet function in Watanabe heritable hyperlipidemic rabbits. Decreased sensitivity to thromboxane A2.
Hypercholesterolemia
Platelet-dependent thrombin generation in patients with hyperlipidemia.
Hypercholesterolemia
Statins decrease thrombin generation in patients with hypercholesterolemia.
Hypercholesterolemia
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Hypercholesterolemia
Thrombin-induced inositol phosphate production by platelets from rats with diet-induced or genetically determined hypercholesterolemia.
Hypercholesterolemia
Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia.
Hypercholesterolemia
[Effect of surgical menopause on the development of cardiovascular diseases]
Hyperemia
[Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review]
Hyperemia
[Multivariate analysis for the understanding of typical diabetic hemostasis criteria. 1: Plasma markers]
Hyperglycemia
A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications.
Hyperglycemia
Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 mitogen-activated protein kinase-dependent actin cytoskeleton organization.
Hyperglycemia
Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus.
Hyperglycemia
Anti inflammatory effect of natural honey on bovine thrombin-induced oxidative burst in phagocytes.
Hyperglycemia
Assessment of acute moderate hyperglycemia on traditional and thromboelastometry coagulation parameters in healthy adult horses.
Hyperglycemia
Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation.
Hyperglycemia
Fibrinopeptide-A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes.
Hyperglycemia
Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.
Hyperglycemia
Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress.
Hyperglycemia
MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expression.
Hyperglycemia
Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon.
Hyperglycemia
Regulation of mitochondrial function as a promising target in platelet activation-related diseases.
Hyperglycemia
Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes.
Hyperglycemia
Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus.
Hyperhomocysteinemia
Hyperhomocysteinemia, antithrombin consumption, and early venous graft closure in surgical coronary revascularization.
Hyperhomocysteinemia
Some considerations about the hypercoagulable states and their treatments.
Hyperhomocysteinemia
The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential.
Hyperhomocysteinemia
Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation.
Hyperhomocysteinemia
[Genetic conditioned changes in activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) and recurrent miscarriages]
Hyperinsulinism
Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject.
Hyperinsulinism
Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation.
Hyperinsulinism
Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity.
Hyperinsulinism
The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima.
Hyperkalemia
Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane.
Hyperlipidemias
In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway.
Hyperlipidemias
Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Hyperlipidemias
Platelet functions in relation to dietary fats in farmers from two regions of France.
Hyperlipidemias
Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients.
Hyperlipidemias
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Hyperlipidemias
VIIaAT complexes, procoagulant phospholipids, and thrombin generation during postprandial lipemia.
Hyperlipidemias
[Effect of alimentary lipemia on thrombin generation in the plasma of healthy persons and in arteriosclerosis]
Hyperlipidemias
[Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy]
Hyperlipidemias
[Evaluation of thrombin generation and clot bound thrombin in plasma of hyperlipidemic patients treated with statins]
Hyperlipoproteinemia Type II
Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?
Hyperlipoproteinemia Type II
The effect of human plasma on platelet function in familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Hyperlipoproteinemia Type V
Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function.
Hyperlipoproteinemia Type V
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Hyperlipoproteinemias
Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function.
Hyperlipoproteinemias
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Hypersensitivity
A Possible Allergic Reaction Case to Thrombin Injected into Pseudoaneurysm After Radiofrequency Ablation.
Hypersensitivity
An innate host response to the neoplastic cell: syngeneic rat tumor cells can elicit a rapid de novo lymphoid procoagulant response.
Hypersensitivity
Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention.
Hypersensitivity
Asthma is associated with enhanced thrombin formation and impaired fibrinolysis.
Hypersensitivity
Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins.
Hypersensitivity
Enzymatic investigation for delayed-type hypersensitivity reaction. Assay for thrombin and plasmin activities in tuberculin reaction sites.
Hypersensitivity
Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection.
Hypersensitivity
Hypersensitivity of phospholipase C in platelets of spontaneously hypertensive rats.
Hypersensitivity
Hypersensitivity of platelets to thrombin: formation of stable thrombin-receptor complexes and the role of shape change.
Hypersensitivity
Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs.
Hypersensitivity
Iatrogenic pseudoaneurysm of femoral artery: case report and literature review.
Hypersensitivity
Increased platelet, but unaltered fibrinogen, accumulation in experimental thrombi in alloxan-induced diabetic rabbits.
Hypersensitivity
Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects.
Hypersensitivity
New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
Hypersensitivity
Progressive relaxation of Go-arrest controls and altered responsiveness to insulin, EGF and thrombin in CCL39 lung fibroblasts over-expressing myc and ras oncogenes.
Hypersensitivity
Protocol for Obtaining Platelet-Rich Plasma (PRP), Platelet-Poor Plasma (PPP), and Thrombin for Autologous Use.
Hypersensitivity
Severe allergic reaction: A rare complication of ultrasound-guided injection of thrombin in a femoral pseudoaneurysm.
Hypersensitivity
The effect of dietary saturated fat and cholesterol on platelet function, platelet survival and response to continuous aortic injury in rats.
Hypersensitivity
The hypersensitivity to thrombin of platelets from diabetic rats is not due to increased thrombin binding.
Hypersensitivity
The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury.
Hypersensitivity
Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects.
Hypersensitivity
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
Hypersensitivity
[Hypersensitivity accidents to thrombin following the use of biological glues]
Hypersensitivity, Delayed
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Hypertension
Association of aortic valve sclerosis with thrombin generation in hypertensive patients.
Hypertension
Cell calcium handling and intracellular pH regulation in hereditary hypertriglyceridemic rats: reduced platelet response to thrombin stimulation.
Hypertension
Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia.
Hypertension
Cytosolic pH and calcium in Dahl salt-sensitive and salt-resistant rats: the relationship to plasma lipids.
Hypertension
Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension.
Hypertension
Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.
Hypertension
Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension.
Hypertension
Impact of angiotensin-converting enzyme inhibition on platelet tissue factor expression in stroke-prone rats.
Hypertension
Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation - The Hoorn Study.
Hypertension
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Hypertension
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
Hypertension
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Hypertension
Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.
Hypertension
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.
Hypertension
Normal thrombin binding leads to greater fibrinogen binding and increased platelet aggregation in spontaneously hypertensive rats.
Hypertension
Perioperative Hidden Blood Loss in Elderly Cervical Spondylosis Patients With Anterior Cervical Discectomy Fusion and Influencing Factors.
Hypertension
Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension.
Hypertension
Platelet-derived miR-142-3p induces apoptosis of endothelial cells in hypertension.
Hypertension
The dynamics of thrombin formation in patients with pulmonary arterial hypertension.
Hypertension
Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Hypertension
Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice.
Hypertension
Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension.
Hypertension
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Hypertension
Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience.
Hypertension
[Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension]
Hypertension
[Effects of taurine and enalapril on blood pressure, platelet aggregation and the regression of left ventricular hypertrophy in two-kidney-one-clip renovascular hypertensive rats]
Hypertension
[Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients]
Hypertension
[Pre- and postpartum hemostatic characteristics in pregnancy-related hypertension and pre-eclampsia in comparison with normotensive pregnancies]
Hypertension
[Thrombin activity in the blood of patients with coronary insufficiency and hypertension]
Hypertension, Portal
Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience.
Hypertension, Pregnancy-Induced
[Pre- and postpartum hemostatic characteristics in pregnancy-related hypertension and pre-eclampsia in comparison with normotensive pregnancies]
Hypertension, Pulmonary
Antithrombin III deficiency in neonatal respiratory distress syndrome.
Hypertension, Pulmonary
Chronic Exposure to Fibrin and Fibrinogen Differentially Regulates Intracellular Ca2+ in Human Pulmonary Arterial Smooth Muscle and Endothelial Cells.
Hypertension, Pulmonary
Effects of antiplatelet drugs on pulmonary responses to thrombin in anesthetized rabbits.
Hypertension, Pulmonary
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
Hypertension, Pulmonary
Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells.
Hypertension, Pulmonary
Role of hemodynamics and vagus nerves in development of fibrin-induced pulmonary edema.
Hypertension, Pulmonary
Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression.
Hypertension, Pulmonary
Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension.
Hypertension, Pulmonary
Thrombin receptor activation peptide induces pulmonary vasoconstriction.
Hypertension, Pulmonary
Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension.
Hypertension, Pulmonary
Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome.
Hyperthyroidism
Hypothyroidism Exacerbates Thrombophilia in Female Rats Fed with a High Fat Diet.
Hypertriglyceridemia
Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
Hypertriglyceridemia
Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma.
Hypertriglyceridemia
Platelet-dependent thrombin generation in patients with hyperlipidemia.
Hypertrophy, Left Ventricular
Acute myocardial infarction with diminutive right coronary artery and obstructive hypertrophic cardiomyopathy without significant coronary stenoses.
Hypoalbuminemia
Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.
Hypoalbuminemia
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.
Hypoalbuminemia
Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia.
Hypoglycemia
Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics.
Hypoglycemia
Thrombin action on astrocytes in the hindbrain of the rat disrupts glycemic and respiratory control.
Hypoglycemia
Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults.
Hypotension
A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis.
Hypotension
Different hypotensive responses to intravenous bovine and human thrombin preparations in swine.
Hypotension
Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit.
Hypotension
Effect of reticuloendothelial blockade on the development of hypotension after trauma, sepsis, and intravascular coagulation.
Hypotension
Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system.
Hypotension
Induction of hypotension in rhesus monkeys and rabbits by intravenous thrombin infusion.
Hypotension
Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.
Hypotension
Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
Hypotension
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
Hypotension
The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents--lack of relationship to pretreatment streptokinase resistance.
Hypotension
Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
Hypothyroidism
Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy.
Hypothyroidism
Thrombin -Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidism.
Hypoxia-Ischemia, Brain
Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy.
Idiopathic Pulmonary Fibrosis
Increased expression of protease nexin-1 in fibroblasts during idiopathic pulmonary fibrosis regulates thrombin activity and fibronectin expression.
Idiopathic Pulmonary Fibrosis
Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
[Protein C system in patients with idiopathic pulmonary fibrosis - preliminary report.]
Ileus
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Iliac Aneurysm
The occlusion of an internal iliac aneurysm by the trans-catheter injection of thrombin.
Immunoglobulin Light-chain Amyloidosis
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Infarction, Middle Cerebral Artery
A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke.
Infarction, Middle Cerebral Artery
A novel histochemical method for the visualization of thrombin activity in the nervous system.
Infarction, Middle Cerebral Artery
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Infarction, Middle Cerebral Artery
Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice.
Infarction, Middle Cerebral Artery
Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis.
Infarction, Middle Cerebral Artery
Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
Infarction, Middle Cerebral Artery
EMBOLIC MIDDLE CEREBRAL ARTERY OCCLUSION MODEL USING THROMBIN AND FIBRINOGEN COMPOSED CLOTS IN RAT.
Infarction, Middle Cerebral Artery
Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus.
Infarction, Middle Cerebral Artery
Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection.
Infarction, Middle Cerebral Artery
Quantitative Detection of Thrombin Activity in an Ischemic Stroke Model.
Infarction, Middle Cerebral Artery
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
Infarction, Middle Cerebral Artery
Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
Infections
A bacterially produced virus enhancing factor from an entomopoxvirus enhances nucleopolyhedrovirus infection in armyworm larvae.
Infections
A Bail Out Solution for an Urgent Situation: Endovascular Exclusion and Embolization of an Infected Femoral Pseudoaneurysm.
Infections
A host basal transcription factor is a key component for infection of rice by TALE-carrying bacteria.
Infections
A novel medical device coating prevents Staphylococcus aureus biofilm formation on medical device surfaces.
Infections
A Predictive Model for Assessing Surgery-Related Acute Kidney Injury Risk in Hypertensive Patients: A Retrospective Cohort Study.
Infections
Analysis of the relationship between serum amyloid protein A, procalcitonin, C-reactive protein, and peripherally inserted central catheter infection in patients with malignant tumor.
Infections
Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation.
Infections
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Infections
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates.
Infections
Concentration- and pH-Dependent Oligomerization of the Thrombin-Derived C-Terminal Peptide TCP-25.
Infections
DIAGNOSING DISSEMINATED INTRAVASCULAR COAGULATION IN ACUTE INFECTION : CAN WE DO WITHOUT FDP & D-DIMER.
Infections
Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection.
Infections
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Infections
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Infections
Effect of Puumala hantavirus infection on human umbilical vein endothelial cell hemostatic function: platelet interactions, increased tissue factor expression and fibrinolysis regulator release.
Infections
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Infections
Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium.
Infections
Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice.
Infections
Evaluation of hemostaseological status of pigs experimentally infected with African swine fever virus.
Infections
Femoral pseudoaneurysms post-cardiac catheterization surgically treated: evolution and prognosis.
Infections
Fibrin deposition and clearance in chronic granulomatous inflammation: correlation with T-cell function and proteinase inhibitor activity in tissue.
Infections
Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral, and catalytical properties and their potency in the formation of all-trans-retinoic acid.
Infections
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Infections
Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis.
Infections
Increasing endothelial cell permeability improves the efficiency of myocyte adenoviral vector infection.
Infections
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Infections
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Infections
Measurement of intracellular calcium concentration in intact monolayers of human endothelial cells.
Infections
New insights into pathways that determine the link between infection and thrombosis.
Infections
Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
Infections
Possible involvement of platelets in Plasmodium yoelii nigeriensis malaria infection in mice.
Infections
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Infections
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.
Infections
Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium.
Infections
Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections.
Infections
Reservations against new oral anticoagulants after stroke and cerebral bleeding.
Infections
Role of CaM kinase II and ERK activation in thrombin-induced endothelial cell barrier dysfunction.
Infections
Short-term prognosis and influencing factors of patients with acute kidney injury treated with prolonged intermittent renal replacement therapy.
Infections
Study of haemostatic disorders in experimentally induced leishmaniasis in Beagle dogs.
Infections
Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy.
Infections
The frequency of bleeding complications after invasive dental treatment in patients receiving single and dual antiplatelet therapy.
Infections
The host basal transcription factor IIA subunits coordinate for facilitating infection of TALEs-carrying bacterial pathogens in rice.
Infections
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Infections
Thrombin and interleukin-1beta regulate HOXA10 expression in human term decidual cells: implications for preterm labor.
Infections
Thrombin and Interleukin-1{beta} Decrease HOX Gene Expression in Human First Trimester Decidual Cells: Implications for Pregnancy Loss.
Infections
Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.
Infections
Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child.
Infections
Thrombocytopenia in the experimental leptospirosis of guinea pig is not related to disseminated intravascular coagulation.
Infections
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Infections
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Infections
Vacuolating cytotoxin A is associated with increased thrombin generation in gastric mucosa.
Infections
[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]
Infections
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Inflammatory Bowel Diseases
A role for proteinase-activated receptor-1 in inflammatory bowel diseases.
Inflammatory Bowel Diseases
Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
Inflammatory Bowel Diseases
D-dimer tests detect both plasmin and neutrophil elastase derived split products.
Inflammatory Bowel Diseases
Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
Inflammatory Bowel Diseases
Increased procoagulant function of microparticles in pediatric inflammatory bowel disease: role in increased thrombin generation.
Inflammatory Bowel Diseases
Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.
Inflammatory Bowel Diseases
Thrombin generation and microparticles in inflammatory bowel diseases.
Inflammatory Bowel Diseases
Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease.
Inflammatory Breast Neoplasms
Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway.
Influenza in Birds
A label-free light-up fluorescent sensing platform based upon hybridization chain reaction amplification and DNA triplex assembly.
Influenza, Human
Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.
Influenza, Human
Critical role of oxidized LDL receptor-1 in intravascular thrombosis in a severe influenza mouse model.
Influenza, Human
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Influenza, Human
Extraction of catalytically active neuraminidase of H5N1 influenza virus using thrombin proteolytic cleavage.
Influenza, Human
Influenza virus H1N1 activates platelets through Fc?RIIA signaling and thrombin generation.
Influenza, Human
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
Insulin Coma
[Blood fibrinogenase in insulin shock, in electroshock, and in epileptic seizure.]
Insulin Resistance
Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women.
Insulin Resistance
Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes.
Insulin Resistance
Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation.
Insulin Resistance
Heparin-binding EGF-like growth factor (HB-EGF) mediates 5-HT-induced insulin resistance through activation of EGF receptor-ERK1/2-mTOR pathway.
Insulin Resistance
Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice.
Insulin Resistance
The Role of Heparin Cofactor ? in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice.
Insulin Resistance
Thrombin stimulates insulin secretion via protease-activated receptor-3.
Insulinoma
Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines.
Intermittent Claudication
Platelet activation increases with the severity of peripheral arterial disease: implications for clinical management.
Intestinal Diseases
Protease-activated receptor-1 stimulates Ca(2+)-dependent Cl(-) secretion in human intestinal epithelial cells.
Intestinal Neoplasms
[Clinical study of hemostatic molecular markers expression in patients with cancer.]
Intestinal Obstruction
The Diagnostic Value of Coagulation Indicators and Inflammatory Markers in Distinguishing Between Strangulated and Simple Intestinal Obstruction.
Intracranial Aneurysm
Lyophilizing thrombin powder-based treatment for hemostasis during coil embolization of ruptured cerebral aneurysm: Two case reports.
Intracranial Hemorrhages
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Intracranial Hemorrhages
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation.
Intracranial Hemorrhages
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Intracranial Hemorrhages
Effect of minimally invasive surgery for cerebral hematoma evacuation in different stages on motor evoked potential and thrombin in dog model of intracranial hemorrhage.
Intracranial Hemorrhages
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.
Intracranial Hemorrhages
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage : A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
Intracranial Hemorrhages
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
Intracranial Hemorrhages
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic.
Intracranial Hemorrhages
Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis.
Intracranial Hemorrhages
New antithrombotics for secondary prevention of acute coronary syndrome.
Intracranial Hemorrhages
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Intracranial Hemorrhages
Novel oral anticoagulant management issues for the stroke clinician.
Intracranial Hemorrhages
Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1.
Intracranial Hemorrhages
Thromboelastographic profiles of the premature infants with and without intracranial hemorrhage at birth: a pilot study.
Intracranial Hemorrhages
Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes.
Intracranial Hemorrhages
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Intracranial Hypertension
Steps to consider in the approach and management of critically ill patient with spontaneous intracerebral hemorrhage.
Intracranial Hypertension
Treatment of intractable arterial hemorrhage during stereotactic brain biopsy with thrombin. Report of three patients.
Intracranial Thrombosis
Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke.
Intracranial Thrombosis
Development of argatroban as an anticoagulant and antithrombin agent in Japan.
Intracranial Thrombosis
Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis.
Intracranial Thrombosis
Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis.
Intracranial Thrombosis
Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization.
Iron Overload
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Ischemic Attack, Transient
Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia.
Ischemic Attack, Transient
High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study.
Ischemic Attack, Transient
Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab.
Ischemic Attack, Transient
Platelet function and thrombin activity in patients with recent cerebral transient ischemic attacks.
Ischemic Attack, Transient
Thrombin generation is associated with ischemic stroke at a young age.
Ischemic Attack, Transient
Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies.
Ischemic Stroke
?-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-? in stroke.
Ischemic Stroke
A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke.
Ischemic Stroke
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
Ischemic Stroke
Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPA.
Ischemic Stroke
Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study.
Ischemic Stroke
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Ischemic Stroke
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
Ischemic Stroke
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Ischemic Stroke
Antithrombin gamma attenuates macrophage/microglial activation and brain damage after transient focal cerebral ischemia in mice.
Ischemic Stroke
Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke.
Ischemic Stroke
Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.
Ischemic Stroke
Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients.
Ischemic Stroke
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
Ischemic Stroke
Chronic hyper-reactivity of platelets resulting in enhanced monocyte recruitment in patients after ischaemic stroke.
Ischemic Stroke
Coated-platelet levels are elevated in patients with transient ischemic attack.
Ischemic Stroke
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation.
Ischemic Stroke
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Ischemic Stroke
Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Ischemic Stroke
Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Ischemic Stroke
Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
Ischemic Stroke
Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.
Ischemic Stroke
Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke.
Ischemic Stroke
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.
Ischemic Stroke
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
Ischemic Stroke
Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression.
Ischemic Stroke
High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study.
Ischemic Stroke
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.
Ischemic Stroke
In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke.
Ischemic Stroke
Increase of aquaporin 9 expression in astrocytes participates in astrogliosis.
Ischemic Stroke
Increased procoagulant platelet levels are predictive of death in COVID-19.
Ischemic Stroke
Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus.
Ischemic Stroke
Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study.
Ischemic Stroke
Independent ischemic stroke risk factors in older Americans: a systematic review.
Ischemic Stroke
Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.
Ischemic Stroke
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
Ischemic Stroke
LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury.
Ischemic Stroke
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Ischemic Stroke
Looking for Our Ten Years Results for Coronary Heart Disease and Ischemic Stroke Group for the Standpoint of Haemostasis.
Ischemic Stroke
Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis.
Ischemic Stroke
Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA.
Ischemic Stroke
Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition.
Ischemic Stroke
Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection.
Ischemic Stroke
New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke.
Ischemic Stroke
Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan.
Ischemic Stroke
Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation.
Ischemic Stroke
Platelet Reactivity in Patients With Stroke and Hyperlipidemia, GPIb? Assessment.
Ischemic Stroke
Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).
Ischemic Stroke
Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke.
Ischemic Stroke
Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke.
Ischemic Stroke
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration.
Ischemic Stroke
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Ischemic Stroke
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke.
Ischemic Stroke
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
Ischemic Stroke
The effects of heatwaves and cold spells on patients admitted with acute ischemic stroke.
Ischemic Stroke
The influence of immunoglobulin class G from blood plasma of patients with stroke on the activity of some parameters of hemostasis system.
Ischemic Stroke
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
Ischemic Stroke
The use of a desktop scanning electron microscope as a diagnostic tool in studying fibrin networks of thrombo-embolic ischemic stroke.
Ischemic Stroke
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke.
Ischemic Stroke
Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke.
Ischemic Stroke
Thrombin inhibition in the acute phase of ischaemic stroke using argatroban.
Ischemic Stroke
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Ischemic Stroke
Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells.
Ischemic Stroke
Thrombin stimulates mitogenesis in pig cerebrovascular smooth muscle cells involving activation of pro-matrix metalloproteinase-2.
Ischemic Stroke
Treatment for Patients with Acute Ischemic Stroke Presenting beyond Six Hours of Ischemic Symptom Onset : Effectiveness of Intravenous Direct Thrombin Inhibitor, Argatroban.
Ischemic Stroke
Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Ischemic Stroke
Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata.
Ischemic Stroke
[Effect of surgical menopause on the development of cardiovascular diseases]
Joint Diseases
Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue.
Joint Diseases
[1st studies on the problem of rectal resorption of MPS in the treatment of arthroses]
Joint Diseases
[Successful results of intra-articular injections of thrombin solutions, after irrigation of the joint in the treatment of hemophilic joint diseases.]
Kasabach-Merritt Syndrome
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Kidney Cortex Necrosis
Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits.
Kidney Diseases
Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells.
Kidney Failure, Chronic
A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.
Kidney Failure, Chronic
Atrial fibrillation in dialysis patients: time to abandon warfarin?
Kidney Failure, Chronic
Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial.
Kidney Failure, Chronic
Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients.
Kidney Failure, Chronic
Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Kidney Failure, Chronic
Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
Kidney Failure, Chronic
Increased thrombin generation in patients with chronic renal failure.
Kidney Failure, Chronic
Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure.
Kidney Failure, Chronic
Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients.
Kidney Failure, Chronic
Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient.
Kidney Failure, Chronic
Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.
Kidney Failure, Chronic
[Local microviscosity of platelet membranes from patients with chronic renal failure on hemodialysis]
Kidney Neoplasms
The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer.
Kidney Neoplasms
von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.
Klinefelter Syndrome
Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry.
Klinefelter Syndrome
Testosterone treatment and association with thrombin generation and coagulation inhibition in Klinefelter syndrome: A cross-sectional study.
Laryngeal Neoplasms
Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.
Lecithin Cholesterol Acyltransferase Deficiency
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Leiomyosarcoma
[Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis]
Leprosy
Markers of platelet, endothelial cell and blood coagulation activation in leprosy patients with antiphospholipid antibodies.
Leptospirosis
Evaluating the moonlight role of supramolecule ErpY-like lipoprotein of Leptospira in thrombin-catalyzed fibrin clot inhibition, binding to complement factors H & -I, and its diagnostic potential.
Leukemia
alpha-Thrombin inhibits signal transducers and activators of transcription 3 signaling by interleukin-6, leukemia inhibitory factor, and ciliary neurotrophic factor in CCL39 cells.
Leukemia
Analysis of a Ca2+-activated K+ channel that mediates hyperpolarization via the thrombin receptor pathway.
Leukemia
Elevated extracellular trap formation and contact system activation in acute leukemia.
Leukemia
Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion.
Leukemia
High fibrinopeptide A (FPA) levels in acute non-lymphocytic leukemia are reduced by heparin administration.
Leukemia
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
Leukemia
Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias.
Leukemia
Molecular cloning of the rat vascular smooth muscle thrombin receptor. Evidence for in vitro regulation by basic fibroblast growth factor.
Leukemia
Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme.
Leukemia
Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.
Leukemia
Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme asparaginase by biocompatible multilayered polyelectrolyte microcapsules.
Leukemia
Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML).
Leukemia
Successful treatment of spontaneous rupture of the internal carotid artery in an acute promyelocytic leukemia patient using ultrasound-guided thrombin injection.
Leukemia
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia.
Leukemia
The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis?
Leukemia
Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups.
Leukemia
Thrombin, but not thromboxane, stimulates megakaryocytic differentiation in human megakaryoblastic leukemia cells.
Leukemia
Thrombin-induced calcium oscillation in human platelets and MEG-01, a megakaryoblastic leukemia cell line.
Leukemia
Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants.
Leukemia
[Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance].
Leukemia, Erythroblastic, Acute
Analysis of receptor-G protein interactions in permeabilized cells.
Leukemia, Erythroblastic, Acute
Antisense-mediated loss of calcium homoeostasis endoplasmic reticulum protein (CHERP; ERPROT213-21) impairs Ca2+ mobilization, nuclear factor of activated T-cells (NFAT) activation and cell proliferation in Jurkat T-lymphocytes.
Leukemia, Erythroblastic, Acute
Effect of protein kinase A on inositide metabolism and rap 1 G-protein in human erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Extracellular signal-regulated kinases and g protein-coupled receptors in megakaryocytic human erythroleukemia cells: selective activation, differential regulation, and dissociation from mitogenesis.
Leukemia, Erythroblastic, Acute
Internalization and recycling of activated thrombin receptors.
Leukemia, Erythroblastic, Acute
Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL.
Leukemia, Erythroblastic, Acute
Thrombin stimulates the production of phosphatidylinositol 3,4-bisphosphate in human erythroleukemia cells.
Leukemia, Megakaryoblastic, Acute
Thrombin receptors activate potassium and chloride channels.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Commonly used drugs in hematologic disorders.
Leukemia, Myeloid
Interleukins and colony stimulating factors in human myeloid leukemia cell lines.
Leukemia, Myeloid, Acute
Hemostatic function on hyper-fibrinolytic disseminated intravascular coagulation.
Leukemia, Myeloid, Acute
Identification and characterization of human hemopoietic mast cell colonies.
Leukemia, Myeloid, Acute
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Leukemia, Myeloid, Acute
Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML).
Leukemia, Myeloid, Acute
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Leukemia, Myeloid, Acute
[Blood coagulation changes in children with acute myelogenous leukemia: thrombin effect or proteolysis]
Leukemia, Promyelocytic, Acute
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
Leukemia, Promyelocytic, Acute
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Leukemia, Promyelocytic, Acute
Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML).
Leukemia, Promyelocytic, Acute
Successful treatment of spontaneous rupture of the internal carotid artery in an acute promyelocytic leukemia patient using ultrasound-guided thrombin injection.
Leukemia, Promyelocytic, Acute
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia.
Leukocytosis
Multi-cellular activation in vivo by endotoxin in humans--limited protection by adenosine infusion.
Leukocytosis
Pleocytosis and elevation of prostaglandins F2a and E2 in cerebrospinal fluid following intracisternal injection of thrombin.
Leukopenia
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Leukostasis
Experimental studies on the adult respiratory distress syndrome: effects of induced DIC; granulocytes and elastase in mini pigs.
Livedo Reticularis
Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata.
Liver Cirrhosis
Bile Acids Do Not Contribute to the Altered Calcium Homeostasis of Platelets from Rats with Biliary Cirrhosis.
Liver Cirrhosis
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.
Liver Cirrhosis
Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage.
Liver Cirrhosis
Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association?
Liver Cirrhosis
Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis.
Liver Cirrhosis
Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis.
Liver Cirrhosis
Evaluation of fibrinolysis in hepatic cirrhosis. Relation of serial thrombin time and euglobulin lysis time.
Liver Cirrhosis
Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event.
Liver Cirrhosis
Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats.
Liver Cirrhosis
Progressive antithrombin activity and the concentration of three thrombin inhibitors in liver cirrhosis.
Liver Cirrhosis
Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis.
Liver Cirrhosis
Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors.
Liver Cirrhosis
Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?
Liver Cirrhosis
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Liver Cirrhosis
Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis.
Liver Cirrhosis
The Coagulation System Contributes to {alpha}V{beta}6 Integrin Expression and Liver Fibrosis Induced by Cholestasis.
Liver Cirrhosis
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Liver Cirrhosis
Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis.
Liver Cirrhosis
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
Liver Cirrhosis
[The characteristics of clinical course of chronic hepatitis B and liver cirrhosis pathology of child patient]
Liver Diseases
Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.
Liver Diseases
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
Liver Diseases
Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury.
Liver Diseases
Assessment of haemostasis in patients with cirrhosis: Relevance of the ROTEM tests?: A prospective, cross-sectional study.
Liver Diseases
Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure.
Liver Diseases
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.
Liver Diseases
Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease.
Liver Diseases
Clinical utility of viscoelastic tests of coagulation in patients with liver disease.
Liver Diseases
Coagulation Profile and its Correlation with Severity of Liver Dysfunction and Gastrointestinal Bleed in Alcoholic Liver Disease Patients.
Liver Diseases
Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyser.
Liver Diseases
Effect of liver damage on the level of coagulation factor II, X and VII in human and bovine plasma.
Liver Diseases
Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia.
Liver Diseases
Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation.
Liver Diseases
In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation.
Liver Diseases
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis.
Liver Diseases
Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Liver Diseases
Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage.
Liver Diseases
Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Liver Diseases
Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin.
Liver Diseases
Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease.
Liver Diseases
Quantification of thrombelastographic changes after blood component transfusion in patients with liver disease in the intensive care unit.
Liver Diseases
Relation of simple clotting tests to clotting factor levels in liver disease.
Liver Diseases
The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.
Liver Diseases
The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains.
Liver Diseases
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Liver Diseases
Thrombin activation and increased fibrinolysis in patients with chronic liver disease.
Liver Diseases
Thrombin dynamics in children with liver disease or extrahepatic portal vein obstruction or shunt.
Liver Diseases
Thrombin generation in patients with non-cirrhotic vascular liver diseases treated or not treated with vitamin K antagonist.
Liver Diseases
Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease.
Liver Diseases
Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis.
Liver Diseases
Thrombin generation test in children and adolescents with chronic liver disease.
Liver Diseases
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Liver Diseases
Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury.
Liver Diseases
[Hemostatic studies on acquired abnormal fibrinogenemia in severe liver diseases and umbilical cord blood]
Liver Diseases
[INFLUENCE OF THE "COTHROMBIN PLASMATIC FACTOR" IN THE INCREASE OF THROMBIN TIME IN LIVER DISEASE PATIENTS.]
Liver Failure
Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
Liver Failure
Efficacy of Nafamostat Mesilate for improving the performance of a bioartificial liver using porcine hepatocytes.
Liver Failure, Acute
Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation.
Liver Failure, Acute
Hemostasis in patients with acute kidney injury secondary to acute liver failure.
Liver Failure, Acute
Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure.
Liver Failure, Acute
[Increased thrombin synthesis in patients with fulminant hepatic failure and its treatment with antithrombin III evaluated by plasma levels of thrombin-antithrombin III complex]
Liver Neoplasms
The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer.
Lung Diseases
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Lung Diseases
PKCdelta mediates thrombin-augmented fibroblast-mediated collagen gel contraction.
Lung Diseases
Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells.
Lung Diseases
Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.
Lung Diseases
Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury.
Lung Diseases
Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant.
Lung Diseases
Thrombin Increases Lung Fibroblast Survival While Promoting Alveolar Epithelial Cell Apoptosis via the ER Stress Marker CHOP.
Lung Diseases
Thrombin Induces CCL2 Expression in Human Lung Fibroblasts via p300 Mediated Histone Acetylation and NF-KappaB Activation.
Lung Diseases
Thrombin induces collagen gel contraction partially through PAR1 activation and PKC-epsilon.
Lung Diseases
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Lung Diseases
Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).
Lung Diseases, Interstitial
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Lung Diseases, Interstitial
Associations of D-dimer with CT Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study.
Lung Diseases, Interstitial
Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings.
Lung Diseases, Interstitial
Fibrinopeptide A reactive peptides and procoagulant activity in bronchoalveolar lavage: relationship to rheumatoid interstitial lung disease.
Lung Diseases, Interstitial
Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.
Lung Diseases, Interstitial
Significance of thrombin in bleomycin-induced pulmonary fibrosis.
Lung Diseases, Interstitial
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Lung Diseases, Interstitial
Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.
Lung Diseases, Interstitial
Thrombin Increases Lung Fibroblast Survival While Promoting Alveolar Epithelial Cell Apoptosis via the ER Stress Marker CHOP.
Lung Diseases, Interstitial
[The role of thrombin on lung fibroblast growth and fibrosis in bleomycin-induced lung disorder]
Lung Injury
Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis.
Lung Injury
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Lung Injury
Caveolar uptake and endothelial-protective effects of nanostructured lipid carriers in acid aspiration murine acute lung injury.
Lung Injury
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
Lung Injury
Early coagulation events induce acute lung injury in a rat model of blunt traumatic brain injury.
Lung Injury
Hematopoietic protease nexin-1 protects against lung injury by preventing thrombin signaling in mice.
Lung Injury
PAR2-Mediated cAMP Generation Suppresses TRPV4-Dependent Ca2+ Signaling in Alveolar Macrophages to Resolve TLR4-Induced Inflammation.
Lung Injury
Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice.
Lung Injury
Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury.
Lung Injury
Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats.
Lung Injury
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
Lung Injury
The coagulation system and pulmonary endothelial function in acute lung injury.
Lung Injury
The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.
Lung Injury
The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome.
Lung Injury
Thrombin induces ICAM-1 expression in human lung epithelial cells via c-Src/PDGFR/PI3K/Akt-dependent NF-?B/p300 activation.
Lung Injury
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Lung Injury
Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-?B and activator protein-1.
Lung Injury
Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice.
Lung Injury
[Specific inhibition of thrombin activity during cardiopulmonary bypass reduces ischemia-reperfusion injury of the lung]
Lung Neoplasms
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
Lung Neoplasms
Air-leak management after upper lobectomy in patients with fused fissure and chronic obstructive pulmonary disease: a pilot trial comparing sealant and standard treatment.
Lung Neoplasms
Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.
Lung Neoplasms
Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking.
Lung Neoplasms
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
Lung Neoplasms
Cooperation of protease-activated receptor 1 and integrin ???5 in thrombin-mediated lung cancer cell invasion.
Lung Neoplasms
Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.
Lung Neoplasms
Procoagulant effects of lung cancer chemotherapy: impact on microparticles and cell-free DNA.
Lung Neoplasms
PTEN plays an important role in thrombin-mediated lung cancer cell functions.
Lung Neoplasms
Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines.
Lung Neoplasms
TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.
Lung Neoplasms
The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin.
Lung Neoplasms
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Lung Neoplasms
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Lung Neoplasms
[Analysis of the Incidence of Lower Extremity Venous Thrombosis and Its Related Risk Factors in Admitted Patients with Lung Cancer].
Lung Neoplasms
[Selected parameters of coagulation, fibrinolysis and antibodies to fibrinogen in lung cancer]
Lupus Erythematosus, Systemic
Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Lupus Erythematosus, Systemic
Characterization of the thrombin generation profile in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.
Lupus Erythematosus, Systemic
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state.
Lupus Erythematosus, Systemic
Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE).
Lupus Erythematosus, Systemic
Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation.
Lupus Erythematosus, Systemic
Osteopontin: another piece in the systemic lupus erythematosus immunopathology puzzle.
Lupus Erythematosus, Systemic
Sole existence of antithrombin antibody in patients with systemic lupus erythematosus showing tendency of its antigenic determinants directing against exosite II (antithrombin/heparin binding site) of thrombin.
Lupus Erythematosus, Systemic
The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
Lupus Erythematosus, Systemic
[Hemorrhagic syndrome due to a heparin-like anticoagulant in a patient with systemic lupus erythematosus].
Lupus Nephritis
Calorie restriction decreases platelet-derived growth factor (PDGF)-A and thrombin receptor mRNA expression in autoimmune murine lupus nephritis.
Lymphocele
Application of thrombin gel matrix for the prevention of lymphocele in patients with endometrial cancer: A prospective randomized trial.
Lymphocele
[Fibrinogen and thrombin coated patch use on collagen support for lymphocele prevention after lumbar-aortic lymphadenectomy in gynecological neoplasms].
Lymphoma
Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets.
Lymphoma
Procoagulant activity of T lymphoblastoid cells in extrinsic and intrinsic coagulation systems.
Lymphoma
Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa.
Lymphoma
Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants.
Lymphoma
[Relationship between coagulation function and international prognostic index in lymphoma patients].
Lymphoma, B-Cell
Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets.
Lymphoma, B-Cell
Thrombin Maybe Plays an Important Role in MK Differentiation into Platelets.
Lymphoma, Non-Hodgkin
Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias.
Macular Degeneration
Different Effects of Thrombin on VEGF Secretion, Proliferation, and Permeability in Polarized and Non-polarized Retinal Pigment Epithelial Cells.
Malaria
Coagulation Status and Platelet Functions in Children with Severe Falciparum Malaria and their Correlation of Outcome.
Malaria
Functional analyses yield detailed insight into the mechanism of thrombin inhibition by the antihemostatic salivary protein cE5 from Anopheles gambiae.
Malaria
Monocyte tissue factor expression induced by Plasmodium falciparum-infected erythrocytes.
Malaria
Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases.
Malaria
Possible involvement of platelets in Plasmodium yoelii nigeriensis malaria infection in mice.
Malaria
Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria vector.
Malaria, Cerebral
Testing the effect of PAR1 inhibitors on Plasmodium falciparum-induced loss of endothelial cell barrier function.
Malaria, Cerebral
Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence.
Marfan Syndrome
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Mastitis
Crosstalk between coagulation and inflammation in mastitis and metritis in dairy cows.
Mastocytoma
Cytosol promotes the guanine nucleotide-induced release of the alpha subunit of Gi2 from the membrane of mouse mastocytoma P-815 cells.
Mastocytoma
Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cells.
Mastocytoma
Involvement of protein kinase C in thrombin-induced translocation of Gi2 alpha from the membrane to the cytosol in mouse mastocytoma P-815 cells.
Melanoma
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Melanoma
Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation.
Melanoma
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Melanoma
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Melanoma
Fibrin serves as a divalent ligand that regulates neutrophil-mediated melanoma cells adhesion to endothelium under shear conditions.
Melanoma
Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets.
Melanoma
Identification of a synthetic nonapeptide sequence that inhibits motility in culture of a melanoma subclone that possesses a high metastatic potential.
Melanoma
Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor.
Melanoma
Microcarrier culture of bowes melanoma cells in serum-free medium with Human plasma fraction IV-4+ V.
Melanoma
Microfluidic reveals generation of platelet-strings on tumor-activated endothelium.
Melanoma
miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells.
Melanoma
Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown.
Melanoma
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.
Melanoma
Platelet-cytokine Complex Suppresses Tumour Growth by Exploiting Intratumoural Thrombin-dependent Platelet Aggregation.
Melanoma
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis.
Melanoma
Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Melanoma
Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF.
Melanoma
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.
Melanoma
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.
Melanoma
Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes.
Melanoma
Regulatory Effect of Cell Density on the Platelet-aggregating Activity of Human Melanoma Cell Line.
Melanoma
Sequential binding of ?V?3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils.
Melanoma
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
Melanoma
The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target.
Melanoma
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
Melanoma
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
Melanoma
The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.
Melanoma
The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy.
Melanoma
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Melanoma
Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA.
Melanoma
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Melanoma
Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.
Melanoma
Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.
Melanoma
Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment.
Melanoma
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1.
Melanoma
Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth.
Melanoma, Amelanotic
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Melanoma, Amelanotic
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Melanoma, Amelanotic
Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.
Melanoma, Experimental
Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Melanoma, Experimental
Effects of thrombin/thrombosis in angiogenesis and tumour progression.
Melanoma, Experimental
Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
MELAS Syndrome
Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.
Melioidosis
Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
Memory Disorders
Impaired adult hippocampal neurogenesis and cognitive ability in a mouse model of intrastriatal hemorrhage.
Memory Disorders
Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin.
Memory Disorders
Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice.
Meningioma
PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells.
Menorrhagia
Defective fibrinogen polymerization associated with a novel gamma279Ala-->Asp mutation.
Menorrhagia
High prevalence of reduced thrombin generation and/or decreased platelet response in women with unexplained heavy menstrual bleeding.
Menorrhagia
Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization.
Menorrhagia
Successful use of recombinant factor VIIa for management of severe menorrhagia in an adolescent with an acquired inhibitor of human thrombin.
Mesenteric Ischemia
Prothrombin Arg541Trp Mutation Leads to Defective PC (Protein C) Pathway Activation and Constitutes a Novel Genetic Risk Factor for Venous Thrombosis.
Mesothelioma
Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth.
Mesothelioma
Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth.
Metabolic Syndrome
Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study).
Metabolic Syndrome
Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation.
Metabolic Syndrome
Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels.
Metabolic Syndrome
Increased RhoA/Rho-Kinase Activity and Markers of Endothelial Dysfunction in Young Adult Subjects with Metabolic Syndrome.
Metabolic Syndrome
Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.
Metabolic Syndrome
The intestinal microbiome potentially affects thrombin generation in human subjects.
Metabolic Syndrome
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?
Metrorrhagia
Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment.
Migraine Disorders
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
MINOCA
Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA).
Mirizzi Syndrome
EUS-guided thrombin injection of cystic artery pseudoaneurysm leading to Mirizzi's syndrome and hemobilia.
Mitral Valve Insufficiency
Platelet and blood clotting activation in patients with mitral valve prolapse.
Mitral Valve Prolapse
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Mitral Valve Stenosis
Changes in Platelet, Coagulation, and Fibrinolytic Activities in Mitral Stenosis After Percutaneous Mitral Valvotomy: Role of Hemodynamic Changes and Systemic Inflammation.
Mitral Valve Stenosis
Coagulation activity is increased in the left atrium of patients with mitral stenosis.
Mitral Valve Stenosis
Effect of mitral valvuloplasty in mitral stenosis on coagulation activity.
Mitral Valve Stenosis
Effects of balloon mitral valvuloplasty on systemic and regional left atrial levels of prothrombin fragment 1+2 in mitral stenosis.
Mitral Valve Stenosis
Hypercoagulability existing in the local left atrium of patient with mitral stenosis.
Mitral Valve Stenosis
Increased left atrial thrombin generation in mitral stenosis is not reflected in arterial prothrombin fragment 1+2 levels.
Monoclonal Gammopathy of Undetermined Significance
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Mucopolysaccharidoses
Heparin Cofactor II Thrombin Complex as a Biomarker for Mucopolysaccharidosis: Indian Experience.
Multiple Myeloma
A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder.
Multiple Myeloma
Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin.
Multiple Myeloma
Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.
Multiple Myeloma
Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.
Multiple Myeloma
Effect of heparin thromboprophylaxis on thrombin generation in multiple myeloma patients.
Multiple Myeloma
Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma.
Multiple Myeloma
Elevated extracellular trap formation and contact system activation in acute leukemia.
Multiple Myeloma
Hypocoagulability as assessed by thrombin generation test in newly-diagnosed patients with multiple myeloma.
Multiple Myeloma
Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.
Multiple Myeloma
Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications.
Multiple Myeloma
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
Multiple Myeloma
PO-27 - Thrombin generation in pancreatic cancer and multiple myeloma with use of calibrated automated thrombography.
Multiple Myeloma
Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway.
Multiple Myeloma
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
Multiple Myeloma
The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test.
Multiple Myeloma
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients.
Multiple Myeloma
Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study.
Multiple Myeloma
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma.
Multiple Myeloma
[Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma]
Multiple Sclerosis
Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis.
Multiple Sclerosis
Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic.
Multiple Sclerosis
The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.
Multiple Sclerosis
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Multiple Sclerosis
Thrombin generation correlates with disease duration in multiple sclerosis (MS): Novel insights into the MS-associated prothrombotic state.
Multiple Sclerosis
Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis.
Muscular Diseases
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Muscular Dystrophies
Expression of trypsin-like proteases and protease nexin-1 in mdx mouse muscles.
Myelodysplastic Syndromes
Elevated extracellular trap formation and contact system activation in acute leukemia.
Myelodysplastic Syndromes
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Myeloproliferative Disorders
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Myeloproliferative Disorders
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
Myeloproliferative Disorders
Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation.
Myeloproliferative Disorders
[Abnormalities of thrombocyte function in myeloproliferative disorders. I. Defective thrombocyte aggregation by ADP, collagen, noradrenaline and thrombin]
Myocardial Infarction
A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.
Myocardial Infarction
A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.
Myocardial Infarction
A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.
Myocardial Infarction
A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study.
Myocardial Infarction
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Myocardial Infarction
Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.
Myocardial Infarction
Activation of blood coagulation by plaque rupture: mechanisms and prevention.
Myocardial Infarction
Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease.
Myocardial Infarction
Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
Myocardial Infarction
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
Myocardial Infarction
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction.
Myocardial Infarction
Advances in antithrombin therapy for ST-elevation myocardial infarction.
Myocardial Infarction
Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results.
Myocardial Infarction
Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Myocardial Infarction
Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates.
Myocardial Infarction
Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Myocardial Infarction
Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation.
Myocardial Infarction
Association of a common polymorphism in the factor XIII gene with myocardial infarction.
Myocardial Infarction
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Myocardial Infarction
Association of recurrent myocardial infarction with hemostatic factors: a prospective study.
Myocardial Infarction
Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction.
Myocardial Infarction
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
Myocardial Infarction
Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction.
Myocardial Infarction
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
Myocardial Infarction
Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
Myocardial Infarction
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Myocardial Infarction
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Myocardial Infarction
Coagulation activation and long-term outcome in acute coronary syndromes.
Myocardial Infarction
Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction.
Myocardial Infarction
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Myocardial Infarction
Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
Myocardial Infarction
Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential.
Myocardial Infarction
Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.
Myocardial Infarction
Course of indicators of thrombin activity in the early phase of acute myocardial infarction: effect of fibrinolytic therapy and acute percutaneous coronary angioplasty.
Myocardial Infarction
Desirudin: a review of its use in the management of thrombotic disorders.
Myocardial Infarction
Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.
Myocardial Infarction
Development and evaluation of a new canine myocardial infarction model using a closed-chest injection of thrombogenic material.
Myocardial Infarction
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy).
Myocardial Infarction
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy).
Myocardial Infarction
Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group.
Myocardial Infarction
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Myocardial Infarction
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Myocardial Infarction
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Myocardial Infarction
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
Myocardial Infarction
Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
Myocardial Infarction
Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction.
Myocardial Infarction
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial.
Myocardial Infarction
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Myocardial Infarction
Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors.
Myocardial Infarction
Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction.
Myocardial Infarction
Effects of thrombin and thrombin receptor activation on cardiac function after acute myocardial infarction.
Myocardial Infarction
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Myocardial Infarction
Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.
Myocardial Infarction
Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Myocardial Infarction
Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin.
Myocardial Infarction
Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
Myocardial Infarction
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Myocardial Infarction
Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
Myocardial Infarction
Failure of thrombin generation markers to triage patients presenting with chest pain.
Myocardial Infarction
Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study.
Myocardial Infarction
Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction.
Myocardial Infarction
Functional and antigenic antithrombin III in angina pectoris and acute myocardial infarction patients.
Myocardial Infarction
G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
Myocardial Infarction
Haemostatic function changes in a trial on the secondary prevention of myocardial infarction with sulphinpyrazone.
Myocardial Infarction
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.
Myocardial Infarction
Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
Myocardial Infarction
Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
Myocardial Infarction
In the Bivalirudin Era, are we still Looking for a Potent Antiplatelet Agent?
Myocardial Infarction
Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone.
Myocardial Infarction
Increased factor XIa levels in patients with a first acute myocardial infarction: the introduction of a new thrombin generation based factor XIa assay.
Myocardial Infarction
Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
Myocardial Infarction
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Myocardial Infarction
Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
Myocardial Infarction
Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood.
Myocardial Infarction
Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction.
Myocardial Infarction
Influence of aromatic and aliphatic moieties on thrombin inhibitors potency.
Myocardial Infarction
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Myocardial Infarction
Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.
Myocardial Infarction
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
Myocardial Infarction
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Myocardial Infarction
Intima-Media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction.
Myocardial Infarction
Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture.
Myocardial Infarction
Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications.
Myocardial Infarction
Intramyocardial thrombin promotes angiogenesis and improves cardiac function in an experimental rabbit model of acute myocardial infarction.
Myocardial Infarction
Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin?
Myocardial Infarction
Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study.
Myocardial Infarction
Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Myocardial Infarction
Long-term anticoagulation in patients with coronary disease, and future developments.
Myocardial Infarction
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Myocardial Infarction
Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction.
Myocardial Infarction
Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction.
Myocardial Infarction
Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction.
Myocardial Infarction
Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
Myocardial Infarction
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors.
Myocardial Infarction
Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction.
Myocardial Infarction
Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials.
Myocardial Infarction
Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?
Myocardial Infarction
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Myocardial Infarction
Oral antiplatelet therapy in acute coronary syndromes: recent developments.
Myocardial Infarction
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Myocardial Infarction
Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Myocardial Infarction
Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.
Myocardial Infarction
Plaque herniation after stenting the culprit lesion with myocardial bridging in ST elevation myocardial infarction: A case report.
Myocardial Infarction
Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction.
Myocardial Infarction
Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Myocardial Infarction
Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets.
Myocardial Infarction
Plasmin-mediated activation of contact system in response to pharmacological thrombolysis.
Myocardial Infarction
Platelet hyperreactivity to thrombin in patients with myocardial infarction and normal or slightly abnormal coronary arteries.
Myocardial Infarction
Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
Myocardial Infarction
Procedural outcomes with use of the flash ostial system in aorto-coronary ostial lesions.
Myocardial Infarction
Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants.
Myocardial Infarction
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Myocardial Infarction
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Myocardial Infarction
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Myocardial Infarction
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Myocardial Infarction
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
Myocardial Infarction
Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
Myocardial Infarction
Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction.
Myocardial Infarction
Risk of myocardial infarction with oral direct thrombin inhibitors: trial sequential analysis based on two published data sets.
Myocardial Infarction
Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction.
Myocardial Infarction
Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
Myocardial Infarction
Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction.
Myocardial Infarction
Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction.
Myocardial Infarction
Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction.
Myocardial Infarction
Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
Myocardial Infarction
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
Myocardial Infarction
Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine.
Myocardial Infarction
Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction.
Myocardial Infarction
The -5061/D polymorphism of the thrombin receptor (PAR-1) gene is not related to myocardial infarction in the ECTIM study. The Etude Cas-Temoins de l'Infarctus du Myocarde. MONICA Members Group.
Myocardial Infarction
The clinical effects of IABP pumps combined with tirofiban in the treatment of acute myocardial infarction and on patients' serum levels.
Myocardial Infarction
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
Myocardial Infarction
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.
Myocardial Infarction
The Narrow Therapeutic Index of Thrombin Inhibition: Implications for Newer Antithrombotic Therapies.
Myocardial Infarction
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Myocardial Infarction
The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial.
Myocardial Infarction
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Myocardial Infarction
Thrombin and its receptor enhance ST segment elevation in acute myocardial infarction by activating the K(ATP) channel.
Myocardial Infarction
Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest.
Myocardial Infarction
Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury.
Myocardial Infarction
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.
Myocardial Infarction
Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
Myocardial Infarction
Thrombin generation and myocardial infarction during infusion of tissue-plasminogen activator.
Myocardial Infarction
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Myocardial Infarction
Thrombin generation in patients with a first acute myocardial infarction.
Myocardial Infarction
Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023).
Myocardial Infarction
Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Myocardial Infarction
Thrombin induced platelet-fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction.
Myocardial Infarction
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Myocardial Infarction
Thrombin receptor and ventricular arrhythmias after acute myocardial infarction.
Myocardial Infarction
Thrombinogenesis and its pharmacological modulation in atherosclerosis.
Myocardial Infarction
Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Myocardial Infarction
Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.
Myocardial Infarction
Thromboxane A2 synthesizing activity of platelets in coronary artery diseases.
Myocardial Infarction
Tissue factor-induced Thrombin Generation in the Fasting and Postprandial State among Elderly Survivors of Myocardial Infarction.
Myocardial Infarction
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Myocardial Infarction
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.
Myocardial Infarction
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Myocardial Infarction
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Myocardial Infarction
Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.
Myocardial Infarction
Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction.
Myocardial Infarction
Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Myocardial Infarction
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Myocardial Infarction
What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction?
Myocardial Infarction
[Assessment of hemostasis in patients with myocardial infarction complicated by deep venous thrombosis]
Myocardial Infarction
[Comparative analysis of thrombin and anti-thrombin antibody levels in donors and myocardial infarction patients]
Myocardial Infarction
[Contributory changes in variables of coagulation and fibrinolysis to the patency of coronary arteries in patients with acute myocardial infarction]
Myocardial Infarction
[Effect of surgical menopause on the development of cardiovascular diseases]
Myocardial Infarction
[Effects of exercise on markers of hemostatic activation in young survivors of myocardial infarction]
Myocardial Infarction
[Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.]
Myocardial Infarction
[Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction]
Myocardial Infarction
[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins]
Myocardial Infarction
[Thrombin and anti-thrombin antibody levels in the blood of patients with acute myocardial infarction]
Myocardial Infarction
[Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status]
Myocardial Ischemia
Activation of thrombin receptor increases intracellular Na+ during myocardial ischemia.
Myocardial Ischemia
Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
Myocardial Ischemia
Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling.
Myocardial Ischemia
Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.
Myocardial Ischemia
Calcium-independent phospholipase A2-catalyzed plasmalogen hydrolysis in hypoxic human coronary artery endothelial cells.
Myocardial Ischemia
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy).
Myocardial Ischemia
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy).
Myocardial Ischemia
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Myocardial Ischemia
Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine.
Myocardial Ischemia
Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease.
Myocardial Ischemia
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Myocardial Ischemia
Effects of exercise test on plasma markers of an activation of coagulation and/or fibrinolysis in patients with symptomatic or silent myocardial ischemia.
Myocardial Ischemia
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.
Myocardial Ischemia
Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion.
Myocardial Ischemia
Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Myocardial Ischemia
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Myocardial Ischemia
Inhibition of thrombin-induced endothelium-dependent relaxation after coronary ischemia in the dog: possible role of the coagulation cascade.
Myocardial Ischemia
Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study.
Myocardial Ischemia
Mediation of cardiac ischemia by thromboxanes released from human platelets.
Myocardial Ischemia
Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury.
Myocardial Ischemia
Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection.
Myocardial Ischemia
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
Myocardial Ischemia
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Myocardial Ischemia
The Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in Hypercholesterolemic Pigs.
Myocardial Ischemia
The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
Myocardial Ischemia
Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart.
Myocardial Ischemia
Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease.
Myocardial Ischemia
Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study Group.
Myocardial Ischemia
[Contents of natural antibodies to thrombin and alpha-2-macroglobulins in the blood of donors and patients with ischemic heart disease]
Myocardial Ischemia
[Effect of surgical menopause on the development of cardiovascular diseases]
Myocardial Ischemia
[Signs of thrombin formation in venous occlusion in patients with ischemic heart disease and the role of the protein C activation system in its utilization]
Myocardial Ischemia
[The advantage of test on thrombin generation for evaluation of hemostasis potential under implementation of coronary bypass surgery in patients with ischemic heart disease.]
Myocardial Ischemia
[The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity in patients with ischemic heart disease and a disordered carbohydrate tolerance]
Myocardial Ischemia
[THE TEST OF GENERATION OF THROMBIN IN DYNAMICS IN PATIENTS AFTER TRANSCUTANEOUS CORONARY INTERVENTION].
Myocarditis
Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction.
Myocarditis
The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications.
Myocarditis
[Total index of thrombocyte aggregation in patients with an acute viral myocarditis]
Myoma
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Myotoxicity
New immunization protocol to produce crotalic antivenom combining Crotalus durissus terrificus venom and its PLA2.
Nasal Polyps
Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts via protease-activated receptors.
Nasopharyngeal Carcinoma
Routine coagulation molecules predict nasopharyngeal carcinoma and associated metastases.
Neonatal Sepsis
Prognostic value of plasma pro-adrenomedullin and antithrombin levels in neonatal sepsis.
Neoplasm Metastasis
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
Neoplasm Metastasis
A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma.
Neoplasm Metastasis
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Neoplasm Metastasis
Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation.
Neoplasm Metastasis
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Neoplasm Metastasis
Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro.
Neoplasm Metastasis
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Neoplasm Metastasis
Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice.
Neoplasm Metastasis
Deadly allies: the fatal interplay between platelets and metastasizing cancer cells.
Neoplasm Metastasis
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
Neoplasm Metastasis
Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung.
Neoplasm Metastasis
Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues.
Neoplasm Metastasis
Does haemophilia influence cancer-related mortality in HIV-negative patients?
Neoplasm Metastasis
Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation.
Neoplasm Metastasis
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Neoplasm Metastasis
Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Neoplasm Metastasis
Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?
Neoplasm Metastasis
Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice.
Neoplasm Metastasis
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Neoplasm Metastasis
Evidence that thrombin present in lungs of patients with pulmonary metastasis may contribute to the development of the disease.
Neoplasm Metastasis
Experimental metastasis and primary tumor growth in mice with hemophilia A.
Neoplasm Metastasis
Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function.
Neoplasm Metastasis
Glycosaminoglycans and activated contact system in cancer patient plasmas.
Neoplasm Metastasis
Heparin enhances serpin inhibition of the cysteine protease cathepsin L.
Neoplasm Metastasis
Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor.
Neoplasm Metastasis
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Neoplasm Metastasis
Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway.
Neoplasm Metastasis
Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis.
Neoplasm Metastasis
Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination.
Neoplasm Metastasis
Mechanistic insights into thrombin's switch between "slow" and "fast" forms.
Neoplasm Metastasis
Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.
Neoplasm Metastasis
Nanochannels for diagnostic of thrombin-related diseases in human blood.
Neoplasm Metastasis
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.
Neoplasm Metastasis
PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
Neoplasm Metastasis
Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity.
Neoplasm Metastasis
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis.
Neoplasm Metastasis
PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?
Neoplasm Metastasis
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Neoplasm Metastasis
Promotion of lung tumor colonization in mice by the synthetic thrombin inhibitor (no. 805) and its reversal by leech salivary gland extracts.
Neoplasm Metastasis
Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer.
Neoplasm Metastasis
Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.
Neoplasm Metastasis
Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.
Neoplasm Metastasis
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
Neoplasm Metastasis
Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis.
Neoplasm Metastasis
Role of platelet integrin GPIIb-GPIIIa, fibronectin, von Willebrand factor, and thrombin in platelet-tumor interaction in vitro and metastasis in vivo.
Neoplasm Metastasis
Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo.
Neoplasm Metastasis
Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
Neoplasm Metastasis
Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas.
Neoplasm Metastasis
Special pharmacokinetics of dipetarudin suggests a potential antitumor activity of this thrombin inhibitor.
Neoplasm Metastasis
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
Neoplasm Metastasis
The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor.
Neoplasm Metastasis
The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target.
Neoplasm Metastasis
The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells.
Neoplasm Metastasis
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
Neoplasm Metastasis
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
Neoplasm Metastasis
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Neoplasm Metastasis
Three label-free thrombin aptasensors based on aptamers and [Ru(bpy)2(o-mopip)]2.
Neoplasm Metastasis
Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway.
Neoplasm Metastasis
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Neoplasm Metastasis
Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells.
Neoplasm Metastasis
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Neoplasm Metastasis
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Neoplasm Metastasis
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Neoplasm Metastasis
Thrombin Inhibition and Cyclophosphamide Synergistically Block Tumor Progression and Metastasis.
Neoplasm Metastasis
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Neoplasm Metastasis
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Neoplasm Metastasis
Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma.
Neoplasm Metastasis
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Neoplasm Metastasis
Thrombin is present in the lungs of patients with primary extremity osteosarcoma and pulmonary metastases.
Neoplasm Metastasis
Thrombin Regulates the Metastatic Potential of Human Rhabdomyosarcoma Cells: Distinct Role of PAR1 and PAR3 Signaling.
Neoplasm Metastasis
Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.
Neoplasm Metastasis
Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.
Neoplasm Metastasis
Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis.
Neoplasm Metastasis
Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis.
Neoplasm Metastasis
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.
Neoplasm Metastasis
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Neoplasm Metastasis
Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.
Neoplasm Metastasis
Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment.
Neoplasm Metastasis
Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors.
Neoplasm Metastasis
Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin.
Neoplasm Metastasis
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Neoplasm Metastasis
[Construction and application of a new prokaryotic expression vector derivative of pBV220]
Neoplasm Metastasis
[The efficacy of transarterial immuno-embolization therapy in patients with hepatocellular carcinoma]
Neoplasm Micrometastasis
Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination.
Neoplasms
'Sailing in troubled waters': a review of the use of anticoagulation in adult cancer patients with thrombocytopenia.
Neoplasms
(S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Neoplasms
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Neoplasms
A 24-h work shift in intensive care personnel: biological pathways between work stress and ill health.
Neoplasms
A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells.
Neoplasms
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo.
Neoplasms
A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer.
Neoplasms
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
Neoplasms
A new mechanism for tumor induced platelet aggregation. Comparison with mechanisms shared by other tumor with possible pharmacologic strategy toward prevention of metastases.
Neoplasms
A New Paradigm for the Treatment of Alzheimer's Disease: Targeting Vascular Activation.
Neoplasms
A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma.
Neoplasms
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
Neoplasms
A novel recombinant snake venom metalloproteinase from Agkistrodon acutus protects against taurocholate-induced severe acute pancreatitis in rats.
Neoplasms
A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.
Neoplasms
A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma.
Neoplasms
A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression.
Neoplasms
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.
Neoplasms
A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model.
Neoplasms
Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase.
Neoplasms
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Neoplasms
Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature.
Neoplasms
Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Neoplasms
Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.
Neoplasms
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Neoplasms
Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.
Neoplasms
Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
Neoplasms
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients.
Neoplasms
Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Neoplasms
Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro.
Neoplasms
Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain.
Neoplasms
Agonist-stimulated release of von Willebrand factor and procoagulant factor VIII in rats with and without risk factors for stroke.
Neoplasms
Alkylation of phosphorothioated thrombin binding aptamers improves the selectivity of inhibition of tumor cell proliferation upon anticoagulation.
Neoplasms
Altered adhesive properties of cord blood endothelial outgrowth cells expressing IL-1ra.
Neoplasms
Altered plasma fibrin clot properties in patients with digestive tract cancers: Links with the increased thrombin generation.
Neoplasms
An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients.
Neoplasms
An intracisternal A-particle DNA sequence is closely linked to the thrombomodulin gene in some strains of laboratory mice.
Neoplasms
Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma.
Neoplasms
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Neoplasms
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Neoplasms
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Neoplasms
Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation.
Neoplasms
Aquaporin 4 is increased in association with human immunodeficiency virus dementia: implications for disease pathogenesis.
Neoplasms
Arsenic May Act as a Pro-Metastatic Carcinogen Through Promoting Tumor Cell-Induced Platelet Aggregation.
Neoplasms
Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity.
Neoplasms
Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Neoplasms
Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells.
Neoplasms
Bi-cell surface plasmon resonance detection of aptamer mediated thrombin capture in serum.
Neoplasms
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Neoplasms
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.
Neoplasms
Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.
Neoplasms
Bradykinin and thrombin synergistically potentiate interleukin 1 and tumour necrosis factor induced prostanoid biosynthesis in human dental pulp fibroblasts.
Neoplasms
Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion.
Neoplasms
Caffeine induces endothelial tissue factor expression via phosphatidylinositol 3-kinase inhibition.
Neoplasms
Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP.
Neoplasms
Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression.
Neoplasms
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Neoplasms
Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms.
Neoplasms
Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer.
Neoplasms
Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.
Neoplasms
Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics.
Neoplasms
Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding.
Neoplasms
Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Neoplasms
Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
Neoplasms
Characteristic biological features of human megakaryoblastic leukaemia cell lines.
Neoplasms
Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2).
Neoplasms
Characterization of thrombin generation potential of leukemic and solid tumor cells by the calibrated automated thrombography.
Neoplasms
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
Neoplasms
Chronic idiopathic non-cirrhotic portal vein thrombosis treated with a mesocaval shunt procedure and anticoagulation.
Neoplasms
Chronological expression of PAR isoforms in acute liver injury and its amelioration by PAR2 blockade in a rat model of sepsis.
Neoplasms
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Neoplasms
Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop.
Neoplasms
Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk.
Neoplasms
Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation.
Neoplasms
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Neoplasms
Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.
Neoplasms
Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer.
Neoplasms
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Neoplasms
Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts.
Neoplasms
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Neoplasms
Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles.
Neoplasms
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
Neoplasms
Comparison of blood activation in the wound, active vent, and cardiopulmonary bypass circuit.
Neoplasms
Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro.
Neoplasms
Comparison of stimulated tissue factor expression by brain microvascular endothelial cells from normotensive (WKY) and hypertensive (SHR) rats.
Neoplasms
Concentration dependent anti-inflammatory effects thrombin on polyphosphate-mediated inflammatory responses in vitro and in vivo.
Neoplasms
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Neoplasms
Contribution of thrombin-reactive brain pericytes to blood-brain barrier dysfunction in an in vivo mouse model of obesity-associated diabetes and an in vitro rat model.
Neoplasms
Controllable gelation of artificial extracellular matrix for altering mass transport and improving cancer therapies.
Neoplasms
Cooperation of protease-activated receptor 1 and integrin ???5 in thrombin-mediated lung cancer cell invasion.
Neoplasms
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Neoplasms
Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells.
Neoplasms
Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.
Neoplasms
Defective Arachidonate Release and PGE2 Production in Gialpha2-Deficient Intestinal and Colonic Subepithelial Myofibroblasts.
Neoplasms
Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interaction.
Neoplasms
Development of a sandwich ELISA for the thrombin light chain identified by serum proteome analysis.
Neoplasms
Development of an Image-Based HCS-Compatible Method for Endothelial Barrier Function Assessment.
Neoplasms
Development of aptamer-conjugated magnetic graphene/gold nanoparticle hybrid nanocomposites for specific enrichment and rapid analysis of thrombin by MALDI-TOF MS.
Neoplasms
Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.
Neoplasms
Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cell versus endothelial cells.
Neoplasms
Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues.
Neoplasms
Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.
Neoplasms
Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes.
Neoplasms
Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents.
Neoplasms
Distinct mechanisms for N-acetylcysteine inhibition of cytokine-induced E-selectin and VCAM-1 expression.
Neoplasms
Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.
Neoplasms
Divergent effects of protein kinase C (PKC) inhibitors staurosporine and bisindolylmaleimide I (GF109203X) on bone resorption.
Neoplasms
Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis.
Neoplasms
DP-1904, a specific inhibitor of thromboxane A2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells.
Neoplasms
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study.
Neoplasms
Effect of ascorbate on plasminogen activator inhibitor-1 expression and release from platelets and endothelial cells in an in-vitro model of sepsis.
Neoplasms
Effect of autologous transplant of peripheral blood mononuclear cells in combination with proangiogenic factors during experimental revascularization of lower limb ischemia.
Neoplasms
Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth.
Neoplasms
Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation.
Neoplasms
Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure.
Neoplasms
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Neoplasms
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.
Neoplasms
Effects of Lower Concentration Thrombin on High-Mobility Group Box 1 Protein-Mediated Inflammatory Responses.
Neoplasms
Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?
Neoplasms
Elevated extracellular trap formation and contact system activation in acute leukemia.
Neoplasms
Emergence of hamster fibroblast tumors in nude mice--evidence for in vivo selection leading to loss of growth factor requirement.
Neoplasms
Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-?B inactivation.
Neoplasms
Endothelial cell monolayers as a model system to investigate dengue shock syndrome.
Neoplasms
Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice.
Neoplasms
Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion.
Neoplasms
Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors.
Neoplasms
Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas.
Neoplasms
Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Neoplasms
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Neoplasms
Epigenetic regulation of tissue factor inducibility in endothelial cell senescence.
Neoplasms
Evaluation of the Activity of Heparin Injected into the Fully Implantable Catheter for Chemotherapy (Portocath) between Two Moments of Use.
Neoplasms
Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay.
Neoplasms
Evidence for actin cytoskeleton-dependent and -independent pathways for RelA/p65 nuclear translocation in endothelial cells.
Neoplasms
Evidence that thrombin present in lungs of patients with pulmonary metastasis may contribute to the development of the disease.
Neoplasms
Experimental and clinical studies on liver regeneration following transcatheter portal embolization.
Neoplasms
Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin.
Neoplasms
Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation.
Neoplasms
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Neoplasms
Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains.
Neoplasms
Fibrin monomer increases platelet adherence to tumor cells in a flowing system: a possible role in metastasis?
Neoplasms
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Neoplasms
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Neoplasms
Fibrinogen-coated droplets of olive oil for delivery of docetaxel to a fibrin(ogen)-rich ascites form of a murine mammary tumor.
Neoplasms
Fibrinolytic abnormalities associated with progression of pediatric solid tumors.
Neoplasms
Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors.
Neoplasms
Fibronectin Matrix Formation is a Prerequisite for Colonization of Kidney Tumor Cells in Fibrin.
Neoplasms
Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability.
Neoplasms
Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis.
Neoplasms
Further inhibition studies on guanidinobenzoatase, a trypsin-like enzyme associated with tumour cells.
Neoplasms
Genetic determinants of cancer coagulopathy, angiogenesis and disease progression.
Neoplasms
Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection.
Neoplasms
Growth regulation of vessel wall cells and of tumor cells by thrombin, factor XIII and fibronectin.
Neoplasms
Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin.
Neoplasms
Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies.
Neoplasms
Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?
Neoplasms
Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels.
Neoplasms
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.
Neoplasms
Heparin modulates chemokines in human endometrial stromal cells by interaction with tumor necrosis factor ? and thrombin.
Neoplasms
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
Neoplasms
Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester.
Neoplasms
Highly purified human alpha-thrombin promotes morphological transformation of BALB/c 3T3 cells.
Neoplasms
Highly stable surface-enhanced Raman spectroscopy assay on abnormal thrombin levels in the blood plasma of cancer patients.
Neoplasms
Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure.
Neoplasms
Histamine differentially interacts with tumor necrosis factor-alpha and thrombin in endothelial tissue factor induction: the role of c-Jun NH2-terminal kinase.
Neoplasms
Human alpha-thrombin stimulates proliferation of interferon-gamma differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1.
Neoplasms
Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties.
Neoplasms
Human tumor cells cultured "in vitro" activate platelet function by producing ADP or thrombin.
Neoplasms
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Neoplasms
Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells.
Neoplasms
Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis.
Neoplasms
Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
Neoplasms
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.
Neoplasms
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Neoplasms
Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma.
Neoplasms
Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal).
Neoplasms
In an in-vitro model using human fetal membranes, 17-? hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
Neoplasms
In an in-vitro model using human fetal membranes, ?-lipoic acid inhibits inflammation induced fetal membrane weakening.
Neoplasms
In vitro antitumor and anti-angiogenic activities of a shrimp chondroitin sulfate.
Neoplasms
Incidence of thromboembolic events after use of gelatin-thrombin-based hemostatic matrix during intracranial tumor surgery.
Neoplasms
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Neoplasms
Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
Neoplasms
Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma.
Neoplasms
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway.
Neoplasms
Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis.
Neoplasms
Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent.
Neoplasms
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Neoplasms
Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Neoplasms
Inhibition of coagulation proteases Xa and IIa decreases ischemia-reperfusion injuries in a preclinical renal transplantation model.
Neoplasms
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.
Neoplasms
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide.
Neoplasms
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Neoplasms
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Neoplasms
Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Neoplasms
Injured tissues favor cancer cell implantation via fibrin deposits on scar zones.
Neoplasms
Insoluble fibrinogen particles for harvesting and expanding attachment-dependent cells and for trapping suspended cancer cells in the presence of blood.
Neoplasms
Interplay of Plasmodium falciparum and thrombin in brain endothelial barrier disruption.
Neoplasms
Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1.
Neoplasms
JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro.
Neoplasms
Label-free visualization and quantification of single cell signaling activity using metal-clad waveguide (MCWG)-based microscopy.
Neoplasms
Laparoscopic partial nephrectomy for selected central tumours: omitting the bolster.
Neoplasms
Large femoral aneurysm as a late complication after vessel closure device application.
Neoplasms
Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities.
Neoplasms
Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression.
Neoplasms
Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients.
Neoplasms
Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model.
Neoplasms
Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway.
Neoplasms
Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.
Neoplasms
Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis.
Neoplasms
Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.
Neoplasms
Markers of coagulation activation after hepatic resection for cancer: evidence of sustained upregulation of coagulation.
Neoplasms
Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2.
Neoplasms
Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.
Neoplasms
Matrix metalloproteinases target protease-activated receptors on the tumor cell surface.
Neoplasms
Measurement of heparin in plasma: influence of inter-subject and circadian variability in heparin sensitivity according to method.
Neoplasms
Mechanisms involved in the early interaction between HeLa cells, platelets and endothelial cells in vitro under the influence of thrombin. Effects of acetylsalicylic acid and Na-salicylate.
Neoplasms
Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination.
Neoplasms
Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma.
Neoplasms
Microfluidic reveals generation of platelet-strings on tumor-activated endothelium.
Neoplasms
Modulation of human uterine smooth muscle cell collagen contractility by thrombin, Y-27632, TNF alpha and indomethacin.
Neoplasms
Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells.
Neoplasms
Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators.
Neoplasms
Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.
Neoplasms
Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells.
Neoplasms
Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages.
Neoplasms
Mononuclear cell-conditioned medium enhances thrombin-stimulated PGI2 production by human umbilical vein endothelial cells in culture.
Neoplasms
Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown.
Neoplasms
Mutation analysis of the non-muscle myosin light chain kinase (MLCK) deletion constructs on CV1 fibroblast contractile activity and proliferation.
Neoplasms
New nonlipid effects of statins and their clinical relevance in cardiovascular disease.
Neoplasms
Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation.
Neoplasms
OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa.
Neoplasms
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Neoplasms
Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation.
Neoplasms
Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling.
Neoplasms
PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress.
Neoplasms
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
Neoplasms
PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells.
Neoplasms
PAR-3 Knockdown Enhances Adhesion Rate of PANC-1 Cells via Increased Expression of Integrin?v and E-Cadherin.
Neoplasms
PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism.
Neoplasms
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.
Neoplasms
Phelligridimer A, a highly oxygenated and unsaturated 26-membered macrocyclic metabolite with antioxidant activity from the fungus Phellinus igniarius.
Neoplasms
Phosphatidylcholine synthesis in platelets is stimulated by diacylglycerol but not by phorbol ester.
Neoplasms
Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Neoplasms
Plasma composition distribution in cancer: Discrimination by thrombin and factor Xa generation.
Neoplasms
Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer - Relationship with Clinical Outcome.
Neoplasms
Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro.
Neoplasms
Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation.
Neoplasms
Platelet enhancement of tumor cell adhesion to subendothelial matrix: role of platelet cytoskeleton and platelet membrane.
Neoplasms
Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties.
Neoplasms
Platelet-aggregating activities of metastasizing tumor cells. II. Variety of the aggregation mechanisms.
Neoplasms
Platelet-aggregating activities of metastasizing tumor cells. III. Platelet aggregation as resulting from thrombin generation by tumor cells.
Neoplasms
Platelet-aggregating activities of metastasizing tumor cells. IV. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent lung colonization.
Neoplasms
Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity.
Neoplasms
Platelet-derived microparticles and coagulation activation in breast cancer patients.
Neoplasms
Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro.
Neoplasms
Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity.
Neoplasms
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Neoplasms
PMA inhibits the growth of human fibroblasts after the induction of immediate-early genes.
Neoplasms
PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation.
Neoplasms
PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?
Neoplasms
PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion.
Neoplasms
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Neoplasms
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.
Neoplasms
PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer.
Neoplasms
Preconditioning of primary human endothelial cells with inflammatory mediators alters the "set point" of the cell.
Neoplasms
Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study.
Neoplasms
PreproEndothelin-1 expression in human mesangial cells: evidence for a p38 mitogen-activated protein kinase/protein kinases-C-dependent mechanism.
Neoplasms
Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation.
Neoplasms
Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of Veterans Affairs Cooperative Study 188.
Neoplasms
Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate.
Neoplasms
Pro-Coagulant and Pro-Thrombotic Effects of Paclitaxel Mediated by Red Blood Cells.
Neoplasms
Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.
Neoplasms
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
Neoplasms
Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.
Neoplasms
Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury.
Neoplasms
Progestin and thrombin regulate tissue factor expression in human term decidual cells.
Neoplasms
Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung.
Neoplasms
Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2).
Neoplasms
Promotion of lung tumor colonization in mice by the synthetic thrombin inhibitor (no. 805) and its reversal by leech salivary gland extracts.
Neoplasms
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Neoplasms
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.
Neoplasms
Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor. Comparison with umbilical vein endothelial cells.
Neoplasms
Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
Neoplasms
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.
Neoplasms
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.
Neoplasms
Protease-activated receptor 2 (PAR2) blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure.
Neoplasms
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.
Neoplasms
Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.
Neoplasms
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin.
Neoplasms
Protein kinase C is differentially regulated by thrombin, insulin, and epidermal growth factor in human mammary tumor cells.
Neoplasms
Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury.
Neoplasms
Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
Neoplasms
Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF?, in Peripheral Blood.
Neoplasms
Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not.
Neoplasms
Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay.
Neoplasms
Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase.
Neoplasms
Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-alpha.
Neoplasms
Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.
Neoplasms
Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1.
Neoplasms
Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report.
Neoplasms
Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer.
Neoplasms
Regulation of P-selectin expression by inflammatory mediators in canine jugular endothelial cells.
Neoplasms
Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample.
Neoplasms
Rhamnan sulfate extracted from Monostroma nitidum attenuates blood coagulation and inflammation of vascular endothelial cells.
Neoplasms
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
Neoplasms
rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells.
Neoplasms
Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study.
Neoplasms
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Neoplasms
RNA-seq Reveals Novel Transcriptome of Genes and Their Isoforms in Human Pulmonary Microvascular Endothelial Cells Treated with Thrombin.
Neoplasms
Role of E- and P-selectin in migration of monocytes and polymorphonuclear leucocytes to cytokine and chemoattractant-induced cutaneous inflammation in the rat.
Neoplasms
Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis.
Neoplasms
Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells.
Neoplasms
Role of Hypercoagulable State for Predictive Ovarian Malignancy in Women with a Pelvic Mass.
Neoplasms
Role of platelet membrane in enhancement of tumor cell adhesion to endothelial cell extracellular matrix.
Neoplasms
Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo.
Neoplasms
Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis.
Neoplasms
Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice.
Neoplasms
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Neoplasms
Role of thrombin in the proliferative response of T-47D mammary tumor cells. Mitogenic action and pleiotropic modifications induced together with epidermal growth factor and insulin.
Neoplasms
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Neoplasms
Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells.
Neoplasms
Selective recognition of co-assembled thrombin aptamer and docetaxel on mesoporous silica nanoparticles against tumor cell proliferation.
Neoplasms
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Neoplasms
Sex differences in the expression of cell adhesion molecules on microvesicles derived from cultured human brain microvascular endothelial cells treated with inflammatory and thrombotic stimuli.
Neoplasms
Signaling mechanism in the induction of apoptosis by thrombin in human tumor cells.
Neoplasms
Single gold nanoparticles counter: an ultrasensitive detection platform for one-step homogeneous immunoassays and DNA hybridization assays.
Neoplasms
Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.
Neoplasms
Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis.
Neoplasms
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Neoplasms
Special pharmacokinetics of dipetarudin suggests a potential antitumor activity of this thrombin inhibitor.
Neoplasms
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
Neoplasms
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
Neoplasms
Stiff Substrates Increase Inflammation-Induced Endothelial Monolayer Tension and Permeability.
Neoplasms
Stimulation of proteinase activated receptor-2 causes endothelial cells to promote blood coagulation in vitro.
Neoplasms
Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines.
Neoplasms
Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine.
Neoplasms
Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy.
Neoplasms
Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability.
Neoplasms
Synergistic interactions of bradykinin, thrombin, interleukin 1 and tumor necrosis factor on prostanoid biosynthesis in human periodontal-ligament cells.
Neoplasms
Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile.
Neoplasms
Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation.
Neoplasms
Targeting nucleolin to obstruct vasculature feeding with an intelligent DNA nanorobot.
Neoplasms
Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice.
Neoplasms
TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.
Neoplasms
TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.
Neoplasms
The action of Amblyomma cajennense tick saliva in compounds of the hemostatic system and cytotoxicity in tumor cell lines.
Neoplasms
The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor.
Neoplasms
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Neoplasms
The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread.
Neoplasms
The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.
Neoplasms
The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development.
Neoplasms
The chemotherapy of C3H mice bearing Gardner lymphosarcoma with bovine fibrinogen-methotrexate derivative.
Neoplasms
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
Neoplasms
The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.
Neoplasms
The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial.
Neoplasms
The effects of thrombin and cytokines upon the biomechanics and remodeling of isolated amnion membrane, in vitro.
Neoplasms
The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
Neoplasms
The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions.
Neoplasms
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
Neoplasms
The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
Neoplasms
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
Neoplasms
The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.
Neoplasms
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Neoplasms
The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology.
Neoplasms
The Percentage of Anaplastic Lymphoma Kinase-Positive Tumor Cells Has Clinical Implications for Patients with Non-Small Cell Lung Cancer.
Neoplasms
The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression.
Neoplasms
The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer.
Neoplasms
The synergistic effect of Au-COF nanosheets and artificial peroxidase Au@ZIF-8(NiPd) rhombic dodecahedra for signal amplification for biomarker detection.
Neoplasms
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
Neoplasms
The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells.
Neoplasms
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Neoplasms
Three-dimensional porous microarray of gold modified electrode for ultrasensitive and simultaneous assay of various cancer biomarkers.
Neoplasms
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Neoplasms
Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms.
Neoplasms
Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells.
Neoplasms
Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun.
Neoplasms
Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro.
Neoplasms
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Neoplasms
Thrombin biology in the 21st century: implications in hemostasis, inflammation, coagulopathies, and cancer. Proceedings of a seminar. September, 2005.
Neoplasms
Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products.
Neoplasms
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?.
Neoplasms
Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway.
Neoplasms
Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration.
Neoplasms
Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.
Neoplasms
Thrombin enhances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase.
Neoplasms
Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms.
Neoplasms
Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin.
Neoplasms
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Neoplasms
Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
Neoplasms
Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups.
Neoplasms
Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients.
Neoplasms
Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells.
Neoplasms
Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes.
Neoplasms
Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma.
Neoplasms
Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222.
Neoplasms
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Neoplasms
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Neoplasms
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Neoplasms
Thrombin Inhibition and Cyclophosphamide Synergistically Block Tumor Progression and Metastasis.
Neoplasms
Thrombin inhibition by malignant and normal cells: a cell-bound antithrombin effect.
Neoplasms
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Neoplasms
Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C.
Neoplasms
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Neoplasms
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Neoplasms
Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism.
Neoplasms
Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes.
Neoplasms
Thrombin Promotes Macrophage Polarization into M1-Like Phenotype to Induce Inflammatory Responses.
Neoplasms
Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA.
Neoplasms
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Neoplasms
Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation.
Neoplasms
Thrombin receptor overexpression in malignant and physiological invasion processes.
Neoplasms
Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.
Neoplasms
Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.
Neoplasms
Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway.
Neoplasms
Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis.
Neoplasms
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Neoplasms
Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium.
Neoplasms
Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells.
Neoplasms
Thrombin-induced, TNFR-dependent miR-181c downregulation promotes MLL1 and NF-?B target gene expression in human microglia.
Neoplasms
Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling.
Neoplasms
Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
Neoplasms
Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis.
Neoplasms
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.
Neoplasms
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Neoplasms
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Neoplasms
Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
Neoplasms
Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.
Neoplasms
Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp.
Neoplasms
Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy.
Neoplasms
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.
Neoplasms
Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation.
Neoplasms
Tissue factor: A potent stimulator of Von Willebrand factor synthesis by human umbilical vein endothelial cells.
Neoplasms
TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation.
Neoplasms
Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression.
Neoplasms
Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment.
Neoplasms
Translational inhibition of E-selectin expression stimulates P-selectin-dependent neutrophil recruitment.
Neoplasms
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.
Neoplasms
Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors.
Neoplasms
Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin.
Neoplasms
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Neoplasms
Tumor necrosis factor causes amplification of arachidonic acid metabolism in response to interleukin 1, bradykinin, and other agonists.
Neoplasms
Tumor necrosis factor decreases thrombin receptor expression in endothelial cells.
Neoplasms
Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression.
Neoplasms
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Neoplasms
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.
Neoplasms
Ultrasensitive Ambient Mass Spectrometry Immunoassays: Multiplexed Detection of Proteins in Serum and on Cell Surfaces.
Neoplasms
Universal surface-enhanced Raman scattering amplification detector for ultrasensitive detection of multiple target analytes.
Neoplasms
Unraveling thrombin's true microglia-activating potential: markedly disparate profiles of pharmaceutical-grade and commercial-grade thrombin preparations.
Neoplasms
Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects.
Neoplasms
Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy.
Neoplasms
Use of gelatin matrix thrombin tissue sealant as an effective hemostatic agent during laparoscopic partial nephrectomy.
Neoplasms
Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.
Neoplasms
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.
Neoplasms
Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells.
Neoplasms
Vascular origin of Kaposi's sarcoma. Expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor.
Neoplasms
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
Neoplasms
Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth.
Neoplasms
Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling.
Neoplasms
von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.
Neoplasms
[A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin]
Neoplasms
[Acquired factor V deficiency: A rare bleeding disorder with variable clinical presentations.]
Neoplasms
[Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model.]
Neoplasms
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection]
Neoplasms
[Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors]
Neoplasms
[Evaluation of hypercoagulable state in patients with malignancies by using prothrombin fragment F1 + 2]
Neoplasms
[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.]
Neoplasms
[Fibrin glue injection therapy with diluted thrombin for complicated postoperative fistulas following digestive surgery].
Neoplasms
[Improvement of hemostasis in laparoscopic and open partial nephrectomy with gelatin thrombin matrix (FloSeal)]
Neoplasms
[Occlusion of the renal artery by intra-arterial injection of thrombin in a case of inoperable renal tumour (author's transl)]
Neoplasms
[Reactions of derivatives of beta-lactam antibiotics with non-antibacterial biological activity]
Neoplasms
[Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis]
Neoplasms
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Neoplasms
[Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin]
Neoplasms
[Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells]
Neoplasms
[Thrombocytopenia induced by lipopolysaccharide may be not related to coagulation and inflammatory response].
Neoplasms
[Ultrasound diagnosis of venous tumor thrombi in kidney cancer. A prospective study]
Neoplastic Cells, Circulating
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Neoplastic Cells, Circulating
Modeling and simulation of procoagulant circulating tumor cells in flow.
Nephrotic Syndrome
A study of impaired fibrin polymerization in patients with the nephrotic syndrome.
Nephrotic Syndrome
Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome.
Nephrotic Syndrome
Concentration of three thrombin inhibitors in the nephrotic syndrome in adults.
Nephrotic Syndrome
Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.
Nephrotic Syndrome
Human alpha2-macroglobulin and its antitrypsic and antithrombin activities in serum and plasma.
Nephrotic Syndrome
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Nephrotic Syndrome
Mechanisms of the development of acquired antithrombin III deficiency in the experimental nephrotic syndromes.
Nephrotic Syndrome
Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia.
Nephrotic Syndrome
Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
Nephrotic Syndrome
The assesment of prothrombotic potential using thrombin generation assay in pediatric patients with nephrotic syndrome: preliminary study.
Nephrotic Syndrome
Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.
Nephrotic Syndrome
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Nephrotic Syndrome
[Disorders of thrombin interaction with the blood vessel wall and its inactivation by antithrombin III in experimental nephrotic syndrome]
Nephrotic Syndrome
[Howie's antithrombin activity and thrombin inhibitors in the nephrotic syndrome]
Nephrotic Syndrome
[Use of chromogenic substrates for estimation of indicators of kallikrein-kinin and blood coagulation systems in blood plasma of patients with nephrotic syndrome]
Nervous System Diseases
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Neurilemmoma
Local Regulation of Thrombin Activity by Factor Xa in Peripheral Nerve Schwann Cells.
Neuritis
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Neuritis, Autoimmune, Experimental
Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis.
Neuritis, Autoimmune, Experimental
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Neuroblastoma
Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombins.
Neuroblastoma
Addition of protease inhibitors to culture medium of neuroblastoma cells induces both neurite outgrowth and phosphorylation of microtubule-associated protein MAP-1B.
Neuroblastoma
Characterization of the prothrombin gene expression during nerve differentiation.
Neuroblastoma
Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells.
Neuroblastoma
Exogenous thrombin inhibits neuritogenesis in cultured neuroblastoma cells but not in rat hippocampal neurons.
Neuroblastoma
Functional sites of glia-derived nexin (GDN): importance of the site reacting with the protease.
Neuroblastoma
Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation.
Neuroblastoma
Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor.
Neuroblastoma
Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban.
Neuroblastoma
Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Neuroblastoma
Modulation of morphological differentiation of human neuroepithelial cells by serine proteases: independence from blood coagulation.
Neuroblastoma
Modulation of neurite outgrowth in neuroblastoma cells by protein kinase C and platelet-activating factor.
Neuroblastoma
Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase.
Neuroblastoma
Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition.
Neuroblastoma
Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line.
Neuroblastoma
Proteolytic regulation of neurite outgrowth from neuroblastoma cells by thrombin and protease nexin-1.
Neuroblastoma
Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes in vitro.
Neuroblastoma
Thrombin binding and stimulation of cyclic guanosine monophosphate formation in neuroblastoma cells.
Neuroblastoma
Thrombin causes neurite retraction in neuronal cells through activation of cell surface receptors.
Neuroblastoma
Thrombin induced inhibition of neurite outgrowth from dorsal root ganglion neurons.
Neuroblastoma
Thrombin is the major serum factor stimulating phosphoinositide turnover, but not DNA synthesis in human neuroblastoma SH-EP cells.
Neuroblastoma
Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation.
Neuroblastoma
Thrombin receptor on rat primary hippocampal neurons: coupled calcium and cAMP responses.
Neuroblastoma
Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP.
Neuroblastoma
Thrombin stimulation of guanosine 3',5'-monophosphate formation in murine neuroblastoma cells (clone N1E-115).
Neuroblastoma
Transient neuritogenesis in NB2a/d1 neuroblastoma cells induced by glial-derived protease inhibitors.
Neuroblastoma
Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants.
Neurodegenerative Diseases
Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease.
Neurodegenerative Diseases
Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection.
Neurodegenerative Diseases
Membrane lipid peroxidation in neurodegeneration: Role of thrombin and proteinase-activated receptor-1.
Neurodegenerative Diseases
Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca(2+) mobilization, and apoptosis.
Neurodegenerative Diseases
Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases.
Neurodegenerative Diseases
Quantitative reverse transcriptase PCR to gauge increased protease-activated receptor 1 (PAR-1) mRNA copy numbers in the Wobbler mutant mouse.
Neurodegenerative Diseases
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Neurodegenerative Diseases
Specific fibrinogen and thrombin concentrations promote neuronal rather than glial growth when primary neural cells are seeded within plasma-derived fibrin gels.
Neurodegenerative Diseases
Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile.
Neurodegenerative Diseases
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain.
Neurodegenerative Diseases
Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders.
Neurodegenerative Diseases
Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities.
Neurodegenerative Diseases
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase.
Neurodegenerative Diseases
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase.
Neurodegenerative Diseases
Thrombin: a potential proinflammatory mediator in neurotrauma and neurodegenerative disorders.
Neuroectodermal Tumors, Primitive
[Study on the mechanisms of thrombin to inhibit neurite outgrowth]
Neuroinflammatory Diseases
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Neuroinflammatory Diseases
Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes.
Neuroinflammatory Diseases
Deficiency of tPA Exacerbates White Matter Damage, Neuroinflammation, Glymphatic Dysfunction and Cognitive Dysfunction in Aging Mice.
Neuroinflammatory Diseases
Differential effects on glial activation by a direct versus an indirect thrombin inhibitor.
Neuroinflammatory Diseases
Early detection of thrombin activity in neuroinflammatory disease.
Neuroinflammatory Diseases
Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes.
Neuroinflammatory Diseases
Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation.
Neuroinflammatory Diseases
HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.
Neuroinflammatory Diseases
Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease.
Neuroinflammatory Diseases
Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.
Neuroinflammatory Diseases
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
Neuroinflammatory Diseases
Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1.
Neuroinflammatory Diseases
Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells.
Neuroinflammatory Diseases
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Neuroinflammatory Diseases
[Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?]
Neurologic Manifestations
Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population.
Non-alcoholic Fatty Liver Disease
Coagulation-driven hepatic fibrosis requires protease activated receptor-1 (PAR-1) in a mouse model of TCDD-elicited steatohepatitis.
Non-alcoholic Fatty Liver Disease
Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.
Non-alcoholic Fatty Liver Disease
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Non-ST Elevated Myocardial Infarction
Anticoagulation during and after acute coronary syndrome.
Non-ST Elevated Myocardial Infarction
Contemporary use of glycoprotein IIb/IIIa inhibitors.
Non-ST Elevated Myocardial Infarction
Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory.
Non-ST Elevated Myocardial Infarction
Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction.
Obesity
Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
Obesity
Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation.
Obesity
Maternal thrombin generation and D-dimer levels in obesity and pregnancy: results from the maternal thrombin generation in obesity and pregnancy (MaTOPs) study.
Obesity
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Obesity
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Obesity
Postprandial factor VII activation does not increase plasma concentrations of prothrombin fragment 1 + 2 in patients with morbid obesity.
Obesity
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
Obesity
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Obesity
Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study.
Obesity
Thrombin increases inflammatory cytokine and angiogenic growth factor secretion in human adipose cells in vitro.
Obesity
Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation.
Obesity, Morbid
Postprandial factor VII activation does not increase plasma concentrations of prothrombin fragment 1 + 2 in patients with morbid obesity.
Obesity, Morbid
Staple-Line Reinforcement with a Thrombin Matrix During Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Case Series.
Obesity, Morbid
Thrombin generation in morbid obesity: significant reduction after weight loss.
Obesity, Morbid
Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity.
Obstetric Labor, Premature
Activation of coagulation system in preterm labor and preterm premature rupture of membranes.
Obstetric Labor, Premature
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: Evidence of an increased thrombin generation.
Obstetric Labor, Premature
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation.
Obstetric Labor, Premature
Early second trimester maternal plasma levels of thrombin-inhibitor complexes and subsequent spontaneous preterm delivery.
Obstetric Labor, Premature
Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor.
Obstetric Labor, Premature
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Obstetric Labor, Premature
High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor.
Obstetric Labor, Premature
Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Obstetric Labor, Premature
The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications.
Obstetric Labor, Premature
Thrombin and interleukin-1beta regulate HOXA10 expression in human term decidual cells: implications for preterm labor.
Obstetric Labor, Premature
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Optic Nerve Diseases
Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child.
Oral Submucous Fibrosis
Regulation of protease-activated receptor-1 expression in human buccal fibroblasts stimulated with arecoline.
Osteitis
Management of chronic osteitis and osteomyelitis with a coagulum of autogenous blood + penicillin + thrombin; (on the base of 56 cases results).
Osteoarthritis
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Osteoarthritis
Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation.
Osteoarthritis
Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis.
Osteoarthritis
Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor.
Osteoarthritis
Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue.
Osteoarthritis
Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis.
Osteoma, Osteoid
Percutaneous thrombin injection treatment of a gluteal pseudoaneurysm following radiofrequency ablation of a hip osteoid osteoma in a 6-year-old boy.
Osteomyelitis
Management of chronic osteitis and osteomyelitis with a coagulum of autogenous blood + penicillin + thrombin; (on the base of 56 cases results).
Osteomyelitis
The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis.
Osteonecrosis
Preventive effects of the anti-vasospasm agent via the regulation of the Rho-kinase pathway on the development of steroid-induced osteonecrosis in rabbits.
Osteoporosis
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.
Osteoporosis
[Biological effects of vitamin K and concentration of vitamin K in Norwegian food]
Osteosarcoma
A novel phospholipase C inhibitor and phorbol esters reveal selective regulation of thrombin- and parathyroid hormone-stimulated signaling pathways in rat osteosarcoma cells.
Osteosarcoma
Endothelin-1 modulates calcium signaling by epidermal growth factor, alpha-thrombin, and prostaglandin E1 in UMR-106 osteoblastic cells.
Osteosarcoma
Platelet-Derived TGF-? Induces Tissue Factor Expression via the Smad3 Pathway in Osteosarcoma Cells.
Osteosarcoma
Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line.
Osteosarcoma
Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of alphavbeta3 integrin.
Osteosarcoma
The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity.
Osteosarcoma
The zymogen prothrombin stimulates cell locomotion and calcium influx in murine osteosarcoma cells by different mechanism from thrombin.
Osteosarcoma
Thrombin and parathyroid hormone mobilize intracellular calcium in rat osteosarcoma cells by distinct pathways.
Osteosarcoma
Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma.
Osteosarcoma
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Osteosarcoma
Thrombin is present in the lungs of patients with primary extremity osteosarcoma and pulmonary metastases.
Osteosarcoma
Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells.
Osteosarcoma
Thrombin's effects on osteoblastic cells. I. Cytosolic calcium and phosphoinositides.
Ovarian Neoplasms
A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.
Ovarian Neoplasms
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Ovarian Neoplasms
PO-24 - Determinants of thrombin generation in gynaecological malignancies.
Ovarian Neoplasms
Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome.
Ovarian Neoplasms
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
Ovarian Neoplasms
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Ovarian Neoplasms
Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells.
Ovarian Neoplasms
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Ovarian Neoplasms
Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition.
Ovarian Neoplasms
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Ovarian Neoplasms
[Expression of the cell surface receptor for thrombin, thrombomodulin, in human ovarian cancer cells]
Overweight
Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.
Overweight
Effects of 6 Months of Active Commuting and Leisure-Time Exercise on Fibrin Turnover in Sedentary Individuals with Overweight and Obesity: A Randomised Controlled Trial.
Overweight
Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
Overweight
Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels.
Overweight
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events.
Overweight
Normalization of haemostatic alterations in overweight children with weight loss due to lifestyle intervention.
Overweight
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
Overweight
Three months of strictly controlled daily endurance exercise reduces thrombin generation and fibrinolytic risk markers in younger moderately overweight men.
Pancreatic Diseases
Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis.
Pancreatic Neoplasms
A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells.
Pancreatic Neoplasms
Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2).
Pancreatic Neoplasms
Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.
Pancreatic Neoplasms
Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.
Pancreatic Neoplasms
Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.
Pancreatic Neoplasms
Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.
Pancreatic Neoplasms
Effect of Low Molecular Weight Heparins and Fondaparinux upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3.
Pancreatic Neoplasms
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Pancreatic Neoplasms
Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients.
Pancreatic Neoplasms
PO-27 - Thrombin generation in pancreatic cancer and multiple myeloma with use of calibrated automated thrombography.
Pancreatic Neoplasms
The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls.
Pancreatic Neoplasms
Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.
Pancreatic Neoplasms
Thrombin stimulates integrin ?1-dependent adhesion of human pancreatic cancer cells to vitronectin through protease-activated receptor (PAR)-1.
Pancreatic Neoplasms
[A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin]
Pancreatic Pseudocyst
Endoscopic use of oxidized regenerated cellulose and topical thrombin: a novel approach for control of bleeding pancreatic pseudocyst wall after endoscopic cystgastrostomy.
Pancreatitis
Acute pancreatitis in Soweto, South Africa: relationship between trypsinogen load, trypsinogen activation, and fibrinolysis.
Pancreatitis
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Pancreatitis
Endoscopic ultrasound guided thrombin injection of angiographically occult pancreatitis associated visceral artery pseudoaneurysms: Case series.
Pancreatitis
Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis.
Pancreatitis
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Pancreatitis
Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man.
Pancreatitis
Percutaneous ultrasound-guided thrombin injection as first-line treatment of pancreatic pseudoaneurysm.
Pancreatitis
The relationship of coagulation factors to clinical complications of acute pancreatitis.
Pancreatitis
Thrombin Generation in vitro and in vivo, and Disturbed Tissue Factor Regulation in Patients with Acute Pancreatitis.
Pancreatitis
Treatment of a splenic artery pseudoaneurysm by endoscopic ultrasound-guided thrombin injection.
Pancreatitis
Ultrasonic-guided percutaneous injection of pancreatic pseudoaneurysm with thrombin.
Pancreatitis
[Role of increase in permeability and circulatory failure in the development of organ dysfunction in severe acute pancreatitis]
Pancreatitis, Chronic
Endoscopic ultrasound-guided thrombin injection in a large splenic artery aneurysm: first report in a patient with tropical chronic pancreatitis.
Pancreatitis, Chronic
Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection.
Pancreatitis, Chronic
Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm.
Pancreatitis, Chronic
Ultrasound guided thrombin injection to treat a pseudoaneurysm secondary to chronic pancreatitis.
Paraproteinemias
Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab.
Paraproteinemias
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Paratuberculosis
Cloning and expression in Escherichia coli of DNA encoding a 60 kDa stress protein of Mycobacterium paratuberculosis, the causative agent of Johne's disease.
Paresthesia
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Parkinson Disease
Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease.
Parkinson Disease
Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats.
Parkinson Disease
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
Parkinson Disease
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Parkinson Disease
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Parkinson Disease
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
Parkinson Disease
Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
Parkinson Disease
Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways.
Parkinson Disease
Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo.
Parkinson Disease
Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase.
Pelvic Floor Disorders
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Pemphigoid, Bullous
Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases.
Penile Induration
Multicenter Prospective Study of Grafting With Collagen Fleece TachoSil in Patients With Peyronie's Disease.
Peptic Ulcer
A randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer.
Peptic Ulcer
Adding heat probe treatment to adrenaline injection for spurting haemorrhage of peptic ulcers. Injection of adrenaline and human thrombin is best option.
Peptic Ulcer
Discussion on a randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer.
Peptic Ulcer
Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin.
Peptic Ulcer
Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Peptic Ulcer
Injection therapy of bleeding peptic ulcer. A prospective, randomized trial using epinephrine and thrombin.
Peptic Ulcer
[Endoscopic hemostasis against hemorrhage from the upper gastrointestinal tract: its indication and limitation]
Peptic Ulcer
[Endoscopic hemostasis in hemorrhagic peptic ulcer. A review and pilot study of local thrombin injection combined with systemic fibrinolysis inhibition (with tranexamic acid)]
Peptic Ulcer Hemorrhage
Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin.
Pericarditis
Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population.
Periodontal Diseases
Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro.
Periodontal Diseases
Expression and activity of thrombomodulin in human gingival epithelium: in vivo and in vitro studies.
Periodontal Diseases
Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts.
Periodontitis
Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis.
Periodontitis
Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis.
Periodontitis
Activation of human prothrombin by arginine-specific cysteine proteinases (Gingipains R) from porphyromonas gingivalis.
Periodontitis
Expression and activity of thrombomodulin in human gingival epithelium: in vivo and in vitro studies.
Periodontitis
Thrombin and bradykinin enhance prostaglandin production in human peripheral blood monocytes.
Peripheral Arterial Disease
Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease.
Peripheral Arterial Disease
Altered coagulation profile in peripheral artery disease patients.
Peripheral Arterial Disease
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Peripheral Arterial Disease
Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?
Peripheral Arterial Disease
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.
Peripheral Arterial Disease
Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Case-Control Study.
Peripheral Arterial Disease
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
Peripheral Arterial Disease
Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease.
Peripheral Arterial Disease
Use of Bivalirudin as the Foundation Anticoagulant during Percutaneous Peripheral Interventions.
Peripheral Arterial Disease
Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Peripheral Arterial Disease
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Peripheral Arterial Disease
Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.
Peripheral Nerve Injuries
Neural thrombin and protease nexin I kinetics after murine peripheral nerve injury.
Peripheral Nervous System Diseases
A novel histochemical method for the visualization of thrombin activity in the nervous system.
Peripheral Nervous System Diseases
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
Peripheral Vascular Diseases
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Peripheral Vascular Diseases
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Peripheral Vascular Diseases
Exercise in claudicants is accompanied by excessive thrombin generation.
Peripheral Vascular Diseases
Hypercoagulability in patients with peripheral vascular disease.
Peritonitis
Effect of activated protein C on secretory activity of rat peritoneal mast cells.
Peritonitis
Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.
Peritonitis
[The role of PAR family receptors in activation of mast cells in the norm and in acute inflammation in rats]
Peroneal Neuropathies
Calf compartment syndrome and lumbar plexopathy following topical bovine thrombin-induced coagulopathy.
Pilonidal Sinus
Novel Approach of Treatment of Pilonidal Sinus Disease With Thrombin Gelatin Matrix as a Sealant.
Pilonidal Sinus
Treatment of pilonidal sinus disease with thrombin gelatin matrix - a video vignette.
Pituitary ACTH Hypersecretion
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.
Placental Insufficiency
Placental insufficiency is characterized by platelet activation in the fetus.
Plague
Structure-function analysis of Yersinia pestis YopM's interaction with alpha-thrombin to rule on its significance in systemic plague and to model YopM's mechanism of binding host proteins.
plasmin deficiency
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
plasmin deficiency
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
plasmin deficiency
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.
Platelet Storage Pool Deficiency
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
Platelet Storage Pool Deficiency
Thrombin and ionophore A23187-induced dense granule secretion in storage pool deficient platelets: evidence for impaired nucleotide storage as the primary dense granule defect.
Pleural Effusion
Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion.
Pleural Effusion
Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis.
Pleurisy
Release of endothelins and platelet-activating factor by a rat pleural mesothelial cell line.
Pleurisy
[Action of thrombin on the serofibrinous pleurisies of substitution of therapeutic pneumothorax.]
Pneumonia
Asef controls vascular endothelial permeability and barrier recovery in the lung.
Pneumonia
Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.
Pneumonia
Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice.
Pneumonia
Enhanced thrombin generation and depressed anticoagulant function in children with pneumonia.
Pneumonia
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19.
Pneumonia
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.
Pneumonia
Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.
Pneumonia
Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling.
Pneumonia
Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells.
Pneumonia
p300 and C/EBP?-regulated IKK? expression are involved in thrombin-induced IL-8/CXCL8 expression in human lung epithelial cells.
Pneumonia
Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection.
Pneumonia
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
Pneumonia
SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity.
Pneumonia
Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury.
Pneumonia
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Pneumonia
Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis.
Pneumonia
Thrombin-induced CCAAT/enhancer-binding protein ? activation and IL-8/CXCL8 expression via MEKK1, ERK, and p90 ribosomal S6 kinase 1 in lung epithelial cells.
Pneumonia
Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-?B pathways in human lung epithelial cells.
Pneumonia
Thrombin-induced NF-?B activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells.
Pneumonia
[Coagulopathy correlates with outcomes in patients with community- acquired pneumonia].
Pneumonia
[Peculiarities of thrombin generation and prognosis of unfavourable outcome in patients with severe pneumonia and pneumogenic sepsis].
Pneumonia
[The DNA binding activity of nuclear factor-?B in patients with severe pneumonia and the intervention effects of Xuebijing injection.]
Pneumonia
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Pneumonia, Bacterial
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
Pneumoperitoneum
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Pneumothorax
Chemical pleurodesis with autologous blood and freeze-dried concentrated human thrombin improved spontaneous pneumothorax and thoracic endometriosis: The first case involving a pregnant woman.
Pneumothorax
Comparative studies using a rigid thoracoscope and fiberoptic bronchoscope to treat spontaneous pneumothorax.
Pneumothorax
Intrabronchial Infusion of Autologous Blood Plus Thrombin for Intractable Pneumothorax After Bronchial Occlusion Using Silicon Spigots: A Case Series of 9 Patients With Emphysema.
Pneumothorax
[Action of thrombin on the serofibrinous pleurisies of substitution of therapeutic pneumothorax.]
Pneumothorax
[Chemical pleurodesis induced with fibrin glue in the treatment of inoperable spontaneous pneumothorax]
Pneumothorax
[Efficacy and safety of position selection combined with intra-pleural thrombin injection in the treatment of postoperative persistent air leakage in bullous pulmonary-pleural diseases].
Pneumothorax
[Intramuscular injections of thrombase can absorb the sero-fibrinous effusions of therapeutic pneumothorax.]
Polyarteritis Nodosa
WIDELY DISTRIBUTED NECROTIZING ARTERITIS INDUCED IN RABBITS BY EXPERIMENTAL RENAL ALTERATIONS. IV. DEMONSTRATION OF DECREASED AMOUNT OF THROMBIN CLOTTABLE PLASMA PROTEIN DURING DEVELOPMENT OF THE ARTERIAL LESIONS.
Polycystic Ovary Syndrome
Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation.
Polycystic Ovary Syndrome
Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
Polycystic Ovary Syndrome
Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
Polycythemia Vera
ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Polycythemia Vera
Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment.
Polycythemia Vera
Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Polycythemia Vera
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Polyneuropathies
An electrochemical aptasensor based on TiO2/MWCNT and a novel synthesized Schiff base nanocomposite for the ultrasensitive detection of thrombin.
Polyneuropathies
Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic.
Postpartum Hemorrhage
Hematome peridural chez une parturiente au decours d'un choc hemorragique: [Epidural hematoma after hemorrhagic shock in a parturient].
Postpartum Hemorrhage
Pelvic arterial pseudoaneurysm-a rare complication of Cesarean section: diagnosis and novel treatment.
Pre-Eclampsia
A prospective study investigating the mechanism of thrombocytopenia in preeclampsia.
Pre-Eclampsia
A suggestion about the cause of inflammation in acute atherosis complicating poor placentation in preeclampsia.
Pre-Eclampsia
Activation of PAR-1/NADPH oxidase/ROS signaling pathways is crucial for the thrombin-induced sFlt-1 production in extravillous trophoblasts: possible involvement in the pathogenesis of preeclampsia.
Pre-Eclampsia
Alterations of profibrinolytic receptor annexin A2 in pre-eclampsia: A possible role in placental thrombin formation.
Pre-Eclampsia
Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth.
Pre-Eclampsia
Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins.
Pre-Eclampsia
Blood coagulation profile in Indian patients with pre-eclampsia and eclampsia.
Pre-Eclampsia
Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia.
Pre-Eclampsia
Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis.
Pre-Eclampsia
Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women.
Pre-Eclampsia
Effects of serum from preeclamptic women on prostacyclin production by human endothelial cells.
Pre-Eclampsia
Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro.
Pre-Eclampsia
Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia.
Pre-Eclampsia
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Pre-Eclampsia
Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia.
Pre-Eclampsia
Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia.
Pre-Eclampsia
Factor VIII-related antigen and factor VIII coagulant activity in normal and pre-eclamptic pregnancy.
Pre-Eclampsia
Identification of unexplored substrates of the serine protease, thrombin, using N-terminomics strategy.
Pre-Eclampsia
Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia.
Pre-Eclampsia
Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia.
Pre-Eclampsia
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation.
Pre-Eclampsia
Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension.
Pre-Eclampsia
Possibility of Coagulation System Activation Determination with Tissue Factor in Pregnancy Complications.
Pre-Eclampsia
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Pre-Eclampsia
The pattern and magnitude of "in vivo thrombin generation" differ in women with preeclampsia and in those with SGA fetuses without preeclampsia.
Pre-Eclampsia
The procoagulant activity of red blood cells from patients with severe preeclampsia.
Pre-Eclampsia
Thrombin enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts; possible involvement in the pathogenesis of preeclampsia.
Pre-Eclampsia
Thrombin impairs the angiogenic activity of extravillous trophoblast cells via monocyte chemotactic protein-1 (MCP-1): A possible link with preeclampsia.
Pre-Eclampsia
Thrombin regulates monocyte chemoattractant protein-1 expression in human first trimester and term decidual cells.
Pre-Eclampsia
Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.
Pre-Eclampsia
Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thrombin generation in children with febrile neutropenia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: an impact of peripheral blasts.
Pregnancy Complications
Possibility of Coagulation System Activation Determination with Tissue Factor in Pregnancy Complications.
Premature Birth
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: Evidence of an increased thrombin generation.
Premature Birth
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation.
Premature Birth
Early second trimester maternal plasma levels of thrombin-inhibitor complexes and subsequent spontaneous preterm delivery.
Premature Birth
Effect of Thrombin on Human Amnion Mesenchymal Cells, Mouse Fetal Membranes, and Preterm Birth.
Premature Birth
Nrf2 Activation Inhibits Effects of Thrombin in Human Amnion Cells and Thrombin-induced Preterm Birth in Mice.
Premature Birth
Phospholipid Scramblase Expression in the Pregnant Mouse Uterus in LPS-Induced Preterm Delivery.
Premature Birth
Prospective investigation of second-trimester thrombin activation and preterm birth.
Premature Birth
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Priapism
Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection.
Prion Diseases
Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin.
Prolactinoma
Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.
Prostatic Hyperplasia
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Prostatic Hyperplasia
Transurethral resection versus holmium laser enucleation of the prostate: A prospective randomized trial comparing perioperative thrombin generation and fibrinolysis.
Prostatic Hyperplasia
[Effect of thrombin on hematuria after operation for benign prostatic hyperplasia]
Prostatic Neoplasms
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines.
Prostatic Neoplasms
A SERS-LFA biosensor combined with aptamer recognition for simultaneous detection of thrombin and PDGF-BB in prostate cancer plasma.
Prostatic Neoplasms
Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B.
Prostatic Neoplasms
Correlates of thrombin generation in patients with advanced prostate cancer.
Prostatic Neoplasms
Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells.
Prostatic Neoplasms
Effect of thrombin tube on PSA determination, a clue for false negative in screening for prostate cancer.
Prostatic Neoplasms
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Prostatic Neoplasms
Expression of functional protease-activated receptor 1 in human prostate cancer cell lines.
Prostatic Neoplasms
Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability.
Prostatic Neoplasms
PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.
Prostatic Neoplasms
PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
Prostatic Neoplasms
Rational design and applications of a Rac GTPase-specific small molecule inhibitor.
Prostatic Neoplasms
The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies.
Prostatic Neoplasms
Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells.
Prostatic Neoplasms
Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222.
Prostatic Neoplasms
Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells.
Protein C Deficiency
Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association?
Protein C Deficiency
Increased thrombin generation in a child with a combined factor IX and protein C deficiency.
Protein C Deficiency
Protein C deficiency screening using a thrombin generation assay - an upgrade.
Protein C Deficiency
Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.
Protein C Deficiency
The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation.
Protein S Deficiency
A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma.
Protein S Deficiency
Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus.
Protein S Deficiency
Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels.
Protein S Deficiency
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Protein S Deficiency
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Protein S Deficiency
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Protein S Deficiency
Sequential multiple retinal vein occlusions and transient ischemic attack in MTHFR polymorphism and protein S deficiency.
Protein S Deficiency
Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.
Protein S Deficiency
Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency.
Protein-Energy Malnutrition
[Prolonged thrombin time observed in protein-energy malnutrition]
protein-glutamine gamma-glutamyltransferase deficiency
Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
protein-glutamine gamma-glutamyltransferase deficiency
Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Proteinuria
Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs.
Proteinuria
Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.
Proteinuria
Favorable Maternal and Fetal Effects of Danshensu in an Experimental Mice Model of Preeclampsia.
Proteinuria
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Proteinuria
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Proteinuria
Mechanisms of the development of acquired antithrombin III deficiency in the experimental nephrotic syndromes.
Proteinuria
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.
Proteinuria
The assesment of prothrombotic potential using thrombin generation assay in pediatric patients with nephrotic syndrome: preliminary study.
Proteinuria
Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes.
Proteinuria
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Psoriasis
[Relationship between syndrome pattern of psoriasis and platelet thrombin sensitive protein and CD36 molecular expression]
Pulmonary Arterial Hypertension
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
Pulmonary Arterial Hypertension
The dynamics of thrombin formation in patients with pulmonary arterial hypertension.
Pulmonary Atresia
[Acquired thrombin inhibitor in a 9-year-old child after total correction of univentricular heart with pulmonary atresia and administration of fibrin glue]
Pulmonary Disease, Chronic Obstructive
Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation.
Pulmonary Disease, Chronic Obstructive
Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation.
Pulmonary Disease, Chronic Obstructive
Air-leak management after upper lobectomy in patients with fused fissure and chronic obstructive pulmonary disease: a pilot trial comparing sealant and standard treatment.
Pulmonary Disease, Chronic Obstructive
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Pulmonary Disease, Chronic Obstructive
Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.
Pulmonary Disease, Chronic Obstructive
In vivo thrombin generation and platelet hyperactivity in patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Increased Platelet-Monocyte Interaction in Stable COPD in the Absence of Platelet Hyper-Reactivity.
Pulmonary Disease, Chronic Obstructive
Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells.
Pulmonary Disease, Chronic Obstructive
Thrombin generation in chronic obstructive pulmonary disease: Dependence on plasma factor composition.
Pulmonary Disease, Chronic Obstructive
Ultrasensitive electrochemical aptasensor for the detection of thrombin based on dual signal amplification strategy of Au@GS and DNA-CoPd NPs conjugates.
Pulmonary Edema
Beneficial effects of a leukotriene receptor antagonist on thrombin-induced pulmonary edema in the rat.
Pulmonary Edema
Blockade of histamine receptors and thrombin-induced microembolic pulmonary edema in the rat.
Pulmonary Edema
Capsaicin-sensitive nerves exert an inhibitory effect on the development of fibrin-induced pulmonary edema in rats.
Pulmonary Edema
Effects of vasodilators on fibrin-induced pulmonary edema, so-called neurogenic pulmonary edema, in the rat.
Pulmonary Edema
Ezrin/radixin/moesin proteins differentially regulate endothelial hyperpermeability after thrombin.
Pulmonary Edema
Opposing effects of isoflurane and sevoflurane on neurogenic pulmonary edema development in an animal model.
Pulmonary Edema
Presence and quantification of neuropeptide Y in pulmonary edema fluids in rats.
Pulmonary Edema
Role of central nervous system nitric oxide in the development of neurogenic pulmonary edema in rats.
Pulmonary Edema
Role of hemodynamics and vagus nerves in development of fibrin-induced pulmonary edema.
Pulmonary Embolism
14-3-3? regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function.
Pulmonary Embolism
Anticoagulant Decapeptide Interacts with Thrombin at the Active Site and Exosite-I.
Pulmonary Embolism
Anticoagulant Dodecapeptide Suppresses Thrombosis In Vivo by Inhibiting the Thrombin Exosite-I Binding Site.
Pulmonary Embolism
Bothrojaracin, a Bothrops jararaca snake venom-derived (pro)thrombin inhibitor, as an anti-thrombotic molecule.
Pulmonary Embolism
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies.
Pulmonary Embolism
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
Pulmonary Embolism
Development and Characterization of an Inducible Rat Model of Chronic Thromboembolic Pulmonary Hypertension.
Pulmonary Embolism
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Pulmonary Embolism
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Pulmonary Embolism
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.
Pulmonary Embolism
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
Pulmonary Embolism
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Pulmonary Embolism
Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Pulmonary Embolism
Molecular Imaging of Activated Platelets Allows the Detection of Pulmonary Embolism with Magnetic Resonance Imaging.
Pulmonary Embolism
Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography.
Pulmonary Embolism
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Pulmonary Embolism
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Pulmonary Embolism
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Pulmonary Embolism
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Pulmonary Embolism
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Pulmonary Embolism
Platelet hyperactivation, apoptosis and hypercoagulability in patients with acute pulmonary embolism.
Pulmonary Embolism
Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice.
Pulmonary Embolism
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
Pulmonary Embolism
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Pulmonary Embolism
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Pulmonary Embolism
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Pulmonary Embolism
Study of factors that may condition scintigraphic detection of venous thrombi and pulmonary emboli with indium-111-labeled platelets.
Pulmonary Embolism
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Pulmonary Embolism
The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
Pulmonary Embolism
The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism.
Pulmonary Embolism
Treatment of accidental perianal injection of topical thrombin with intravenous antithrombin.
Pulmonary Embolism
Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice.
Pulmonary Embolism
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Pulmonary Embolism
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
Pulmonary Embolism
[Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma]
Pulmonary Embolism
[Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin]
Pulmonary Embolism
[Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia].
Pulmonary Fibrosis
ADAM17/EGFR-dependent ERK activation mediates thrombin-induced CTGF expression in human lung fibroblasts.
Pulmonary Fibrosis
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Pulmonary Fibrosis
Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Pulmonary Fibrosis
Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis.
Pulmonary Fibrosis
Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.
Pulmonary Fibrosis
Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis.
Pulmonary Fibrosis
Roles of high-mobility group box 1 and thrombin in murine pulmonary fibrosis and the therapeutic potential of thrombomodulin.
Pulmonary Fibrosis
Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.
Pulmonary Fibrosis
Therapeutic effects of the rhSOD2-Hirudin fusion protein on bleomycin-induced pulmonary fibrosis in mice.
Pulmonary Fibrosis
Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant.
Pulmonary Fibrosis
Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
Thrombin Induces CCL2 Expression in Human Lung Fibroblasts via p300 Mediated Histone Acetylation and NF-KappaB Activation.
Pulmonary Fibrosis
Thrombin induces epithelial-mesenchymal transition via PAR-1, PKC, and ERK1/2 pathways in A549 cells.
Pulmonary Fibrosis
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).
Pulmonary Fibrosis
Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-?B and activator protein-1.
Pulmonary Fibrosis
Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis.
Pulmonary Fibrosis
Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
Pulmonary Fibrosis
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
Pulmonary Fibrosis
[The role of thrombin on lung fibroblast growth and fibrosis in bleomycin-induced lung disorder]
Purpura, Thrombocytopenic, Idiopathic
Anaesthetic management of a patient with thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Arterial thrombosis associated with immune thrombocytopenia: presence of a platelet aggregating IgG synergistic with thrombin and adrenalin.
Purpura, Thrombocytopenic, Idiopathic
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
Purpura, Thrombocytopenic, Idiopathic
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
Purpura, Thrombotic Thrombocytopenic
Identification and treatment of arterial thrombophilia.
Purpura, Thrombotic Thrombocytopenic
Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Thrombin generation in thrombotic thrombocytopenic purpura.
Quadriplegia
Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study.
Radiation Pneumonitis
Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis.
Radiculopathy
The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury.
Renal Insufficiency
A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure.
Renal Insufficiency
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Renal Insufficiency
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
Renal Insufficiency
Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin.
Renal Insufficiency
Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
Renal Insufficiency
Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
Renal Insufficiency
Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure.
Renal Insufficiency
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
Renal Insufficiency
Protective effect of angiotensin II inhibition on acute renal failure after intravascular coagulation in the rat.
Renal Insufficiency
Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy.
Renal Insufficiency
[Markers of thrombin generation in kidney failure of children with epidemic hemolytic uremic syndrome]
Renal Insufficiency
[Novel oral anticoagulants and their use in the perioperative setting].
Renal Insufficiency, Chronic
Evaluation of a heparin assay method using a fluorogenic synthetic peptide substrate for thrombin.
Renal Insufficiency, Chronic
Evaluation of hemostasis in patients with end-stage renal disease.
Renal Insufficiency, Chronic
Systemic anticoagulation considerations in chronic kidney disease.
Reperfusion Injury
Antithrombin III prevents deleterious effects of remote ischemia-reperfusion injury on healing of colonic anastomoses.
Reperfusion Injury
Crosstalk between thrombosis and inflammation in lung reperfusion injury.
Reperfusion Injury
Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine.
Reperfusion Injury
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Reperfusion Injury
Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia-reperfusion in rats.
Reperfusion Injury
Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass.
Reperfusion Injury
Local and systemic coagulation marker response to musculocutaneous flap ischemia-reperfusion injury and remote ischemic conditioning: An experimental study in a porcine model.
Reperfusion Injury
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Reperfusion Injury
Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury.
Reperfusion Injury
Quantification of vascular damage in acute kidney injury with fluorine magnetic resonance imaging and spectroscopy.
Reperfusion Injury
Recovery of endothelium-dependent relaxations four weeks after ischemia and progressive reperfusion in canine coronary arteries.
Reperfusion Injury
Sodium/hydrogen exchange inhibition with cariporide reduces leukocyte adhesion via P-selectin suppression during inflammation.
Reperfusion Injury
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
Reperfusion Injury
The Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in Hypercholesterolemic Pigs.
Reperfusion Injury
Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury.
Reperfusion Injury
Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage.
Reperfusion Injury
Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury.
Reperfusion Injury
[Specific inhibition of thrombin activity during cardiopulmonary bypass reduces ischemia-reperfusion injury of the lung]
Respiratory Distress Syndrome
Adult respiratory distress syndrome (ARDS): experimental models with elastase and thrombin infusion in pigs.
Respiratory Distress Syndrome
Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters.
Respiratory Distress Syndrome
Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.
Respiratory Distress Syndrome
Critical role of non-muscle myosin light chain kinase in thrombin-induced endothelial cell inflammation and lung PMN infiltration.
Respiratory Distress Syndrome
Fibrinolytic activity, thrombin inhibitor and kinetics of clot formation in premature infants with respiratory distress syndrome.
Respiratory Distress Syndrome
Fresh frozen plasma/red blood cell resuscitation regimen that restores procoagulants without causing adult respiratory distress syndrome.
Respiratory Distress Syndrome
Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.
Respiratory Distress Syndrome
Protease-activated receptor 1 as a potential therapeutic target for COVID-19.
Respiratory Distress Syndrome
Regulation of endothelial cell inflammation and lung polymorphonuclear lymphocyte infiltration by transglutaminase 2.
Respiratory Distress Syndrome, Newborn
A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome.
Respiratory Distress Syndrome, Newborn
Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome.
Respiratory Insufficiency
Effect of reptilase on respiratory insufficiency induced by intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog.
Respiratory Insufficiency
Experimental studies on the adult respiratory distress syndrome: effects of induced DIC; granulocytes and elastase in mini pigs.
Respiratory Insufficiency
Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.
Retinal Detachment
Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment.
Retinal Detachment
[Thrombin-antithrombin III complexes in plasma and subretinal fluid in patients with perforated retinal detachment]
Retinal Diseases
Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation.
Retinal Diseases
Thrombin regulates chemokine induction during human retinal pigment epithelial cell/monocyte interaction.
Retinal Hemorrhage
[Experimental retinal vein obstruction induced by transadventitial administration of thrombin in the rabbit]
Retinal Perforations
Broad internal limiting membrane peeling with adjunctive plasma-thrombin for repair of large macular holes: A retrospective case series.
Retinal Perforations
High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment.
Retinal Perforations
Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery.
Retinal Vein Occlusion
In retinal vein occlusion platelet response to thrombin is increased.
Retinal Vein Occlusion
Intravitreal thrombin activity is elevated in retinal vein occlusion.
Retinopathy of Prematurity
Thrombin infusion to control bleeding during vitrectomy for stage V retinopathy of prematurity.
Rhabdomyolysis
New considerations on pathways involved in acute traumatic coagulopathy: the thrombin generation paradox.
Rhabdomyosarcoma
Stimulation of cell surface plasminogen activation by heparin and related polyionic substances.
Rhabdomyosarcoma
Thrombin Regulates the Metastatic Potential of Human Rhabdomyosarcoma Cells: Distinct Role of PAR1 and PAR3 Signaling.
Rheumatic Diseases
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Rhinitis, Allergic
Role of the coagulation system in allergic inflammation in the upper airways.
Rhinitis, Allergic, Seasonal
Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma.
Sagittal Sinus Thrombosis
A rabbit model of cerebral venous sinus thrombosis established by ferric chloride and thrombin injection.
Sarcoma
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Sarcoma
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Sarcoma
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Sarcoma
[Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells]
Sarcoma, Avian
Binding and internalization of thrombin by normal and transformed chick cells.
Sarcoma, Avian
Plasminogen-independent fibrinolysis by proteases produced by transformed chick embryo fibroblasts.
Schistosomiasis
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Scleroderma, Systemic
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Scleroderma, Systemic
Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers.
Scleroderma, Systemic
Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through endothelin-1 receptor A up-regulation.
Scoliosis
Bleeding and coagulation changes during spinal fusion surgery: a comparison of neuromuscular and idiopathic scoliosis patients.
Scoliosis
Gelatine matrix with human thrombin decreases blood loss in adolescents undergoing posterior spinal fusion for idiopathic scoliosis: a multicentre, randomised clinical trial.
Seizures
Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs.
Seizures
Minimal Traumatic Brain Injury in Mice: Protease-Activated Receptor 1 and Thrombin-Related Changes.
Seizures
Platelet-derived growth factor B-chain homodimer suppressing a convulsion of epilepsy model mouse El.
Seizures
Prolonged Localized Mild Hypothermia Does Not Affect Seizure Activity After Intracerebral Hemorrhage in Rats.
Seizures
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Seizures
Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus.
Seizures
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
Seizures
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Seizures
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Seizures
Thrombin and the Protease-Activated Receptor-1 in Organophosphate-Induced Status Epilepticus.
Seizures
Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults.
Seizures
[Blood fibrinogenase in insulin shock, in electroshock, and in epileptic seizure.]
Seizures, Febrile
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
Sepsis
A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis.
Sepsis
A Double-Chambered Protein Nanocage Loaded with Thrombin Receptor Agonist Peptide (TRAP) and ?-Carboxyglutamic Acid of Protein C (PC-Gla) for Sepsis Treatment.
Sepsis
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Sepsis
Activated protein C inhibits high mobility group box 1 signaling in endothelial cells.
Sepsis
Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin.
Sepsis
Activation of endothelial cell protease activated receptor 1 by the protein C pathway.
Sepsis
Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.
Sepsis
Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Sepsis
Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.
Sepsis
Antimicrobial and Anticoagulant Activity of N-chlorotaurine (NCT), N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-monochloro-2,2-dimethyltaurine (NVC-612) in Human Blood.
Sepsis
Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells.
Sepsis
Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.
Sepsis
Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters.
Sepsis
Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase.
Sepsis
Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumoniae sepsis.
Sepsis
Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure.
Sepsis
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
Sepsis
Critical role of autophagy regulator Beclin1 in endothelial cell inflammation and barrier disruption.
Sepsis
Current clinical practice. DIC 2002: a review of disseminated intravascular coagulation.
Sepsis
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis.
Sepsis
Dielectric Blood Coagulometry for the Early Detection of Sepsis-Induced Disseminated Intravascular Coagulation: A Prospective Observational Study.
Sepsis
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Sepsis
Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
Sepsis
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
Sepsis
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
Sepsis
Endogenous thrombin potential as marker of procoagulant response that can be useful in early stage of sepsis.
Sepsis
Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients.
Sepsis
Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-?B and AP-1.
Sepsis
Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls.
Sepsis
Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Sepsis
Heparin-induced thrombocytopenia in the cardiac patient: 10 points to help the physician.
Sepsis
Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis.
Sepsis
Impairment of thrombin generation in the early phases of the host response of sepsis.
Sepsis
Lipopolysaccharide-Induced Hemolysis Is Abolished by Inhibition of Thrombin Generation but Not Inhibition of Platelet Aggregation.
Sepsis
Macrophage Migration Inhibitory Factor-Induced Autophagy Contributes to Thrombin-Triggered Endothelial Hyperpermeability in Sepsis.
Sepsis
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Sepsis
Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.
Sepsis
Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms.
Sepsis
Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome.
Sepsis
Platelet-derived microparticles regulates thrombin generation via phophatidylserine in abdominal sepsis.
Sepsis
Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice.
Sepsis
Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood.
Sepsis
Rac1 regulates sepsis-induced formation of platelet-derived microparticles and thrombin generation.
Sepsis
Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-alpha.
Sepsis
Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.
Sepsis
Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
Sepsis
Regulation of endothelial cell inflammation and lung polymorphonuclear lymphocyte infiltration by transglutaminase 2.
Sepsis
Regulation of RelA/p65 and Endothelial Cell Inflammation by Proline-Rich Tyrosine Kinase 2.
Sepsis
Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
Sepsis
Review of cellular and molecular pathways linking thrombosis and innate immune system during sepsis.
Sepsis
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Sepsis
Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets.
Sepsis
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Sepsis
Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation.
Sepsis
Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.
Sepsis
Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability.
Sepsis
The Dynamics of Angiogenic Factors and Their Soluble Receptors in Relation to Organ Dysfunction in Disseminated Intravascular Coagulation Associated with Sepsis.
Sepsis
The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome.
Sepsis
Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun.
Sepsis
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Sepsis
Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms.
Sepsis
Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin.
Sepsis
Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation.
Sepsis
Thrombin-cleaved syndecan-3/-4 ectodomain fragments mediate endothelial barrier dysfunction.
Sepsis
Tissue Factor Pathway Inhibitor and P-Selectin as Markers of Sepsis-Induced Non-overt Disseminated Intravascular Coagulopathy.
Sepsis
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.
Sepsis
[Approbation of a new test system determining the activity of a plasmin inhibitor in patients with sepsis]
Sepsis
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
Sepsis
[Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults]
Sepsis
[Predictive value of complement and coagulation indicators in sepsis related acute kidney injury].
Sepsis
[Use of thrombin generation assay for the evaluation of coagulation and anticoagulant activity of hemostasis system in patients with abdominal sepsis].
Shock, Septic
A purified antithrombin III--heparin complex as a potent inhibitor of thrombin in porcine endotoxin shock.
Shock, Septic
Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.
Shock, Septic
Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells.
Shock, Septic
Characterization of circulating thrombin in patients with septic shock: a prospective observational study.
Shock, Septic
Coagulation phenotypes in septic shock as evaluated by calibrated automated thrombography.
Shock, Septic
Effects of dexamethasone on endotoxin shock in the anesthetized pony: hematologic, blood gas, and coagulation changes.
Shock, Septic
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
Shock, Septic
Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs.
Shock, Septic
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.
Shock, Septic
Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Shock, Septic
Influence of antithrombin III on coagulation and inflammation in porcine septic shock.
Shock, Septic
Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
Shock, Septic
Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation.
Shock, Septic
Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction.
Shock, Septic
Porins from Salmonella typhimurium accelerate human blood coagulation in vitro by selective stimulation of thrombin activity: implications in septic shock DIC pathogenesis.
Shock, Septic
Recombinant antitrypsin Pittsburgh undergoes proteolytic cleavage during E. coli sepsis and fails to prevent the associated coagulopathy in a primate model.
Shock, Septic
The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution.
Shock, Septic
The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic shock.
Shock, Septic
Thrombin does not alter vascular hyporeactivity in models of endotoxin-induced septic shock in rats.
Shock, Septic
Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study.
Shock, Septic
Ulinastatin as an Adjuvant Therapy to Restricting Volumes of Resuscitation Fluid Strategy for Patients with Septic Shock after Initial Management.
Shoulder Dislocation
A Rare Case of Axillary Artery Pseudoaneurysm Due to Shoulder Dislocation Treated With Percutaneous Thrombin Injection.
Shwartzman Phenomenon
PRODUCTION OF THE GENERALIZED SHWARTZMAN REACTION IN PREGNANT RATS BY INTRAVENOUS INFUSION OF THROMBIN.
Shwartzman Phenomenon
Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits.
Shwartzman Phenomenon
The effects of infusion of thrombin or endotoxin in rabbits treated with cortisone.
Shwartzman Phenomenon
Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Sinus Thrombosis, Intracranial
A rabbit model of cerebral venous sinus thrombosis established by ferric chloride and thrombin injection.
Sinus Thrombosis, Intracranial
Photothrombosis combined with thrombin injection establishes a rat model of cerebral venous sinus thrombosis.
Sinus Thrombosis, Intracranial
Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis.
Skin Diseases
Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1.
Skin Ulcer
Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban.
Skin Ulcer
Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series.
Sleep Apnea Syndromes
Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing.
Sleep Apnea, Central
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Sleep Apnea, Obstructive
Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing.
Sleep Apnea, Obstructive
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Sleep Deprivation
Chronic sleep deprivation markedly reduces coagulation factor VII expression.
Spasm
Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina.
Spasm
Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm.
Spasm
Pleocytosis and elevation of prostaglandins F2a and E2 in cerebrospinal fluid following intracisternal injection of thrombin.
Spinal Cord Injuries
Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats.
Spinal Cord Injuries
Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.
Spinal Cord Injuries
Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.
Spinal Cord Injuries
Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling.
Spinal Cord Injuries
Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury.
Spinal Cord Injuries
The thrombin receptor links brain derived neurotrophic factor to neuron cholesterol production, resiliency and repair after spinal cord injury.
Spinal Cord Injuries
The thrombin receptor modulates astroglia-neuron trophic coupling and neural repair after spinal cord injury.
Spinal Cord Injuries
Thrombin enhances NGF-mediated neurite extension via increased and sustained activation of p44/42 MAPK and p38 MAPK.
ST Elevation Myocardial Infarction
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
ST Elevation Myocardial Infarction
Anticoagulation during and after acute coronary syndrome.
ST Elevation Myocardial Infarction
Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction.
ST Elevation Myocardial Infarction
Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.
ST Elevation Myocardial Infarction
Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
ST Elevation Myocardial Infarction
Emergency Percutaneous Coronary Interven-tion (PCI) for the care of patients with ST-Elevation Myocardial Infarction (STEMI).
ST Elevation Myocardial Infarction
Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
ST Elevation Myocardial Infarction
Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction.
ST Elevation Myocardial Infarction
New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications.
ST Elevation Myocardial Infarction
Plaque herniation after stenting the culprit lesion with myocardial bridging in ST elevation myocardial infarction: A case report.
ST Elevation Myocardial Infarction
Platelet dysfunction after Out of Hospital Cardiac Arrest. Results from POHCAR: A prospective observational, cohort study.
ST Elevation Myocardial Infarction
Platelet Reactivity and Intramyocardial Hemorrhage in Patients With ST-Segment Elevation Myocardial Infarction.
ST Elevation Myocardial Infarction
Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory.
ST Elevation Myocardial Infarction
Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
ST Elevation Myocardial Infarction
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
ST Elevation Myocardial Infarction
Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients.
ST Elevation Myocardial Infarction
[Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.]
Starvation
EGF and insulin action in fibroblasts. Evidence that phosphoinositide hydrolysis is not an essential mitogenic signalling pathway.
Status Epilepticus
Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.
Status Epilepticus
Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus.
Status Epilepticus
Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus.
Status Epilepticus
Thrombin and the Protease-Activated Receptor-1 in Organophosphate-Induced Status Epilepticus.
Status Epilepticus
Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury.
Stomach Neoplasms
Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis.
Stomach Neoplasms
Thrombin conducts epithelial?mesenchymal transition via protease?activated receptor?1 in human gastric cancer.
Stomach Ulcer
A prospective, randomized trial of thrombin versus cyanoacrylate injection in the control of acute gastric variceal hemorrhage.
Stomach Ulcer
Control of upper gastrointestinal hemorrhage by endoscopic spraying of clotting factors.
Stomach Ulcer
Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Stomach Ulcer
Hemostatic effects of powdered gelfoam thrombin solution and blood transfusions in an instance of recurring massive hemorrhage from a large chronic gastric ulcer: report of a case.
Stomach Ulcer
Thrombin receptor agonist Peptide immobilized in microspheres stimulates reparative processes in rats with gastric ulcer.
Streptococcal Infections
Reduced thrombin generation increases host susceptibility to group A streptococcal infection.
Stroke
?T -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Stroke
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Stroke
A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke.
Stroke
A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke.
Stroke
A murine photothrombotic stroke model with an increased fibrin content and improved responses to tPA-lytic treatment.
Stroke
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
Stroke
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Stroke
A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
Stroke
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Stroke
Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.
Stroke
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Stroke
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
Stroke
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
Stroke
An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.
Stroke
Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.
Stroke
Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
Stroke
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Stroke
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Stroke
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
Stroke
Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both transient and permanent focal ischemia.
Stroke
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Stroke
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Stroke
Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda.
Stroke
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Stroke
Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study.
Stroke
Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction.
Stroke
Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates.
Stroke
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Stroke
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Stroke
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Stroke
Benefit-Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation.
Stroke
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Stroke
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
Stroke
Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms.
Stroke
Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy.
Stroke
Changing the guard in long-term anticoagulation: clinical and economic implications.
Stroke
Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series.
Stroke
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Stroke
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Stroke
Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different.
Stroke
Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study.
Stroke
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease.
Stroke
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Stroke
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Stroke
Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
Stroke
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Stroke
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
Stroke
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.
Stroke
Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential.
Stroke
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Stroke
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation.
Stroke
Ctnnb1 transcriptional upregulation compensates for Mdm2/p53-mediated ?-catenin degradation in neutrophils following cardioembolic stroke.
Stroke
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Stroke
Cutting through the statistical fog: understanding and evaluating non-inferiority trials.
Stroke
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Stroke
Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation.
Stroke
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Stroke
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Stroke
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Stroke
Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
Stroke
Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
Stroke
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.
Stroke
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Stroke
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Stroke
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Stroke
Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source?- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
Stroke
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience.
Stroke
Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice.
Stroke
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Stroke
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Stroke
Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients.
Stroke
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Stroke
Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities.
Stroke
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Stroke
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Stroke
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Stroke
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Stroke
Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Stroke
Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation.
Stroke
Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
Stroke
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Stroke
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Stroke
DYSREGULATION OF Ca(2+) MOVEMENT IN PLATELETS FROM PATIENTS WITH ACUTE ISCHAEMIC STROKE.
Stroke
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Stroke
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
Stroke
Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.
Stroke
Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation.
Stroke
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Stroke
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
Stroke
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Stroke
Efficacy And Safety of Dabigatran Etexilate Utilization With Concomitant Dual Antiplatelet Therapy In Atrial Fibrillation.
Stroke
Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis.
Stroke
Elderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering.
Stroke
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
Stroke
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Stroke
Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke.
Stroke
Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.
Stroke
Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome.
Stroke
Functional Occurrence of the Interaction of Tissue Plasminogen Activator With the NR1 Subunit of N-Methyl-D-Aspartate Receptors During Stroke.
Stroke
G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
Stroke
Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection.
Stroke
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Stroke
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Stroke
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Stroke
Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation.
Stroke
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Stroke
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Stroke
Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane.
Stroke
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
Stroke
In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke.
Stroke
Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment.
Stroke
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Stroke
Increased thrombin generation potential in symptomatic versus asymptomatic moderate or severe carotid stenosis and relationship with cerebral microemboli.
Stroke
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Stroke
Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow.
Stroke
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Stroke
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic.
Stroke
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
Stroke
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect.
Stroke
Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report.
Stroke
Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study.
Stroke
Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
Stroke
Mechanisms of modulation of brain microvascular endothelial cells function by thrombin.
Stroke
Membrane lipid peroxidation in neurodegeneration: Role of thrombin and proteinase-activated receptor-1.
Stroke
Mild hypothermia enhances the neuroprotective effects of a selective thrombin inhibitor following transient focal ischemia in rats.
Stroke
Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis.
Stroke
Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage.
Stroke
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Stroke
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Stroke
No Association between Thrombin Generation and Intra-Plaque Haemorrhage in Symptomatic Carotid Atherosclerotic Plaques: The Plaque at RISK (PARISK) Study.
Stroke
Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Stroke
Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease.
Stroke
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
Stroke
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Stroke
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Stroke
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Stroke
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Stroke
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Stroke
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Stroke
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Stroke
Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Stroke
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Stroke
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Stroke
Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations.
Stroke
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Stroke
Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan.
Stroke
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Stroke
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Stroke
Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events.
Stroke
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Stroke
Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk.
Stroke
Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).
Stroke
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Stroke
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
Stroke
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Stroke
Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke.
Stroke
Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models.
Stroke
Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1.
Stroke
Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).
Stroke
Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels.
Stroke
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Stroke
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Stroke
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Stroke
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
Stroke
Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.
Stroke
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Stroke
Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Stroke
S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Stroke
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Stroke
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke.
Stroke
SPORTIF III and SPORTIF V: Stroke Prevention Using the Direct Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation.
Stroke
Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack.
Stroke
Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Stroke
Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.
Stroke
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. Pooled Analysis from the SPORTIF III and V Studies.
Stroke
Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices.
Stroke
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Stroke
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Stroke
Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine.
Stroke
t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction.
Stroke
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
Stroke
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Stroke
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
Stroke
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
Stroke
The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation.
Stroke
The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation.
Stroke
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
Stroke
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
Stroke
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Stroke
The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation.
Stroke
The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke.
Stroke
The role of leukocytes in acute ischemic stroke-related thrombosis: a notable but neglected topic.
Stroke
The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.
Stroke
The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients.
Stroke
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
Stroke
Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.
Stroke
Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke.
Stroke
Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults.
Stroke
Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
Stroke
Thrombin preferentially induces autophagy in glia cells in the rat central nervous system.
Stroke
Thrombin-induced hyperactivity of platelets of young stroke patients: involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation.
Stroke
Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
Stroke
Tissue factor/factor VIIa pathway mediates coagulation activation in induced-heat stroke in the baboon.
Stroke
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
Stroke
Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Stroke
Ulinastatin as an Adjuvant Therapy to Restricting Volumes of Resuscitation Fluid Strategy for Patients with Septic Shock after Initial Management.
Stroke
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Stroke
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Stroke
Validation of a stroke model in rat compatible with rt-PA-induced thrombolysis: new hope for successful translation to the clinic.
Stroke
Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies.
Stroke
Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
Stroke
Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Stroke
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Stroke
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
Stroke
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
Stroke
[Characteristics of circulation and microcirculation in healthy people of Han nationality at different altitudes].
Stroke
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
Stroke
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
Stroke
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Stroke
[Dabigatran therapy--perioperative management and interpretation of coagulation tests].
Stroke
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Stroke
[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Stroke
[Inflammatory mechanisms, arteriosclerosis and ischemic stroke: clinical data and perspectives]
Stroke
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Stroke
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
Stroke
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Stroke, Lacunar
Chronic Systemic Immune Dysfunction in African-Americans with Small Vessel-Type Ischemic Stroke.
Subarachnoid Hemorrhage
Activation of epiplexus macrophages in hydrocephalus caused by subarachnoid hemorrhage and thrombin.
Subarachnoid Hemorrhage
Basic and translational research on proteinase-activated receptors: the role of thrombin receptor in cerebral vasospasm in subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB.
Subarachnoid Hemorrhage
Cerebral arterial contractions induced by human and bovine thrombin.
Subarachnoid Hemorrhage
Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Effect of thrombin injection on cerebral vascular in rats with subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model.
Subarachnoid Hemorrhage
Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Impairment of endothelium-dependent relaxation in human basilar artery after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin.
Subarachnoid Hemorrhage
Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.
Subarachnoid Hemorrhage
Role of SCH79797 in Maintaining Vascular Integrity in Rat Model of Subarachnoid Hemorrhage.
Subarachnoid Hemorrhage
Thrombin activity in cerebrospinal fluid after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats.
Subarachnoid Hemorrhage
Thrombin reduces cerebral arterial contractions caused by cerebrospinal fluid from patients with subarachnoid hemorrhage.
Surgical Wound Infection
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Surgical Wound Infection
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Syphilis
Analysis of the N-terminal region of the 47-kilodalton integral membrane lipoprotein of Treponema pallidum.
Systemic Vasculitis
Thromboembolic disease in systemic vasculitis is associated with enhanced microparticle-mediated thrombin generation.
Tangier Disease
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Tauopathies
Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling.
Telangiectasia, Hereditary Hemorrhagic
Hereditary hemorrhagic telangiectasia with intestinal bleeding; case report and therapy with tropical thrombin.
Telangiectasis
Hereditary hemorrhagic telangiectasia with intestinal bleeding; case report and therapy with tropical thrombin.
Tetanus
Effects of tetanus toxin, Salmonella typhimurium porin, and bacterial lipopolysaccharide on platelet aggregation.
Tetanus
The anticoagulant activated protein C (aPC) promotes metaplasticity in the hippocampus through an EPCR-PAR1-S1P1 receptors dependent mechanism.
Thalassemia
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma.
Thrombasthenia
Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP.
Thrombasthenia
Antibodies against platelet membrane glycoproteins. II. Influence on ADP- and collagen-induced platelet aggregation, crossed immunoelectrophoresis studies and relevance to Glanzmann's thrombasthenia.
Thrombasthenia
Association of Factor V Secretion with Protein Kinase B Signaling in Platelets from Horses with Atypical Equine Thrombasthenia.
Thrombasthenia
Impaired platelet procoagulant mechanisms in patients with bleeding disorders.
Thrombasthenia
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Thrombasthenia
Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasma.
Thrombasthenia
Involvement of GPIIb-IIIa on human platelets in phosphotyrosine-specific dephosphorylation.
Thrombasthenia
Involvement of platelet glycoprotein IIb-IIIa (alpha IIb-beta 3 integrin) in thrombin-induced synthesis of phosphatidylinositol 3',4'-bisphosphate.
Thrombasthenia
Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients.
Thrombasthenia
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
Thrombasthenia
Recombinant activated factor VII: mechanisms of action and current indications.
Thrombasthenia
Redistribution of activated pp60c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets.
Thrombasthenia
The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders.
Thrombasthenia
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
thrombin deficiency
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
thrombin deficiency
Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling.
thrombin deficiency
Warfarin pretreatment reduces cell death and mmp-9 activity in experimental intracerebral hemorrhage.
Thrombocythemia, Essential
ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Thrombocythemia, Essential
Cytoskeleton protein composition upon platelet stimulation with thrombin in essential thrombocythemia.
Thrombocythemia, Essential
Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.
Thrombocythemia, Essential
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.
Thrombocythemia, Essential
Lactate production by thrombin-activated platelets of patients with primary thrombocythemia.
Thrombocythemia, Essential
Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Thrombocythemia, Essential
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombocythemia, Essential
Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis.
Thrombocytopenia
5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
Thrombocytopenia
A case series describing the use of argatroban in patients on extracorporeal circulation.
Thrombocytopenia
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Thrombocytopenia
A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience.
Thrombocytopenia
A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis.
Thrombocytopenia
A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation.
Thrombocytopenia
A Predictive Model for the Anticoagulant Bivalirudin Administered to Cardiac Surgical Patients.
Thrombocytopenia
A prospective study investigating the mechanism of thrombocytopenia in preeclampsia.
Thrombocytopenia
A thrombin generation test; the application in haemophilia and thrombocytopenia.
Thrombocytopenia
Abnormal coagulation and fibrinolysis in eclampsia. A clinical and laboratory correlation study.
Thrombocytopenia
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
Thrombocytopenia
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Thrombocytopenia
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Thrombocytopenia
Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease.
Thrombocytopenia
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Thrombocytopenia
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
Thrombocytopenia
Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Anticoagulation with a selective thrombin inhibitor in a woman with heparin-induced thrombocytopenia.
Thrombocytopenia
Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.
Thrombocytopenia
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development.
Thrombocytopenia
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Thrombocytopenia
Antithrombotic Management during Percutaneous Mitral Valve Repair with the Mitraclip System in a Patient with Heparin-Induced Thrombocytopenia.
Thrombocytopenia
Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.
Thrombocytopenia
Application of Piezo-Based Measuring System for Evaluation of Nucleic Acid-Based Drugs Influencing the Coagulation.
Thrombocytopenia
Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
Thrombocytopenia
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Thrombocytopenia
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Argatroban Therapy in Patients with Coronary Artery Disease and Heparin-Induced Thrombocytopenia.
Thrombocytopenia
Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia.
Thrombocytopenia
Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.
Thrombocytopenia
Argatroban: a review of its use in the management of heparin-induced thrombocytopenia.
Thrombocytopenia
Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies.
Thrombocytopenia
Bivalirudin Anticoagulation for a Pediatric Patient with Heparin-Induced Thrombocytopenia and Thrombosis Requiring Cardiopulmonary Bypass for Ventricular Assist Device Placement.
Thrombocytopenia
Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
Thrombocytopenia
Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review.
Thrombocytopenia
Bivalirudin use during radiofrequency catheter ablation procedures in two patients with a history of heparin-induced thrombocytopenia.
Thrombocytopenia
Bivalirudin use in an infant with persistent clotting on unfractionated heparin.
Thrombocytopenia
Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected].
Thrombocytopenia
Bleeding risk factors associated with argatroban therapy in the critically ill.
Thrombocytopenia
Blood coagulation abnormalities associated with envenoming by Trimeresurus albolabris in Hong Kong.
Thrombocytopenia
Bothrops jararaca envenomation: Pathogenesis of hemostatic disturbances and intravascular hemolysis.
Thrombocytopenia
Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation.
Thrombocytopenia
Characterization and quantitation by flow cytometry of membranous microparticles formed during activation of platelet suspensions with ionophore or thrombin.
Thrombocytopenia
Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.
Thrombocytopenia
Coagulation management of a patient with factor V Leiden mutation, lupus anticoagulant, and activated protein C resistance: a case report.
Thrombocytopenia
Coagulopathy and hyperfibrinolysis in ruptured abdominal aortic aneurysm repair.
Thrombocytopenia
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Thrombocytopenia
Concentration of D-dimers in healthy cats and sick cats with and without disseminated intravascular coagulation (DIC).
Thrombocytopenia
Correction to the article "Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection", Published on Acta Med Port 2021 Jan;34(1):35-46.
Thrombocytopenia
Crystallographic, Spectroscopic, and Theoretical Investigation of the Efficiently Separated 21R and 21S-Diastereoisomers of Argatroban.
Thrombocytopenia
Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
Thrombocytopenia
Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Thrombocytopenia
Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia.
Thrombocytopenia
Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol.
Thrombocytopenia
Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes.
Thrombocytopenia
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Thrombocytopenia
Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia.
Thrombocytopenia
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Thrombocytopenia
Disseminated intravascular coagulation: a clinical/laboratory study of 48 patients.
Thrombocytopenia
Diverging signaling events control the pathway of GPVI down-regulation in vivo.
Thrombocytopenia
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.
Thrombocytopenia
Early Identification of Argatroban Resistance and the Consideration of Factor VIII.
Thrombocytopenia
Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.
Thrombocytopenia
Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
Thrombocytopenia
Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.
Thrombocytopenia
Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit.
Thrombocytopenia
Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis.
Thrombocytopenia
Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
Thrombocytopenia
Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
Thrombocytopenia
Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin - induced thrombocytopenia.
Thrombocytopenia
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Thrombocytopenia
Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.
Thrombocytopenia
Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection.
Thrombocytopenia
Epoprostenol Therapy for a Pediatric Patient With Subacute Heparin-Induced Thrombocytopenia and a Ventricular Assist Device Undergoing Heart Transplant: A Case Report.
Thrombocytopenia
Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia.
Thrombocytopenia
Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Thrombocytopenia
Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.
Thrombocytopenia
Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.
Thrombocytopenia
Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit.
Thrombocytopenia
Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Thrombocytopenia
Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
Thrombocytopenia
Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients.
Thrombocytopenia
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
Thrombocytopenia
Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
Thrombocytopenia
From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.
Thrombocytopenia
Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
Thrombocytopenia
Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.
Thrombocytopenia
Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial.
Thrombocytopenia
Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality.
Thrombocytopenia
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.
Thrombocytopenia
Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis.
Thrombocytopenia
Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors.
Thrombocytopenia
Heparin-induced thrombocytopenia: clinical manifestations and management strategies.
Thrombocytopenia
Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents.
Thrombocytopenia
Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin-fibrinogen interactions.
Thrombocytopenia
Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs.
Thrombocytopenia
Impact of an Immunoglobulin G-Specific Enzyme-Linked Immunosorbent Assay on the Management of Heparin-Induced Thrombocytopenia.
Thrombocytopenia
Impact of renal function on argatroban therapy during percutaneous coronary intervention.
Thrombocytopenia
Impaired platelet-dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro.
Thrombocytopenia
In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes.
Thrombocytopenia
In vitro study of r-hirudin permeability through membranes of different haemodialysers.
Thrombocytopenia
Incidence of Thrombocytopenia among Patients Receiving Heparin Venous Thromboembolism Prophylaxis.
Thrombocytopenia
Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis.
Thrombocytopenia
Induction of endogenous fibrinolysis inhibition in the dog. Effect of intravascular coagulation and release of free fatty acids.
Thrombocytopenia
Infectious canine hepatitis: animal model for viral-induced disseminated intravascular coagulation.
Thrombocytopenia
Inhibition by adenosine diphosphate of the thrombocytopenia induced in rabbits by collagen or thrombin.
Thrombocytopenia
Interference of thrombin in immunological assays for hirudin specific antibodies.
Thrombocytopenia
Laboratory tests for heparin-induced thrombocytopenia: a multicenter study.
Thrombocytopenia
Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy.
Thrombocytopenia
Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.
Thrombocytopenia
Low-Molecular-Weight Heparins : Mechanisms, Trials, and Role in Contemporary Interventional Medicine.
Thrombocytopenia
Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke.
Thrombocytopenia
Mammary gland carcinoma in a dog with peripheral blood and bone marrow involvement associated with disseminated intravascular coagulation.
Thrombocytopenia
Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review.
Thrombocytopenia
Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
Thrombocytopenia
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
Thrombocytopenia
Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex.
Thrombocytopenia
Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Thrombocytopenia
Natural language processor as a tool to assess heparin induced thrombocytopenia awareness.
Thrombocytopenia
Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood.
Thrombocytopenia
New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
Thrombocytopenia
Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation.
Thrombocytopenia
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Thrombocytopenia
Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Thrombocytopenia
Plasma exchange for heparin-induced thrombocytopenia in patients on extracorporeal circuits: A challenging case and a survey of the field.
Thrombocytopenia
Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes.
Thrombocytopenia
Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia.
Thrombocytopenia
Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome.
Thrombocytopenia
Postpartum coronary artery dissection complicated by heparin-induced thrombocytopenia and thrombosis.
Thrombocytopenia
Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation.
Thrombocytopenia
Predicting and Evaluating the Effect of Bivalirudin in Cardiac Surgical Patients.
Thrombocytopenia
Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition.
Thrombocytopenia
Procoagulant activity of the MC28 fibrosarcoma cell line in vitro and in vivo.
Thrombocytopenia
Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.
Thrombocytopenia
Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia.
Thrombocytopenia
Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model.
Thrombocytopenia
Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia.
Thrombocytopenia
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
Thrombocytopenia
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Thrombocytopenia
Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis.
Thrombocytopenia
Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study.
Thrombocytopenia
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
Thrombocytopenia
Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis.
Thrombocytopenia
Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.
Thrombocytopenia
Reversible crystallization of argatroban after subcutaneous application in pigs.
Thrombocytopenia
Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study.
Thrombocytopenia
Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.
Thrombocytopenia
Simultaneous Pancreas-Kidney Transplantation in a Patient with Heparin-Induced Thrombocytopenia on Dabigatran Therapy.
Thrombocytopenia
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation.
Thrombocytopenia
Study of haemostatic disorders in experimentally induced leishmaniasis in Beagle dogs.
Thrombocytopenia
Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature.
Thrombocytopenia
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.
Thrombocytopenia
Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis.
Thrombocytopenia
TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia.
Thrombocytopenia
The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment.
Thrombocytopenia
The pathogenesis of leptospirosis I. Hemorrhages in experimental leptospirosis in guinea pigs.
Thrombocytopenia
The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
Thrombocytopenia
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
Thrombocytopenia
The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Thrombocytopenia
Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions.
Thrombocytopenia
Thrombin-induced leukopenia and thrombocytopenia are attenuated by PAF antagonist WEB 2086.
Thrombocytopenia
Thrombocytopenia and release of platelet amines induced by thrombin and bacterial lipopolysaccharide. Observations after infusion of low molecular weight dextran.
Thrombocytopenia
Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia.
Thrombocytopenia
Thrombocytopenia following liver transplantation is associated with platelet consumption and thrombin generation.
Thrombocytopenia
Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation.
Thrombocytopenia
Thromboelastometry analysis of thrombocytopenic dengue patients: a cross-sectional study.
Thrombocytopenia
Titration of Bivalirudin Infusion in the Pediatric Cardiac Catheterization Laboratory: A Case Report.
Thrombocytopenia
Transfusion medicine service policies for recombinant factor VIIa administration.
Thrombocytopenia
Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
Thrombocytopenia
Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
Thrombocytopenia
Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program.
Thrombocytopenia
Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor.
Thrombocytopenia
Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
Thrombocytopenia
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
Thrombocytopenia
Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.
Thrombocytopenia
Usefulness of pretest clinical score (4Ts) combined with immunoassay for the diagnosis of heparin-induced thrombocytopenia.
Thrombocytopenia
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia.
Thrombocytopenia
Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis.
Thrombocytopenia
Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome.
Thrombocytopenia
Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
Thrombocytopenia
[Anesthetic management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor]
Thrombocytopenia
[Calcium heparin-induced immunologic thrombocytopenia complicated with venous gangrene of the legs. Report of a clinical case]
Thrombocytopenia
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
Thrombocytopenia
[Fondaparinux treatment in heparin induced thrombocytopenia:a case report].
Thrombocytopenia
[Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report]
Thrombocytopenia
[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.]
Thrombocytopenia
[Intraoperative management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor]
Thrombocytopenia
[Optimal dose of bivalirudin in dialysis patients at high risk of heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case report].
Thrombocytopenia
[Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma]
Thrombocytopenia
[Two surgical case reports showing atypical heparin-induced thrombocytopenia]
Thrombocytopenia, Neonatal Alloimmune
Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood.
Thrombocytosis
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Thrombocytosis
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count.
Thrombocytosis
Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism.
Thrombocytosis
Exercise-induced platelet and leucocyte activation is not enhanced in well-controlled Type 1 diabetes, despite increased activity at rest.
Thrombocytosis
Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E.
Thrombocytosis
Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis.
Thromboembolism
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Thromboembolism
A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses.
Thromboembolism
A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
Thromboembolism
A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice.
Thromboembolism
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Thromboembolism
Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.
Thromboembolism
Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
Thromboembolism
Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals.
Thromboembolism
Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice.
Thromboembolism
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Thromboembolism
Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature.
Thromboembolism
Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.
Thromboembolism
Both ADP and thrombin regulate arteriolar thrombus stabilization and embolization, but are not involved in initial hemostasis as induced by micropuncture.
Thromboembolism
Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy.
Thromboembolism
Changes in Markers of Thrombin Generation and Interleukin-6 During Unicondylar Knee and Total Knee Arthroplasty.
Thromboembolism
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Thromboembolism
Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period. Comparison with chronic atrial fibrillation.
Thromboembolism
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Thromboembolism
Comparison between ultrasound-guided compression and para-aneurysmal saline injection in the treatment of postcatheterization femoral artery pseudoaneurysms.
Thromboembolism
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Thromboembolism
Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Thromboembolism
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Thromboembolism
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Thromboembolism
Elevated levels of soluble thrombomodulin in plasma from children with Arg 506 to Gln mutation in the factor V gene.
Thromboembolism
Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Thromboembolism
Further simplification of cryoprecipitate coagulum pyelolithotomy without thrombin.
Thromboembolism
Generation of an anti-dabigatran monoclonal antibody and its employment in a highly sensitive and specific enzyme-linked immunosorbent assay for serum dabigatran.
Thromboembolism
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Thromboembolism
Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.
Thromboembolism
Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients.
Thromboembolism
Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 (Fraxiparine) on several parameters of haemostasis in patients under dialysis and receiving either unfractionated heparin or CY 216.
Thromboembolism
Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
Thromboembolism
Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation.
Thromboembolism
Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model.
Thromboembolism
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
Thromboembolism
Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials.
Thromboembolism
New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation.
Thromboembolism
Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Thromboembolism
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Thromboembolism
Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.
Thromboembolism
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
Thromboembolism
Pharmacophore Design, Virtual Screening, Molecular Docking and Optimization Approaches to Discover Potent Thrombin Inhibitors.
Thromboembolism
Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats.
Thromboembolism
Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment.
Thromboembolism
Salvage of autogenous dialysis access with balloon-assisted thrombin injection.
Thromboembolism
Sequential multiple retinal vein occlusions and transient ischemic attack in MTHFR polymorphism and protein S deficiency.
Thromboembolism
Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism.
Thromboembolism
Should all patients with non-valvular atrial fibrillation be anticoagulated?
Thromboembolism
Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?
Thromboembolism
Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Thromboembolism
The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor/Glycoprotein IIbIIIa Antagonist, Exceeds That of the Coadministered Parent Compounds.
Thromboembolism
The association of direct thrombin inhibitor anticoagulants with cardiac thromboses.
Thromboembolism
The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits.
Thromboembolism
The effect of major surgery, low doses of heparin and thromboembolism on plasma antithrombin. Comparison of immediate thrombin inhibiting capacity and the antithrombin III content.
Thromboembolism
The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI.
Thromboembolism
The thrombin inhibitors hirudin and Refludan® activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets.
Thromboembolism
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Thromboembolism
Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
Thromboembolism
Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis.
Thromboembolism
Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation.
Thromboembolism
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Thromboembolism
Use of Direct Thrombin Inhibitor for Treatment of Cerebral Venous Thrombosis.
Thromboembolism
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
Thromboembolism
Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit.
Thromboembolism
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Thromboembolism
[Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives]
Thromboembolism
[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]
Thromboembolism
[Association of dysfibrinogenemia and thrombosis. Apropos of a family (Fibrinogen Melun) and review of the literature]
Thromboembolism
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Thromboembolism
[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Thromboembolism
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Thromboembolism
[Update on the prevention of thromboembolic phenomena in atrial fibrillation]
Thromboinflammation
Histones link inflammation and thrombosis through the induction of Weibel-Palade Body exocytosis.
Thromboinflammation
Inflammation and thrombosis in COVID-19 pathophysiology: Proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.
Thromboinflammation
Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?
Thromboinflammation
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Thromboinflammation
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Thromboinflammation
Tissue Factor-Enriched Neutrophil Extracellular Traps Promote Immunothrombosis and Disease Progression in Sepsis-Induced Lung Injury.
Thromboinflammation
TMEM16F-Mediated Platelet Membrane Phospholipid Scrambling Is Critical for Hemostasis and Thrombosis but not Thromboinflammation in Mice.
Thrombophilia
A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure.
Thrombophilia
A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.
Thrombophilia
A novel approach for detecting hypercoagulability utilizing thromboelastography.
Thrombophilia
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.
Thrombophilia
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Thrombophilia
Activated protein C resistance: from phenotype to genotype and clinical practice.
Thrombophilia
Activity levels of natural anticoagulant proteins in childhood acute lymphoblastic leukemia: relation to thromboembolic complications and treatment.
Thrombophilia
Age-Based Difference in Activation Markers of Coagulation and Fibrinolysis in Extracorporeal Membrane Oxygenation.
Thrombophilia
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Thrombophilia
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Thrombophilia
Assessment of the procoagulant potential after laparoscopic sleeve gastrectomy: a potential role for extended thromboprophylaxis.
Thrombophilia
Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study.
Thrombophilia
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.
Thrombophilia
Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism.
Thrombophilia
c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype.
Thrombophilia
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.
Thrombophilia
Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study.
Thrombophilia
Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension.
Thrombophilia
Cardiopulmonary bypass pumps and thrombin generation: what goes around comes around.
Thrombophilia
Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer.
Thrombophilia
Chronic idiopathic non-cirrhotic portal vein thrombosis treated with a mesocaval shunt procedure and anticoagulation.
Thrombophilia
Clinical and biochemical characterization of the prothrombin Belgrade mutation in a large Serbian pedigree: new insights into the antithrombin resistance mechanism.
Thrombophilia
Clinical and biological factors that contribute to thrombin generation in prothrombin G20210A carriers: a case-control study in a single Thrombophilia Center.
Thrombophilia
Coagulation phenotypes in septic shock as evaluated by calibrated automated thrombography.
Thrombophilia
Coagulation profile during induction chemotherapy in childhood acute lymphoblastic leukemia.
Thrombophilia
Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay.
Thrombophilia
Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies.
Thrombophilia
Computational analysis of intersubject variability and thrombin generation in dilutional coagulopathy.
Thrombophilia
D-Dimers, Thrombin-Antithrombin Complexes, and Risk Factors for Thromboembolism in Hospitalized Patients.
Thrombophilia
Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis.
Thrombophilia
Differentiation of enzymatic from platelet hypercoagulability using the novel thrombelastography parameter delta (delta).
Thrombophilia
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Thrombophilia
Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users.
Thrombophilia
Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes.
Thrombophilia
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Thrombophilia
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.
Thrombophilia
Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus.
Thrombophilia
Establishment of Methods for Performing Thrombelastography and Calibrated Automated Thrombography in Rats.
Thrombophilia
Evaluation of Hypercoagulability in Obese Children With Thrombin Generation Test and Microparticle Release: Effect of Metabolic Parameters.
Thrombophilia
Evaluation of the in vitro detection of the hypercoagulable state using the thrombin generation test and plasma clot impedance test.
Thrombophilia
Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis.
Thrombophilia
Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
Thrombophilia
Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia.
Thrombophilia
Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability.
Thrombophilia
Genetic Determinants of Thrombin Generation and Their Relation to Venous Thrombosis: Results from the GAIT-2 Project.
Thrombophilia
Grave's disease with transverse and sigmoid sinus thrombosis needing surgical intervention.
Thrombophilia
Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin.
Thrombophilia
Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with ST-Genesia.
Thrombophilia
Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation.
Thrombophilia
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Thrombophilia
Hypercoagulability following major partial liver resection - detected by thrombomodulin-modified thrombin generation testing.
Thrombophilia
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events.
Thrombophilia
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.
Thrombophilia
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.
Thrombophilia
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma.
Thrombophilia
Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.
Thrombophilia
Hypercoagulability is most prevalent early after injury and in female patients.
Thrombophilia
Hypercoagulability panel testing predicts thrombosis in neonates undergoing cardiac surgery.
Thrombophilia
Idiopathic pulmonary fibrosis associated with pulmonary vein thrombosis: a case report.
Thrombophilia
Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.
Thrombophilia
Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus.
Thrombophilia
Increased activity of procoagulant factors in patients with small cell lung cancer.
Thrombophilia
Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis.
Thrombophilia
Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report.
Thrombophilia
Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting.
Thrombophilia
Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
Thrombophilia
Iron-Deficiency and Estrogen Are Associated With Ischemic Stroke by Up-Regulating Transferrin to Induce Hypercoagulability.
Thrombophilia
Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism.
Thrombophilia
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Thrombophilia
Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG).
Thrombophilia
Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry.
Thrombophilia
Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells.
Thrombophilia
Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr.
Thrombophilia
Onset of Thrombin Generation Occurs More Rapidly in Pediatric Patients With Celiac Disease.
Thrombophilia
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Thrombophilia
Panax notoginseng saponins reduce high-risk factors for thrombosis through peroxisome proliferator-activated receptor -? pathway.
Thrombophilia
Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay.
Thrombophilia
Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis.
Thrombophilia
Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation.
Thrombophilia
PLASMA RESUSCITATION PROMOTES COAGULATION HOMEOSTASIS FOLLOWING SHOCK-INDUCED HYPERCOAGULABILITY.
Thrombophilia
Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia.
Thrombophilia
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Thrombophilia
Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
Thrombophilia
Presence of nucleosomes in plasma and increased thrombin generation in dogs with acute and chronic gastroenteropathies.
Thrombophilia
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Thrombophilia
Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
Thrombophilia
Prominent protein Z-induced thrombin inhibition in cirrhosis: A new functional assay for hypercoagulability assessment.
Thrombophilia
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Thrombophilia
Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.
Thrombophilia
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Thrombophilia
Reactivation of the coagulation system: rationale for long-term antithrombotic treatment.
Thrombophilia
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals.
Thrombophilia
Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA).
Thrombophilia
Role of platelets in thrombin generation amongst patients with non-transfusion-dependent thalassaemia.
Thrombophilia
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Thrombophilia
Short-term venous stasis induces fibrinolytic activation but not thrombin formation.
Thrombophilia
Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions.
Thrombophilia
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
Thrombophilia
The APC-PCI concentration as an early marker of activation of blood coagulation A study of women on combined oral contraceptives.
Thrombophilia
The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy.
Thrombophilia
The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.
Thrombophilia
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.
Thrombophilia
The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states.
Thrombophilia
The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability.
Thrombophilia
Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Thrombophilia
Thrombin activity and platelet microparticle formation are increased in type 2 diabetic platelets: a potential correlation with caspase activation.
Thrombophilia
Thrombin elaboration in endotoxin-induced intravascular fibrin deposition. A leukocyte dependent process distinct from systemic hypercoagulability.
Thrombophilia
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
Thrombophilia
Thrombin generation and international normalized ratio in inherited thrombophilia patients receiving thromboprophylactic therapy.
Thrombophilia
Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia.
Thrombophilia
Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism.
Thrombophilia
Thrombin Generation Assay Detects Moderate-Intensity Statin-Induced Reduction of Hypercoagulability in Diabetes.
Thrombophilia
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Thrombophilia
Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Thrombophilia
Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.
Thrombophilia
Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients.
Thrombophilia
Thrombin regulates monocyte chemoattractant protein-1 expression in human first trimester and term decidual cells.
Thrombophilia
Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.
Thrombophilia
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Thrombophilia
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma.
Thrombophilia
Thrombophilic variables do not increase the generation or procoagulant activity of thrombin during cardiopulmonary bypass.
Thrombophilia
Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood.
Thrombophilia
Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies.
Thrombophilia
Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity.
Thrombophilia
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
Thrombophilia
[Changes in the blood clotting system of patients with atherosclerotic and senile dementias]
Thrombophilia
[Effects of the synthetic proteinase inhibitor, FOY, on hypercoagulability after surgery for esophageal carcinoma]
Thrombophilia
[Usefulness of a modified thrombin generation test in the diagnosis of chronometric hypercoagulability]
Thrombophlebitis
[Morphologic changes in the thrombus and venous wall in experimental phleobothrombosis and thrombophlebitis]
Thrombosis
"Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure.
Thrombosis
111In-labeled platelet scintigraphy and two-dimensional echocardiography for detection of left atrial appendage thrombi. Studies in a new canine model.
Thrombosis
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
Thrombosis
1982 George Simon Memorial Fellowship Award. Experimental studies with 111indium-labeled platelets in pulmonary embolism.
Thrombosis
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Thrombosis
4-thio-deoxyuridylate-modified thrombin aptamer and its inhibitory effect on fibrin clot formation, platelet aggregation and thrombus growth on subendothelial matrix.
Thrombosis
99mTc-NC100668, an agent for imaging venous thromboembolism: The effect of anticoagulant or thrombolytic therapy on the uptake and retention of radioactivity in blood clots in vivo.
Thrombosis
A biologically active surface enzyme assembly that attenuates thrombus formation.
Thrombosis
A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
Thrombosis
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
Thrombosis
A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity.
Thrombosis
A Critical Role of Thrombin/PAR-1 in ADP-induced Platelet Secretion and the Second Wave of Aggregation.
Thrombosis
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
Thrombosis
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo.
Thrombosis
A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis.
Thrombosis
A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells.
Thrombosis
A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis.
Thrombosis
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
Thrombosis
A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides.
Thrombosis
A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis.
Thrombosis
A model of thrombin inactivation in heparinized and nonheparinized tubes with consequences for thrombus formation.
Thrombosis
A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.
Thrombosis
A multiscale model of venous thrombus formation with surface-mediated control of blood coagulation cascade.
Thrombosis
A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition.
Thrombosis
A non-occlusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function, or thrombin activity.
Thrombosis
A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
Thrombosis
A novel class of small functional peptides that bind and inhibit human alpha-thrombin isolated by mRNA display.
Thrombosis
A novel di-peptide Met-Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq-mediated signaling.
Thrombosis
A novel fibrinogenase from Agkistrodon acutus venom protects against DIC via direct degradation of thrombosis and activation of protein C.
Thrombosis
A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
Thrombosis
A novel near-infrared fluorescence sensor for detection of thrombin activation in blood.
Thrombosis
A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation.
Thrombosis
A novel serine protease with anticoagulant and fibrinolytic activities from the fruiting bodies of mushroom Agrocybe aegerita.
Thrombosis
A peptide analogue of thrombin receptor-activating peptide inhibits thrombin and thrombin-receptor-activating peptide-induced vascular smooth muscle cell proliferation.
Thrombosis
A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass.
Thrombosis
A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.
Thrombosis
A porcine deep vein thrombosis model for magnetic resonance-guided monitoring of different thrombectomy procedures.
Thrombosis
A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication.
Thrombosis
A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty.
Thrombosis
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
Thrombosis
A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
Thrombosis
A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
Thrombosis
A role for proteinase-activated receptor 2 and PKC-epsilon in thrombin-mediated induction of decay-accelerating factor on human endothelial cells.
Thrombosis
A simple, cost-effective, and rapid separation process for the isolation of anticoagulant active fraction from the fruit extract of Momordica charantia: Characterization of bioactive components and anticoagulant mechanism of active fraction in a mouse model.
Thrombosis
A systems approach to hemostasis: 2. Computational analysis of molecular transport in the thrombus microenvironment.
Thrombosis
A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity.
Thrombosis
A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly.
Thrombosis
A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V.
Thrombosis
A Thrombin-Responsive Nanoprobe for In Vivo Visualization of Thrombus Formation through Three-Dimensional Optical/Computed Tomography Hybrid Imaging.
Thrombosis
A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters.
Thrombosis
Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets.
Thrombosis
Absence of platelet-dependent fibrin formation in a patient with Scott syndrome.
Thrombosis
Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Thrombosis
Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase.
Thrombosis
Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation.
Thrombosis
Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond.
Thrombosis
Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis.
Thrombosis
Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Thrombosis
Activated contact system and abnormal glycosaminoglycans in lupus and other auto- and non-autoimmune diseases.
Thrombosis
Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation.
Thrombosis
Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces.
Thrombosis
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Thrombosis
Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Thrombosis
Activation of coagulation and fibrinolysis in microsurgical reconstructions in the lower extremities.
Thrombosis
Activation of coagulation system in dilated cardiomyopathy: comparison of patients with and without left ventricular thrombus.
Thrombosis
Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men.
Thrombosis
Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis.
Thrombosis
Activity of coagulation and fibrinolytic system components in the vein thrombus.
Thrombosis
Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma.
Thrombosis
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
Thrombosis
Acute arterial occlusion after ultrasound-guided thrombin injection of a common femoral artery pseudoaneurysm with a wide, short neck.
Thrombosis
Acute thrombogenic effects of fibrin sealant on microvascular anastomoses in a rat model.
Thrombosis
Adamts18 deficiency increases arterial thrombus formation associated with vascular defects in mice.
Thrombosis
Adhesion and aggregation of thrombin prestimulated human platelets: evaluation of surface-bound fibrinogen and surface-bound albumin.
Thrombosis
Aeruginosin analogs and other compounds with rigid bicyclic structure as potential antithrombotic agents.
Thrombosis
African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation.
Thrombosis
Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT).
Thrombosis
Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.
Thrombosis
Agkihpin, a novel SVTLE from Gloydius halys Pallas, promotes platelet aggregation in vitro and inhibits thrombus formation in vivo in murine models of thrombosis.
Thrombosis
Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor.
Thrombosis
alpha-thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood.
Thrombosis
alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis.
Thrombosis
Alpha-thrombin-catalyzed hydrolysis of fibrin I. Alternative binding modes and the accessibility of the active site in fibrin I-bound alpha-thrombin.
Thrombosis
Alterations in endothelial thrombomodulin expression in zymosan-induced lung injury.
Thrombosis
Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
Thrombosis
Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway.
Thrombosis
Amplified electrochemical aptasensor taking AuNPs based sandwich sensing platform as a model.
Thrombosis
An addition was made to the abstract: the association of direct thrombin inhibitor anticoagulants with cardiac thromboses.
Thrombosis
An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey.
Thrombosis
An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
Thrombosis
An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells, and protein C activation.
Thrombosis
Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.
Thrombosis
Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome.
Thrombosis
Anti-hypertensive effect of the Dongchunghacho, Isaria sinclairii, in the spontaneously hypertensive rats.
Thrombosis
Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis C.H. Wright.
Thrombosis
Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
Thrombosis
Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome.
Thrombosis
Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis.
Thrombosis
Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
Thrombosis
Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate.
Thrombosis
Anticoagulant and antithrombotic properties of a gamma-carboxyglutamic acid-rich peptide derived from the light chain of blood coagulation factor X.
Thrombosis
Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Thrombosis
Anticoagulant Dodecapeptide Suppresses Thrombosis In Vivo by Inhibiting the Thrombin Exosite-I Binding Site.
Thrombosis
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Thrombosis
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
Thrombosis
Anticoagulation of patients with heparin-induced thrombocytopenia in cardiac surgery.
Thrombosis
Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty.
Thrombosis
Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis.
Thrombosis
Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis.
Thrombosis
Antithrombin III modulates the effect of thrombin on the metabolism of glycosaminoglycans in cultured endothelial cells.
Thrombosis
Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
Thrombosis
Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.
Thrombosis
Antithrombin-heparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention.
Thrombosis
Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin.
Thrombosis
Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation.
Thrombosis
Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Thrombosis
Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Thrombosis
Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Thrombosis
Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Thrombosis
Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.
Thrombosis
Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo.
Thrombosis
Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor.
Thrombosis
Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
Thrombosis
Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Thrombosis
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Thrombosis
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Thrombosis
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.
Thrombosis
Antithrombotic effect in vivo of thrombotic substances adsorbed on a platinum surface.
Thrombosis
Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model.
Thrombosis
Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.
Thrombosis
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Thrombosis
Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
Thrombosis
Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.
Thrombosis
Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
Thrombosis
Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis.
Thrombosis
Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.
Thrombosis
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Thrombosis
Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
Thrombosis
Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Thrombosis
Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin.
Thrombosis
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Thrombosis
Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
Thrombosis
Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Thrombosis
Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction.
Thrombosis
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Thrombosis
Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.
Thrombosis
Aqueous extracts of Ocimum basilicum L. (sweet basil) decrease platelet aggregation induced by ADP and thrombin in vitro and rats arterio--venous shunt thrombosis in vivo.
Thrombosis
Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation.
Thrombosis
Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat.
Thrombosis
Argatroban administration as therapy for thrombosis in patients with continuous-flow ventricular assist devices.
Thrombosis
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Thrombosis
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Thrombosis
Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits.
Thrombosis
Argatroban as novel therapy for suspected thrombosis in patients with continuous flow left ventricle assist device and hemolysis.
Thrombosis
Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture.
Thrombosis
Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.
Thrombosis
Argatroban: a review of its use in the management of heparin-induced thrombocytopenia.
Thrombosis
Arginase activity is increased by thrombin: a mechanism for endothelial dysfunction in arterial thrombosis.
Thrombosis
Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
Thrombosis
Arterial thrombosis associated with immune thrombocytopenia: presence of a platelet aggregating IgG synergistic with thrombin and adrenalin.
Thrombosis
Arterial thrombosis: relevance of a model with two levels of severity assessed by histological, ultrastructural and functional characterization.
Thrombosis
Artificial microvascular graft thrombosis: the consequences of platelet membrane glycoprotein Ib inhibition and thrombin inhibition.
Thrombosis
Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation.
Thrombosis
Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation.
Thrombosis
Assessment and management of coagulopathy in critically-ill patients with liver failure.
Thrombosis
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Thrombosis
Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease.
Thrombosis
Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity.
Thrombosis
Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.
Thrombosis
Association of aortic valve sclerosis with thrombin generation in hypertensive patients.
Thrombosis
Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions.
Thrombosis
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Thrombosis
Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula.
Thrombosis
Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique.
Thrombosis
Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin.
Thrombosis
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Thrombosis
Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies.
Thrombosis
Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position.
Thrombosis
Binding-Induced 3D-Bipedal DNA Walker for Cascade Signal Amplification Detection of Thrombin Combined with Catalytic Hairpin Assembly Strategy.
Thrombosis
Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
Thrombosis
Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future.
Thrombosis
Bioengineered surfaces to improve the blood compatibility of biomaterials through direct thrombin inactivation.
Thrombosis
Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization.
Thrombosis
Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Thrombosis
Biorheology of platelet activation in the bloodstream distal to thrombus formation.
Thrombosis
Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure.
Thrombosis
Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis.
Thrombosis
Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
Thrombosis
Bivalirudin, thrombin and platelets: clinical implications and future directions.
Thrombosis
Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.
Thrombosis
Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
Thrombosis
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Thrombosis
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
Thrombosis
BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
Thrombosis
Both ADP and thrombin regulate arteriolar thrombus stabilization and embolization, but are not involved in initial hemostasis as induced by micropuncture.
Thrombosis
Brachial pseudoaneurysm of the neonate with partial response to thrombin injections and late spontaneous thrombosis and regression during expectant management.
Thrombosis
By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin.
Thrombosis
C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates and protects against carotid artery occlusion and cerebral stroke.
Thrombosis
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.
Thrombosis
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.
Thrombosis
Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival.
Thrombosis
Cardiac-Specific Overexpression of Oxytocin Receptor Leads to Cardiomyopathy in Mice.
Thrombosis
Catalytic microgelators for decoupled control of gelation rate and rigidity of the biological gels.
Thrombosis
Catheter-directed endovascular application of thrombin: Report of 3 cases and review of the literature.
Thrombosis
Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface.
Thrombosis
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Thrombosis
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Thrombosis
Characteristics of a cheese-like food produced by fermentation of the mushroom Schizophyllum commune.
Thrombosis
Characteristics of Fibrin Formation and Clot Stability in Individuals with Congenital Type IIb Protein C Deficiency.
Thrombosis
Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits.
Thrombosis
Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.
Thrombosis
Chemically modified thrombin and anhydrothrombin that differentiate macromolecular substrates of thrombin.
Thrombosis
Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity.
Thrombosis
Clinical and Experimental Analysis of Platelet Micro Particles Inducing Thrombosis after Coronary Stenting.
Thrombosis
Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update.
Thrombosis
Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.
Thrombosis
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Thrombosis
Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene.
Thrombosis
Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Thrombosis
Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation.
Thrombosis
Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates.
Thrombosis
Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk.
Thrombosis
Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation.
Thrombosis
Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.
Thrombosis
Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow.
Thrombosis
Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S.
Thrombosis
Coil embolization of inferior epigastric artery pseudoaneurysm after percutaneous thrombin injection failure: a case report.
Thrombosis
Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
Thrombosis
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Thrombosis
Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
Thrombosis
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
Thrombosis
Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.
Thrombosis
Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction.
Thrombosis
Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
Thrombosis
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
Thrombosis
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Thrombosis
Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Thrombosis
Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.
Thrombosis
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Thrombosis
Comparison of Effects of Anti-thrombin Aptamers HD1 and HD22 on Aggregation of Human Platelets, Thrombin Generation, Fibrin Formation, and Thrombus Formation Under Flow Conditions.
Thrombosis
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Thrombosis
Comparison of in vitro and in vivo properties of rhirudin (HBW 023) and a synthetic analogous peptide.
Thrombosis
Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin.
Thrombosis
Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Thrombosis
Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors.
Thrombosis
Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Thrombosis
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Thrombosis
Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Thrombosis
Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Thrombosis
Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin.
Thrombosis
Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Thrombosis
Compression repair versus low-dose thrombin injection for the treatment of iatrogenic femoral pseudoaneurysm: a retrospective case-control study.
Thrombosis
Compressive mechanical properties of the intraluminal thrombus in abdominal aortic aneurysms and fibrin-based thrombus mimics.
Thrombosis
Computational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions.
Thrombosis
Congenital structural and functional fibrinogen disorders: a primer for internists.
Thrombosis
Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models.
Thrombosis
Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Thrombosis
Constitutive Dimerization of Glycoprotein VI (GPVI) in Resting Platelets Is Essential for Binding to Collagen and Activation in Flowing Blood.
Thrombosis
Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion.
Thrombosis
Contrast-enhanced ultrasound-guided thrombin injection in the management of iatrogenic pseudoaneurysm (PSA): A case report and review of literatures.
Thrombosis
Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin.
Thrombosis
Core and shell platelets of a thrombus: A new microfluidic assay to study mechanics and biochemistry.
Thrombosis
Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo.
Thrombosis
Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters.
Thrombosis
Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: a dose-response study.
Thrombosis
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Thrombosis
Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity.
Thrombosis
Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface.
Thrombosis
Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement.
Thrombosis
Critical role of FcR gamma-chain, LAT, PLCgamma2 and thrombin in arteriolar thrombus formation upon mild, laser-induced endothelial injury in vivo.
Thrombosis
Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis.
Thrombosis
Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors.
Thrombosis
Crystal structures of protease nexin-1 in complex with heparin and thrombin suggest a 2-step recognition mechanism.
Thrombosis
Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with ?-thrombin.
Thrombosis
Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk.
Thrombosis
Current role of antithrombotic agents in the treatment of acute coronary syndromes.
Thrombosis
CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
Thrombosis
Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection.
Thrombosis
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
Thrombosis
D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis.
Thrombosis
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Thrombosis
Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium.
Thrombosis
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Thrombosis
Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.
Thrombosis
Delayed femoral vein thrombosis after ultrasound-guided thrombin injection of a postcatheterization pseudoaneurysm.
Thrombosis
Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.
Thrombosis
Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
Thrombosis
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Thrombosis
Design and synthesis of para-fluorophenylalanine amide derivatives as thrombin receptor antagonists.
Thrombosis
Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Thrombosis
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.
Thrombosis
Detection of marked reduction of sensitivity to activated protein C prior to the onset of thrombosis during puerperium as detected by endogenous thrombin potential-based assay.
Thrombosis
Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation.
Thrombosis
Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
Thrombosis
Development of a new model of transvenous thrombosis in the pig superior sagittal sinus using thrombin injection and balloon occlusion.
Thrombosis
Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Thrombosis
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Thrombosis
Deviations in coagulation activation due to treatment with different haemodialysis membranes.
Thrombosis
Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status.
Thrombosis
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Thrombosis
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
Thrombosis
Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
Thrombosis
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Thrombosis
Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
Thrombosis
Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Thrombosis
Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Thrombosis
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
Thrombosis
Dilutional control of prothrombin activation at physiologically relevant shear rates.
Thrombosis
Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.
Thrombosis
Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions.
Thrombosis
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Thrombosis
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Thrombosis
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Thrombosis
Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice.
Thrombosis
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
Thrombosis
Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Thrombosis
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Thrombosis
Distribution of sac pressure in an experimental aneurysm model after endovascular repair: the effect of endoleak types I and II.
Thrombosis
DNA Aptamers to Thrombin Exosite I. Structure-Function Relationships and Antithrombotic Effects.
Thrombosis
Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Thrombosis
Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Thrombosis
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial.
Thrombosis
Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood.
Thrombosis
Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia.
Thrombosis
Dual P2Y 12 receptor signaling in thrombin-stimulated platelets--involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity.
Thrombosis
Dual role of platelet protein kinase C in thrombus formation: stimulation of pro-aggregatory and suppression of procoagulant activity in platelets.
Thrombosis
Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Thrombosis
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Thrombosis
Dynamics of thrombin generation and flux from clots during whole human blood flow over collagen/tissue factor surfaces.
Thrombosis
Early Identification of Argatroban Resistance and the Consideration of Factor VIII.
Thrombosis
Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure.
Thrombosis
Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction.
Thrombosis
Early thrombolysis by recombinant tissue-plasminogen activator is beneficial to the ischemic myocardium.
Thrombosis
Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Thrombosis
Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.
Thrombosis
Effect of a potent thrombin inhibitor, No. 407, on novel experimental thrombosis generated by acetic acid.
Thrombosis
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Thrombosis
Effect of anticoagulants and antiplatelet agents on platelet-mediated thrombin generation.
Thrombosis
Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo.
Thrombosis
Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters.
Thrombosis
Effect of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface.
Thrombosis
Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat.
Thrombosis
Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina.
Thrombosis
Effect of monomethylmethacrylate on procoagulant activities of human monocytes and umbilical vein endothelial cells in vitro.
Thrombosis
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Thrombosis
Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
Thrombosis
Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Thrombosis
Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model.
Thrombosis
Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin.
Thrombosis
Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Thrombosis
Effect of Tranexamic Acid on Coagulation and Fibrin Clot Properties in Children Undergoing Craniofacial Surgery.
Thrombosis
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Thrombosis
Effects of alpha(2)-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma.
Thrombosis
Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis.
Thrombosis
Effects of balloon mitral valvuloplasty on systemic and regional left atrial levels of prothrombin fragment 1+2 in mitral stenosis.
Thrombosis
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Thrombosis
Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo.
Thrombosis
Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Thrombosis
Effects of FEIBA on platelet and leucocyte activation in severe haemophilia patients with inhibitors.
Thrombosis
Effects of focal mild hypothermia on thrombin-induced brain edema formation and the expression of protease activated receptor-1, matrix metalloproteinase-9 and aquaporin 4 in rats.
Thrombosis
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Thrombosis
Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.
Thrombosis
Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.
Thrombosis
Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Thrombosis
Effects of polysulfonate derivative (GL 522-Y-1) on coagulation in vitro and thrombosis in vivo.
Thrombosis
Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma.
Thrombosis
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Thrombosis
Effects of scorpion venom bioactive polypolypeptides on platelet aggregation and thrombosis and plasma 6-keto-PG F1alpha and TXB2 in rabbits and rats.
Thrombosis
Effects of shear rate on propagation of blood clotting determined using microfluidics and numerical simulations.
Thrombosis
Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
Thrombosis
Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Thrombosis
Effects of thermal exposure on binding of heparin in vitro to the arterial wall and to clot and on the chronic angiographic luminal response to local application of a heparin film during angioplasty in an in vivo rabbit model.
Thrombosis
Effects of thrombin on interactions between beta3-integrins and extracellular matrix in platelets and vascular cells.
Thrombosis
Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis.
Thrombosis
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
Thrombosis
Efficacy and safety of a coagulated thrombus injection for peripheral artery perforation: The coagulated thrombus hemostasis method.
Thrombosis
Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.
Thrombosis
Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts.
Thrombosis
Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases.
Thrombosis
Elevated plasma factor VIII enhances venous thrombus formation in rabbits: contribution of factor XI, von Willebrand factor and tissue factor.
Thrombosis
Embolization of hepatic artery pseudo-aneurysm facilitated by selective injection of thrombin and thrombin-soaked coils.
Thrombosis
Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Thrombosis
Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis.
Thrombosis
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.
Thrombosis
Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen.
Thrombosis
Endovascular treatment of a massive retroperitoneal bleeding: successful balloon-catheter delivery of intra-arterial thrombin.
Thrombosis
Endovascular treatment of refractory iatrogenic femoral artery pseudoaneurysm using Amplatzer vascular plugs following unsuccessful retrograde Angio-Seal deployment.
Thrombosis
Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS).
Thrombosis
Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome.
Thrombosis
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Thrombosis
Erythrocyte compression index is impaired in patients with residual vein obstruction.
Thrombosis
Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
Thrombosis
Establishing the Transient Mass Balance of Thrombosis: From Tissue Factor to Thrombin to Fibrin Under Venous Flow.
Thrombosis
Evaluation of a post-operative thrombin inhibitor replacement protocol to reduce haemorrhagic and thrombotic complications after paediatric liver transplantation.
Thrombosis
Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model.
Thrombosis
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Thrombosis
Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents.
Thrombosis
Evaluation of Morphological and Clinical Factors Related to Failure of Percutaneous Treatment with Thrombin Injection of Femoral Pseudoaneurysms from Cardiac Catheterization.
Thrombosis
Evaluation of plaque stability of advanced atherosclerotic lesions in apo e-deficient mice after treatment with the oral factor xa inhibitor rivaroxaban.
Thrombosis
Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis.
Thrombosis
Evaluation of the effects of esophageal varicosclerosants on local vascular occlusion and systemic blood coagulation.
Thrombosis
Evaluation of the in vitro detection of the hypercoagulable state using the thrombin generation test and plasma clot impedance test.
Thrombosis
Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography.
Thrombosis
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Thrombosis
Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression.
Thrombosis
Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation.
Thrombosis
Expect the unexpected: acute and subacute coronary stent thrombosis following percutaneous thrombin injection for treatment of femoral pseudoaneurysm.
Thrombosis
Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Thrombosis
Experimental studies of injection agents for peptic ulcer bleeding endoscopic control.
Thrombosis
Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor.
Thrombosis
Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Thrombosis
Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding.
Thrombosis
Exploring potential anticoagulant drug formulations using thrombin generation test.
Thrombosis
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Thrombosis
Expression of thrombin receptors in endothelial cells and neutrophils from normal and preeclamptic pregnancies.
Thrombosis
Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.
Thrombosis
Facilitating roles of murine platelet glycoprotein Ib and alphaIIbbeta3 in phosphatidylserine exposure during vWF-collagen-induced thrombus formation.
Thrombosis
Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions.
Thrombosis
Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates.
Thrombosis
Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available.
Thrombosis
Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.
Thrombosis
Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.
Thrombosis
Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
Thrombosis
Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.
Thrombosis
Failure of thrombin-antithrombin III complexes in the diagnosis of deep vein thrombosis.
Thrombosis
Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.
Thrombosis
Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis.
Thrombosis
Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V.
Thrombosis
Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia.
Thrombosis
Femoral artery thrombosis after percutaneous thrombin injection of an external iliac artery pseudoaneurysm.
Thrombosis
Femoral artery thrombosis following percutaneous treatment with thrombin injection of a femoral artery pseudoaneurysm: a case report.
Thrombosis
Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery.
Thrombosis
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Thrombosis
Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
Thrombosis
Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin.
Thrombosis
Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo.
Thrombosis
Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway.
Thrombosis
Fibrinolytic and Thrombolytic Effects of an Enzyme Purified from the Fruiting Bodies of Boletus pseudocalopus (Agaricomycetes) from Korea.
Thrombosis
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Thrombosis
First trimester maternal concentrations of thrombin-inhibitor complexes and the presence of histologic placental lesions at delivery.
Thrombosis
Flow and delta-P dictate where thrombin, fibrin, and von Willebrand Factor will be found.
Thrombosis
Flow and thrombosis at orifices simulating mechanical heart valve leakage regions.
Thrombosis
Flow mediated fibrin thrombus formation in an endothelium-lined model of arterial branching.
Thrombosis
Food-derived antithrombotic peptides: Preparation, identification, and interactions with thrombin.
Thrombosis
Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages.
Thrombosis
Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin.
Thrombosis
Functional cyclophilin D moderates platelet adhesion, but enhances the lytic resistance of fibrin.
Thrombosis
Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom.
Thrombosis
Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits.
Thrombosis
FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834.
Thrombosis
Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis.
Thrombosis
Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.
Thrombosis
Genome sequencing, purification, and biochemical characterization of a strongly fibrinolytic enzyme from Bacillus amyloliquefaciens Jxnuwx-1 isolated from Chinese traditional douchi.
Thrombosis
Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
Thrombosis
Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin.
Thrombosis
Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction.
Thrombosis
Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction: tailoring therapies to optimize outcome.
Thrombosis
Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo.
Thrombosis
GPV is a marker of in vivo platelet activation--study in a rat thrombosis model.
Thrombosis
Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation.
Thrombosis
Hemocompatibility and anti-fouling behavior of multilayer biopolymers immobilized on gold-thiolized drug-eluting cardiovascular stents.
Thrombosis
Hemostasis and anti-necrotic activity of wound-healing dressing containing chitosan nanoparticles.
Thrombosis
Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers.
Thrombosis
Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
Thrombosis
Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction.
Thrombosis
Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus.
Thrombosis
Heparin, heparin plus ASA and dipyridamole, and arteriovenous fistula as adjuvant methods to prevent rethrombosis after venous thrombectomy. Experimental study in rabbits.
Thrombosis
Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
Thrombosis
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.
Thrombosis
Heparin-induced thrombocytopenia type II: a serious hazard in preemptive renal transplantation: a case report.
Thrombosis
Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis.
Thrombosis
Heparin-Like Chitosan Hydrogels with Tunable Swelling Behavior, Prolonged Clotting Times, and Prevented Contact Activation and Complement Activation.
Thrombosis
High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.
Thrombosis
High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains.
Thrombosis
Hirudin and other thrombin inhibitors experimental results and potential clinical applications.
Thrombosis
Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries.
Thrombosis
Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.
Thrombosis
Homology model of human prothrombinase based on the crystal structure of Pseutarin C.
Thrombosis
Human endometrial endothelial cells: isolation, characterization, and inflammatory-mediated expression of tissue factor and type 1 plasminogen activator inhibitor.
Thrombosis
Human platelets contain SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is phosphorylated after thrombin activation: implications for platelet secretion.
Thrombosis
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.
Thrombosis
Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass.
Thrombosis
Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity.
Thrombosis
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.
Thrombosis
Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect.
Thrombosis
Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes.
Thrombosis
Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI.
Thrombosis
Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth.
Thrombosis
Identification of a thrombin sequence with growth factor activity on macrophages.
Thrombosis
Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2).
Thrombosis
Identification of the functional food ingredients with antithrombotic properties via virtual screen and experimental studies.
Thrombosis
Impact of aerobic exercise on haemostatic indices in pediatric patients with haemophilia.
Thrombosis
Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots.
Thrombosis
Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.
Thrombosis
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis.
Thrombosis
Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets.
Thrombosis
Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys.
Thrombosis
Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
Thrombosis
In prothrombin G20210A carriers the genetic mutation and the history of Venous Thrombosis contribute both to thrombin generation independently of factor II plasma levels.
Thrombosis
In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
Thrombosis
In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIb?.
Thrombosis
In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
Thrombosis
In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach.
Thrombosis
In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recanalization.
Thrombosis
In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe.
Thrombosis
In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi.
Thrombosis
In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy.
Thrombosis
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
Thrombosis
In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Thrombosis
Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.
Thrombosis
Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina.
Thrombosis
Increased platelet, but unaltered fibrinogen, accumulation in experimental thrombi in alloxan-induced diabetic rabbits.
Thrombosis
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Thrombosis
Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event.
Thrombosis
Independent ischemic stroke risk factors in older Americans: a systematic review.
Thrombosis
Indium-111 platelet scintigraphy and two-dimensional echocardiography for detection of left ventricular thrombus: influence of clot size and age.
Thrombosis
Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis.
Thrombosis
Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.
Thrombosis
Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.
Thrombosis
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
Thrombosis
Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist.
Thrombosis
Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Thrombosis
Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis.
Thrombosis
Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy.
Thrombosis
Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
Thrombosis
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Thrombosis
Inhibition of platelets and thrombin: implications for treatment of coronary artery thrombosis.
Thrombosis
Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
Thrombosis
Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor.
Thrombosis
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
Thrombosis
Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro.
Thrombosis
Inhibitors of serine proteinases from blood coagulation cascade - view on current developments.
Thrombosis
Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
Thrombosis
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Thrombosis
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Thrombosis
Initial clinical use of a novel mechanical thrombectomy device, XCOILTM, in hemodialysis graft and fistula declot procedures.
Thrombosis
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Thrombosis
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Thrombosis
Interaction of the factor XIII activation peptide with alpha -thrombin. Crystal structure of its enzyme-substrate analog complex.
Thrombosis
Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in haemostasis.
Thrombosis
Intercostal artery pseudoaneurysm after ultrasound-guided liver biopsy: a case report and review of the literature.
Thrombosis
Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism.
Thrombosis
Interindividual Variability and Normal Ranges of Whole Blood and Plasma Thrombin Generation.
Thrombosis
Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice.
Thrombosis
Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis.
Thrombosis
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Thrombosis
Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report.
Thrombosis
Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
Thrombosis
Interventional therapy for stenosis and aneurysm in renal graft artery: report of 9 cases.
Thrombosis
Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury.
Thrombosis
Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab.
Thrombosis
Intracardiac thrombus in a patient with mitral bioprosthesis and atrial fibrillation treated with direct oral anticoaugulant: A case report.
Thrombosis
Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical and angiographic correlation.
Thrombosis
Intraoperative thrombolytic therapy as a treatment of small vessel thrombosis: an experimental study.
Thrombosis
Intraprocedural and postprocedural perigraft arterial sac embolization (PASE) for endoleak treatment.
Thrombosis
Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in precapillary pulmonary arterioles.
Thrombosis
Intravascular thrombosis: definitive detection by quantitative tissue characterization in vitro.
Thrombosis
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Thrombosis
Introducing the pro-coagulant contact system in the numerical assessment of device-related thrombosis.
Thrombosis
Introduction of a thrombin sensor based on its interaction with dabigatran as an oral direct thrombin inhibitor.
Thrombosis
Investigation into the mechanism(s) of antithrombotic effects of carbon monoxide releasing molecule-3 (CORM-3).
Thrombosis
Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models.
Thrombosis
Investigation of Interactions between Thrombin and Ten Phenolic Compounds by Affinity Capillary Electrophoresis and Molecular Docking.
Thrombosis
Investigation of the anticoagulant and antithrombotic effects of chlorogenic acid.
Thrombosis
Investigation of the selectivity of thrombin-binding aptamers for thrombin titration in murine plasma.
Thrombosis
Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days.
Thrombosis
Ipsilateral femoral vein compression: a contraindication to thrombin injection of femoral pseudoaneurysms.
Thrombosis
Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass?
Thrombosis
Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Thrombosis
Is thrombin generation at the time of an acute thromboembolic episode a predictor of recurrence? The LInköping Study on Thrombosis (LIST)--a 7-year follow-up.
Thrombosis
Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1.
Thrombosis
Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition.
Thrombosis
Kinetics of pulmonary platelet deposition and clearance during thrombin-induced microembolism in rabbits.
Thrombosis
Kinetics of the coagulation cascade including the contact activation system: sensitivity analysis and model reduction.
Thrombosis
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor.
Thrombosis
Label-free aptamer biosensor for thrombin detection based on functionalized graphene nanocomposites.
Thrombosis
Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons.
Thrombosis
LB30057, an orally effective direct thrombin inhibitor, prevents arterial and venous thrombosis in rats and dogs.
Thrombosis
Leaf-Inspired Authentically Complex Microvascular Networks for Deciphering Biological Transport Process.
Thrombosis
Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report.
Thrombosis
Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism.
Thrombosis
Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis.
Thrombosis
Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty.
Thrombosis
Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock.
Thrombosis
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Thrombosis
Local thrombin synthesis and fibrin formation in an in vitro thrombosis model result in platelet recruitment and thrombus stabilization on collagen in heparinized blood.
Thrombosis
Long-term estrogen treatment of mice with a prothrombotic phenotype induces sustained increases in thrombin generation without affecting tissue fibrin deposition.
Thrombosis
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Thrombosis
Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm.
Thrombosis
Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells.
Thrombosis
Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients.
Thrombosis
Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow.
Thrombosis
M-AAA-Thrombin: Potent anticoagulant and antiplatelet thrombin derivative with differential affinity for factor VIII and PAR1.
Thrombosis
Management of a spontaneous renal capsule hematoma following cardiac catheterization involving use of a platelet glycoprotein IIb/IIIa inhibitor: a case report.
Thrombosis
Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
Thrombosis
Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction.
Thrombosis
Mathematical analysis of mural thrombogenesis. Concentration profiles of platelet-activating agents and effects of viscous shear flow.
Thrombosis
Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
Thrombosis
Measurement of hematological, clinical chemistry, and infection parameters from hirudinized blood collected in universal blood sampling tubes.
Thrombosis
Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations.
Thrombosis
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
Thrombosis
Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).
Thrombosis
Mechanical thrombectomy and intravascular imaging for cerebral venous sinus thrombosis: a preclinical model.
Thrombosis
Mechanical Thrombectomy of Iliac Vein Thrombosis in a Pig Model Using the Rotarex and Aspirex Catheters.
Thrombosis
Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
Thrombosis
Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S.
Thrombosis
Mechano-rheological properties of the murine thrombus determined via nanoindentation and finite element modeling.
Thrombosis
Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice.
Thrombosis
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Thrombosis
Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis.
Thrombosis
MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10.
Thrombosis
Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages.
Thrombosis
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.
Thrombosis
Modality-Specific Occult Intrarenal Pseudoaneurysm in a Renal Allograft and the Legacy of Catheter Angiography.
Thrombosis
Modeling Thrombus Shell: Linking Adhesion Receptor Properties and Macroscopic Dynamics.
Thrombosis
Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha.
Thrombosis
Modulation of osteoblast-like cell behavior by activation of protease-activated receptor-1.
Thrombosis
Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A.
Thrombosis
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Thrombosis
Molecular biology: insight into the causes and prevention of restenosis after arterial intervention.
Thrombosis
Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.
Thrombosis
Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes.
Thrombosis
Monitoring Compound-Related Effects on Coagulability in Rats and Cynomolgus and Rhesus Monkeys by Thrombin Generation Kinetic Measurement.
Thrombosis
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Thrombosis
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
Thrombosis
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary Intervention.
Thrombosis
Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor.
Thrombosis
Multifunctional Thrombin-Activatable Polymer Capsules for Specific Targeting to Activated Platelets.
Thrombosis
Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis.
Thrombosis
Multiscale model of fibrin accumulation on the blood clot surface and platelet dynamics.
Thrombosis
Multiscale simulation of thrombus growth and vessel occlusion triggered by collagen/tissue factor using a data-driven model of combinatorial platelet signalling.
Thrombosis
Multivessel coronary thrombosis resulting from heparin induced thrombocytopenia.
Thrombosis
NADPH oxidase 1 is a novel pharmacological target for the development of an antiplatelet drug without bleeding side effects.
Thrombosis
NADPH Oxidases Are Required for Full Platelet Activation In Vitro and Thrombosis In Vivo but Dispensable for Plasma Coagulation and Hemostasis.
Thrombosis
Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis.
Thrombosis
Near-Patient Thrombin Generation in Patients Undergoing Elective Cardiac Surgery.
Thrombosis
Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation.
Thrombosis
New acrylic microspheres for arterial embolization: combining radiopacity for precise localization with immobilized thrombin to trigger local blood coagulation.
Thrombosis
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Thrombosis
NLRP3 regulates platelet integrin ?IIb?3 outside-in signaling, hemostasis and arterial thrombosis.
Thrombosis
NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation.
Thrombosis
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.
Thrombosis
Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.
Thrombosis
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Thrombosis
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Thrombosis
Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Thrombosis
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Thrombosis
Normal pregnancy is associated with an increase in thrombin generation from the very early stages of the first trimester.
Thrombosis
Novel anti-platelet activity of protocatechuic acid through inhibition of high shear stress-induced platelet aggregation.
Thrombosis
Novel Anticoagulant Peptide from Lactoferrin Binding Thrombin at the Active Site and Exosite-I.
Thrombosis
Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.
Thrombosis
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Thrombosis
Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia.
Thrombosis
Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation.
Thrombosis
Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression.
Thrombosis
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Thrombosis
Novel single nucleotide mutations in exon-10 of human coagulation Factor V gene in patients with pulmonary thromboembolism.
Thrombosis
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Thrombosis
Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin.
Thrombosis
On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences.
Thrombosis
Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation.
Thrombosis
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Thrombosis
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.
Thrombosis
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.
Thrombosis
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Thrombosis
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Thrombosis
Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog.
Thrombosis
Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.
Thrombosis
Organ-on-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems.
Thrombosis
Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction.
Thrombosis
Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis.
Thrombosis
PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Thrombosis
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.
Thrombosis
Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.
Thrombosis
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.
Thrombosis
Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Thrombosis
Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization.
Thrombosis
Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: an alternative to sonographically guided compression.
Thrombosis
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Thrombosis
Percutaneous repair of abdominal aortic pseudoaneurysm by catheter-based delivery of thrombin.
Thrombosis
Percutaneous thrombin injection in an infant to treat hepatic artery pseudoaneurysm after failed embolization.
Thrombosis
Percutaneous thrombin injection of a pulmonary artery pseudoaneurysm refractory to coil embolization.
Thrombosis
Percutaneous ultrasonographically guided thrombin injection of iatrogenic pseudoaneurysms in unusual sites.
Thrombosis
Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms.
Thrombosis
Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis.
Thrombosis
Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Thrombosis
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Thrombosis
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Thrombosis
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Thrombosis
Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
Thrombosis
Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin.
Thrombosis
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Thrombosis
Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis.
Thrombosis
Pharmacological Profile of JNJ-64179375: A Novel, Long Acting Exosite-1 Thrombin Inhibitor.
Thrombosis
Pharmacophore Design, Virtual Screening, Molecular Docking and Optimization Approaches to Discover Potent Thrombin Inhibitors.
Thrombosis
Phenolic-amine chemistry mediated synergistic modification with polyphenols and thrombin inhibitor for combating the thrombosis and inflammation of cardiovascular stents.
Thrombosis
Phloretin suppresses thrombin-mediated leukocyte-platelet-endothelial interactions.
Thrombosis
Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties.
Thrombosis
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia.
Thrombosis
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Thrombosis
Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI.
Thrombosis
Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis.
Thrombosis
Plasma level changes of fibrinopeptide A after uncomplicated coronary angioplasty.
Thrombosis
Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets.
Thrombosis
Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII.
Thrombosis
Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.
Thrombosis
Platelet adhesion to human brain microvascular endothelial cells in vitro. Observation with video-enhanced contrast microscopy.
Thrombosis
Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists.
Thrombosis
Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin.
Thrombosis
Platelet and leukocyte activation in salvaged blood and the effect of its reinfusion on the circulating blood.
Thrombosis
Platelet Control of Fibrin Distribution and Microelasticity in Thrombus Formation Under Flow.
Thrombosis
Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Thrombosis
Platelet full length TFPI-? in healthy volunteers is not affected by sex or hormonal use.
Thrombosis
Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects.
Thrombosis
Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion.
Thrombosis
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
Thrombosis
Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.
Thrombosis
Platelet-derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice.
Thrombosis
Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study.
Thrombosis
Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis.
Thrombosis
Platelet-targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse.
Thrombosis
Platelets and coagulation in thrombus formation: aberrations in the Scott syndrome.
Thrombosis
Platelets loaded with thrombin-encapsulated liposomes have increased coagulability.
Thrombosis
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment.
Thrombosis
PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?
Thrombosis
Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
Thrombosis
Possibility of Using Mesenchymal Stromal Cells to Restore Lymph Flow in Experimental Phlebothrombosis.
Thrombosis
Post-sternotomy intercostal artery pseudoaneurysm. Sonographic diagnosis and thrombosis by ultrasound-guided percutaneous thrombin injection.
Thrombosis
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Thrombosis
Postpartum coronary artery dissection complicated by heparin-induced thrombocytopenia and thrombosis.
Thrombosis
Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
Thrombosis
Potent Trivalent Inhibitors of Thrombin through Hybridization of Salivary Sulfopeptides from Hematophagous Arthropods.
Thrombosis
Potential different impact of inhibition of thrombin function and thrombin generation rate for the growth of thrombi formed at site of endothelial injury under blood flow condition.
Thrombosis
Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes.
Thrombosis
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Thrombosis
Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice.
Thrombosis
Practical recommendations on incorporating new oral anticoagulants into routine practice.
Thrombosis
Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method.
Thrombosis
Preclinical safety and efficacy evaluation of the Pipeline Vantage Embolization Device with Shield Technology.
Thrombosis
Prediction of enzyme binding: human thrombin inhibition study by quantum chemical and artificial intelligence methods based on X-ray structures.
Thrombosis
Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study.
Thrombosis
Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition.
Thrombosis
Prekallikrein deficiency in a 15-year-old boy with Ménière's disease: a case report.
Thrombosis
Preparation of anhydrothrombin and characterization of its interaction with natural thrombin substrates.
Thrombosis
Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
Thrombosis
Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis.
Thrombosis
Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin.
Thrombosis
Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
Thrombosis
Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Thrombosis
Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Thrombosis
Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Thrombosis
Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II.
Thrombosis
Prevention of thrombus formation with glyprolines on various models of prethrombotic state and thrombosis in rats.
Thrombosis
Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy.
Thrombosis
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.
Thrombosis
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Thrombosis
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Thrombosis
Procoagulant Adaptation of a Blood Coagulation Prothrombinase-like Enzyme Complex in Australian Elapid Venom.
Thrombosis
Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli.
Thrombosis
Production of thrombi on intact endothelium by use of antiheparin agents in vivo.
Thrombosis
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Thrombosis
Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants.
Thrombosis
Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245.
Thrombosis
Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.
Thrombosis
Prolonged expression of procoagulant activity of human platelets degranulated by thrombin.
Thrombosis
Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries.
Thrombosis
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.
Thrombosis
Prospective randomized study comparing ultrasound-guided thrombin injection to compression in the treatment of femoral pseudoaneurysms.
Thrombosis
Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes.
Thrombosis
Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Thrombosis
Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism.
Thrombosis
Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice.
Thrombosis
Proteomic Signature of Thrombin-Activated Platelets After In Vivo Nitric Oxide-Donor Treatment: Coordinated Inhibition of Signaling (Phosphatidylinositol 3-Kinase-{gamma}, 14-3-3{zeta}, and Growth Factor Receptor-Bound Protein 2) and Cytoskeleton Protein Translocation.
Thrombosis
Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.
Thrombosis
Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease.
Thrombosis
Prothrombotic effects of high uric acid in mice via activation of MEF2C-dependent NF-?B pathway by upregulating let-7c.
Thrombosis
Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va.
Thrombosis
Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.
Thrombosis
Prototype percutaneous thrombolytic device: preclinical testing in subacute inferior vena caval thrombosis in a pig model.
Thrombosis
Protraction of whole blood and plasma clot lysis in patients with high levels of an inhibitor of tissue-type plasminogen activator.
Thrombosis
Purification and Biochemical Characterization of a Novel Fibrinolytic Enzyme from Culture Supernatant of Cordyceps militaris.
Thrombosis
Purification, compositional analysis, and anticoagulant capacity of chondroitin sulfate/dermatan sulfate from bone of corb (Sciaena umbra).
Thrombosis
Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis.
Thrombosis
QSAR studies of N(1)-(5-chloro-2-pyridyl)-2-{[4-(alkyl methyl)benzoyl]amino}-5-chlorobenzamide analogs.
Thrombosis
Quantification of device adherent, circulating, and organ pool of thrombin and fibrinogen after cardiopulmonary bypass in a pig model.
Thrombosis
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Thrombosis
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Thrombosis
Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase.
Thrombosis
Rate-limiting roles of tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.
Thrombosis
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
Thrombosis
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes.
Thrombosis
Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia.
Thrombosis
Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review.
Thrombosis
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Thrombosis
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Thrombosis
Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo.
Thrombosis
Recombinant human activated protein C: current insights into its mechanism of action.
Thrombosis
Recombinant soluble human thrombomodulin: a randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model.
Thrombosis
Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.
Thrombosis
Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin.
Thrombosis
Recombinant thrombomodulin inhibits thrombin-induced vascular endothelial growth factor production in neuronal cells.
Thrombosis
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Thrombosis
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Thrombosis
Reduced model to predict thrombin and fibrin during thrombosis on collagen/tissue factor under venous flow: Roles of ?'-fibrin and factor XIa.
Thrombosis
Reduced thrombus formation in native blood of homozygous factor VII-deficient patients at high arterial wall shear rate.
Thrombosis
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
Thrombosis
Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice.
Thrombosis
Regulation of mitochondrial function as a promising target in platelet activation-related diseases.
Thrombosis
Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina.
Thrombosis
Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity.
Thrombosis
Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
Thrombosis
Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis.
Thrombosis
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Thrombosis
Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs.
Thrombosis
Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran: A first case report.
Thrombosis
Resolution of intracoronary thrombus with direct thrombin inhibition in a cocaine abuser.
Thrombosis
Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
Thrombosis
Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.
Thrombosis
Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment.
Thrombosis
Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Thrombosis
Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis.
Thrombosis
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Thrombosis
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Thrombosis
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Thrombosis
Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis.
Thrombosis
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
Thrombosis
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Thrombosis
Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Thrombosis
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis.
Thrombosis
Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation.
Thrombosis
Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model.
Thrombosis
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Thrombosis
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice.
Thrombosis
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Thrombosis
Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms.
Thrombosis
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction.
Thrombosis
Scanning electron microscopy of experimental thrombus formation in canine lateral saphena vein.
Thrombosis
Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms.
Thrombosis
Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation.
Thrombosis
Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.
Thrombosis
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Thrombosis
Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing.
Thrombosis
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Thrombosis
Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
Thrombosis
Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury.
Thrombosis
Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.
Thrombosis
Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A.
Thrombosis
Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II.
Thrombosis
Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation.
Thrombosis
Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Thrombosis
Simultaneous measurement of thrombin generation and fibrin formation in whole blood under flow conditions.
Thrombosis
Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation.
Thrombosis
Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa.
Thrombosis
Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation.
Thrombosis
Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo.
Thrombosis
Solidification mechanisms of chitosan-glycerol phosphate/blood implant for articular cartilage repair.
Thrombosis
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke.
Thrombosis
Spatial aspects of blood coagulation: Two decades of research on the self-sustained traveling wave of thrombin.
Thrombosis
Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear.
Thrombosis
Spontaneous pseudo-aneurysm of the deep femoral artery treated by a covered stent.
Thrombosis
Standardization of a well-controlled in vivo mouse model of thrombus formation induced by mechanical injury.
Thrombosis
Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells.
Thrombosis
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Thrombosis
Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
Thrombosis
Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding.
Thrombosis
Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist.
Thrombosis
Structural stability of human alpha-thrombin studied by disulfide reduction and scrambling.
Thrombosis
Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19.
Thrombosis
STUDIES ON BLOOD COAGULATION : IV. THE NATURE OF THE CLOTTING DEFICIENCY IN HEMOPHILIA.
Thrombosis
Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits.
Thrombosis
Study of factors that may condition scintigraphic detection of venous thrombi and pulmonary emboli with indium-111-labeled platelets.
Thrombosis
Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay.
Thrombosis
Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor.
Thrombosis
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability.
Thrombosis
Sulfated modification and anticoagulant activity of pumpkin (Cucurbita pepo, Lady Godiva) polysaccharide.
Thrombosis
Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets.
Thrombosis
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Thrombosis
Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain.
Thrombosis
Surface characterization and platelet adhesion studies on polyethylene surface with hirudin immobilization.
Thrombosis
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
Thrombosis
Susceptibility to thrombosis in normal young, aging, cortisone-treated, heparinized and x-irradiated hamsters as tested by topical application of thrombin.
Thrombosis
Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Thrombosis
Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
Thrombosis
Sustained-release synthetic biomarkers for monitoring thrombosis and inflammation using point-of-care compatible readouts.
Thrombosis
Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation.
Thrombosis
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Thrombosis
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Thrombosis
Synergy between thrombin and serotonin in inducing vascular smooth muscle cell proliferation.
Thrombosis
Systemic thromboses after cardiopulmonary bypass: is it thrombin or antithrombin?
Thrombosis
t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction.
Thrombosis
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.
Thrombosis
Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation.
Thrombosis
Targeting Factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Thrombosis
Targeting of externalized ?B-crystallin on irradiated endothelial cells with pro-thrombotic vascular targeting agents: Potential applications for brain arteriovenous malformations.
Thrombosis
Targeting platelet GPIb? reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis.
Thrombosis
Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis.
Thrombosis
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
Thrombosis
The 29-kDa proteins phosphorylated in thrombin-activated human platelets are forms of the estrogen receptor-related 27-kDa heat shock protein.
Thrombosis
The activated factor X-antithrombin III reaction rate: a measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits.
Thrombosis
The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
Thrombosis
The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays.
Thrombosis
The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Thrombosis
The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Thrombosis
The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis.
Thrombosis
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Thrombosis
The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis.
Thrombosis
The association of direct thrombin inhibitor anticoagulants with cardiac thromboses.
Thrombosis
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Thrombosis
The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.
Thrombosis
The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha(IIb)beta(3) function.
Thrombosis
The class I phosphoinositide 3-kinases ? and ? control antiphospholipid antibodies-induced platelet activation.
Thrombosis
The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro.
Thrombosis
The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding.
Thrombosis
The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Thrombosis
The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Thrombosis
The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment.
Thrombosis
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A.
Thrombosis
The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Thrombosis
The discovery and characterization of a novel nucleotide-based thrombin inhibitor.
Thrombosis
The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats.
Thrombosis
The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine.
Thrombosis
The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study.
Thrombosis
The effect of cigarette smoke extract on thrombomodulin-thrombin binding: an atomic force microscopy study.
Thrombosis
The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models.
Thrombosis
The effect of high-density-lipoprotein on thrombus formation on and endothelial cell attachement to biomaterial surfaces.
Thrombosis
The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
Thrombosis
The effect of thrombin on low-density lipoprotein permeability and uptake by an arterial endothelial smooth muscle cell bilayer.
Thrombosis
The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
Thrombosis
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
Thrombosis
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Thrombosis
The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI.
Thrombosis
The factor VII zymogen structure reveals reregistration of beta strands during activation.
Thrombosis
The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test.
Thrombosis
The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury.
Thrombosis
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Thrombosis
The Importance of Tissue Factor Expression by Porcine NICC in Triggering IBMIR in the Xenograft Setting.
Thrombosis
The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Thrombosis
The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin.
Thrombosis
The Influence of Flow on the Concentration of Platelet Active Substances in the Vicinity of Mural Microthrombi.
Thrombosis
The Influence of Hindered Transport on the Development of Platelet Thrombi Under Flow.
Thrombosis
The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein.
Thrombosis
The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
Thrombosis
The levels of five markers of hemostasis and endothelial status at different stages of normotensive pregnancy.
Thrombosis
The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.
Thrombosis
The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
Thrombosis
The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner.
Thrombosis
The relation among vessel injury, thrombus formation, and platelet survival in rabbits.
Thrombosis
The relationship between aortic aneurysm sac thrombus volume on coagulation, fibrinolysis and platelet activity.
Thrombosis
The relationship between thrombin and platelets: linking vessel injury to thrombosis and inflammation.
Thrombosis
The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
Thrombosis
The response of smooth muscle cells to alpha-thrombin depends on its arterial origin: comparison among different species.
Thrombosis
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.
Thrombosis
The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.
Thrombosis
The role of leukocytes in acute ischemic stroke-related thrombosis: a notable but neglected topic.
Thrombosis
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
Thrombosis
The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer.
Thrombosis
The thrombin inhibitors hirudin and Refludan® activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets.
Thrombosis
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo.
Thrombosis
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
Thrombosis
The trimeric autotransporter DsrA is a major mediator of fibrinogen binding in Haemophilus ducreyi.
Thrombosis
The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism.
Thrombosis
The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial.
Thrombosis
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Thrombosis
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Thrombosis
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Thrombosis
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Thrombosis
Thrombin and fibrin-induced growth of fibroblasts: role in wound repair and thrombus organization.
Thrombosis
Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process.
Thrombosis
Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells.
Thrombosis
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis.
Thrombosis
Thrombin augments vascular cell-dependent migration of human mast cells: role of MGF.
Thrombosis
Thrombin binding to GPIbalpha induces integrin alphaIIbbeta3 dependent platelet adhesion to fibrin in ex vivo flowing whole blood.
Thrombosis
Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells.
Thrombosis
Thrombin bound to a fibrin clot confers angiogenic and hemostatic properties on endothelial progenitor cells.
Thrombosis
Thrombin elaboration in endotoxin-induced intravascular fibrin deposition. A leukocyte dependent process distinct from systemic hypercoagulability.
Thrombosis
Thrombin Exosite 1 Inhibition with JNJ-64179375 Inhibits Thrombus Formation in a Human Translational Model of Thrombosis.
Thrombosis
Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow.
Thrombosis
Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
Thrombosis
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Thrombosis
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombosis
Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics.
Thrombosis
Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis.
Thrombosis
Thrombin generation by intimal tissue factor contributes to thrombus formation on macrophage-rich neointima but not normal intima of hyperlipidemic rabbits.
Thrombosis
Thrombin Generation Following Severe Trauma: Mechanisms, Modulators, and Implications For Hemostasis And Thrombosis.
Thrombosis
Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in Patients with GDM.
Thrombosis
Thrombin generation in plasma: its assessment via the endogenous thrombin potential.
Thrombosis
Thrombin generation in subjects with lupus anticoagulant without prior thrombosis or gestational morbidities.
Thrombosis
Thrombin generation test as a marker for high risk venous thrombosis pregnancies.
Thrombosis
Thrombin generation test based on a 96-channel pipettor for evaluation of FXIa procoagulant activity in pharmaceuticals.
Thrombosis
Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells.
Thrombosis
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Thrombosis
Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism.
Thrombosis
Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
Thrombosis
Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection.
Thrombosis
Thrombin Inhibition: Preliminary Assessment of the Anticoagulant Potential of Turnera subulata (Passifloraceae).
Thrombosis
Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
Thrombosis
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Thrombosis
Thrombin injection for treatment of false aneurysms after failed compression therapy in patients on full-dose antiplatelet and heparin therapy.
Thrombosis
Thrombin mediates the extraintestinal thrombosis associated with experimental colitis.
Thrombosis
Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency.
Thrombosis
Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation.
Thrombosis
Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood.
Thrombosis
Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes.
Thrombosis
Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell.
Thrombosis
Thrombin rapidly induces protein kinase D phosphorylation, and protein kinase C delta mediates the activation.
Thrombosis
Thrombin regulation in children differs from adults in the absence and presence of heparin.
Thrombosis
Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation.
Thrombosis
Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase C-dependent and -independent pathways.
Thrombosis
Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification.
Thrombosis
Thrombin stimulated platelet accumulation on protein coated glass capillaries: role of adhesive platelet alpha-granule proteins.
Thrombosis
Thrombin stimulates syndecan-1 promotor activity and expression of a form of syndecan-1 that binds antithrombin III in vascular smooth muscle cells.
Thrombosis
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
Thrombosis
Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro.
Thrombosis
Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-?B pathways in human lung epithelial cells.
Thrombosis
Thrombin-induced NF-?B activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells.
Thrombosis
Thrombin-loaded alginate-calcium microspheres: A novel hemostatic embolic material for transcatheter arterial embolization.
Thrombosis
Thrombin-sensitive expression of the store operated Ca(2+) channel Orai1 in platelets.
Thrombosis
Thrombin-Targeted Liposomes Establish A Sustained Localized Anticlotting Barrier Against Acute Thrombosis.
Thrombosis
Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.
Thrombosis
Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis.
Thrombosis
Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.
Thrombosis
Thrombogenicity of small-diameter prosthetic grafts: relative contributions of graft-associated thrombin and factor Xa.
Thrombosis
Thrombolysis by rotational thrombectomy followed by tissue plasminogen activator: evaluation by angioscopy.
Thrombosis
Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism.
Thrombosis
Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis.
Thrombosis
Thrombomodulin is associated with increased mortality and organ failure in mechanically ventilated children with acute respiratory failure: biomarker analysis from a multicenter randomized controlled trial.
Thrombosis
Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis.
Thrombosis
Thrombomodulin, an endothelial anticoagulant; its structure, function and expression.
Thrombosis
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Thrombosis
Thromboplastic activity of human arterial walls and its interaction with the plasmatic coagulation system.
Thrombosis
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.
Thrombosis
Thrombosis of a proximal aortic false aneurysm following AAA repair by endovascular thrombin injection.
Thrombosis
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
Thrombosis
Thrombus formation by the application of thrombin to the outer surface of mouse mesenteric vein: comparison with the application of ADP.
Thrombosis
Thrombus formation on apex of arterial stenoses: the need for a fluid high shear stenosis diagnostic device.
Thrombosis
Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
Thrombosis
Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi.
Thrombosis
Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.
Thrombosis
Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?
Thrombosis
Thrombus-induced endothelial dysfunction: Hemoglobin and fibrin decrease nitric oxide bioactivity without altering eNOS.
Thrombosis
Thrombus-targeted nanoparticles for thrombin-triggered thrombolysis and local inflammatory microenvironment regulation.
Thrombosis
Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.
Thrombosis
Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model.
Thrombosis
Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity.
Thrombosis
Titration of Bivalirudin Infusion in the Pediatric Cardiac Catheterization Laboratory: A Case Report.
Thrombosis
Towards standardization of thrombin generation assays: Inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey.
Thrombosis
Transient intermittent lymphocyte activation is responsible for the instability of angina.
Thrombosis
Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylserine exposure.
Thrombosis
Translational regulation of the serum- and glucocorticoid-inducible kinase-1 (SGK1) in platelets.
Thrombosis
Transport-Reaction Model of Mural Thrombogenesis: Comparisons of Mathematical Model Predictions and Results from Baboon Models.
Thrombosis
Traumatic Pseudoaneurysm of Anterior Tibial Artery Treated by Thrombin Injection.
Thrombosis
Treatment of accidental perianal injection of topical thrombin with intravenous antithrombin.
Thrombosis
Treatment of Dabigatran-Associated Bleeding: Case Report and Review of the Literature.
Thrombosis
Treatment of femoral artery pseudoaneurysms using ultrasound-guided thrombin injection.
Thrombosis
Treatment of heparin-induced thrombocytopenia: a practical argatroban dosing protocol for nurses.
Thrombosis
Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair.
Thrombosis
Treatment of iatrogenic femoral artery false aneurysms with ultrasound-guided thrombin injection.
Thrombosis
Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection.
Thrombosis
Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin.
Thrombosis
Treatment of iatrogenic pseudoaneurysm of brachial artery with percutaneous ultrasonographically guided thrombin injection (PUGTI): a case report and a literature review.
Thrombosis
Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Thrombosis
Tripeptide SQL Inhibits Platelet Aggregation and Thrombus Formation by Affecting PI3K/Akt Signaling.
Thrombosis
Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.
Thrombosis
Ultrasonography-guided percutaneous thrombin injection of postcatheterization pseudoaneurysms.
Thrombosis
Ultrasound guided human thrombin injection. A new modality in the management of femoral artery pseudo-aneurysms.
Thrombosis
Ultrasound Guided Percutaneous Injection of Thrombin: Effective Technique for Treatment of Iatrogenic Femoral Pseudoaneurysms.
Thrombosis
Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention.
Thrombosis
Ultrasound-Guided Fibrin Glue Injection for Treatment of Iatrogenic Femoral Pseudoaneurysms.
Thrombosis
Ultrasound-guided thrombin injection for the treatment of iatrogenic pseudoaneurysm of the femoral artery.
Thrombosis
Ultrasound-guided thrombin injection for treatment of superficial traumatic pseudoaneurysms and associated expanding hematomas: experience in five patients.
Thrombosis
Ultrasound-guided thrombin injection is the treatment of choice for femoral pseudoaneurysms.
Thrombosis
Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience.
Thrombosis
Ultrasound-guided thrombin injections for arterial pseudoaneurysms: a 14-year study conducted at King Khalid University Hospital Vascular Lab.
Thrombosis
Ultrasound-guided thrombin-gelatin injection is effective for the treatment of iatrogenic femoral artery pseudoaneurysms: Initial results.
Thrombosis
Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation.
Thrombosis
Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
Thrombosis
Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Thrombosis
Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib.
Thrombosis
Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators.
Thrombosis
Up-regulation of fibrinogen-like protein 2 in porcine endothelial cells by xenogeneic CD40 signal.
Thrombosis
Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II.
Thrombosis
Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
Thrombosis
Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.
Thrombosis
Usefulness of Platelet Function Tests to Predict Bleeding with Antithrombotic Medications.
Thrombosis
Validation and application of an automated 96 -well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the quantitative determination of SCH 201781 in human plasma.
Thrombosis
VAMP3 is associated with endothelial Weibel-Palade bodies and participates in their Ca(2+)-dependent exocytosis.
Thrombosis
Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.
Thrombosis
Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Thrombosis
Vasoactive agents and production of thrombosis during intravascular coagulation. 2. alpha-Adrenergic stimulation: effects and mechanisms.
Thrombosis
VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis.
Thrombosis
Vena cava superior syndrome developing in a dialysis patient with antithrombin III deficiency following temporary catheterization.
Thrombosis
Venous puncture wound hemostasis results in a vaulted thrombus structured by locally nucleated platelet aggregates.
Thrombosis
Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
Thrombosis
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
Thrombosis
Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.
Thrombosis
Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Thrombosis
Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.
Thrombosis
Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation.
Thrombosis
[A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)]
Thrombosis
[A novel photochemical model of the middle cerebral artery for thrombosis research and evaluation of anti-thrombotic agents]
Thrombosis
[An experimental study of arterial graft implantation--the effects of an anti-thrombin agent, argatroban, and an anti-platelet agent, clopidogrel (SR 25990 C) on the inner capsule]
Thrombosis
[Antiphospholipid antibodies and thrombosis: the putative mechanisms of hypercoagulable state in patients with anticardiolipin antibody]
Thrombosis
[Application of a monoclonal antibody SZ-51 specific for activated human platelets in canine thrombosis imaging]
Thrombosis
[Artificial arterial thrombosis using solutions of fibrinogen and thrombin (preliminary report)]
Thrombosis
[Besides fibrinogen, are haemostatic, coagulation and/or fibrinolytic parameters predictors or markers of the risk of cardiovascular events?]
Thrombosis
[Coagulation and fibrinolytic activity of lymph in various pathological conditions (review of own and literature data)].
Thrombosis
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
Thrombosis
[Determination of biological activity of extract from hirudo by N-benzoyl-L-arginine ethyl ester]
Thrombosis
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
Thrombosis
[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].
Thrombosis
[Disorders of thrombin interaction with the blood vessel wall and its inactivation by antithrombin III in experimental nephrotic syndrome]
Thrombosis
[Disseminated intravascular coagulation syndrome and thromboembolic complications of non-small-cell lung cancer. A case report]
Thrombosis
[Effects of tetrandrine on platelet aggregation, platelet adhesion and coagulation]
Thrombosis
[Experimental model of early chronic pelvic vein thrombosis with occlusion spirals and thrombin]
Thrombosis
[Experimental retinal vein obstruction induced by transadventitial administration of thrombin in the rabbit]
Thrombosis
[Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report]
Thrombosis
[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.]
Thrombosis
[Influence of suture material on the development of postoperative complications in vascular surgery and their prevention].
Thrombosis
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Thrombosis
[Mechanism of thrombosis: physiopathology, role of thrombin and its inhibition by modern therapies]
Thrombosis
[MORPHOLOGICAL CHANGES AFTER THE USE OF MULTIPOTENT STROMAL CELLS OF BONE MARROW ORIGIN TO RESTORE THE LYMPH FLOW IN THE REGION OF THROMBOSED VEIN].
Thrombosis
[Morphological composition and functions of the human blood coagulating and anticoagulating systems in prolonged exposure to low ammonia concentrations in a sealed environment]
Thrombosis
[Morphological results of stromal stem cells of bone marrow origin into the thrombosed vein in experiment].
Thrombosis
[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)]
Thrombosis
[New pharmaceuticals in cardiology : Heart failure, anticoagulation, dyslipidemia].
Thrombosis
[Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation]
Thrombosis
[Preliminary study on epidemiology of deep venous thrombosis of lower extremity in patients with high risk]
Thrombosis
[Programmed cellular death and atherogenesis: from molecular mechanisms to clinical aspects]
Thrombosis
[Progression from a routine examination to a study. Having come this far, what should be done from now? A thrombosis risk factor study]
Thrombosis
[Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs]
Thrombosis
[Relation of the formation of the fibrin network of a blood clot to the amount of thrombin in complexes with endogenous heparin]
Thrombosis
[Relation of Thromboelastography with Coagulation Function and Plt Count in Different Coagulation States].
Thrombosis
[Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin]
Thrombosis
[Strategies to improve reperfusion with fibrinolytic therapy in ST-T elevation myocardial infarction]
Thrombosis
[Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)].
Thrombosis
[Study on antithrombotic activities and structure-activity relationships of Veratrum nigrum Alkaloids].
Thrombosis
[Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy].
Thrombosis
[The formation of paradoxical thrombin and emboli by an interauricular shunt. Comments on F. Wilh, Zahn's articles: Thrombus formation, current status of this problem. Thrombosis of several branches of the inferior vena cava with consecutive emboli in the pulmonary, splenic, renal and right iliac arteries]
Thrombosis
[The hemostatic system in the acute coronary syndromes: physiopathological and therapeutic implications]
Thrombosis
[The importance of the plasmatic blood clotting system in the early stages of arterial thrombogenesis (author's transl)]
Thrombosis
[Thrombin, enzyme of hemostasis and thrombosis: a model of enzymatic autoregulation]
Thrombosis
[Thrombin-antithrombin III complexes as a measure of effective heparin treatment?]
Thrombosis
[Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)]
Thrombosis
[Treatment of iatrogenic femoral pseudoaneurysms by ultrasound-guided percutaneous thrombin injection: effectiveness and complications]
Thrombosis
[Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.]
Thrombosis
[Ultrasound guided percutaneous thrombin injection for treatment of a pseudoaneurysm after inguinal or brachial catheterization; good results in 14 patients]
Thrombosis
[Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia].
Thrombosis
[Use of thrombin generation assay for the evaluation of coagulation and anticoagulant activity of hemostasis system in patients with abdominal sepsis].
Thrombosis
[Usefulness of sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms]
Thrombotic Microangiopathies
Constitutive expression and modulation of the functional thrombin receptor in the human kidney.
Thrombotic Stroke
Preclinical Evidence Toward the Use of Ketamine for Recombinant Tissue-Type Plasminogen Activator-Mediated Thrombolysis Under Anesthesia or Sedation.
Torsades de Pointes
Computer prediction of cardiovascular and hematological agents by statistical learning methods.
Toxemia
Fibrinopeptide A and intravascular coagulation in normotensive and hypertensive pregnancy and parturition.
Trauma, Nervous System
A novel aspect of thrombin in the tissue reaction following central nervous system injury.
Trauma, Nervous System
Thrombin may contribute to the pathophysiology of central nervous system injury.
Tricuspid Valve Prolapse
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Trypanosomiasis, African
Isolation and characterization of the tsetse thrombin inhibitor: a potent antithrombotic peptide from the saliva of Glossina morsitans morsitans.
Tuberculosis
Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis.
Tuberculosis
[Blood coagulation function in pulmonary tuberculosis patients at the stages of surgical treatment]
Tuberculosis, Pulmonary
[The use of a concentrate of antithrombin III and disaggregants in the preoperative preparation of patients with pulmonary tuberculosis]
Tuberous Sclerosis
Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection.
Univentricular Heart
[Acquired thrombin inhibitor in a 9-year-old child after total correction of univentricular heart with pulmonary atresia and administration of fibrin glue]
Uremia
Deranged platelet calcium homeostasis in diabetic patients with end-stage renal failure. A possible link to increased cardiovascular mortality?
Uremia
Mechanisms of platelet aggregation disturbances and their relation to treatment in patients with chronic uremia.
Uremia
Modulation of the cationic amino acid transport system y+L by surface potential, ouabain and thrombin in human platelets: effects of uremia.
Uremia
Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release.
Urinary Bladder Neoplasms
Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity.
Urinary Incontinence
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Urticaria
Activation of the Blood Coagulation System in Patients with Chronic Spontaneous Urticaria.
Urticaria
Chronic urticaria: A disease at a crossroad between autoimmunity and coagulation.
Urticaria
Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed-pressure urticaria.
Urticaria
Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test.
Urticaria
Increased thrombin generation potential in patients with chronic spontaneous urticaria.
Urticaria
Mast cells are critical for the limitation of thrombin-induced skin inflammation.
Uterine Cervical Neoplasms
Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases.
Uterine Hemorrhage
Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding.
Uterine Hemorrhage
Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells.
Uterine Hemorrhage
The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states.
Uterine Hemorrhage
Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding.
Uterine Hemorrhage
Transvaginal ultrasound-guided direct thrombin injection for the treatment of intramyometrial pseudoaneurysm in a young female with uterine hemorrhage after failed uterine artery embolization.
Uterine Hemorrhage
Vaginal bleeding in early pregnancy and circulating markers of thrombin generation.
Uterine Prolapse
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Varicose Veins
A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis.
Varicose Veins
Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices: a prospective randomized trial.
Varicose Veins
Manifestations of temporary symptoms during endoscopic variceal sclerotherapy using thrombin as a sclerosant.
Varicose Veins
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Varicose Veins
Superficial thrombophlebitis of the lower limbs in patients with varicose veins.
Varicose Veins
Thrombin and ethanolamine injection therapy in arresting uncontrolled bleeding from duodenal varices.
Varicose Veins
Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience.
Vascular Diseases
A steady-state competition model describes the modulating effects of thrombomodulin on thrombin inhibition by plasminogen activator inhibitor-1 in the absence and presence of vitronectin.
Vascular Diseases
A Thrombin-Responsive Nanoprobe for In Vivo Visualization of Thrombus Formation through Three-Dimensional Optical/Computed Tomography Hybrid Imaging.
Vascular Diseases
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Vascular Diseases
Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.
Vascular Diseases
Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice.
Vascular Diseases
Fibrinopeptide A excretion in urine in patients with atherosclerotic artery disease.
Vascular Diseases
Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin (PAR1) Receptor Antagonist.
Vascular Diseases
Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases.
Vascular Diseases
New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology.
Vascular Diseases
PKC-delta/c-Src-mediated EGF receptor transactivation regulates thrombin-induced COX-2 expression and PGE(2) production in rat vascular smooth muscle cells.
Vascular Diseases
Placental insufficiency is characterized by platelet activation in the fetus.
Vascular Diseases
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Vascular Diseases
Shear stress reduces protease activated receptor-1 expression in human endothelial cells.
Vascular Diseases
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Vascular Diseases
Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation.
Vascular Diseases
Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation.
Vascular System Injuries
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Vascular System Injuries
A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production.
Vascular System Injuries
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.
Vascular System Injuries
A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity.
Vascular System Injuries
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Vascular System Injuries
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Vascular System Injuries
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.
Vascular System Injuries
Activation of blood coagulation by plaque rupture: mechanisms and prevention.
Vascular System Injuries
Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
Vascular System Injuries
Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB.
Vascular System Injuries
Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Vascular System Injuries
Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells.
Vascular System Injuries
Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists.
Vascular System Injuries
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.
Vascular System Injuries
Bidirectional transmembrane modulation of integrin alphaIIbbeta3 conformations.
Vascular System Injuries
Biorheology of platelet activation in the bloodstream distal to thrombus formation.
Vascular System Injuries
Characterization of thrombin receptor expression during vascular lesion formation.
Vascular System Injuries
Chloride channels are necessary for full platelet phosphatidylserine exposure and procoagulant activity.
Vascular System Injuries
Complement factor C4a does not activate protease-activated receptor 1 (PAR1) or PAR4 on human platelets.
Vascular System Injuries
Continuous Detection of Increasing Concentrations of Thrombin Employing a Label-Free Photonic Crystal Aptasensor.
Vascular System Injuries
Conversion of thrombin into an anticoagulant by protein engineering.
Vascular System Injuries
Coordination of platelet agonist signaling during the hemostatic response in vivo.
Vascular System Injuries
Corneal activation of prothrombin to form thrombin, independent of vascular injury.
Vascular System Injuries
Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation.
Vascular System Injuries
CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
Vascular System Injuries
Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells.
Vascular System Injuries
Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Vascular System Injuries
Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development.
Vascular System Injuries
Dual P2Y 12 receptor signaling in thrombin-stimulated platelets--involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity.
Vascular System Injuries
Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells.
Vascular System Injuries
Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation.
Vascular System Injuries
Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats.
Vascular System Injuries
Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1.
Vascular System Injuries
Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid.
Vascular System Injuries
Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
Vascular System Injuries
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
Vascular System Injuries
Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations.
Vascular System Injuries
Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells.
Vascular System Injuries
HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.
Vascular System Injuries
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
Vascular System Injuries
Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Vascular System Injuries
Homocysteine and thrombosis: from basic science to clinical evidence.
Vascular System Injuries
Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.
Vascular System Injuries
Human brain pericytes differentially regulate expression of procoagulant enzyme complexes comprising the extrinsic pathway of blood coagulation.
Vascular System Injuries
Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.
Vascular System Injuries
Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes.
Vascular System Injuries
Identification of critical residues on thrombin mediating its interaction with fibrin.
Vascular System Injuries
Impairment of the hemostatic potential of platelets during storage as evaluated by flow cytometry, thrombin generation, and thrombelastography under conditions promoting formation of coated platelets.
Vascular System Injuries
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
Vascular System Injuries
Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery.
Vascular System Injuries
Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide.
Vascular System Injuries
Inhibition of neointimal hyperplasia by a specific thrombin inhibitor.
Vascular System Injuries
Inhibition of thrombin receptor signaling on ?-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury.
Vascular System Injuries
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Vascular System Injuries
Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide.
Vascular System Injuries
Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling.
Vascular System Injuries
Leukocyte repletion reverses protective effect of neutropenia in thrombin-induced increase in lung vascular permeability.
Vascular System Injuries
LIM and cysteine-rich domains 1 is required for thrombin-induced smooth muscle cell proliferation and promotes atherogenesis.
Vascular System Injuries
LPS-induced expression and release of monocyte tissue factor in patients with haemophilia.
Vascular System Injuries
Lysoplasmenylcholine increases neutrophil adherence to human coronary artery endothelial cells.
Vascular System Injuries
Mechanisms Regulating Acquisition of Platelet-Derived Factor V/Va by Megakaryocytes.
Vascular System Injuries
Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits.
Vascular System Injuries
NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells.
Vascular System Injuries
Necrotic platelets provide a procoagulant surface during thrombosis.
Vascular System Injuries
New insights into the spatiotemporal localization of prothrombinase in vivo.
Vascular System Injuries
PKCtheta is required for hemostasis and positive regulation of thrombin-induced platelet aggregation and alpha-granule secretion.
Vascular System Injuries
Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
Vascular System Injuries
Platelet receptors and signaling in the dynamics of thrombus formation.
Vascular System Injuries
Platelets and their membranes in hemostasis: physiology and pathophysiology.
Vascular System Injuries
Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
Vascular System Injuries
Protease-activated receptor 3 is a second thrombin receptor in humans.
Vascular System Injuries
Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.
Vascular System Injuries
Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets.
Vascular System Injuries
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Vascular System Injuries
Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Vascular System Injuries
Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin.
Vascular System Injuries
Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation.
Vascular System Injuries
Reduction in vascular lesion formation by hirudin secreted from retrovirus-transduced confluent endothelial cells on vascular grafts in baboons.
Vascular System Injuries
Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors.
Vascular System Injuries
Relative Contribution of STIM1 and CalDAG-GEFI to Calcium-Dependent Platelet Activation and Thrombosis.
Vascular System Injuries
Restenosis following percutaneous revascularization--the potential role of thrombin and the thrombin receptor.
Vascular System Injuries
rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation.
Vascular System Injuries
Role of caveolin-1 expression in the pathogenesis of pulmonary edema in ventilator-induced lung injury.
Vascular System Injuries
Role of the thrombin receptor in development and evidence for a second receptor.
Vascular System Injuries
Roles of platelets and factor XI in the initiation of blood coagulation by thrombin.
Vascular System Injuries
Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury.
Vascular System Injuries
Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Role of protein kinase C and protein tyrosine kinases.
Vascular System Injuries
Shear stress reduces protease activated receptor-1 expression in human endothelial cells.
Vascular System Injuries
Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation.
Vascular System Injuries
Stimulation of human smooth muscle cell proliferation by thrombin involves increased synthesis of platelet-derived growth factor.
Vascular System Injuries
Structure and function of platelet receptors initiating blood clotting.
Vascular System Injuries
Suboptimal activation of protease-activated receptors enhances {alpha}2{beta}1 integrin-mediated platelet adhesion to collagen.
Vascular System Injuries
Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency.
Vascular System Injuries
Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition.
Vascular System Injuries
Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit.
Vascular System Injuries
The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice.
Vascular System Injuries
The in vitro effect of recombinant factor VIIa on coated platelet formation and clot dynamics of stored platelet concentrates.
Vascular System Injuries
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Vascular System Injuries
The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty.
Vascular System Injuries
The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells.
Vascular System Injuries
The role of the membrane in the expression of the vitamin K-dependent enzymes.
Vascular System Injuries
The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.
Vascular System Injuries
Thrombin activates the growth, cell-cycle kinetics, and clustering of human dental pulp cells.
Vascular System Injuries
Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression.
Vascular System Injuries
Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Vascular System Injuries
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis.
Vascular System Injuries
Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species.
Vascular System Injuries
Thrombin contraction of vascular smooth muscle: implications for vasospasm.
Vascular System Injuries
Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Vascular System Injuries
Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process.
Vascular System Injuries
Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha.
Vascular System Injuries
Thrombin induces cyclooxygenase-2 expression and prostaglandin E(2) release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages.
Vascular System Injuries
Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells.
Vascular System Injuries
Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells.
Vascular System Injuries
Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells.
Vascular System Injuries
Thrombin promotes aortic endothelial cell spreading and microfilament formation in nonconfluent monolayer cultures.
Vascular System Injuries
Thrombin receptor expression in normal and atherosclerotic human arteries.
Vascular System Injuries
Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells.
Vascular System Injuries
Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells.
Vascular System Injuries
Thrombin regulates nerve growth factor secretion from vascular, but not bladder smooth muscle cells.
Vascular System Injuries
Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells.
Vascular System Injuries
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Vascular System Injuries
Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin.
Vascular System Injuries
Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism.
Vascular System Injuries
Thrombin stimulates syndecan-1 promotor activity and expression of a form of syndecan-1 that binds antithrombin III in vascular smooth muscle cells.
Vascular System Injuries
Thrombin stimulates synthesis of type IV collagen and tissue inhibitor of metalloproteinases-1 by cultured human mesangial cells.
Vascular System Injuries
Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4.
Vascular System Injuries
Thrombin-induced CCAAT/enhancer-binding protein ? activation and IL-8/CXCL8 expression via MEKK1, ERK, and p90 ribosomal S6 kinase 1 in lung epithelial cells.
Vascular System Injuries
Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).
Vascular System Injuries
Thromboxane A2 potentiates thrombin-induced proliferation of coronary artery smooth muscle cells.
Vascular System Injuries
Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.
Vascular System Injuries
Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease.
Vascular System Injuries
Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells.
Vascular System Injuries
Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib.
Vascular System Injuries
Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor.
Vascular System Injuries
Zinc is a transmembrane agonist that induces platelet activation in a tyrosine phosphorylation-dependent manner.
Vasculitis
Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis.
Vasculitis
Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.
Vasospasm, Intracranial
Basic and translational research on proteinase-activated receptors: the role of thrombin receptor in cerebral vasospasm in subarachnoid hemorrhage.
Vasospasm, Intracranial
Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB.
Vasospasm, Intracranial
Cerebral arterial contractions induced by human and bovine thrombin.
Vasospasm, Intracranial
Comparison of responses elicited by alpha-thrombin in isolated canine basilar, coronary, mesenteric, and renal arteries.
Vasospasm, Intracranial
Comparison of the inhibitory effects of antithrombin III, alpha 2-macroglobulin, and thrombin in human basilar arteries: relevance to cerebral vasospasm.
Vasospasm, Intracranial
Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage.
Vasospasm, Intracranial
Does thrombin prevent cerebral vasospasm following aneurysmal subarachnoid haemorrhage?
Vasospasm, Intracranial
Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model.
Vasospasm, Intracranial
Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage.
Vasospasm, Intracranial
Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin.
Vasospasm, Intracranial
Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.
Venous Thromboembolism
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
Venous Thromboembolism
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
Venous Thromboembolism
A mathematical model to quantify the effects of platelet count, shear rate, and injury size on the initiation of blood coagulation under venous flow conditions.
Venous Thromboembolism
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Venous Thromboembolism
A review of global coagulation assays - Is there a role in thrombosis risk prediction?
Venous Thromboembolism
A review of the clinical uses of ximelagatran in thrombosis syndromes.
Venous Thromboembolism
Acute management of bleeding in patients on novel oral anticoagulants.
Venous Thromboembolism
An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients.
Venous Thromboembolism
Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
Venous Thromboembolism
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Venous Thromboembolism
Antithrombotic therapy in atrial fibrillation. -Evaluation and positioning of new oral anticoagulant agents-.
Venous Thromboembolism
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.
Venous Thromboembolism
Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.
Venous Thromboembolism
Challenges in the prevention of venous thromboembolism in the elderly.
Venous Thromboembolism
Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients.
Venous Thromboembolism
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Venous Thromboembolism
Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
Venous Thromboembolism
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Venous Thromboembolism
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Venous Thromboembolism
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Venous Thromboembolism
Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies.
Venous Thromboembolism
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Venous Thromboembolism
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
Venous Thromboembolism
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Venous Thromboembolism
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies.
Venous Thromboembolism
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.
Venous Thromboembolism
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity.
Venous Thromboembolism
Dabigatran Etexilate for the Prophylaxis of Venous Thromboembolism After Hip or Knee Replacement: Rationale for Dose Regimen.
Venous Thromboembolism
Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
Venous Thromboembolism
Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
Venous Thromboembolism
Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Venous Thromboembolism
Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty.
Venous Thromboembolism
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials.
Venous Thromboembolism
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Venous Thromboembolism
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience.
Venous Thromboembolism
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Venous Thromboembolism
Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography.
Venous Thromboembolism
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Venous Thromboembolism
Diagnostic Accuracy in Acute Venous Thromboembolism: Comparing D-Dimer, Thrombin Generation, Overall Hemostatic Potential, and Fibrin Monomers.
Venous Thromboembolism
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Venous Thromboembolism
Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population.
Venous Thromboembolism
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment.
Venous Thromboembolism
Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
Venous Thromboembolism
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Venous Thromboembolism
Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Venous Thromboembolism
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Venous Thromboembolism
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Venous Thromboembolism
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
Venous Thromboembolism
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Venous Thromboembolism
Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach.
Venous Thromboembolism
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study.
Venous Thromboembolism
Early Identification of Argatroban Resistance and the Consideration of Factor VIII.
Venous Thromboembolism
Early thrombin formation capacity in trauma patients and association with venous thromboembolism.
Venous Thromboembolism
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
Venous Thromboembolism
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Venous Thromboembolism
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram.
Venous Thromboembolism
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Venous Thromboembolism
Ex Vivo Thrombin Generation in Patients With Venous Thromboembolic Disease or Atrial Fibrillation on Long-Term Oral Anticoagulation.
Venous Thromboembolism
Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study.
Venous Thromboembolism
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Venous Thromboembolism
Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.
Venous Thromboembolism
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Venous Thromboembolism
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism.
Venous Thromboembolism
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
Venous Thromboembolism
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Venous Thromboembolism
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Venous Thromboembolism
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.
Venous Thromboembolism
Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Venous Thromboembolism
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Venous Thromboembolism
Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.
Venous Thromboembolism
Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens.
Venous Thromboembolism
Interference of thrombin in immunological assays for hirudin specific antibodies.
Venous Thromboembolism
Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man.
Venous Thromboembolism
Lessons From Ximelagatran : Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery.
Venous Thromboembolism
Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.
Venous Thromboembolism
Long-term anticoagulation in patients with coronary disease, and future developments.
Venous Thromboembolism
Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism.
Venous Thromboembolism
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Venous Thromboembolism
More on: high thrombin generation and the risk of recurrent venous thromboembolism.
Venous Thromboembolism
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Venous Thromboembolism
New concepts in heparin-induced thrombocytopenia: diagnosis and management.
Venous Thromboembolism
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Venous Thromboembolism
New oral anticoagulants for the treatment of venous thromboembolism.
Venous Thromboembolism
New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors.
Venous Thromboembolism
New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients.
Venous Thromboembolism
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct xa inhibitors.
Venous Thromboembolism
Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
Venous Thromboembolism
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Venous Thromboembolism
Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Venous Thromboembolism
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Venous Thromboembolism
Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism.
Venous Thromboembolism
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
Venous Thromboembolism
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
Venous Thromboembolism
Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.
Venous Thromboembolism
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism.
Venous Thromboembolism
Phased-array intracardiac echocardiographic imaging of acute cardiovascular emergencies: Experimental studies in dogs.
Venous Thromboembolism
PK evaluation of fondaparinux sodium for the treatment of thrombosis.
Venous Thromboembolism
PO-24 - Determinants of thrombin generation in gynaecological malignancies.
Venous Thromboembolism
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Venous Thromboembolism
Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer.
Venous Thromboembolism
Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study.
Venous Thromboembolism
Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.
Venous Thromboembolism
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Venous Thromboembolism
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Venous Thromboembolism
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Venous Thromboembolism
Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism.
Venous Thromboembolism
Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
Venous Thromboembolism
Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not.
Venous Thromboembolism
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Venous Thromboembolism
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Venous Thromboembolism
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Venous Thromboembolism
Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.
Venous Thromboembolism
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Venous Thromboembolism
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Venous Thromboembolism
Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack.
Venous Thromboembolism
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Venous Thromboembolism
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Venous Thromboembolism
The direct thrombin inhibitors: their role and use for rational anticoagulation.
Venous Thromboembolism
The effect of beta-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism.
Venous Thromboembolism
The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature.
Venous Thromboembolism
The endogenous thrombin potential and the risk of venous thromboembolism.
Venous Thromboembolism
The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
Venous Thromboembolism
The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer.
Venous Thromboembolism
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
Venous Thromboembolism
The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
Venous Thromboembolism
The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism.
Venous Thromboembolism
The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism.
Venous Thromboembolism
The role of ximelagatran in the treatment of venous thromboembolism.
Venous Thromboembolism
Therapeutic inhibition of thrombin activities, receptors, and production.
Venous Thromboembolism
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Venous Thromboembolism
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Venous Thromboembolism
Thrombin generation and procoagulant microparticle profiles after acute trauma: A prospective cohort study.
Venous Thromboembolism
Thrombin generation as an intermediate phenotype for venous thrombosis.
Venous Thromboembolism
Thrombin Generation Assay in Hospitalized Nonsurgical Patients: A New Tool to Assess Venous Thromboembolism Risk?
Venous Thromboembolism
Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Venous Thromboembolism
Thrombin Generation in Patients With Suspected Venous Thromboembolism.
Venous Thromboembolism
Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study.
Venous Thromboembolism
Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism.
Venous Thromboembolism
Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement.
Venous Thromboembolism
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Venous Thromboembolism
Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran.
Venous Thromboembolism
Treatment of venous thromboembolism with new oral anticoagulants according to patient risk.
Venous Thromboembolism
Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
Venous Thromboembolism
Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience.
Venous Thromboembolism
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Venous Thromboembolism
Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype.
Venous Thromboembolism
Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
Venous Thromboembolism
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
Venous Thromboembolism
Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Venous Thromboembolism
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Venous Thromboembolism
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Venous Thromboembolism
[Dabigatran therapy--perioperative management and interpretation of coagulation tests].
Venous Thromboembolism
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics]
Venous Thromboembolism
[Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals]
Venous Thromboembolism
[The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement]
Venous Thromboembolism
[Therapeutic approach to the bleeding in association with "old" and "new" anticoagulants].
Venous Thrombosis
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
Venous Thrombosis
A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Venous Thrombosis
A novel near-infrared fluorescence sensor for detection of thrombin activation in blood.
Venous Thrombosis
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
Venous Thrombosis
A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly.
Venous Thrombosis
Abdominal Contouring Procedures Increase Activity of the Coagulation Cascade.
Venous Thrombosis
Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond.
Venous Thrombosis
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Venous Thrombosis
African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation.
Venous Thrombosis
An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Venous Thrombosis
An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
Venous Thrombosis
Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo.
Venous Thrombosis
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Venous Thrombosis
Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Venous Thrombosis
Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals.
Venous Thrombosis
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Venous Thrombosis
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Venous Thrombosis
Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
Venous Thrombosis
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Venous Thrombosis
Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor.
Venous Thrombosis
Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.
Venous Thrombosis
Association Analysis of Tissue Factor Pathway Inhibitor Polymorphisms and Haplotypes with Osteonecrosis of the Femoral Head in the Korean Population.
Venous Thrombosis
Association of G20210A Prothrombin Gene Mutation and Cerebral Ischemic Stroke in Young Patients.
Venous Thrombosis
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Venous Thrombosis
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Venous Thrombosis
Chronic inflammatory bowel disease, deep-venous thrombosis and antithrombin activity.
Venous Thrombosis
Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Venous Thrombosis
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
Venous Thrombosis
Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models.
Venous Thrombosis
Comparative study on the antithrombotic efficacy of four low-molecular-weight heparins in three different models of experimental venous thrombosis.
Venous Thrombosis
Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Venous Thrombosis
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
Venous Thrombosis
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies.
Venous Thrombosis
Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement.
Venous Thrombosis
CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
Venous Thrombosis
D-dimer, thrombin generation, and risk of a first venous thrombosis in the elderly.
Venous Thrombosis
D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis.
Venous Thrombosis
Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.
Venous Thrombosis
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Venous Thrombosis
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Venous Thrombosis
Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
Venous Thrombosis
Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin.
Venous Thrombosis
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Venous Thrombosis
Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.
Venous Thrombosis
Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat.
Venous Thrombosis
Effect of heparin on the activation of factor XI by fibrin-bound thrombin.
Venous Thrombosis
Effect of monomethylmethacrylate on procoagulant activities of human monocytes and umbilical vein endothelial cells in vitro.
Venous Thrombosis
Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Venous Thrombosis
Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.
Venous Thrombosis
Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Venous Thrombosis
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Venous Thrombosis
Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.
Venous Thrombosis
Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial.
Venous Thrombosis
Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.
Venous Thrombosis
Enhanced thrombin generation in women with a history of oral contraception-related venous thrombosis.
Venous Thrombosis
Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor.
Venous Thrombosis
Failure of thrombin-antithrombin III complexes in the diagnosis of deep vein thrombosis.
Venous Thrombosis
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Venous Thrombosis
Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment.
Venous Thrombosis
Genetic Determinants of Thrombin Generation and Their Relation to Venous Thrombosis: Results from the GAIT-2 Project.
Venous Thrombosis
Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice.
Venous Thrombosis
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.
Venous Thrombosis
High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.
Venous Thrombosis
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis.
Venous Thrombosis
In prothrombin G20210A carriers the genetic mutation and the history of Venous Thrombosis contribute both to thrombin generation independently of factor II plasma levels.
Venous Thrombosis
In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
Venous Thrombosis
Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.
Venous Thrombosis
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Venous Thrombosis
Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study.
Venous Thrombosis
Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders.
Venous Thrombosis
Inhibition of annexin V binding to cardiolipin and thrombin generation in an unselected population with venous thrombosis.
Venous Thrombosis
Inhibition of thrombin generation in human plasma by phospholipid transfer protein.
Venous Thrombosis
Interleukin-10 promoter polymorphism and venous thrombosis: a case-control study.
Venous Thrombosis
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Venous Thrombosis
Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition.
Venous Thrombosis
Laparoscopic ligation of the infrarenal vena cava in combination with transfemoral thrombin infusion: a new animal model of chronic deep venous thrombosis.
Venous Thrombosis
LB30057, an orally effective direct thrombin inhibitor, prevents arterial and venous thrombosis in rats and dogs.
Venous Thrombosis
Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Venous Thrombosis
Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.
Venous Thrombosis
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.
Venous Thrombosis
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
Venous Thrombosis
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Venous Thrombosis
Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor.
Venous Thrombosis
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Venous Thrombosis
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Venous Thrombosis
NMR solution structure of a novel hirudin variant HM2, N-terminal 1-47 and N64-->V + G mutant.
Venous Thrombosis
Novel single nucleotide mutations in exon-10 of human coagulation Factor V gene in patients with pulmonary thromboembolism.
Venous Thrombosis
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Venous Thrombosis
Obesity and thrombin-generation profiles in women with venous thromboembolism.
Venous Thrombosis
Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients.
Venous Thrombosis
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Venous Thrombosis
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Venous Thrombosis
Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay.
Venous Thrombosis
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Venous Thrombosis
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
Venous Thrombosis
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Venous Thrombosis
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Venous Thrombosis
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Venous Thrombosis
Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study.
Venous Thrombosis
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Venous Thrombosis
Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis.
Venous Thrombosis
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
Venous Thrombosis
Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
Venous Thrombosis
Prevention of thrombus formation with glyprolines on various models of prethrombotic state and thrombosis in rats.
Venous Thrombosis
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Venous Thrombosis
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Venous Thrombosis
Prophylactic use of antithrombin III concentrate following surgery in congenital antithrombin III deficiency.
Venous Thrombosis
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Venous Thrombosis
Rapid screening and identification of anticoagulation component from carthami flos by two-dimensional thrombin affinity chromatography combined with HPLC-MS/MS.
Venous Thrombosis
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
Venous Thrombosis
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Venous Thrombosis
Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation.
Venous Thrombosis
Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment.
Venous Thrombosis
Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Venous Thrombosis
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Venous Thrombosis
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Venous Thrombosis
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Venous Thrombosis
Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism.
Venous Thrombosis
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
Venous Thrombosis
The activated factor X-antithrombin III reaction rate: a measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits.
Venous Thrombosis
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Venous Thrombosis
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Venous Thrombosis
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
Venous Thrombosis
The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential.
Venous Thrombosis
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Venous Thrombosis
The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.
Venous Thrombosis
The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179.
Venous Thrombosis
The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
Venous Thrombosis
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.
Venous Thrombosis
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: comment.
Venous Thrombosis
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: reply.
Venous Thrombosis
The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C.
Venous Thrombosis
The role of procoagulants and anticoagulants in the development of venous thromboembolism.
Venous Thrombosis
The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism.
Venous Thrombosis
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Venous Thrombosis
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
Venous Thrombosis
Thrombin and plasmin activity and platelet activation in the development of venous thrombosis.
Venous Thrombosis
Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions.
Venous Thrombosis
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Venous Thrombosis
Thrombin generation test as a marker for high risk venous thrombosis pregnancies.
Venous Thrombosis
Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification.
Venous Thrombosis
Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?
Venous Thrombosis
Trypsin and thrombin induced venous thrombosis and its prevention with dicumarol, 3,3' methylenebis (4 hydroxycoumarin).
Venous Thrombosis
Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes.
Venous Thrombosis
Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
Venous Thrombosis
Use of Direct Thrombin Inhibitor for Treatment of Cerebral Venous Thrombosis.
Venous Thrombosis
Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.
Venous Thrombosis
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia.
Venous Thrombosis
Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.
Venous Thrombosis
Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation.
Venous Thrombosis
[Clinical research on Sanmiao powder combined fibrinogenase for injection in treatment of acute deep venous thrombosis of lower limbs].
Venous Thrombosis
[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors]
Venous Thrombosis
[Continuous heparin therapy in deep venous thrombosis and its monitoring with the Howel and thrombin times. Prospective study]
Venous Thrombosis
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
Venous Thrombosis
[Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis]
Venous Thrombosis
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
Venous Thrombosis
[Morphologic changes in the thrombus and venous wall in experimental phleobothrombosis and thrombophlebitis]
Venous Thrombosis
[Preliminary study on epidemiology of deep venous thrombosis of lower extremity in patients with high risk]
Venous Thrombosis
[Progression from a routine examination to a study. Having come this far, what should be done from now? A thrombosis risk factor study]
Venous Thrombosis
[Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs]
Venous Thrombosis
[Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin]
Venous Thrombosis
[Thrombin-antithrombin III complexes as a measure of effective heparin treatment?]
Venous Thrombosis
[Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia].
Ventilator-Induced Lung Injury
Induction of cellular antioxidant defense by amifostine improves ventilator-induced lung injury.
Ventilator-Induced Lung Injury
Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling.
Ventilator-Induced Lung Injury
Measurement of local permeability at subcellular level in cell models of agonist- and ventilator-induced lung injury.
Ventricular Dysfunction, Left
Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model.
Ventricular Fibrillation
Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation.
Ventricular Fibrillation
Ins(1,4,5)P3 and arrhythmogenic responses during myocardial reperfusion: evidence for receptor specificity.
Virus Diseases
A novel surgical glue composed of gelatin and N-hydroxysuccinimide activated poly(L-glutamic acid): Part 1. Synthesis of activated poly(L-glutamic acid) and its gelation with gelatin.
Virus Diseases
Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice.
Virus Diseases
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Virus Diseases
Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.
Virus Diseases
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Virus Diseases
Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells.
Vitamin D Deficiency
Thrombin generation and fibrin clot structure after vitamin D supplementation.
Vitamin K Deficiency
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
Vitamin K Deficiency
Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency.
Vitamin K Deficiency
Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.
Vitamin K Deficiency Bleeding
[Prevention of hemorrhagic disease of newborn with oral plasmatic thrombin.]
Vitreoretinopathy, Proliferative
Intraocular human thrombin infusion in diabetic vitrectomies.
Vitreoretinopathy, Proliferative
Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment.
Vitreoretinopathy, Proliferative
Thrombin induces Slug-mediated E-Cadherin transcriptional repression and the parallel up-regulation of N-cadherin by a transcription-independent mechanism in RPE cells.
Vitreoretinopathy, Proliferative
Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation.
Vitreoretinopathy, Proliferative
Thrombin promotes the expression of Ccnd1 gene in RPE cells through the activation of converging signaling pathways.
Vitreoretinopathy, Proliferative
Thrombin stimulates RPE cell motility by PKC-zeta- and NF-kappaB-dependent gene expression of MCP-1 and CINC-1/GRO chemokines.
Vitreoretinopathy, Proliferative
Thrombin stimulates RPE cell proliferation by promoting c-Fos-mediated cyclin D1 expression.
Vitreoretinopathy, Proliferative
Vitreous and subretinal fluid concentrations of orally administered dabigatran in patients with rhegmatogenous retinal detachment.
Vitreous Hemorrhage
The use of intravitreal thrombin to control hemorrhage during vitrectomy.
von Willebrand Disease, Type 1
Key role of glycoprotein Ib-V-IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow.
von Willebrand Disease, Type 3
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
von Willebrand Diseases
Effect of thrombin and ADP on a membrane bound cyclic AMP dependent kinase of human platelets. Studies on normal platelets and those from patients with Von Willebrand's disease.
von Willebrand Diseases
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
von Willebrand Diseases
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
von Willebrand Diseases
Key role of glycoprotein Ib-V-IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow.
von Willebrand Diseases
Platelets compensate for poor thrombin generation in type 3 von Willebrand disease.
von Willebrand Diseases
The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
von Willebrand Diseases
Thrombin generation during a regular menstrual cycle in women with von Willebrand disease.
von Willebrand Diseases
Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages.
von Willebrand Diseases
Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective.
Whooping Cough
Activation of phospholipase C by heat shock requires GTP analogs and is resistant to pertussis toxin.
Whooping Cough
Agonist stimulation of Na+/K+/Cl- cotransport in rat glomerular mesangial cells. Evidence for protein kinase C-dependent and Ca2+/calmodulin-dependent pathways.
Whooping Cough
Bombesin and thrombin affect discrete pools of intracellular calcium through different G-proteins.
Whooping Cough
Ca2+ ionophore A23187 and thrombin inhibit the pertussis-toxin-induced ADP-ribosylation of the alpha-subunit of the inhibitory guanine-nucleotide-binding protein and other proteins in human platelets.
Whooping Cough
Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.
Whooping Cough
Changes in G protein pattern and in G protein-dependent signaling during erythropoietin- and dimethylsulfoxide-induced differentiation of murine erythroleukemia cells.
Whooping Cough
Changes of cytosolic calcium ion concentrations in human endothelial cells in response to thrombin, platelet-activating factor, and leukotriene B4.
Whooping Cough
Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition.
Whooping Cough
Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells.
Whooping Cough
Crosstalk between thrombin and adenylyl cyclase-stimulating agonists in proliferating human erythroid progenitor cells.
Whooping Cough
Cytosol promotes the guanine nucleotide-induced release of the alpha subunit of Gi2 from the membrane of mouse mastocytoma P-815 cells.
Whooping Cough
Differences in intracellular calcium signaling after activation of the thrombin receptor by thrombin and agonist peptide in osteoblast-like cells.
Whooping Cough
Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cells.
Whooping Cough
Differential routes of Ca2+ influx in Swiss 3T3 fibroblasts in response to receptor stimulation.
Whooping Cough
Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells.
Whooping Cough
Dual effect of thrombin on voltage-dependent Ca2+ channels of portal vein smooth muscle cells.
Whooping Cough
Effect of pertussis toxin on the phosphodiesteratic cleavage of the polyphosphoinositides by guanosine 5'-O-thiotriphosphate and thrombin in permeabilized human platelets.
Whooping Cough
Effect of thrombin on calcium homeostasis in chick embryonic heart cells. Receptor-operated calcium entry with inositol trisphosphate and a pertussis toxin-sensitive G protein as second messengers.
Whooping Cough
Effects of thrombin, phorbol myristate acetate and prostaglandin D2 on 40-41 kDa protein that is ADP ribosylated by pertussis toxin in platelets.
Whooping Cough
Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment.
Whooping Cough
Endothelin-induced increases in vascular smooth muscle Ca2+ do not depend on dihydropyridine-sensitive Ca2+ channels.
Whooping Cough
Evidence that thrombin-stimulated DNA synthesis in pulmonary arterial fibroblasts involves phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation.
Whooping Cough
Expression of a mutant Gi2 alpha subunit inhibits ATP and thrombin stimulation of cytoplasmic phospholipase A2-mediated arachidonic acid release independent of Ca2+ and mitogen-activated protein kinase regulation.
Whooping Cough
Extracellular signal-regulated kinases and g protein-coupled receptors in megakaryocytic human erythroleukemia cells: selective activation, differential regulation, and dissociation from mitogenesis.
Whooping Cough
Further evidence for a phospholipase C-coupled G protein in hamster fibroblasts. Induction of inositol phosphate formation by fluoroaluminate and vanadate and inhibition by pertussis toxin.
Whooping Cough
G proteins and phospholipase C mediate thrombin-induced generation of plasminogen activator inhibitor-1 from vascular smooth muscle cells.
Whooping Cough
Gi-mediated activation of the Ras/MAP kinase pathway involves a 100 kDa tyrosine-phosphorylated Grb2 SH3 binding protein, but not Src nor Shc.
Whooping Cough
GTP gamma S increases thrombin-mediated inositol trisphosphate accumulation in permeabilized human endothelial cells.
Whooping Cough
Guanosine 5'-O-(3-thiotrisphosphate) potentiates both thrombin- and platelet-derived growth factor-induced inositol phosphate release in permeabilized vascular smooth muscle cells. Signaling mechanisms distinguished by sensitivity to pertussis toxin and phorbol esters.
Whooping Cough
Histamine-stimulated and GTP-binding proteins-mediated phospholipase A2 activation in rabbit platelets.
Whooping Cough
Homologous desensitization of HEL cell thrombin receptors. Distinguishable roles for proteolysis and phosphorylation.
Whooping Cough
Identification of G protein-coupled receptors potently stimulating migration of human transitional-cell carcinoma cells.
Whooping Cough
Identification of the pertussis toxin-sensitive G proteins in platelets, megakaryocytes, and human erythroleukemia cells.
Whooping Cough
Inhibition of Rho-Kinase Abrogates Migration of Human Transitional Cell Carcinoma Cells: Results of an in vitro Study.
Whooping Cough
Inositol 1,4,5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin.
Whooping Cough
Involvement of 5-HT2 receptors in chronic endothelial dysfunction after balloon injury of porcine coronary arteries.
Whooping Cough
Involvement of pertussis toxin-sensitive and -insensitive G proteins in alpha-thrombin signalling on cultured human vascular smooth muscle cells.
Whooping Cough
Involvement of protein kinase C in thrombin-induced translocation of Gi2 alpha from the membrane to the cytosol in mouse mastocytoma P-815 cells.
Whooping Cough
Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.
Whooping Cough
Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells.
Whooping Cough
Mediation of growth factor induced DNA synthesis and calcium mobilization by Gq and Gi2.
Whooping Cough
Multiple Signaling Pathways Contribute to the Thrombin-induced Secretory Phenotype in Vascular Smooth Muscle Cells.
Whooping Cough
Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein.
Whooping Cough
Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca(2+) mobilization, and apoptosis.
Whooping Cough
No direct correlation between Ca2+ mobilization and dissociation of Gi during platelet phospholipase A2 activation.
Whooping Cough
PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells.
Whooping Cough
Pertussis toxin inhibits thrombin-induced activation of phosphoinositide hydrolysis and Na+/H+ exchange in hamster fibroblasts.
Whooping Cough
Pertussis toxin reduces endothelium-dependent and independent responses to alpha-2- adrenergic stimulation in systemic canine arteries and veins.
Whooping Cough
Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts.
Whooping Cough
Pertussis toxin-sensitive and -insensitive thrombin stimulation of Shc phosphorylation and mitogenesis are mediated through distinct pathways.
Whooping Cough
Pertussis toxin-sensitive GTP-binding proteins may regulate phospholipase A2 in response to thrombin in rabbit platelets.
Whooping Cough
Phospholipase C-beta3 mediates the thrombin-induced Ca2+ response in glial cells.
Whooping Cough
Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL.
Whooping Cough
Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle.
Whooping Cough
Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases.
Whooping Cough
Receptor-mediated increases in cytosolic Ca2+ in the human erythroleukaemia cell line involve pertussis toxin-sensitive and -insensitive pathways.
Whooping Cough
Regulation of HSP70 by PTH: a model of gene regulation not mediated by changes in cAMP levels.
Whooping Cough
Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line.
Whooping Cough
Regulation of the extracellular signal-regulated kinase pathway in adult myocardium: differential roles of G(q/11), Gi and G(12/13) proteins in signalling by alpha1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors.
Whooping Cough
Regulation of thrombin-induced endothelial cell activation by bacterial toxins.
Whooping Cough
Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2.
Whooping Cough
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
Whooping Cough
Role of the third intracellular loop and of the cytoplasmic tail in the mitogenic signaling of the protease-activated receptor 1.
Whooping Cough
Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein.
Whooping Cough
Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor.
Whooping Cough
Sodium fluoride induces phosphoinositide hydrolysis, Ca2+ mobilization, and prostacyclin synthesis in cultured human endothelium: further evidence for regulation by a pertussis toxin-insensitive guanine nucleotide-binding protein.
Whooping Cough
Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin.
Whooping Cough
Stimulus-response coupling in a cell-free platelet membrane system. GTP-dependent release of Ca2+ by thrombin, and inhibition by pertussis toxin and a monoclonal antibody that blocks calcium release by IP3.
Whooping Cough
Strong and persistent activation of inositol lipid breakdown induces early mitogenic events but not Go to S phase progression in hamster fibroblasts. Comparison of thrombin and carbachol action in cells expressing M1 muscarinic acetylcholine receptors.
Whooping Cough
Suppression of the voltage-gated K+ current of human megakaryocytes by thrombin and prostacyclin.
Whooping Cough
Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells.
Whooping Cough
The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells.
Whooping Cough
The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice.
Whooping Cough
The G-protein G(i) regulates mitosis but not DNA synthesis in growth factor-activated fibroblasts: a role for the nuclear translocation of G(i).
Whooping Cough
The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain.
Whooping Cough
The inositol phosphate response to thrombin in rat right atria differs from the response to noradrenaline.
Whooping Cough
The thrombin receptor in adrenal medullary microvascular endothelial cells is negatively coupled to adenylyl cyclase through a Gi protein.
Whooping Cough
Thrombin activates mitogen-activated protein kinase in primary astrocyte cultures.
Whooping Cough
Thrombin activation of the Na+/H+ exchanger in vascular smooth muscle cells. Evidence for a kinase C-independent pathway which is Ca2+-dependent and pertussis toxin-sensitive.
Whooping Cough
Thrombin exerts a dual effect on stimulated adenylate cyclase in hamster fibroblasts, an inhibition via a GTP-binding protein and a potentiation via activation of protein kinase C.
Whooping Cough
Thrombin induces c-fos expression in cultured human endothelial cells by a Ca2(+)-dependent mechanism.
Whooping Cough
Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.
Whooping Cough
Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart.
Whooping Cough
Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells.
Whooping Cough
Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists.
Whooping Cough
Thrombin receptor on rat primary hippocampal neurons: coupled calcium and cAMP responses.
Whooping Cough
Thrombin signal transduction of the fibrinolytic system in human adult venous endothelium in vitro.
Whooping Cough
Thrombin signalling in U937 human monocytic cells is coupled to inositol phosphate formation but not to thromboxane B2 synthesis nor to inhibition of adenylate cyclase: distinct differences in thrombin signalling between U937 cells and platelets.
Whooping Cough
Thrombin stimulates inositol phosphate formation, intracellular calcium fluxes and DNA synthesis in cultured fetal human non-pigmented ciliary epithelial cells.
Whooping Cough
Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells.
Whooping Cough
Thrombin stimulates PDGF production and monocyte adhesion through distinct intracellular pathways in human endothelial cells.
Whooping Cough
Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP.
Whooping Cough
Thrombin, unlike vasopressin, appears to stimulate two distinct guanine nucleotide regulatory proteins in human platelets.
Whooping Cough
Thrombin-induced Ca2+ mobilization in vascular smooth muscle utilizes a slowly ribosylating pertussis toxin-sensitive G protein. Evidence for the involvement of a G protein in inositol trisphosphate-dependent Ca2+ release.
Whooping Cough
Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells.
Whooping Cough
Thrombin-induced prostacyclin biosynthesis in human endothelium: role of guanine nucleotide regulatory proteins in stimulus/coupling responses.
Whooping Cough
Thrombin-stimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells.
Whooping Cough
Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells.
Whooping Cough
Transfected adenosine A1 receptor-mediated modulation of thrombin-stimulated phospholipase C and phospholipase A2 activity in CHO cells.
Whooping Cough
Treatment of human platelets with trypsin, thrombin, or collagen inhibits the pertussis toxin-induced ADP-ribosylation of a 41-kDa protein.
Whooping Cough
Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase is coupled to platelet thrombin receptor via a pertussis toxin-sensitive heterotrimeric G-protein.
Whooping Cough
[Activation mechanisms by thrombin and vasopressin of fibroblasts in spontaneously hypertensive rats]
html completed